

08/25/00
JC980 U.S. PTO

08-28-00

A

Patent
030586.0009.CIP2

To: Box Patent Application
Commissioner for Patents
Washington, D.C. 20231

JC936 U.S. PTO
09/648123
08/25/00

CONTINUATION-IN-PART APPLICATION
TRANSMITTAL

Sir:

Transmitted herewith for filing is a **Continuation-in-Part** of U.S. Application No. 09/590,783, filed June 8, 2000, which is a continuation-in-part of U.S. Application No. 09/501,955, filed February 10, 2000, which is a continuation-in-part of International Application No. PCT/US00/01392, filed January 20, 2000, U.S. Application No. 09/427,835, filed October 26, 1999 and U.S. Application No. 09/300,747, filed April 26, 1999, and claims the benefit of U.S. Provisional Patent Application No. 60/131,334, filed April 26, 1999 and U.S. Provisional Patent Application No. 60/139,440, filed June 15, 1999.

Inventor(s): Vincent P. Stanton, Jr.

Title: **GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT DISEASE, IN GENES RELATING TO DRUG PROCESSING**

I. PAPERS ENCLOSED HEREWITH FOR FILING UNDER 37 CFR § 1.53(b):

- 263 Page(s) of Written Description
2 Page(s) Claims
1 Page(s) Abstract
____ Other:
____ Sheets of Drawings ____ Informal ____ Formal

CERTIFICATE OF MAILING
(37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

EL 573656533 US
Express Mail Label No.

August 25, 2000
Date of Deposit

Gretchen Dieckmann
Name of Person Mailing Paper
Gretchen Dieckmann
Signature of Person Mailing Paper

09648123 082500

II. ADDITIONAL PAPERS ENCLOSED IN CONNECTION WITH THIS FILING:

- ☒ Declaration
- ☐ Power of Attorney: ☐ Separate or ☐ Combined with Declaration
- ☐ Assignment to _____ and assignment cover sheet
- ☒ Verified Statement establishing "Small Entity" under 37 CFR §§ 1.9 and 1.27
- ☐ Priority Document No(s):
- ☐ Information Disclosure Statement w/PTO 1449 ☐ Copy of Citations
- ☐ Preliminary Amendment
- ☒ Return Postcard

III. THE FILING FEE HAS BEEN CALCULATED AS SHOWN BELOW:

BASIC FILING FEE:						\$690.00
Total Claims	16	-	20	=	x \$18.00	0.00
Independent Claims	3	-	3	=	x \$78.00	0.00
Multiple Dependent Claims	\$260	(if applicable)			<input type="checkbox"/>	\$0.00
TOTAL OF ABOVE CALCULATIONS						\$690.00
Reduction by ½ for Filing by Small Entity. Note 37 CFR §§ 1.9, 1.27, 1.28. If applicable, Verified Statement must be attached.						<input type="checkbox"/>
Misc. Filing Fees (Recordation of Assignment -- \$40)						\$0.00
TOTAL FEES SUBMITTED HERewith						\$345.00

IV. METHOD OF PAYMENT OF FEES

- ☒ A check in the amount of \$345.00.
- ☐ This application is being filed without fee or Declaration under 37 CFR § 1.53.

Respectfully submitted,

BROBECK, PHLEGER & HARRISON LLP

Dated:

August 25, 2000

By:



Wesley B. Ames
Reg. No. 40,893

12390 El Camino Real
San Diego, CA 92130
Telephone: (858) 720-2500
Facsimile: (858) 720-2555

Applicant or Patentee: Vincent P. Stanton, Jr.
Serial or Patent No.: To be assigned
Filed or Issued: Filed herewith
For: **GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE, IN GENES RELATING TO DRUG PROCESSING**

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(d) and 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am:

_____ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN: VARIAGENICS, INC.
ADDRESS OF CONCERN: 60 Hampshire Street
Cambridge, Massachusetts 02139

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third-party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled **GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE, IN GENES RELATING TO DRUG PROCESSING** by inventor Vincent P. Stanton, Jr. described in

☒ the specification filed herewith.
_____ application serial number _____, filed _____.
_____ Patent No. _____, issued _____.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

**NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)*

NAME: _____
ADDRESS: _____

[] INDIVIDUAL [] SMALL BUSINESS CONCERN [] NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: Richard Shea
TITLE OF PERSON IN ORGANIZATION: Chief Financial Officer
ADDRESS OF PERSON SIGNING: Variagenics, Inc.
60 Hampshire Street, Cambridge, Massachusetts 02139

Signature Richard Shea Date 8-23-00

CONTINUATION-IN-PART APPLICATION

UNDER 37 CFR § 1.53(B)


TITLE: GENE SEQUENCE VARIATIONS WITH
UTILITY IN DETERMINING THE TREATMENT
OF DISEASE, IN GENES RELATING TO DRUG
PROCESSING

APPLICANT(S): Vincent P. Stanton, Jr.

Correspondence Enclosed:

Continuation-in-Part Transmittal (3 pgs); Cover
Sheet (1pg); Description (263 pgs); Claims (2 pgs);
Abstract (1 pg); Declaration (2 pgs); Small Entity
Statement (1 pg); Check No. 503380 in the Amount
of \$345.00; and Return Postcard

"EXPRESS MAIL" Mailing Label Number EL 573656533 US Date of Deposit August 25,
2000 I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with
the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient
postage on the date indicated above and is addressed to the Assistant Commissioner for
Patents, Washington, D.C. 20231.


Gretchen Dieckmann

005230 "EL 573656533 US"

DESCRIPTION

GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE
TREATMENT OF DISEASE, IN GENES RELATING TO DRUG PROCESSING

5

RELATED APPLICATIONS

This application is a continuation-in-part of Stanton et al., U.S. Application
09/590,783, filed June 8, 2000, which is a continuation-in-part of Stanton, U.S.
Application No. 09/501,955, filed February 10, 2000, which is a continuation-in-part
10 of Stanton, International Application No. PCT/US00/01392, filed January 20, 2000,
entitled GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING
THE TREATMENT OF DISEASE, Stanton, U.S. Application No. 09/427,835, filed
October 26, 1999, entitled GENE SEQUENCE VARIATIONS WITH UTILITY IN
DETERMINING THE TREATMENT OF DISEASE, and Stanton et al., U.S.
15 Application No. 09/300,747, filed April 26, 1999, entitled GENE SEQUENCE
VARIANCES WITH UTILITY IN DETERMINING THE TREATMENT OF
DISEASE, and claims the benefit of U.S. Provisional Patent Application, Stanton &
Adams, serial number 60/131,334, filed April 26, 1999, entitled GENE SEQUENCE
VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT OF
20 DISEASE, and U.S. Provisional Patent Application, Stanton, serial number
60/139,440, filed June 15, 1999, entitled GENE SEQUENCE VARIATIONS WITH
UTILITY IN DETERMINING THE TREATMENT OF DISEASE, which are
hereby incorporated by reference in their entireties, including drawings and tables.

25

BACKGROUND OF THE INVENTION

This application concerns the field of mammalian therapeutics and the
selection of therapeutic regimens utilizing host genetic information, including gene
sequence variances within the human genome in human populations.

The information provided below is not admitted to be prior art to the present
30 invention, but is provided solely to assist the understanding of the reader.

Many drugs or other treatments are known to have highly variable safety and
efficacy in different individuals. A consequence of such variability is that a given
drug or other treatment may be effective in one individual, and ineffective or not
well-tolerated in another individual. Thus, administration of such a drug to an
35 individual in whom the drug would be ineffective would result in wasted cost and
time during which the patient's condition may significantly worsen. Also,
administration of a drug to an individual in whom the drug would not be tolerated

could result in a direct worsening of the patient's condition and could even result in the patient's death.

For some drugs, over 90% of the measurable intersubject variation in selected pharmacokinetic parameters has been shown to be heritable. For a limited number of drugs, DNA sequence variances have been identified in specific genes that are involved in drug action or metabolism, and these variances have been shown to account for the variable efficacy or safety of the drugs in different individuals. As the sequence of the human genome is completed, and as additional human gene sequence variances are identified, the power of genetic methods for predicting drug response will further increase. This application concerns methods for identifying and exploiting gene sequence variances that account for interpatient variation in drug response, particularly interpatient variation attributable to pharmacokinetic factors and interpatient variation in drug tolerability or toxicity.

The efficacy of a drug is a function of both pharmacodynamic effects and pharmacokinetic effects, or bioavailability. In the present invention, interpatient variability in drug safety, tolerability and efficacy are discussed in terms of the genetic determinants of interpatient variation in absorption, distribution, metabolism, and excretion, i.e. pharmacokinetic parameters.

Adverse drug reactions are a principal cause of the low success rate of drug development programs (less than one in four compounds that enters human clinical testing is ultimately approved for use by the US Food and Drug Administration (FDA)). Adverse drug reactions can be categorized as 1) mechanism based reactions and 2) idiosyncratic, "unpredictable" effects apparently unrelated to the primary pharmacologic action of the compound. Although some side effects appear shortly after administration, in some instances side effects appear only after a latent period. Adverse drug reactions can also be categorized into reversible and irreversible effects. The methods of this invention are useful for identifying the genetic basis of both mechanism based and 'idiosyncratic' toxic effects, whether reversible or not. Methods for identifying the genetic sources of interpatient variation in efficacy and mechanism based toxicity may be initially directed to analysis of genes affecting pharmacokinetic parameters, while the genetic causes of idiosyncratic adverse drug reactions are more likely to be attributable to genes affecting variation in pharmacodynamic responses or immunological responsiveness.

Absorption is the first pharmacokinetic parameter to consider when determining the causes of intersubject variation in drug response. The relevant genes depend on the route of administration of the compound being evaluated. For orally administered drugs the major steps in absorption may occur during exposure

to salivary enzymes in the mouth, exposure to the acidic environment of the stomach, exposure to pancreatic digestive enzymes and bile in the small intestine, exposure to enteric bacteria and exposure to cell surface proteins throughout the gastrointestinal tract. For example, uptake of a drug that is absorbed across the gastrointestinal tract by facilitated transport may vary on account of allelic variation in the gene encoding the transporter protein. Many drugs are lipophilic (a property which promotes passive movement across biological membranes). Variation in levels of such drugs may depend, for example, on the enterohepatic circulation of the drug, which may be affected by genetic variation in liver canalicular transporters, or intestinal transporters; alternatively renal reabsorption mechanisms may vary among patients as a consequence of gene sequence variances. If a compound is delivered parenterally then absorption is not an issue, however transcutaneous administration of a compound may be subject to genetically determined variation in skin absorptive properties.

Once a drug or candidate therapeutic intervention is absorbed, injected or otherwise enters the bloodstream it is distributed to various biological compartments via the blood. The drug may exist free in the blood, or, more commonly, may be bound with varying degrees of affinity to plasma proteins. One classic source of interpatient variation in drug response is attributable to amino acid polymorphisms in serum albumin, which affect the binding affinity of drugs such as warfarin. Consequent interpatient variation in levels of free warfarin have a significant effect on the degree of anticoagulation. From the blood a compound diffuses into and is retained in interstitial and cellular fluids of different organs to different degrees. Interpatient variation in the levels of a drug in different anatomical compartments may be attributable to variation in the genetically encoded chemical environment of those tissues (cell surface proteins, matrix proteins, cytoplasmic proteins and other factors)

Once absorbed by the gastrointestinal tract, compounds encounter detoxifying and metabolizing enzymes in the tissues of the gastrointestinal system. Many of these enzymes are known to be polymorphic in man and account for well studied variation in pharmacokinetic parameters of many drugs. Subsequently compounds enter the hepatic portal circulation in a process commonly known as first pass. The compounds then encounter a vast array of xenobiotic detoxifying mechanisms in the liver, including enzymes that are expressed solely or at high levels only in liver. These enzymes include the cytochrome P450s, glucuronyltransferases, sulfotransferases, acetyltransferases, methyltransferases, the glutathione conjugating system, flavine monooxygenases, and other enzymes known in the art. Polymorphisms have been detected in all of these metabolizing systems,

however the genetic factors responsible for intersubject variation have only been partially identified, and in some cases not yet identified at all. Biotransformation reactions in the liver often have the effect of converting lipophilic compounds into hydrophilic molecules that are then more readily excreted. Variation in these conjugation reactions may affect half-life and other pharmacokinetic parameters. It is important to note that metabolic transformation of a compound not infrequently gives rise to a second or additional compounds that have biological activity greater than, less than, or different from that of the parent compound. Metabolic transformation may also be responsible for producing toxic metabolites.

Biotransformation reactions can be divided into two phases. Phase I are oxidation-reduction reactions and phase II are conjugation reactions. The enzymes involved in both of these phases are located predominantly in the liver, however biotransformation can also occur in the kidney, gastrointestinal tract, skin, lung, and other organs. Phase I reactions occur predominantly in the endoplasmic reticulum, while phase II reactions occur predominantly in the cytosol. Both types of reactions can occur in the mitochondria, nuclear envelope, or plasma membrane. One skilled in the art can, for some compounds, make reasonable predictions concerning likely metabolic systems given the structure of the compound. Experimental means of assessing relevant biotransformation systems are also described.

Drug-induced disease or toxicity presents a unique series of challenges to drug developers, as these reactions are often not predictable from preclinical studies and may not be detected in early clinical trials involving small numbers of subjects. When such effects are detected in later stages of clinical development they often result in termination of a drug development program because, until now, there have been no effective tools to seek the determinants of such reactions. When a drug is approved despite some toxicity, its clinical use is frequently severely constrained by the possible occurrence of adverse reactions in even a small group of patients. The likelihood of such a compound becoming first line therapy is small (unless there are no competing products). Thus, clinical trials that lead to detection of genetic causes of adverse events and subsequently to the creation of genetic tests to identify and screen out patients susceptible to such events have the potential to (i) enable approval of compounds for genetically circumscribed populations or (ii) enable repositioning of approved compounds for broader clinical use.

Similarly, many compounds are not approved due to unimpressive efficacy. The identification of genetic determinants of pharmacokinetic variation may lead to identification of a genetically defined population in whom a significant response is occurring. Approval of a compound for this population, defined by a genetic diagnostic test, may be the only means of getting regulatory approval for a drug. As

healthcare becomes increasingly costly, the ability to allocate healthcare resources effectively becomes increasingly urgent. The use of genetic tests to develop and rationally administer medicines represents a powerful tool for accomplishing more cost effective medical care.

5

SUMMARY OF THE INVENTION

The present invention is concerned generally with the field of pharmacology, specifically pharmacokinetics and toxicology, and more specifically with identifying and predicting inter-patient differences in response to drugs in order to achieve superior efficacy and safety in selected patient populations. It is further concerned with the genetic basis of inter-patient variation in response to therapy, including drug therapy, and with methods for determining and exploiting such differences to improve medical outcomes. Specifically, this invention describes the identification of genes and gene sequence variances useful in the field of therapeutics for optimizing efficacy and safety of drug therapy by allowing prediction of pharmacokinetic and/or toxicologic behavior of specific drugs in specific patients. Relevant pharmacokinetic processes include absorption, distribution, metabolism and excretion. Relevant toxicological processes include both dose related and idiosyncratic adverse reactions to drugs, including, for example, hepatotoxicity, blood dyscrasias and immunological reactions. The invention also describes methods for establishing diagnostic tests useful in (i) the development of, (ii) obtaining regulatory approval for and (iii) safe and efficacious clinical use of pharmaceutical products. These variances may be useful either during the drug development process or in guiding the optimal use of already approved compounds. DNA sequence variances in candidate genes (i.e. genes that may plausibly affect the action of a drug) are tested in clinical trials, leading to the establishment of diagnostic tests useful for improving the development of new pharmaceutical products and/or the more effective use of existing pharmaceutical products. Methods for identifying genetic variances and determining their utility in the selection of optimal therapy for specific patients are also described. In general, the invention relates to methods for identifying and dealing effectively with the genetic sources of interpatient variation in drug response, including both variable efficacy as determined by pharmacokinetic variability and variable toxicity as determined by pharmacokinetic factors or by other genetic factors (e.g. factors responsible for idiosyncratic drug response).

The inventors have determined that the identification of gene sequence variances in genes that may be involved in drug action are useful for determining

whether genetic variances account for variable drug efficacy and safety and for determining whether a given drug or other therapy may be safe and effective in an individual patient. Provided in this invention are identifications of genes and sequence variances which can be useful in connection with predicting differences in response to treatment and selection of appropriate treatment of a disease or condition. A target gene and variances have utility in pharmacogenetic association studies and diagnostic tests to improve the use of certain drugs or other therapies including, but not limited to, the drug classes and specific drugs identified in the 1999 Physicians' Desk Reference (53rd edition), Medical Economics Data, 1998, or the 1995 United States Pharmacopeia XXIII National Formulary XVIII, Interpharm Press, 1994, or other sources as described below.

The terms "disease" or "condition" are commonly recognized in the art and designate the presence of signs and/or symptoms in an individual or patient that are generally recognized as abnormal. Diseases or conditions may be diagnosed and categorized based on pathological changes. Signs may include any objective evidence of a disease such as changes that are evident by physical examination of a patient or the results of diagnostic tests which may include, among others, laboratory tests to determine the presence of DNA sequence variances or variant forms of certain genes in a patient. Symptoms are subjective evidence of disease or a patients condition, i.e. the patients perception of an abnormal condition that differs from normal function, sensation, or appearance, which may include, without limitations, physical disabilities, morbidity, pain, and other changes from the normal condition experienced by an individual. Various diseases or conditions include, but are not limited to; those categorized in standard textbooks of medicine including, without limitation, textbooks of nutrition, allopathic, homeopathic, and osteopathic medicine. In certain aspects of this invention, the disease or condition is selected from the group consisting of the types of diseases listed in standard texts such as Harrison's Principles of Internal Medicine (14th Ed) by Anthony S. Fauci, Eugene Braunwald, Kurt J. Isselbacher, et al. (Editors), McGraw Hill, 1997, or Robbins Pathologic Basis of Disease (6th edition) by Ramzi S. Cotran, Vinay Kumar, Tucker Collins & Stanley L. Robbins, W B Saunders Co., 1998, or the Diagnostic and Statistical Manual of Mental Disorders: DSM-IV (4th edition), American Psychiatric Press, 1994, or other texts described below.

In connection with the methods of this invention, unless otherwise indicated, the term "suffering from a disease or condition" means that a person is either presently subject to the signs and symptoms, or is more likely to develop such signs and symptoms than a normal person in the population. Thus, for example, a person suffering from a condition can include a developing fetus, a person subject to a

[illegible]

20

25

30

35

construct developed for therapeutic, e.g., human therapeutic, use. The term “drug” may include, without limitation, compounds that are approved for sale as pharmaceutical products by government regulatory agencies (e.g., U.S. Food and Drug Administration (USFDA or FDA), European Medicines Evaluation Agency (EMEA), and a world regulatory body governing the International Conference of Harmonization (ICH) rules and guidelines), compounds that do not require approval by government regulatory agencies, food additives or supplements including compounds commonly characterized as vitamins, natural products, and completely or incompletely characterized mixtures of chemical entities including natural compounds or purified or partially purified natural products. The term “drug” as used herein is synonymous with the terms “medicine”, “pharmaceutical product”, or “product”. Most preferably the drug is approved by a government agency for treatment of a specific disease or condition.

The term “candidate therapeutic intervention” refers to a drug, agent or compound that is under investigation, either in laboratory or human clinical testing for a specific disease, disorder, or condition.

A “low molecular weight compound” has a molecular weight <5,000 Da, more preferably <2500 Da, still more preferably <1000 Da, and most preferably <700 Da.

Those familiar with drug use in medical practice will recognize that regulatory approval for drug use is commonly limited to approved indications, such as to those patients afflicted with a disease or condition for which the drug has been shown to be likely to produce a beneficial effect in a controlled clinical trial. Unfortunately, it has generally not been possible with current knowledge to predict which patients will have a beneficial response, with the exception of certain diseases such as bacterial infections where suitable laboratory methods have been developed. Likewise, it has generally not been possible to determine in advance whether a drug will be safe in a given patient. Regulatory approval for the use of most drugs is limited to the treatment of selected diseases and conditions. The descriptions of approved drug usage, including the suggested diagnostic studies or monitoring studies, and the allowable parameters of such studies, are commonly described in the “label” or “insert” which is distributed with the drug. Such labels or inserts are preferably required by government agencies as a condition for marketing the drug and are listed in common references such as the Physicians Desk Reference (PDR). These and other limitations or considerations on the use of a drug are also found in medical journals, publications such as pharmacology, pharmacy or medical textbooks including, without limitation, textbooks of nutrition, allopathic, homeopathic, and osteopathic medicine.

Many widely used drugs are effective in a minority of patients receiving the drug, particularly when one controls for the placebo effect. For example, the PDR shows that about 45% of patients receiving Cognex (tacrine hydrochloride) for Alzheimer's disease show no change or minimal worsening of their disease, as do about 68% of controls (including about 5% of controls who were much worse). About 58% of Alzheimer's patients receiving Cognex were minimally improved, compared to about 33% of controls, while about 2% of patients receiving Cognex were much improved compared to about 1% of controls. Thus a tiny fraction of patients had a significant benefit. Response to many cancer chemotherapy drugs is even worse. For example, 5-fluorouracil is standard therapy for advanced colorectal cancer, but only about 20-40% of patients have an objective response to the drug, and, of these, only 1-5% of patients have a complete response (complete tumor disappearance; the remaining patients have only partial tumor shrinkage). Conversely, up to 20-30% of patients receiving 5-FU suffer serious gastrointestinal or hematopoietic toxicity, depending on the regimen.

Thus, in a first aspect, the invention provides a method for selecting a treatment for a patient suffering from a disease or condition by determining whether or not a gene or genes in cells of the patient (in some cases including both normal and disease cells, such as cancer cells) contain at least one sequence variance which is indicative of the effectiveness of the treatment of the disease or condition. The gene or genes are preferably specified herein, in Table 1 or 3. Preferably the at least one variance includes a plurality of variances which may provide a haplotype or haplotypes. Preferably the joint presence of the plurality of variances is indicative of the potential effectiveness or safety of the treatment in a patient having such plurality of variances. The plurality of variances may each be indicative of the potential effectiveness of the treatment, and the effects of the individual variances may be independent or additive, or the plurality of variances may be indicative of the potential effectiveness if at least 2, 3, 4, or more appear jointly. The plurality of variances may also be combinations of these relationships. The plurality of variances may include variances from one, two, three or more gene loci.

In preferred embodiments of aspects of the invention involving genes relating to pharmacokinetic parameters that affect efficacy and safety, e.g. drug-induced disease or drug-induced, disorder, or dysfunction or other drug-induced pathophysiologic disease, or protection or sensitivity to toxic compounds, the gene product is involved in a function as described in the Background of the Invention or otherwise described herein.

In some cases, the selection of a method of treatment, i.e., a therapeutic regimen, may incorporate selection of one or more from a plurality of medical

therapies. Thus, the selection may be the selection of a method or methods which is/are more effective or less effective than certain other therapeutic regimens (with either having varying safety parameters). Likewise or in combination with the preceding selection, the selection may be the selection of a method or methods, which is safer than certain other methods of treatment in the patient.

The selection may involve either positive selection or negative selection or both, meaning that the selection can involve a choice that a particular method would be an appropriate method to use and/or a choice that a particular method would be an inappropriate method to use. Thus, in certain embodiments, the presence of the at least one variance is indicative that the treatment will be effective or otherwise beneficial (or more likely to be beneficial) in the patient. Stating that the treatment will be effective means that the probability of beneficial therapeutic effect is greater than in a person not having the appropriate presence or absence of particular variances. In other embodiments, the presence of the at least one variance is indicative that the treatment will be ineffective or contra-indicated for the patient. For example, a treatment may be contra-indicated if the treatment results, or is more likely to result, in undesirable side effects, or an excessive level of undesirable side effects. A determination of what constitutes excessive side-effects will vary, for example, depending on the disease or condition being treated, the availability of alternatives, the expected or experienced efficacy of the treatment, and the tolerance of the patient. As for an effective treatment, this means that it is more likely that desired effect will result from the treatment administration in a patient with a particular variance or variances than in a patient who has a different variance or variances. Also in preferred embodiments, the presence of the at least one variance is indicative that the treatment is both effective and unlikely to result in undesirable effects or outcomes, or vice versa (is likely to have undesirable side effects but unlikely to produce desired therapeutic effects).

In reference to response to a treatment, the term "tolerance" refers to the ability of a patient to accept a treatment, based, e.g., on deleterious effects and/or effects on lifestyle. Frequently, the term principally concerns the patients perceived magnitude of deleterious effects such as nausea, weakness, dizziness, and diarrhea, among others. Such experienced effects can, for example, be due to general or cell-specific toxicity, activity on non-target cells, cross-reactivity on non-target cellular constituents (non-mechanism based), and/or side effects of activity on the target cellular substituents (mechanism based), or the cause of toxicity may not be understood. In any of these circumstances one may identify an association between the undesirable effects and variances in specific genes.

Adverse responses to drugs constitute a major medical problem, as shown in two recent meta-analyses (Lazarou, J. et al, Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies, JAMA 279:1200-1205, 1998; Bonn, Adverse drug reactions remain a major cause of death, Lancet 351:1183, 1998). An estimated 2.2 million hospitalized patients in the United States had serious adverse drug reactions in 1994, with an estimated 106,000 deaths (Lazarou et al.). To the extent that some of these adverse events are due to genetically encoded biochemical diversity among patients in pathways that effect drug action, the identification of variances that are predictive of such effects will allow for more effective and safer drug use.

In embodiments of this invention, the variance or variant form or forms of a gene is/are associated with a specific response to a drug. The frequency of a specific variance or variant form of the gene may correspond to the frequency of an efficacious response to administration of a drug. Alternatively, the frequency of a specific variance or variant form of the gene may correspond to the frequency of an adverse event resulting from administration of a drug. Alternatively the frequency of a specific variance or variant form of a gene may not correspond closely with the frequency of a beneficial or adverse response, yet the variance may still be useful for identifying a patient subset with high response or toxicity incidence because the variance may account for only a fraction of the patients with high response or toxicity. In such a case the preferred course of action is identification of a second or third or additional variances that permit identification of the patient groups not usefully identified by the first variance. Preferably, the drug will be effective in more than 20% of individuals with one or more specific variances or variant forms of the gene, more preferably in 40% and most preferably in >60%. In other embodiments, the drug will be toxic or create clinically unacceptable side effects in more than 10% of individuals with one or more variances or variant forms of the gene, more preferably in >30%, more preferably in >50%, and most preferably in >70% or in more than 90%.

Also in other embodiments, the method of selecting a treatment includes eliminating a treatment, where the presence or absence of the at least one variance is indicative that the treatment will be ineffective or contra-indicated, e.g., would result in excessive weight gain. In other preferred embodiments, in cases in which undesirable side-effects may occur or are expected to occur from a particular therapeutic treatment, the selection of a method of treatment can include identifying both a first and second treatment, where the first treatment is effective to treat the disease or condition, and the second treatment reduces a deleterious effect of the first treatment.

The phrase “eliminating a treatment” refers to removing a possible treatment from consideration, e.g., for use with a particular patient based on the presence or absence of a particular variance(s) in one or more genes in cells of that patient, or to stopping the administration of a treatment which was in the course of administration.

5 Usually, the treatment will involve the administration of a compound preferentially active or safe in patients with a form or forms of a gene, where the gene is one identified herein. The administration may involve a combination of compounds. Thus, in preferred embodiments, the method involves identifying such an active compound or combination of compounds, where the compound is less
10 active or is less safe or both when administered to a patient having a different form of the gene.

Also in preferred embodiments, the method of selecting a treatment involves selecting a method of administration of a compound, combination of compounds, or pharmaceutical composition, for example, selecting a suitable dosage level and/or
15 frequency of administration, and/or mode of administration of a compound. The method of administration can be selected to provide better, preferably maximum therapeutic benefit. In this context, “maximum” refers to an approximate local maximum based on the parameters being considered, not an absolute maximum.

Also in this context, a “suitable dosage level” refers to a dosage level which
20 provides a therapeutically reasonable balance between pharmacological effectiveness and deleterious effects. Often this dosage level is related to the peak or average serum levels resulting from administration of a drug at the particular dosage level.

Similarly, a “frequency of administration” refers to how often in a specified
25 time period a treatment is administered, e.g., once, twice, or three times per day, every other day, once per week, etc. For a drug or drugs, the frequency of administration is generally selected to achieve a pharmacologically effective average or peak serum level without excessive deleterious effects (and preferably while still being able to have reasonable patient compliance for self-administered drugs).
30 Thus, it is desirable to maintain the serum level of the drug within a therapeutic window of concentrations for the greatest percentage of time possible without such deleterious effects as would cause a prudent physician to reduce the frequency of administration for a particular dosage level.

A particular gene or genes can be relevant to the treatment of more than one
35 disease or condition, for example, the gene or genes can have a role in the initiation, development, course, treatment, treatment outcomes, or health-related quality of life outcomes of a number of different diseases, disorders, or conditions. Thus, in preferred embodiments, the disease or condition or treatment of the disease or

005230 "EET4960

condition is any which involves a gene from the gene list described herein as Tables 1 and 3.

Determining the presence of a particular variance or plurality of variances in a particular gene in a patient can be performed in a variety of ways. In preferred
5 embodiments, the detection of the presence or absence of at least one variance involves amplifying a segment of nucleic acid including at least one of the at least one variances. Preferably a segment of nucleic acid to be amplified is 500 nucleotides or less in length, more preferably 200 nucleotides or less, and most preferably 45 nucleotides or less. Also, preferably the amplified segment or
10 segments includes a plurality of variances, or a plurality of segments of a gene or of a plurality of genes.

In another aspect determining the presence of a set of variances in a specific gene related to treatment of pharmacokinetic parameters associated efficacy or safety, e.g. drug-induced disease, disorder, dysfunction, or other toxicity-related
15 gene or genes listed in Tables 1 and 3 may entail a haplotyping test that requires allele specific amplification of a large DNA segment of no greater than 25,000 nucleotides, preferably no greater than 10,000 nucleotides and most preferably no greater than 5,000 nucleotides. Alternatively one allele may be enriched by methods other than amplification prior to determining genotypes at specific variant positions
20 on the enriched allele as a way of determining haplotypes. Preferably the determination of the presence or absence of a haplotype involves determining the sequence of the variant site or sites by methods such as chain terminating DNA sequencing or minisequencing, or by oligonucleotide hybridization or by mass spectrometry.

The term "genotype" in the context of this invention refers to the alleles present in DNA from a subject or patient, where an allele can be defined by the particular nucleotide(s) present in a nucleic acid sequence at a particular site(s). Often a genotype is the nucleotide(s) present at a single polymorphic site known to vary in the human population.
25

In preferred embodiments, the detection of the presence or absence of the at least one variance involves contacting a nucleic acid sequence corresponding to one of the genes identified above or a product of such a gene with a probe. The probe is able to distinguish a particular form of the gene or gene product or the presence or a particular variance or variances, e.g., by differential binding or hybridization. Thus,
30 exemplary probes include nucleic acid hybridization probes, peptide nucleic acid probes, nucleotide-containing probes which also contain at least one nucleotide analog, and antibodies, e.g., monoclonal antibodies, and other probes as discussed herein. Those skilled in the art are familiar with the preparation of probes with
35

005280 "E2T34950

particular specificities. Those skilled in the art will recognize that a variety of variables can be adjusted to optimize the discrimination between two variant forms of a gene, including changes in salt concentration, temperature, pH and addition of various compounds that affect the differential affinity of GC vs. AT base pairs, such as tetramethyl ammonium chloride. (See Current Protocols in Molecular Biology by F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.D. Seidman, K. Struhl, and V.B. Chanda (editors, John Wiley & Sons.)

In other preferred embodiments, determining the presence or absence of the at least one variance involves sequencing at least one nucleic acid sample. The sequencing involves sequencing of a portion or portions of a gene and/or portions of a plurality of genes which includes at least one variance site, and may include a plurality of such sites. Preferably, the portion is 500 nucleotides or less in length, more preferably 200 nucleotides or less, and most preferably 45 nucleotides or less in length. Such sequencing can be carried out by various methods recognized by those skilled in the art, including use of dideoxy termination methods (e.g., using dye-labeled dideoxy nucleotides) and the use of mass spectrometric methods. In addition, mass spectrometric methods may be used to determine the nucleotide present at a variance site. In preferred embodiments in which a plurality of variances is determined, the plurality of variances can constitute a haplotype or collection of haplotypes. Preferably the methods for determining genotypes or haplotypes are designed to be sensitive to all the common genotypes or haplotypes present in the population being studied (for example, a clinical trial population).

The terms "variant form of a gene", "form of a gene", or "allele" refer to one specific form of a gene in a population, the specific form differing from other forms of the same gene in the sequence of at least one, and frequently more than one, variant sites within the sequence of the gene. The sequences at these variant sites that differ between different alleles of the gene are termed "gene sequence variances" or "variances" or "variants". The term "alternative form" refers to an allele that can be distinguished from other alleles by having distinct variances at least one, and frequently more than one, variant sites within the gene sequence. Other terms known in the art to be equivalent include mutation and polymorphism, although mutation is often used to refer to an allele associated with a deleterious phenotype. In preferred aspects of this invention, the variances are selected from the group consisting of the variances listed in the variance tables herein or in a patent or patent application referenced and incorporated by reference in this disclosure. In the methods utilizing variance presence or absence, reference to the presence of a variance or variances means particular variances, i.e., particular nucleotides at

particular polymorphic sites, rather than just the presence of any variance in the gene.

Variances occur in the human genome at approximately one in every 500 – 1,000 bases within the human genome when two alleles are compared. When multiple alleles from unrelated individuals are compared the density of variant sites increases as different individuals, when compared to a reference sequence, will often have sequence variances at different sites. At most variant sites there are only two alternative nucleotides involving the substitution of one base for another or the insertion/deletion of one or more nucleotides. Within a gene there may be several variant sites. Variant forms of the gene or alternative alleles can be distinguished by the presence of alternative variances at a single variant site, or a combination of several different variances at different sites (haplotypes).

It is estimated that there are 3,300,000,000 bases in the sequence of a single haploid human genome. All human cells except germ cells are normally diploid. Each gene in the genome may span 100-10,000,000 bases of DNA sequence or 100-20,000 bases of mRNA. It is estimated that there are between 60,000 and 120,000 genes in the human genome. The "identification" of genetic variances or variant forms of a gene involves the discovery of variances that are present in a population. The identification of variances is required for development of a diagnostic test to determine whether a patient has a variant form of a gene that is known to be associated with a disease, condition, or predisposition or with the efficacy or safety of the drug. Identification of previously undiscovered genetic variances is distinct from the process of "determining" the status of known variances by a diagnostic test (often referred to as genotyping). The present invention provides exemplary variances in genes listed in the gene tables, as well as methods for discovering additional variances in those genes and a comprehensive written description of such additional possible variances. Also described are methods for DNA diagnostic tests to determine the DNA sequence at a particular variant site or sites.

The process of "identifying" or discovering new variances involves comparing the sequence of at least two alleles of a gene, more preferably at least 10 alleles and most preferably at least 50 alleles (keeping in mind that each somatic cell has two alleles. The analysis of large numbers of individuals to discover variances in the gene sequence between individuals in a population will result in detection of a greater fraction of all the variances in the population. Preferably the process of identifying reveals whether there is a variance within the gene; more preferably identifying reveals the location of the variance within the gene; more preferably identifying provides knowledge of the sequence of the nucleic acid sequence of the

variance, and most preferably identifying provides knowledge of the combination of different variances that comprise specific variant forms of the gene (referred to as alleles). In identifying new variances it is often useful to screen different population groups based on racial, ethnic, gender, and/or geographic origin because particular
5 variances may differ in frequency between such groups. It may also be useful to screen DNA from individuals with a particular disease or condition of interest because they may have a higher frequency of certain variances than the general population.

The process of genotyping involves using diagnostic tests for specific
10 variances that have already been identified. It will be apparent that such diagnostic tests can only be performed after variances and variant forms of the gene have been identified. Identification of new variances can be accomplished by a variety of methods, alone or in combination, including, for example, DNA sequencing, SSCP, heteroduplex analysis, denaturing gradient gel electrophoresis (DGGE),
15 heteroduplex cleavage (either enzymatic as with T4 Endonuclease 7, or chemical as with osmium tetroxide and hydroxylamine), computational methods (described in "VARIANCE SCANNING METHOD FOR IDENTIFYING GENE SEQUENCE VARIANCES" filed October 14, 1999, serial number 09/419,705, and other methods described herein as well as others known to those skilled in the art. (See,
20 for example: Cotton, R.G.H., Slowly but surely towards better scanning for mutations, Trends in Genetics 13(2): 43-6, 1997 or Current Protocols in Human Genetics by N.C. Dracoli, J.L. Haines, B.R. Korf, D.T. Moir, C.C. Morton, C.E. Seidman, D.R. Smith, and A. Boyle (editors), John Wiley & Sons.)

In the context of this invention, the term "analyzing a sequence" refers to
25 determining at least some sequence information about the sequence, , e.g., determining the nucleotides present at a particular site or sites in the sequence, particularly sites that are known to vary in a population, or determining the base sequence of all of a portion of the particular sequence.

In the context of this invention, the term "haplotype" refers to a *cis*
30 arrangement of two or more polymorphic nucleotides, i.e., variances, on a particular chromosome, e.g., in a particular gene. The haplotype preserves information about the phase of the polymorphic nucleotides – that is, which set of variances were inherited from one parent, and which from the other. A genotyping test does not provide information about phase. For example, an individual heterozygous at
35 nucleotide 25 of a gene (both A and C are present) and also at nucleotide 100 (both G and T are present) could have haplotypes 25A – 100G and 25C – 100T, or alternatively 25A – 100T and 25C – 100G. Only a haplotyping test can discriminate these two cases definitively.

09648133 086500

The terms “variances”, “variants” and “polymorphisms”, as used herein, may also refer to a set of variances, haplotypes or a mixture of the two. Further, the term variance, variant or polymorphism (singular), as used herein, also encompasses a haplotype. This usage is intended to minimize the need for cumbersome phrases such as: “...measure correlation between drug response and *a variance, variances, haplotype, haplotypes or a combination of variances and haplotypes...*”, throughout the application. Instead, the italicized text in the foregoing sentence can be represented by the word “variance”, “variant” or “polymorphism”. Similarly, the term genotype, as used herein, means a procedure for determining the status of one or more variances in a gene, including a set of variances comprising a haplotype. Thus phrases such as “...genotype a patient...” refer to determining the status of one or more variances, including a set of variances for which phase is known (i.e. a haplotype).

In preferred embodiments of this invention, the frequency of the variance or variant form of the gene in a population is known. Measures of frequency known in the art include “allele frequency”, namely the fraction of genes in a population that have one specific variance or set of variances. The allele frequencies for any gene should sum to 1. Another measure of frequency known in the art is the “heterozygote frequency” namely, the fraction of individuals in a population who carry two alleles, or two forms of a particular variance or variant form of a gene, one inherited from each parent. Alternatively, the number of individuals who are homozygous for a particular form of a gene may be a useful measure. The relationship between allele frequency, heterozygote frequency, and homozygote frequency is described for many genes by the Hardy-Weinberg equation, which provides the relationship between allele frequency, heterozygote frequency and homozygote frequency in a freely breeding population at equilibrium. Most human variances are substantially in Hardy-Weinberg equilibrium. In a preferred aspect of this invention, the allele frequency, heterozygote frequency, and homozygote frequencies are determined experimentally. Preferably a variance has an allele frequency of at least 0.01, more preferably at least 0.05, still more preferably at least 0.10. However, the allele may have a frequency as low as 0.001 if the associated phenotype is, for example, a rare form of toxic reaction to a treatment or drug. Beneficial responses may also be rare.

In this regard, “population” refers to a defined group of individuals or a group of individuals with a particular disease or condition or individuals that may be treated with a specific drug identified by, but not limited to geographic, ethnic, race, gender, and/or cultural indices. In most cases a population will preferably encompass at least ten thousand, one hundred thousand, one million, ten million, or

more individuals, with the larger numbers being more preferable. In a preferred aspect of this invention, the population refers to individuals with a specific disease or condition that may be treated with a specific drug. In an aspect of this invention, the allele frequency, heterozygote frequency, or homozygote frequency of a specific variance or variant form of a gene is known. In preferred embodiments of this invention, the frequency of one or more variances that may predict response to a treatment is determined in one or more populations using a diagnostic test.

It should be emphasized that it is currently not generally practical to study an entire population to establish the association between a specific disease or condition or response to a treatment and a specific variance or variant form of a gene. Such studies are preferably performed in controlled clinical trials using a limited number of patients that are considered to be representative of the population with the disease. Since drug development programs are generally targeted at the largest possible population, the study population will generally consist of men and women, as well as members of various racial and ethnic groups, depending on where the clinical trial is being performed. This is important to establish the efficacy of the treatment in all segments of the population.

In the context of this invention, the term "probe" refers to a molecule which detectably distinguishes between target molecules differing in structure. Detection can be accomplished in a variety of different ways depending on the type of probe used and the type of target molecule. Thus, for example, detection may be based on discrimination of activity levels of the target molecule, but preferably is based on detection of specific binding. Examples of such specific binding include antibody binding and nucleic acid probe hybridization. Thus, for example, probes can include enzyme substrates, antibodies and antibody fragments, and nucleic acid hybridization probes. Thus, in preferred embodiments, the detection of the presence or absence of the at least one variance involves contacting a nucleic acid sequence which includes a variance site with a probe, preferably a nucleic acid probe, where the probe preferentially hybridizes with a form of the nucleic acid sequence containing a complementary base at the variance site as compared to hybridization to a form of the nucleic acid sequence having a non-complementary base at the variance site, where the hybridization is carried out under selective hybridization conditions. Such a nucleic acid hybridization probe may span two or more variance sites. Unless otherwise specified, a nucleic acid probe can include one or more nucleic acid analogs, labels or other substituents or moieties so long as the base-pairing function is retained.

As is generally understood, administration of a particular treatment, e.g., administration of a therapeutic compound or combination of compounds, is chosen

depending on the disease or condition which is to be treated. Thus, in certain preferred embodiments, the disease or condition is one for which administration of a treatment is expected to provide a therapeutic benefit.

As used herein, the terms "effective" and "effectiveness" includes both pharmacological effectiveness and physiological safety. Pharmacological effectiveness refers to the ability of the treatment to result in a desired biological effect in the patient. Physiological safety refers to the level of toxicity, or other adverse physiological effects at the cellular, organ and/or organism level (often referred to as side-effects) resulting from administration of the treatment. On the other hand, the term "ineffective" indicates that a treatment does not provide sufficient pharmacological effect to be therapeutically useful, even in the absence of deleterious effects, at least in the unstratified population. (Such a treatment may be ineffective in a subgroup that can be identified by the presence of one or more sequence variances or alleles.) "Less effective" means that the treatment results in a therapeutically significant lower level of pharmacological effectiveness and/or a therapeutically greater level of adverse physiological effects, e.g., greater liver toxicity.

Thus, in connection with the administration of a drug, a drug which is "effective against" a disease or condition indicates that administration in a clinically appropriate manner results in a beneficial effect for at least a statistically significant fraction of patients, such as a improvement of symptoms, a cure, a reduction in disease load, reduction in tumor mass or cell numbers, extension of life, improvement in quality of life, or other effect generally recognized as positive by medical doctors familiar with treating the particular type of disease or condition.

Effectiveness is measured in a particular population. In conventional drug development the population is generally every subject who meets the enrollment criteria (i.e. has the particular form of the disease or condition being treated). It is an aspect of the present invention that segmentation of a study population by genetic criteria can provide the basis for identifying a subpopulation in which a drug is effective against the disease or condition being treated.

The term "deleterious effects" refers to physical effects in a patient caused by administration of a treatment which are regarded as medically undesirable. Thus, for example, deleterious effects can include a wide spectrum of toxic effects injurious to health such as death of normally functioning cells when only death of diseased cells is desired, nausea, fever, inability to retain food, dehydration, damage to critical organs such as arrhythmias, renal tubular necrosis, fatty liver, or pulmonary fibrosis leading to coronary, renal, hepatic, or pulmonary insufficiency among many others. In this regard, the term "adverse reactions" refers to those manifestations of

clinical symptomology of pathological disorder or dysfunction is induced by administration or a drug, agent, or candidate therapeutic intervention. In this regard, the term “contraindicated” means that a treatment results in deleterious effects such that a prudent medical doctor treating such a patient would regard the treatment as unsuitable for administration. Major factors in such a determination can include, for example, availability and relative advantages of alternative treatments, consequences of non-treatment, and permanency of deleterious effects of the treatment.

It is recognized that many treatment methods, e.g., administration of certain compounds or combinations of compounds, may produce side-effects or other deleterious effects in patients. Such effects can limit or even preclude use of the treatment method in particular patients, or may even result in irreversible injury, disorder, dysfunction, or death of the patient. Thus, in certain embodiments, the variance information is used to select both a first method of treatment and a second method of treatment. Usually the first treatment is a primary treatment which provides a physiological effect directed against the disease or condition or its symptoms. The second method is directed to reducing or eliminating one or more deleterious effects of the first treatment, e.g., to reduce a general toxicity or to reduce a side effect of the primary treatment. Thus, for example, the second method can be used to allow use of a greater dose or duration of the first treatment, or to allow use of the first treatment in patients for whom the first treatment would not be tolerated or would be contra-indicated in the absence of a second method to reduce deleterious effects or to potentiate the effectiveness of the first treatment.

In a related aspect, the invention provides a method for selecting a method of treatment for a patient suffering from a disease or condition by comparing at least one variance in at least one gene in the patient, with a list of variances in the gene from Tables 1 and 3, or other gene related to pharmacokinetic parameters, or organ and tissue damage, or inordinate immune response, which are indicative of the effectiveness or safety of at least one method of treatment. Preferably the comparison involves a plurality of variances or a haplotype indicative of the effectiveness of at least one method of treatment. Also, preferably the list of variances includes a plurality of variances.

Similar to the above aspect, in preferred embodiments the at least one method of treatment involves the administration of a compound effective in at least some patients with a disease or condition; the presence or absence of the at least one variance is indicative that the treatment will be effective in the patient; and/or the presence or absence of the at least one variance is indicative that the treatment will be ineffective or contra-indicated in the patient; and/or the treatment is a first treatment and the presence or absence of the at least one variance is indicative that a

second treatment will be beneficial to reduce a deleterious effect or potentiate the effectiveness of the first treatment; and/or the at least one treatment is a plurality of methods of treatment. For a plurality of treatments, preferably the selecting involves determining whether any of the methods of treatment will be more effective than at least one other of the plurality of methods of treatment. Yet other embodiments are provided as described for the preceding aspect in connection with methods of treatment using administration of a compound; treatment of various diseases, and variances in particular genes.

In the context of variance information in the methods of this invention, the term "list" refers to one or more variances which have been identified for a gene of potential importance in accounting for inter-individual variation in treatment response. Preferably there is a plurality of variances for the gene, preferably a plurality of variances for the particular gene. Preferably, the list is recorded in written or electronic form. For example, identified variances of identified genes are recorded for some of the genes in Table 3, additional variances for genes in Table 1 are provided in Table 1 of Stanton & Adams, application number 09/300,747, *supra*, and additional gene variance identification tables are provided in a form which allows comparison with other variance information. The possible additional variances in the identified genes are provided in Table 3 in Stanton & Adams, application number 09/300,747, *supra*.

In addition to the basic method of treatment, often the mode of administration of a given compound as a treatment for a disease or condition in a patient is significant in determining the course and/or outcome of the treatment for the patient. Thus, the invention also provides a method for selecting a method of administration of a compound to a patient suffering from a disease or condition, by determining the presence or absence of at least one variance in cells of the patient in at least one identified gene from Tables 1 and 3, where such presence or absence is indicative of an appropriate method of administration of the compound. Preferably, the selection of a method of treatment (a treatment regimen) involves selecting a dosage level or frequency of administration or route of administration of the compound or combinations of those parameters. In preferred embodiments, two or more compounds are to be administered, and the selecting involves selecting a method of administration for one, two, or more than two of the compounds, jointly, concurrently, or separately. As understood by those skilled in the art, such plurality of compounds may be used in combination therapy, and thus may be formulated in a single drug, or may be separate drugs administered concurrently, serially, or separately. Other embodiments are as indicated above for selection of second

treatment methods, methods of identifying variances, and methods of treatment as described for aspects above.

In another aspect, the invention provides a method for selecting a patient for administration of a method of treatment for a disease or condition, or of selecting a patient for a method of administration of a treatment, by comparing the presence or absence of at least one variance in a gene as identified above in cells of a patient, with a list of variances in the gene, where the presence or absence of the at least one variance is indicative that the treatment or method of administration will be effective in the patient. If the at least one variance is present in the patient's cells, then the patient is selected for administration of the treatment.

In preferred embodiments, the disease or the method of treatment is as described in aspects above, specifically including, for example, those described for selecting a method of treatment.

In another aspect, the invention provides a method for identifying a subset of patients with enhanced or diminished response or tolerance to a treatment method or a method of administration of a treatment where the treatment is for a disease or condition in the patient. The method involves correlating one or more variances in one or more genes as identified in aspects above in a plurality of patients with response to a treatment or a method of administration of a treatment. The correlation may be performed by determining the one or more variances in the one or more genes in the plurality of patients and correlating the presence or absence of each of the variances (alone or in various combinations) with the patient's response to treatment. The variances may be previously known to exist or may also be determined in the present method or combinations of prior information and newly determined information may be used. The enhanced or diminished response should be statistically significant, preferably such that $p = 0.10$ or less, more preferably 0.05 or less, and most preferably 0.02 or less. A positive correlation between the presence of one or more variances and an enhanced response to treatment is indicative that the treatment is particularly effective in the group of patients having those variances. A positive correlation of the presence of the one or more variances with a diminished response to the treatment is indicative that the treatment will be less effective in the group of patients having those variances. Such information is useful, for example, for selecting or de-selecting patients for a particular treatment or method of administration of a treatment, or for demonstrating that a group of patients exists for which the treatment or method of treatment would be particularly beneficial or contra-indicated. Such demonstration can be beneficial, for example, for obtaining government regulatory approval for a new drug or a new use of a drug

In preferred embodiments, the variances are in at least one of the identified genes listed in Tables 1 and 3, or are particular variances described herein. Also, preferred embodiments include drugs, treatments, variance identification or determination, determination of effectiveness, and/or diseases as described for aspects above or otherwise described herein.

In preferred embodiments, the correlation of patient responses to therapy according to patient genotype is carried out in a clinical trial, e.g., as described herein according to any of the variations described. Detailed description of methods for associating variances with clinical outcomes using clinical trials are provided below. Further, in preferred embodiments the correlation of pharmacological effect (positive or negative) to treatment response according to genotype or haplotype in such a clinical trial is part of a regulatory submission to a government agency leading to approval of the drug. Most preferably the compound or compounds would not be approvable in the absence of the genetic information allowing identification of an optimal responder population.

As indicated above, in aspects of this invention involving selection of a patient for a treatment, selection of a method or mode of administration of a treatment, and selection of a patient for a treatment or a method of treatment, the selection may be positive selection or negative selection. Thus, the methods can include eliminating a treatment for a patient, eliminating a method or mode of administration of a treatment to a patient, or elimination of a patient for a treatment or method of treatment.

Also, in methods involving identification and/or comparison of variances present in a gene of a patient, the methods can involve such identification or comparison for a plurality of genes. Preferably, the genes are functionally related to the same disease or condition, or to the aspect of disease pathophysiology that is being subjected to pharmacological manipulation by the treatment (e.g., a drug), or to the activation or inactivation or elimination of the drug, and more preferably the genes are involved in the same biochemical process or pathway.

In another aspect, the invention provides a method for identifying the forms of a gene in an individual, where the gene is one specified as for aspects above, by determining the presence or absence of at least one variance in the gene. In preferred embodiments, the at least one variance includes at least one variance selected from the group of variances identified in variance tables herein. Preferably, the presence or absence of the at least one variance is indicative of the effectiveness of a therapeutic treatment in a patient suffering from a disease or condition and having cells containing the at least one variance.

The presence or absence of the variances can be determined in any of a variety of ways as recognized by those skilled in the art. For example, the nucleotide sequence of at least one nucleic acid sequence which includes at least one variance site (or a complementary sequence) can be determined, such as by chain termination methods, hybridization methods or by mass spectrometric methods. Likewise, in preferred embodiments, the determining involves contacting a nucleic acid sequence or a gene product of one of one of the genes with a probe which specifically identifies the presence or absence of a form of the gene. For example, a probe, e.g., a nucleic acid probe, can be used which specifically binds, e.g., hybridizes, to a nucleic acid sequence corresponding to a portion of the gene and which includes at least one variance site under selective binding conditions. As described for other aspects, determining the presence or absence of at least two variances and their relationship on the two gene copies present in a patient can constitute determining a haplotype or haplotypes.

Other preferred embodiments involve variances related to types of treatment, drug responses, diseases, nucleic acid sequences, and other items related to variances and variance determination as described for aspects above.

In yet another aspect, the invention provides a pharmaceutical composition which includes a compound which has a differential effect in patients having at least one copy, or alternatively, two copies of a form of a gene as identified for aspects above and a pharmaceutically acceptable carrier, excipient, or diluent. The composition is adapted to be preferentially effective to treat a patient with cells containing the one, two, or more copies of the form of the gene.

In preferred embodiments of aspects involving pharmaceutical compositions, active compounds, or drugs, the material is subject to a regulatory limitation, restriction, or recommendation on approved uses or indications, e.g., by the U.S. Food and Drug Administration (FDA), limiting or recommending limiting approved use of the composition to patients having at least one copy of the particular form of the gene which contains at least one variance. Alternatively, the composition is subject to a regulatory limitation, restriction, or recommendation on approved uses indicating or recommending that the composition is not approved for use or should not be used in patients having at least one copy of a form of the gene including at least one variance. Also in preferred embodiments, the composition is packaged, and the packaging includes a label or insert indicating or suggesting beneficial therapeutic approved use of the composition in patients having one or two copies of a form of the gene including at least one variance. Alternatively, the label or insert limits or recommends limiting approved use of the composition to patients having zero or one or two copies of a form of the gene including at least one

variance. The latter embodiment would be likely where the presence of the at least one variance in one or two copies in cells of a patient means that the composition would be ineffective or deleterious to the patient. Also in preferred embodiments, the composition is indicated for use in treatment of a disease or condition that is one of those identified for aspects above. Also in preferred embodiments, the at least one variance includes at least one variance from those identified herein.

The term “packaged” means that the drug, compound, or composition is prepared in a manner suitable for distribution or shipping with a box, vial, pouch, bubble pack, or other protective container, which may also be used in combination. The packaging may have printing on it and/or printed material may be included in the packaging.

In preferred embodiments, the drug is selected from the drug classes or specific exemplary drugs identified in an example, in a table herein, and is subject to a regulatory limitation or suggestion or warning as described above that limits or suggests limiting approved use to patients having specific variances or variant forms of a gene identified in Examples or in the gene list provided below in order to achieve maximal benefit and avoid toxicity or other deleterious effect.

A pharmaceutical composition can be adapted to be preferentially effective in a variety of ways. In some cases, an active compound is selected which was not previously known to be differentially active, or which was not previously recognized as a therapeutic compound. Alternatively the compound was previously known as a therapeutic compound, but the composition is formulated in a manner appropriate for administration for treatment of a disease or condition for which a gene of this invention is involved in treatment response, and the active compound had not been formulated appropriately for such use before. For example, a compound may previously have been formulated for topical treatment of a skin condition, but is found to be effective in IV or other internal treatment of a disease identified for this invention. For compounds that are differentially effective on the gene, such alternative formulations are adapted to be preferentially effective. In some cases, the concentration of an active compound which has differential activity can be adjusted such that the composition is appropriate for administration to a patient with the specified variances. For example, the presence of a specified variance may allow or require the administration of a much larger dose, which would not be practical with a previously utilized composition. Conversely, a patient may require a much lower dose, such that administration of such a dose with a prior composition would be impractical or inaccurate. Thus, the composition may be prepared in a higher or lower unit dose form, or prepared in a higher or lower concentration of the active compound or compounds. In yet other cases, the composition can include

additional compounds useful to enable administration of a particular active compound in a patient with the specified variances, which was not in previous compositions, e.g., because the majority of patients did not require or benefit from the added component.

5 The term “differential” or “differentially” generally refers to a statistically significant different level in the specified property or effect. Preferably, the difference is also functionally significant. Thus, “differential binding or hybridization” is sufficient difference in binding or hybridization to allow discrimination using an appropriate detection technique. Likewise, “differential effect” or “differentially active” in connection with a therapeutic treatment or drug
10 refers to a difference in the level of the effect or activity which is distinguishable using relevant parameters and techniques for measuring the effect or activity being considered. Preferably the difference in effect or activity is also sufficient to be clinically significant, such that a corresponding difference in the course of treatment or treatment outcome would be expected, at least on a statistical basis.

15 Also usefully provided in the present invention are probes which specifically recognize a nucleic acid sequence corresponding to a variance or variances in a gene as identified in aspects above or a product expressed from the gene, and are able to distinguish a variant form of the sequence or gene or gene product from one or more
20 other variant forms of that sequence, gene, or gene product under selective conditions. Those skilled in the art recognize and understand the identification or determination of selective conditions for particular probes or types of probes. An exemplary type of probe is a nucleic acid hybridization probe, which will selectively bind under selective binding conditions to a nucleic acid sequence or a gene product
25 corresponding to one of the genes identified for aspects above. Another type of probe is a peptide or protein, e.g., an antibody or antibody fragment which specifically or preferentially binds to a polypeptide expressed from a particular form of a gene as characterized by the presence or absence of at least one variance. Thus, in another aspect, the invention concerns such probes. In the context of this
30 invention, a “probe” is a molecule, commonly a nucleic acid, though also potentially a protein, carbohydrate, polymer, or small molecule, that is capable of binding to one variance or variant form of the gene to a greater extent than to a form of the gene having a different base at one or more variance sites, such that the presence of the variance or variant form of the gene can be determined. Preferably the probe
35 distinguishes at least one variance identified in Examples, tables or lists below or in Tables 1 or 3 of Stanton & Adams application number 09/300,747.

 In preferred embodiments, the probe is a nucleic acid probe
6,7,8,9,10,11,12,13,14, or 15, preferably at least 17 nucleotides in length, more

preferably at least 20 or 22 or 25, preferably 500 or fewer nucleotides in length, more preferably 200 or 100 or fewer, still more preferably 50 or fewer, and most preferably 30 or fewer. In preferred embodiments, the probe has a length in a range from any one of the above lengths to any other of the above lengths (including endpoints). The probe specifically hybridizes under selective hybridization conditions to a nucleic acid sequence corresponding to a portion of one of the genes identified in connection with above aspects. The nucleic acid sequence includes at least one and preferably two or more variance sites. Also in preferred embodiments, the probe has a detectable label, preferably a fluorescent label. A variety of other detectable labels are known to those skilled in the art. Such a nucleic acid probe can also include one or more nucleic acid analogs.

In preferred embodiments, the probe is an antibody or antibody fragment which specifically binds to a gene product expressed from a form of one of the above genes, where the form of the gene has at least one specific variance with a particular base at the variance site, and preferably a plurality of such variances.

In connection with nucleic acid probe hybridization, the term “specifically hybridizes” indicates that the probe hybridizes to a sufficiently greater degree to the target sequence than to a sequence having a mismatched base at least one variance site to allow distinguishing such hybridization. The term “specifically hybridizes” thus means that the probe hybridizes to the target sequence, and not to non-target sequences, at a level which allows ready identification of probe/target sequence hybridization under selective hybridization conditions. Thus, “selective hybridization conditions” refer to conditions which allow such differential binding. Similarly, the terms “specifically binds” and “selective binding conditions” refer to such differential binding of any type of probe, e.g., antibody probes, and to the conditions which allow such differential binding. Typically hybridization reactions to determine the status of variant sites in patient samples are carried out with two different probes, one specific for each of the (usually two) possible variant nucleotides. The complementary information derived from the two separate hybridization reactions is useful in corroborating the results.

Likewise, the invention provides an isolated, purified or enriched nucleic acid sequence of 15 to 500 nucleotides in length, preferably 15 to 100 nucleotides in length, more preferably 15 to 50 nucleotides in length, and most preferably 15 to 30 nucleotides in length, which has a sequence which corresponds to a portion of one of the genes identified for aspects above. Preferably the lower limit for the preceding ranges is 17, 20, 22, or 25 nucleotides in length. In other embodiments, the nucleic acid sequence is 30 to 300 nucleotides in length, or 45 to 200 nucleotides in length, or 45 to 100 nucleotides in length. The nucleic acid sequence includes at least one

variance site. Such sequences can, for example, be amplification products of a sequence which spans or includes a variance site in a gene identified herein. Likewise, such a sequence can be a primer, or amplification oligonucleotide which is able to bind to or extend through a variance site in such a gene. Yet another
5 example is a nucleic acid hybridization probe comprised of such a sequence. In such probes, primers, and amplification products, the nucleotide sequence can contain a sequence or site corresponding to a variance site or sites, for example, a variance site identified herein. Preferably the presence or absence of a particular variant form in the heterozygous or homozygous state is indicative of the
10 effectiveness of a method of treatment in a patient.

Likewise, the invention provides a set of primers or amplification oligonucleotides (e.g., 2,3,4,6,8,10 or even more) adapted for binding to or extending through at least one gene identified herein. In preferred embodiments the set includes primers or amplification oligonucleotides adapted to bind to or extend
15 through a plurality of sequence variances in a gene(s) identified herein. The plurality of variances preferably provides a haplotype. Those skilled in the art are familiar with the use of amplification oligonucleotides (e.g., PCR primers) and the appropriate location, testing and use of such oligonucleotides. In certain embodiments, the oligonucleotides are designed and selected to provide variance-specific amplification.
20

In reference to nucleic acid sequences which "correspond" to a gene, the term "correspond" refers to a nucleotide sequence relationship, such that the nucleotide sequence has a nucleotide sequence which is the same as the reference gene or an indicated portion thereof, or has a nucleotide sequence which is exactly
25 complementary in normal Watson-Crick base pairing, or is an RNA equivalent of such a sequence, e.g., an mRNA, or is a cDNA derived from an mRNA of the gene.

In another aspect, the invention provides a kit containing at least one probe or at least one primer (or other amplification oligonucleotide) or both (e.g., as described
30 above) corresponding to a gene or genes listed in Tables 1 and 3 or other gene related to a drug-induced disease or condition, or other gene involved in absorption, distribution, metabolism, excretion, or in toxicity-related modification of a drug. The kit is preferably adapted and configured to be suitable for identification of the presence or absence of a particular variance or variances, which can include or consist of a nucleic acid sequence
35 corresponding to a portion of a gene. A plurality of variances may comprise a haplotype of haplotypes. The kit may also contain a plurality of either or both of such probes and/or primers, e.g., 2, 3, 4, 5, 6, or more of such probes and/or primers. Preferably the plurality of probes and/or primers are adapted to provide detection of a plurality of different

sequence variances in a gene or plurality of genes, e.g., in 2, 3, 4, 5, or more genes or to amplify and/or sequence a nucleic acid sequence including at least one variance site in a gene or genes. Preferably one or more of the variance or variances to be detected are correlated with variability in a treatment response or tolerance, and are preferably indicative of an effective response to a treatment. In preferred embodiments, the kit contains components (e.g., probes and/or primers) adapted or useful for detection of a plurality of variances (which may be in one or more genes) indicative of the effectiveness of at least one treatment, preferably of a plurality of different treatments for a particular disease or condition. It may also be desirable to provide a kit containing components adapted or useful to allow detection of a plurality of variances indicative of the effectiveness of a treatment or treatment against a plurality of diseases. The kit may also optionally contain other components, preferably other components adapted for identifying the presence of a particular variance or variances. Such additional components can, for example, independently include a buffer or buffers, e.g., amplification buffers and hybridization buffers, which may be in liquid or dry form, a DNA polymerase, e.g., a polymerase suitable for carrying out PCR (e.g., a thermostable DNA polymerase), and deoxy nucleotide triphosphates (dNTPs). Preferably a probe includes a detectable label, e.g., a fluorescent label, enzyme label, light scattering label, or other label. Preferably the kit includes a nucleic acid or polypeptide array on a solid phase substrate. The array may, for example, include a plurality of different antibodies, and/or a plurality of different nucleic acid sequences. Sites in the array can allow capture and/or detection of nucleic acid sequences or gene products corresponding to different variances in one or more different genes. Preferably the array is arranged to provide variance detection for a plurality of variances in one or more genes which correlate with the effectiveness of one or more treatments of one or more diseases, which is preferably a variance as described herein.

The kit may also optionally contain instructions for use, which can include a listing of the variances correlating with a particular treatment or treatments for a disease or diseases and/or a statement or listing of the diseases for which a particular variance or variances correlates with a treatment efficacy and/or safety.

Preferably the kit components are selected to allow detection of a variance described herein, and/or detection of a variance indicative of a treatment, e.g., administration of a drug, pointed out herein.

Additional configurations for kits of this invention will be apparent to those skilled in the art.

The invention also includes the use of such a kit to determine the genotype(s) of one or more individuals with respect to one or more variance sites in one or more genes identified herein. Such use can include providing a result or report indicating the

presence and/or absence of one or more variant forms or a gene or genes which are indicative of the effectiveness of a treatment or treatments.

In another aspect, the invention provides a method for determining a genotype of an individual in relation to one or more variances in one or more of the genes identified in above aspects by using mass spectrometric determination of a nucleic acid sequence which is a portion of a gene identified for other aspects of this invention or a complementary sequence. Such mass spectrometric methods are known to those skilled in the art. In preferred embodiments, the method involves determining the presence or absence of a variance in a gene; determining the nucleotide sequence of the nucleic acid sequence; the nucleotide sequence is 100 nucleotides or less in length, preferably 50 or less, more preferably 30 or less, and still more preferably 20 nucleotides or less. In general, such a nucleotide sequence includes at least one variance site, preferably a variance site which is informative with respect to the expected response of a patient to a treatment as described for above aspects.

As indicated above, many therapeutic compounds or combinations of compounds or pharmaceutical compositions show variable efficacy and/or safety in various patients in whom the compound or compounds is administered. Thus, it is beneficial to identify variances in relevant genes, e.g., genes related to the action or toxicity of the compound or compounds. Thus, in a further aspect, the invention provides a method for determining whether a compound has a differential effect due to the presence or absence of at least one variance in a gene or a variant form of a gene, where the gene is a gene identified for aspects above.

The method involves identifying a first patient or set of patients suffering from a disease or condition whose response to a treatment differs from the response (to the same treatment) of a second patient or set of patients suffering from the same disease or condition, and then determining whether the occurrence or frequency of occurrence of at least one variance in at least one gene differs between the first patient or set of patients and the second patient or set of patients. A correlation between the presence or absence of the variance or variances and the response of the patient or patients to the treatment indicates that the variance provides information about variable patient response. In general, the method will involve identifying at least one variance in at least one gene. An alternative approach is to identify a first patient or set of patients suffering from a disease or condition and having a particular genotype, haplotype or combination of genotypes or haplotypes, and a second patient or set of patients suffering from the same disease or condition that have a genotype or haplotype or sets of genotypes or haplotypes that differ in a specific way from those of the first set of patients. Subsequently the extent and

005230 "EAT 84950"
5 magnitude of clinical response can be compared between the first patient or set of patients and the second patient or set of patients. A correlation between the presence or absence of a variance or variances or haplotypes and the response of the patient or patients to the treatment indicates that the variance provides information about variable patient response and is useful for the present invention.

10 The method can utilize a variety of different informative comparisons to identify correlations. For example a plurality of pairwise comparisons of treatment response and the presence or absence of at least one variance can be performed for a plurality of patients. Likewise, the method can involve comparing the response of at least one patient homozygous for at least one variance with at least one patient homozygous for the alternative form of that variance or variances. The method can also involve comparing the response of at least one patient heterozygous for at least one variance with the response of at least one patient homozygous for the at least one variance. Preferably the heterozygous patient response is compared to both
15 alternative homozygous forms, or the response of heterozygous patients is grouped with the response of one class of homozygous patients and said group is compared to the response of the alternative homozygous group.

20 Such methods can utilize either retrospective or prospective information concerning treatment response variability. Thus, in a preferred embodiment, it is previously known that patient response to the method of treatment is variable.

Also in preferred embodiments, the disease or condition is as for other aspects of this invention; for example, the treatment involves administration of a compound or pharmaceutical composition.

25 In preferred embodiments, the method involves a clinical trial, e.g., as described herein. Such a trial can be arranged, for example, in any of the ways described herein, e.g., in the Detailed Description.

30 The present invention also provides methods of treatment of a disease or condition, preferably a disease or condition related to pharmacokinetic parameters, e.g. absorption, distribution, metabolism, or excretion, that affect a drug or candidate therapeutic intervention regarding efficacy and or safety, i.e. drug-induced disease, disorder or dysfunction or other toxicity effects or clinical symptomatology. Such methods combine identification of the presence or absence of particular variances, preferably in a gene or genes from Tables 1 and 3, with the administration of a compound; identification of the presence of particular variances with selection of a
35 method of treatment and administration of the treatment; and identification of the presence or absence of particular variances with elimination of a method of treatment based on the variance information indicating that the treatment is likely to be ineffective or contra-indicated, and thus selecting and administering an

alternative treatment effective against the disease or condition. Thus, preferred embodiments of these methods incorporate preferred embodiments of such methods as described for such sub-aspects.

As used herein, a "gene" is a sequence of DNA present in a cell that directs the expression of a "biologically active" molecule or "gene product", most commonly by transcription to produce RNA and translation to produce protein. The "gene product" is most commonly a RNA molecule or protein or a RNA or protein that is subsequently modified by reacting with, or combining with, other constituents of the cell. Such modifications may include, without limitation, modification of proteins to form glycoproteins, lipoproteins, and phosphoproteins, or other modifications known in the art. RNA may be modified without limitation by polyadenylation, splicing, capping or export from the nucleus or by covalent or noncovalent interactions with proteins. The term "gene product" refers to any product directly resulting from transcription of a gene. In particular this includes partial, precursor, and mature transcription products (i.e., pre-mRNA and mRNA), and translation products with or without further processing including, without limitation, lipidation, phosphorylation, glycosylation, or combinations of such processing

The term "gene involved in the origin or pathogenesis of a disease or condition" refers to a gene that harbors mutations or polymorphisms that contribute to the cause of disease, or variances that affect the progression of the disease or expression of specific characteristics of the disease. The term also applies to genes involved in the synthesis, accumulation, or elimination of products that are involved in the origin or pathogenesis of a disease or condition including, without limitation, proteins, lipids, carbohydrates, hormones, or small molecules.

The term "gene involved in the action of a drug" refers to any gene whose gene product affects the efficacy or safety of the drug or affects the disease process being treated by the drug, and includes, without limitation, genes that encode gene products that are targets for drug action, gene products that are involved in the metabolism, activation or degradation of the drug, gene products that are involved in the bioavailability or elimination of the drug to the target, gene products that affect biological pathways that, in turn, affect the action of the drug such as the synthesis or degradation of competitive substrates or allosteric effectors or rate-limiting reaction, or, alternatively, gene products that affect the pathophysiology of the disease process via pathways related or unrelated to those altered by the presence of the drug compound. (Particular variances in the latter category of genes may be associated with patient groups in whom disease etiology is more or less susceptible to amelioration by the drug. For example, there are several pathophysiological

mechanisms in hypertension, and depending on the dominant mechanism in a given patient, that patient may be more or less likely than the average hypertensive patient to respond to a drug that primarily targets one pathophysiological mechanism. The relative importance of different pathophysiological mechanisms in individual

5 patients is likely to be affected by variances in genes associated with the disease pathophysiology.) The "action" of a drug refers to its effect on biological products within the body. The action of a drug also refers to its effects on the signs or symptoms of a disease or condition, or effects of the drug that are unrelated to the disease or condition leading to unanticipated effects on other processes. Such

10 unanticipated processes often lead to adverse events or toxic effects. The terms "adverse event" or "toxic" event" are known in the art and include, without limitation, those listed in the FDA reference system for adverse events.

In accordance with the aspects above and the Detailed Description below, there is also described for this invention an approach for developing drugs that are

15 explicitly indicated for, and/or for which approved use is restricted to individuals in the population with specific variances or combinations of variances, as determined by diagnostic tests for variances or variant forms of certain genes involved in the disease or condition or involved in the action or metabolism or transport of the drug. Such drugs may provide more effective treatment for a disease or condition in a

20 population identified or characterized with the use of a diagnostic test for a specific variance or variant form of the gene if the gene is involved in the action of the drug or in determining a characteristic of the disease or condition. Such drugs may be developed using the diagnostic tests for specific variances or variant forms of a gene to determine the inclusion of patients in a clinical trial.

Thus, the invention also provides a method for producing a pharmaceutical composition by identifying a compound which has differential activity or effectiveness against a disease or condition in patients having at least one variance in a gene, preferably in a gene from Tables 1 and 3, compounding the pharmaceutical composition by combining the compound with a pharmaceutically acceptable

30 carrier, excipient, or diluent such that the composition is preferentially effective in patients who have at least one copy of the variance or variances. In some cases, the patient has two copies of the variance or variances. In preferred embodiments, the disease or condition, gene or genes, variances, methods of administration, or method of determining the presence or absence of variances is as described for other aspects

35 of this invention.

Similarly, the invention provides a method for producing a pharmaceutical agent by identifying a compound which has differential activity against a disease or condition in patients having at least one copy of a form of a gene, preferably a gene

listed in Table 1, having at least one variance and synthesizing the compound in an amount sufficient to provide a pharmaceutical effect in a patient suffering from the disease or condition. The compound can be identified by conventional screening methods and its activity confirmed. For example, compound libraries can be
5 screened to identify compounds which differentially bind to products of variant forms of a particular gene product, or which differentially affect expression of variant forms of the particular gene, or which differentially affect the activity of a product expressed from such gene. Alternatively, the design of a compound can exploit knowledge of the variances provided herein to avoid significant allele
10 specific effects, in order to reduce the likelihood of significant pharmacogenetic effects during the clinical development process. Preferred embodiments are as for the preceding aspect.

In another aspect, the invention provides a method of treating a disease or condition in a patient by selecting a patient whose cells have an allele of an
15 identified gene, preferably a gene selected from the genes listed in Table 1, and determining whether that alteration provides a differential effect (with respect to reducing or alleviating a disease or condition, or with respect to variation in toxicity or tolerance to a treatment) in patients with at least one copy of at least one allele of the gene as compared to patients with at least one copy of one alternative allele.,
20 The presence of such a differential effect indicates that altering the level or activity of the gene provides at least part of an effective treatment for the disease or condition.

Preferably the allele contains a variance as shown in Table 3 or other variance table herein, or in Table 1 or 3 of Stanton & Adams, application number
25 09/300,747, *supra*. Also preferably, the altering involves administering to the patient a compound preferentially active on at least one but less than all alleles of the gene.

Preferred embodiments include those as described above for other aspects of treating a disease or condition.

30 As recognized by those skilled in the art, all the methods of treating described herein include administration of the treatment to a patient.

In a further aspect, the invention provides a method for determining a method of treatment effective to treat a disease or condition by altering the level of activity of a product of an allele of a gene selected from the genes listed in Tables 1
35 and 3, and determining whether that alteration provides a differential effect related to reducing or alleviating a disease or condition as compared to at least one alternative allele or an alteration in toxicity or tolerance of the treatment by a patient or patients. The presence of such a differential effect indicates that altering that

level of activity provides at least part of an effective treatment for the disease or condition.

Preferably the method for determining a method of treatment is carried out in a clinical trial, e.g., as described above and/or in the Detailed Description below.

5 In still another aspect, the invention provides a method for evaluating differential efficacy of or tolerance to a treatment in a subset of patients who have a particular variance or variances in at least one gene, preferably a gene in Tables 1 and 3, by utilizing a clinical trial. In preferred embodiments, the clinical trial is a Phase I, II, III, or IV trial. Preferred embodiments include the stratifications and/or
10 statistical analyses as described below in the Detailed Description.

In yet another aspect, the invention provides experimental methods for finding additional variances in a gene provided in Table 3. A number of experimental methods can also beneficially be used to identify variances. Thus, the invention provides methods for producing cDNA (Example 12) and detecting
15 additional variances in the genes provided in Tables 1 and 2 using the single strand conformation polymorphism (SSCP) method (Example 13), the T4 Endonuclease VII method (Example 14) or DNA sequencing (Example 15) or other methods pointed out below. The application of these methods to the identified genes will provide identification of additional variances that can affect inter-individual
20 variation in drug or other treatment response. One skilled in the art will recognize that many methods for experimental variance detection have been described (in addition to the exemplary methods of examples 13, 14, and 15) which can be utilized. These additional methods include chemical cleavage of mismatches (see, e.g., Ellis TP, et al., Chemical cleavage of mismatch: a new look at an established
25 method. Human Mutation 11(5):345-53, 1998), denaturing gradient gel electrophoresis (see, e.g., Van Orsouw NJ, et al., Design and application of 2-D DGGE-based gene mutational scanning tests. Genet Anal. 14(5-6):205-13, 1999) and heteroduplex analysis (see, e.g., Ganguly A, et al., Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded
30 PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci U S A. 90 (21):10325-9, 1993). Table 3 of Stanton & Adams, application number 09/300,747, *supra*, provides a description of the additional possible variances that could be detected by one skilled in the art by testing an identified gene in Tables 1 and 2 using the variance detection methods
35 described or other methods which are known or are developed.

The present invention provides a method for treating a patient at risk for drug responsiveness, i.e., efficacy differences associated with pharmacokinetic parameters, and safety concerns, i.e. drug-induced disease, disorder, or dysfunction

or diagnosed with organ failure or a disease associated with drug-induced organ failure. The methods include identifying such a patient and determining the patient's genotype or haplotype for an identified gene or genes. The patient identification can, for example, be based on clinical evaluation using conventional clinical metrics and/or evaluation of a genetic variance or variances in one or more genes, preferably a gene or genes from Tables 1 and 3. The invention provides a method for using the patient's genotype status to determine a treatment protocol which includes a prediction of the efficacy and safety of a therapy for concurrent treatment in light of drug-induced disease or an drug-induced or drug associated pathological condition. In a related aspect, the invention features a treatment protocol that provides a prediction of patient outcome. Such predictions are based on a demonstrated correlation between a particular type of treatment and outcome, efficacy, safety, likelihood of development of drug-induced disease, disorder, or dysfunction, or other such parameter relevant to clinical treatment decisions as evaluated by a normal prudent physician.

In an another related aspect, the invention provides a method for identifying a patient for participation in a clinical trial of a therapy for the treatment of drug-induced disease, disorder, or dysfunction, or an associated drug-induced toxicity. The method involves determining the genotype or haplotype of a patient with (or at risk for) a drug-induced disease, disorder, or dysfunction. Preferably the genotype is for a variance in a gene from Table 1. Patients with eligible genotypes are then assigned to a treatment or placebo group, preferably by a blinded randomization procedure. In preferred embodiments, the selected patients have no copies, one copy or two copies of a specific allele of a gene or genes identified in Table 1. Alternatively, patients selected for the clinical trial may have zero, one or two copies of an allele belonging to a set of alleles, where the set of alleles comprise a group of related alleles. One procedure for rigorously defining a set of alleles is by applying phylogenetic methods to the analysis of haplotypes. (See, for example: Templeton A.R., Crandall K.A. and C.F. Sing A cladistic analysis of phenotypic associations with haplotypes inferred from restriction endonuclease mapping and DNA sequence data. III. Cladogram estimation. *Genetics* 1992 Oct;132(2):619-33.) Regardless of the specific tools used to group alleles, the trial would then test the hypothesis that a statistically significant difference in response to a treatment can be demonstrated between two groups of patients each defined by the presence of zero, one or two alleles (or allele groups) at a gene or genes. Said response may be a desired or an undesired response. In a preferred embodiment, the treatment protocol involves a comparison of placebo vs. treatment response rates in two or more genotype-defined groups. For example a group with no copies of an allele may be compared to a

group with two copies, or a group with no copies may be compared to a group consisting of those with one or two copies. In this manner different genetic models (dominant, co-dominant, recessive) for the transmission of a treatment response trait can be tested. Alternatively, statistical methods that do not posit a specific genetic model, such as contingency tables, can be used to measure the effects of an allele on treatment response.

In another preferred embodiment, patients in a clinical trial can be grouped (at the end of the trial) according to treatment response, and statistical methods can be used to compare allele (or genotype or haplotype) frequencies in two groups. For example responders can be compared to nonresponders, or patients suffering adverse events can be compared to those not experiencing such effects. Alternatively response data can be treated as a continuous variable and the ability of genotype to predict response can be measured. In a preferred embodiments patients who exhibit extreme phenotypes are compared with all other patients or with a group of patients who exhibit a divergent extreme phenotype. For example if there is a continuous or semi-continuous measure of treatment response (for example the Alzheimer's Disease Assessment Scale, the Mini-Mental State Examination or the Hamilton Depression Rating Scale) then the 10% of patients with the most favorable responses could be compared to the 10% with the least favorable, or the patients one standard deviation above the mean score could be compared to the remainder, or to those one standard deviation below the mean score. One useful way to select the threshold for defining a response is to examine the distribution of responses in a placebo group. If the upper end of the range of placebo responses is used as a lower threshold for an 'outlier response' then the outlier response group should be almost free of placebo responders. This is a useful threshold because the inclusion of placebo responders in a 'true' response group decreases the ability of statistical methods to detect a genetic difference between responders and nonresponders.

In a related aspect, the invention provides a method for developing a disease management protocol that entails diagnosing a patient with a disease or a disease susceptibility, determining the genotype of the patient at a gene or genes correlated with treatment response and then selecting an optimal treatment based on the disease and the genotype (or genotypes or haplotypes). The disease management protocol may be useful in an education program for physicians, other caregivers or pharmacists; may constitute part of a drug label; or may be useful in a marketing campaign.

By "disease management protocol" or "treatment protocol" is meant a means for devising a therapeutic plan for a patient using laboratory, clinical and genetic data, including the patient's diagnosis and genotype. The protocol clarifies

therapeutic options and provides information about probable prognoses with different treatments. The treatment protocol may provide an estimate of the likelihood that a patient will respond positively or negatively to a therapeutic intervention. The treatment protocol may also provide guidance regarding optimal drug dose and administration and likely timing of recovery or rehabilitation. A “disease management protocol” or “treatment protocol” may also be formulated for asymptomatic and healthy subjects in order to forecast future disease risks based on laboratory, clinical and genetic variables. In this setting the protocol specifies optimal preventive or prophylactic interventions, including use of compounds, changes in diet or behavior, or other measures. The treatment protocol may include the use of a computer program.

In preferred embodiments, the method further involves determining the patient’s allele status and selecting those patients having at least one wild type allele, preferably having two wild type alleles for an identified gene, as candidates likely to develop drug-induced pathological conditions or drug-associated pathological disease or conditions. In a preferred embodiment, the treatment protocol involves a comparison of the allele status of a patient with a control population and a responder population. This comparison allows for a statistical calculation of a patient’s likelihood of responding to a therapy, e.g., a calculation of the correlation between a particular allele status and treatment response. In the context of this aspect, the term “wild-type allele” refers to an allele of a gene which produces a product having a level of activity which is most common in the general population. Two different alleles may both be wild-type alleles for this purpose if both have essentially the same level of activity (e.g., specific activity and numbers of active molecules).

In preferred embodiments of above aspects involving prediction of drug efficacy, the prediction of drug efficacy involves candidate therapeutic interventions that are known or have been identified to be affected by pharmacokinetic parameters, i.e. absorption, distribution, metabolism, or excretion. These parameters may be associated with hepatic or extra-hepatic biological mechanisms. Preferably the candidate therapeutic intervention will be effective in patients with the genotype of a least one allele, and preferably two alleles from Tables 1 and 3, but have a risk of drug ineffectiveness, i.e. nonresponsive to a drug or candidate therapeutic intervention.

In particular applications of the invention, all of the above aspects involving a gene variance evaluation or treatment selection or patient selection or method of treatment, the method includes a determination of the genotypic allele status of the patient, where a determination of the patient’s allele status as being heterozygous or homozygous, is predictive of the patient having a poor response to a candidate

therapeutic intervention and development of drug-induced disease, disorder, or dysfunction.

In preferred embodiments, the above methods are used for or include identification of a safety or toxicity concern involving a drug-induced disease, disorder, or dysfunction and/or the likelihood of occurrence and/or severity of said disease, disorder, or dysfunction.

In preferred embodiments, the invention is suitable for identifying a patient with non-drug-induced disease, disorder, or dysfunction but with dysfunction related to aberrant enzymatic metabolism or excretion of endogenous biologically relevant molecules or compounds. The method preferably involves determination of the allele status or variance presence or absence determination for at least one gene from Tables 1 and 3.

In another aspect, the invention provides a method for treating a patient at risk for a drug-induced disease, disorder or dysfunction by a) identifying a patient with such a risk, b) determining the genotypic allele status of the patient, and c) converting the data obtained in step b) into a treatment protocol that includes a comparison of the genotypic allele status determination with the allele frequency of a control population. This comparison allows for a statistical calculation of the patient's risk for having drug-induced disease, disorder, or dysfunction, e.g., based on correlation of the allele frequencies for a population with response or disease occurrence and/or severity. In preferred embodiments, the method provides a treatment protocol that predicts a patient being heterozygous or homozygous for an identified allele to exhibit signs and or symptoms of drug-induced disease, disorder, or dysfunction and a patient who is wild-type homozygous for the said allele, as responding favorably to these therapies.

In a related aspect, the invention provides a method for treating a patient at risk for or diagnosed with drug-induced disease or pathological condition or dysfunction using the methods of the above aspect and conducting a step c) which involves determining the gene allele load status of the patient. This method further involves converting the data obtained in steps b) and c) into a treatment protocol that includes a comparison of the allele status determinations of these steps with the allele frequency of a control population. This affords a statistical calculation of the patient's risk for having drug-induced disease, disorder or dysfunction. In a preferred embodiment, the method is useful for identifying drug-induced disease, disorder or dysfunction. In addition, in related embodiments, the methods provide a treatment protocol that predicts a patient to be at high risk for drug-induced disease, disorder or dysfunction responding by exhibiting signs and symptoms of drug-induced toxicity, disorders, dysfunction if the patient is determined as having a

genotype or allelic difference in the identified gene or genes. Such patients are preferably given alternative therapies.

The invention also provides a method for improving the safety of candidate therapies for the identification of a drug-induced disease, disorder, or dysfunction.

5 The method includes the step of comparing the relative safety of the candidate therapeutic intervention in patients having different alleles in one or more than one of the genes listed in Tables 1 and 3. Preferably, administration of the drug is preferentially provided to those patients with an allele type associated with increased efficacy. In a preferred embodiment, the alleles of identified gene or genes used are
10 wild-type and those associated with altered biological activity.

As used herein, by "therapy associated with drug-induced disease" is meant any therapy resulting in pathophysiologic dysfunction or signs and symptoms of failure or dysfunction, or those associated with the pathophysiological manifestations of a disorder. A suitable therapy can be a pharmacological agent,
15 drug, or therapy that alters a pathways identified to affect the molecular structure or function of the parent candidate therapeutic intervention thereby affecting drug-induced disease or disorder progression of any of the described organ system dysfunctions.

By "drug-induced disease" or "drug-induced syndrome" is meant any
20 physiologic condition that may be correlated with medical therapy by a drug, agent, or candidate therapeutic intervention.

By "drug-induced dysfunction" is meant a physiologic disorder or syndrome that may be correlated with medical therapy by a drug, agent, or candidate therapeutic intervention in which symptomology is similar to drug-induced disease.
25 Specifically included are: a) hemostasis dysfunction; b) cutaneous disorders; c) cardiovascular dysfunction; d) renal dysfunction; e) pulmonary dysfunction; f) hepatic dysfunction; g) systemic reactions; and h) central nervous system dysfunction.

By "drug associated disorder" is meant a physiologic dysfunction that may
30 be correlated with medical therapy by a drug, agent, or candidate therapeutic intervention. The drug associated disorder may include disease, disorder, or dysfunction.

By "pathway" or "gene pathway" is meant the group of biologically relevant genes involved in a pharmacodynamic or pharmacokinetic mechanism of drug,
35 agent, or candidate therapeutic intervention. These mechanisms may further include any physiologic effect the drug or candidate therapeutic intervention renders.

As used herein, a "clinical trial" is the testing of a therapeutic intervention in a volunteer human population for the purpose of determining whether a therapeutic

005230" E2F24960

intervention is safe and/or efficacious in the human volunteer or patient population for a given disease, disorder, or condition. The analysis of safety and efficacy in genetically defined subgroups differing by at least one variance is of particular interest.

As used herein “clinical study” is that part of a clinical trial that involves
5 determination of the effect a candidate therapeutic intervention on human subjects. It includes clinical evaluations of physiologic responses including pharmacokinetic (absorption, distribution, bioavailability, and excretion) as well as pharmacodynamic (physiologic response and efficacy) parameters. A pharmacogenetic clinical study is a
10 clinical study that involves testing of one or more specific hypotheses regarding the effect of a genetic variance or variances (or set of variances, i.e. haplotype or haplotypes) in enrolled subjects or patients on response to a therapeutic intervention. These hypotheses are articulated before the study in the form of primary or secondary endpoints. For example the endpoint may be that in a particular genetic subgroup the rate of objectively defined responses exceeds some predefined threshold.

As used herein, “supplemental applications” are those in which a candidate
15 therapeutic intervention is tested in a human clinical trial in order for the product to have an expanded label to include additional indications for therapeutic use. In these cases, the previous clinical studies of the therapeutic intervention, i.e. those involving the preclinical safety and Phase I human safety studies can be used to support the testing of
20 the particular candidate therapeutic intervention in a patient population for a different disease, disorder, or condition than that previously approved in the US. In these cases, a limited Phase II study is performed in the proposed patient population. With adequate signs of efficacy, a Phase III study is designed. All other parameters of clinical development for this category of candidate therapeutic interventions proceeds as
25 described above for interventions first tested in human candidates.

As used herein, “outcomes” or “therapeutic outcomes” are used to describe the results and value of healthcare intervention. Outcomes can be multi-dimensional, e.g., including one or more of the following: improvement of symptoms; regression of the disease, disorder, or condition; economic outcomes of healthcare decisions.

As used herein, “pharmacoeconomics” is the analysis of a therapeutic intervention
30 in a population of patients diagnosed with a disease, disorder, or condition that includes at least one of the following studies: cost of illness study (COI); cost benefit analysis (CBA), cost minimization analysis (CMA), or cost utility analysis (CUA), or an analysis comparing the relative costs of a therapeutic intervention with one or a group of other
35 therapeutic interventions. In each of these studies, the cost of the treatment of a disease, disorder, or condition is compared among treatment groups. As used herein, costs are those economic variables associated with a disease, disorder, or condition fall into two

00643-0000

broad categories: direct and indirect. Direct costs are associated with the medical and non-medical resources used as therapeutic interventions, including medical, surgical, diagnostic, pharmacologic, devices, rehabilitation, home care, nursing home care, institutional care, and prosthesis. Indirect costs are associated with loss of productivity due to the disease, disorder, or condition suffered by the patient or relatives. A third category, the tangible and intangible losses due to pain and suffering of a patient or relatives often is included in indirect cost studies.

As used herein, “health-related quality of life” is a measure of the impact of the disease, disorder, or condition on an individual’s or group of patient’s activities of daily living. Preferably, included in pharmacoeconomic studies is an analysis of the health-related quality of life. Standardized surveys or questionnaires for general health-related quality of life or disease, disorder, or condition specific determine the impact the disease, disorder, or condition has on an individuals day to day life activities or specific activities that are affected by a particular disease, disorder, or condition.

As used herein, the term “stratification” refers to the creation of a distinction between patients on the basis of a characteristic or characteristics of the patient. Generally, in the context of clinical trials, the distinction is used to distinguish responses or effects in different sets of patients distinguished according to the stratification parameters. For the present invention, stratification preferably includes distinction of patient groups based on the presence or absence of particular variance or variances in one or more genes. The stratification may be performed only in the course of analysis or may be used in creation of distinct groups or in other ways.

By “drug efficacy” is meant the determination of an appropriate drug, drug dosage, administration schedule, and prediction of therapeutic utility.

By “allele load” is meant the relative ratio of identified gene alleles in the patient’s chromosomal DNA.

By “identified allele” is meant a particular gene isoform that can be distinguished from other identified gene isoforms using the methods of the invention.

By “PCR, PT-PCR, or ligase chain reaction amplification” is meant subjecting a DNA sample to a Polymerase Chain Reaction step or ligase-mediated chain reaction step, or RNA to a RT-PCR step, such that, in the presence of appropriately designed primers, a nucleic acid fragment is synthesized or fails to be synthesized and thereby reveals the allele status of a patient. The nucleic acid may be further analyzed by DNA sequencing using techniques known in the art.

By “gene allele status” is meant a determination of the relative ratio of wild type identified alleles compared to an allelic variant that may encode a gene product

of reduced catalytic activity. This may be accomplished by nucleic acid sequencing, RT-PCR, PCR, examination of the identified gene translated protein, a determination of the identified protein activity, or by other methods available to those skilled in the art.

5 By "treatment protocol" is meant a therapy plan for a patient using genetic and diagnostic data, including the patient's diagnosis and genotype. The protocol enhances therapeutic options and clarifies prognoses. The treatment protocol may include an indication of whether or not the patient is likely to respond positively to a candidate therapeutic intervention that is known to affect physiologic function. The
10 treatment protocol may also include an indication of appropriate drug dose, recovery time, age of disease onset, rehabilitation time, symptomology of attacks, and risk for future disease. A treatment protocol, including any of the above aspects, may also be formulated for asymptomatic and healthy subjects in order to forecast future disease risks and determine what preventive therapies should be considered or
15 invoked in order to lessen these disease risks. The treatment protocol may include the use of a computer software program to analyze patient data.

By "patient at risk for a disease" or "patient with high risk for a disease" is meant a patient identified or diagnosed as having drug-induced disease, disorder, dysfunction or having a genetic predisposition or risk for acquiring drug-induced
20 disease, disorder or dysfunction, where the predisposition or risk is higher than average for the general population or is sufficiently higher than for other individuals as to be clinically relevant. Such risk can be evaluated, for example, using the methods of the invention and techniques available to those skilled in the art.

By "converting" is meant compiling genotype determinations to predict
25 either prognosis, drug efficacy, or suitability of the patient for participating in clinical trials of a candidate therapeutic intervention with known propensity of drug-induced disease, disorder or dysfunction. For example, the genotype may be compiled with other patient parameters such as age, sex, disease diagnosis, and known allelic frequency of a representative control population. The converting step
30 may provide a determination of the statistical probability of the patient having a particular disease risk, drug response, or patient outcome.

By "prediction of patient outcome" is meant a forecast of the patient's likely health status. This may include a prediction of the patient's response to therapy, rehabilitation time, recovery time, cure rate, rate of disease progression,
35 predisposition for future disease, or risk of having relapse.

By "therapy for the treatment of a disease" is meant any pharmacological agent or drug with the property of healing, curing, or ameliorating any symptom or disease mechanism associated with drug-induced disease, disorder or dysfunction.

009280" 004960

By “responder population” is meant a patient or patients that respond favorably to a given therapy.

In another aspect, the invention provides a method for determining whether there is a genetic component to intersubject variation in a surrogate treatment response. The method involves administering the treatment to a group of related (preferably normal) subjects and a group of unrelated (preferably normal) subjects, measuring a surrogate pharmacodynamic or pharmacokinetic drug response variable in the subjects, performing a statistical test measuring the variation in response in the group of related subjects and, separately in the group of unrelated subjects, comparing the magnitude or pattern of variation in response or both between the groups to determine if the responses of the groups are different, using a predetermined statistical measure of difference. A difference in response between the groups is indicative that there is a genetic component to intersubject variation in the surrogate treatment response.

In preferred embodiments, the size of the related and unrelated groups is set in order to achieve a predetermined degree of statistical power.

In another aspect, the invention provides a method for evaluating the combined contribution of two or more variances to a surrogate drug response phenotype in subjects (preferably normal subjects) by a. genotyping a set of unrelated subjects participating in a clinical trial or study, e.g., a Phase I trial, of a compound. The genotyping is for two or more variances (which can be a haplotype), thereby identifying subjects with specific genotypes, where the two or more specific genotypes define two or more genotype-defined groups. A drug is administered to subjects with two or more of said specific genotypes, and a surrogate pharmacodynamic or pharmacokinetic drug response variable is measured in the subjects. A statistical test or tests is performed to measure response in the groups separately, where the statistical tests provide a measurement of variation in response with each group. The magnitude or pattern of variation in response or both is compared between the groups to determine if the groups are different using a predetermined statistical measure of difference.

In preferred embodiments, the specific genotypes are homozygous genotypes for two variances. In preferred embodiments, the comparison is between groups of subjects differing in three or more variances, e.g., 3, 4, 5, 6, or even more variances.

5 In another aspect, the invention provides a method for providing contract research services to clients (preferably in the pharmaceutical and biotechnology industries), by enrolling subjects (e.g., normal and/or patient subjects) in a clinical drug trial or study unit (preferably a Phase I drug trial or study unit) for the purpose of genotyping the subjects in order to assess the contribution of genetic variation to variation in drug response, genotyping the subjects to determine the status of one or
10 more variances in the subjects, administering a compound to the subjects and measuring a surrogate drug response variable, comparing responses between two or more genotype-defined groups of subjects to determine whether there is a genetic component to the interperson variability in response to said compound; and reporting the results of the Phase I drug trial to a contracting entity. Clearly,
15 intermediate results, e.g., response data and/or statistical analysis of response or variation in response can also be reported.

In preferred embodiments, at least some of the subjects have disclosed that they are related to each other and the genetic analysis includes comparison of groups of related individuals. To encourage participation of sufficient numbers of related
20 individuals, it can be advantageous to offer or provide compensation to one or more of the related individuals based on the number of subjects related to them who participate in the clinical trial, or on whether at least a minimum number of related subjects participate, e.g., at least 3, 5, 10, 20, or more.

In a related aspect, the invention provides a method for recruiting a clinical
25 trial population for studies of the influence of genetic variation on drug response, by soliciting subjects to participate in the clinical trial, obtaining consent of each of a set of subjects for participation in the clinical trial, obtaining additional related subjects for participation in the clinical trial by compensating one or more of the related subjects for participation of their related subjects at a level based on the
30 number of related subjects participating or based on participation of at least a minimum specified number of related subjects, e.g., at minimum levels as specified in the preceding aspect.

In addition to application of the present invention to drug-induced diseases and conditions, the present invention also provides for the use of variances in genes and gene pathways involved in drug absorption, distribution, metabolism, or excretion (e.g., as specified in any of Tables 1 and 3 herein) of a drug. Thus, the above aspects can be utilized in connection with virtually any type of drug. For example, the pharmacogenetic effect, and the determination of such effect, of variances in genes in pathways involved in drug absorption, distribution, metabolism, or excretion can be utilized, for example, for in connection with drugs and drug classes as described Stanton, International Application No.

PCT/US00/01392, filed January 20, 2000, entitled GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE. Further, the particular drug and/or pharmacogenetic determination can also be applied in the context of any disease, disorder, or dysfunction for which a drug treatment is considered or tested, e.g., any of the diseases, disorders, or conditions pointed out in Stanton (*Id.*). Still further, such analysis and use of pharmacogenetic information for genes involved in drug adsorption, distribution, metabolism, and excretion can also be combined with any of the different aspects described for genes involved in treatment response for other diseases, conditions, and dysfunctions as described in Stanton (*Id.*).

The use of variance information for genes involved in drug adsorption, distribution, metabolism, and excretion for any drug is advantageous, as those processes can affect the efficacy of any drug. Therefore, variances in such genes that alter one or more of those parameters can be significant in determining interpatient variation in treatment response.

Additional aspects and embodiments as described in Stanton, International Application No. PCT/US00/01392, filed January 20, 2000, entitled GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE, are also included in the scope of this invention.

By "pathway" or "gene pathway" is meant the group of biologically relevant genes involved in a pharmacodynamic or pharmacokinetic mechanism of drug, agent, or candidate therapeutic intervention. These mechanisms may further include any physiologic effect the drug or candidate therapeutic intervention renders. Included in this are "biochemical pathways" which is used in its usual sense to refer to a series of related biochemical processes (and the corresponding genes and gene products) involved in carrying out a reaction or series of reactions. Generally in a cell, a pathway performs a significant process in the cell.

By “pharmacological activity” used herein is meant a biochemical or physiological effect of drugs, compounds, agents, or candidate therapeutic interventions upon administration and the mechanism of action of that effect.

The pharmacological activity is then determined by interactions of drugs, compounds, agents, or candidate therapeutic interventions, or their mechanism of action, on their target proteins or macromolecular components. By “agonist” or “mimetic” or “activators” is meant a drug, agent, or compound that activate physiologic components and mimic the effects of endogenous regulatory compounds. By “antagonists”, “blockers” or “inhibitors” is meant drugs, agents, or compounds that bind to physiologic components and do not mimic endogenous regulatory compounds, or interfere with the action of endogenous regulatory compounds at physiologic components. These inhibitory compounds do not have intrinsic regulatory activity, but prevent the action of agonists. By “partial agonist” or “partial antagonist” is meant an agonist or antagonist, respectively, with limited or partial activity. By “negative agonist” or “inverse antagonists” is meant that a drug, compound, or agent that can interact with a physiologic target protein or macromolecular component and stabilizes the protein or component such that agonist-dependent conformational changes of the component do not occur and agonist mediated mechanism of physiological action is prevented. By “modulators” or “factors” is meant a drug, agent, or compound that interacts with a target protein or macromolecular component and modifies the physiological effect of an agonist.

As used herein the term “chemical class” refers to a group of compounds that share a common chemical scaffold but which differ in respect to the substituent groups linked to the scaffold. Examples of chemical classes of drugs include, for example, phenothiazines, piperidines, benzodiazepines and aminoglycosides. Members of the phenothiazine class include, for example, compounds such as chlorpromazine hydrochloride, mesoridazine besylate, thioridazine hydrochloride, acetophenazine maleate trifluoperazine hydrochloride and others, all of which share a phenothiazine backbone. Members of the piperidine class include, for example, compounds such as meperidine, diphenoxylate and loperamide, as well as phenylpiperidines such as fentanyl, sufentanil and alfentanil, all of which share the piperidine backbone. Chemical classes and their members are recognized by those skilled in the art of medicinal chemistry.

As used herein the term “surrogate marker” refers to a biological or clinical parameter that is measured in place of the biologically definitive or clinically most meaningful parameter. In comparison to definitive markers, surrogate markers are generally either more convenient, less expensive, provide earlier information or provide pharmacological or physiological information not directly obtainable with definitive markers. Examples of surrogate biological parameters: (i) testing erythrocyte membrane acetylcholinesterase levels in subjects treated with an acetylcholinesterase inhibitor intended for use in Alzheimer’s disease patients (where inhibition of brain acetylcholinesterase would be the definitive biological parameter); (ii) measuring levels of CD4 positive lymphocytes as a surrogate marker for response to a treatment for acquired immune deficiency syndrome (AIDS). Examples of surrogate clinical parameters: (i) performing a psychometric test on normal subjects treated for a short period of time with a candidate Alzheimer’s compound in order to determine if there is a measurable effect on cognitive function. The definitive clinical test would entail measuring cognitive function in a clinical trial in Alzheimer’s disease patients. (ii) Measuring blood pressure as a surrogate marker for myocardial infarction. The measurement of a surrogate marker or parameter may be an endpoint in a clinical study or clinical trial, hence “surrogate endpoint”.

As used herein the term “related” when used with respect to human subjects indicates that the subjects are known to share a common line of descent; that is, the subjects have a known ancestor in common. Examples of preferred related subjects include sibs (brothers and sisters), parents, grandparents, children, grandchildren, aunts, uncles, cousins, second cousins and third cousins. Subjects less closely related than third cousins are not sufficiently related to be useful as “related” subjects for the methods of this invention, even if they share a known ancestor, unless some related individuals that lie between the distantly related subjects are also included. Thus, for a group of related individuals, each subject shares a known ancestor within three generations or less with at least one other subject in the group, and preferably with all other subjects in the group or has at least that degree of consanguinity due to multiple known common ancestors. More preferably, subjects share a common ancestor within two generations or less, or otherwise have equivalent level of consanguinity. Conversely, as used herein the term “unrelated”,

when used in respect to human subjects, refers to subjects who do not share a known ancestor within 3 generations or less, or otherwise have known relatedness at that degree.

As used herein the term "pedigree" refers to a group of related individuals, usually comprising at least two generations, such as parents and their children, but often comprising three generations (that is, including grandparents or grandchildren as well). The relation between all the subjects in the pedigree is known and can be represented in a genealogical chart.

As used herein the term "hybridization", when used with respect to DNA fragments or polynucleotides encompasses methods including both natural polynucleotides, non-natural polynucleotides or a combination of both. Natural polynucleotides are those that are polymers of the four natural deoxynucleotides (deoxyadenosine triphosphate [dA], deoxycytosine triphosphate [dC], deoxyguanine triphosphate [dG] or deoxythymidine triphosphate [dT], usually designated simply thymidine triphosphate [T]) or polymers of the four natural ribonucleotides (adenosine triphosphate [A], cytosine triphosphate [C], guanine triphosphate [G] or uridine triphosphate [U]). Non-natural polynucleotides are made up in part or entirely of nucleotides that are not natural nucleotides; that is, they have one or more modifications. Also included among non-natural polynucleotides are molecules related to nucleic acids, such as peptide nucleic acid [PNA]). Non-natural polynucleotides may be polymers of non-natural nucleotides, polymers of natural and non-natural nucleotides (in which there is at least one non-natural nucleotide), or otherwise modified polynucleotides. Non-natural polynucleotides may be useful because their hybridization properties differ from those of natural polynucleotides.

As used herein the term "complementary", when used in respect to DNA fragments, refers to the base pairing rules established by Watson and Crick: A pairs with T or U; G pairs with C. Complementary DNA fragments have sequences that, when aligned in antiparallel orientation, conform to the Watson-Crick base pairing rules at all positions or at all positions except one. As used herein, complementary DNA fragments may be natural polynucleotides, non-natural polynucleotides, or a mixture of natural and non-natural polynucleotides.

As used herein "amplify" when used with respect to DNA refers to a family of methods for increasing the number of copies of a starting DNA fragment.

Amplification of DNA is often performed to simplify subsequent determination of DNA sequence, including genotyping or haplotyping. Amplification methods include the polymerase chain reaction (PCR), the ligase chain reaction (LCR) and methods using Q beta replicase, as well as transcription-based amplification systems such as the isothermal amplification procedure known as self-sustained sequence replication (3SR, developed by T.R. Gingeras and colleagues), strand displacement amplification (SDA, developed by G.T. Walker and colleagues) and the rolling circle amplification method (developed by P. Lizardi and D. Ward).

As used herein "contract research services for a client" refers to a business arrangement wherein a client entity pays for services consisting in part or in whole of work performed using the methods described herein. The client entity may include a commercial or non-profit organization whose primary business is in the pharmaceutical, biotechnology, diagnostics, medical device or contract research organization (CRO) sector, or any combination of those sectors. Services provided to such a client may include any of the methods described herein, particularly including clinical trial services, and especially the services described in the Detailed Description relating to a Pharmacogenetic Phase I Unit. Such services are intended to allow the earliest possible assessment of the contribution of a variance or variances or haplotypes, from one or more genes, to variation in a surrogate marker in humans. The surrogate marker is generally selected to provide information on a biological or clinical response, as defined above.

As used herein, "comparing the magnitude or pattern of variation in response" between two or more groups refers to the use of a statistical procedure or procedures to measure the difference between two different distributions. For example, consider two genotype-defined groups, AA and aa, each homozygous for a different variance or haplotype in a gene believed likely to affect response to a drug. The subjects in each group are subjected to treatment with the drug and a treatment response is measured in each subject (for example a surrogate treatment response). One can then construct two distributions: the distribution of responses in the AA group and the distribution of responses in the aa group. These distributions may be compared in many ways, and the significance of any difference qualified as to its significance (often expressed as a p value), using methods known to those skilled in the art. For example, one can compare the means, medians or modes of the two

distributions, or one can compare the variance or standard deviations of the two distributions. Or, if the form of the distributions is not known, one can use nonparametric statistical tests to test whether the distributions are different, and whether the difference is significant at a specified level (for example, the $p < 0.05$ level, meaning that, by chance, the distributions would differ to the degree measured less than one in 20 similar experiments). The types of comparisons described are similar to the analysis of heritability in quantitative genetics, and would draw on standard methods from quantitative genetics to measure heritability by comparing data from related subjects.

Another type of comparison that can be usefully made is between related and unrelated groups of subjects. That is, the comparison of two or more distributions is of particular interest when one distribution is drawn from a population of related subjects and the other distribution is drawn from a group of unrelated subjects, both subjected to the same treatment. (The related subjects may consist of small groups of related subjects, each compared only to their relatives.) A comparison of the distribution of a drug response variable (e.g. a surrogate marker) between two such groups may provide information on whether the drug response variable is under genetic control. For example, a narrow distribution in the group(s) of related subjects (compared to the unrelated subjects) would tend to indicate that the measured variable is under genetic control (i.e. the related subjects, on account of their genetic homogeneity, are more similar than the unrelated individuals). The degree to which the distribution was narrower in the related individuals (compared to the unrelated individuals) would be proportionate to the degree of genetic control. The narrowness of the distribution could be quantified by, for example, computing variance or standard deviation. In other cases the shape of the distribution may not be known and nonparametric tests may be preferable. Nonparametric tests include methods for comparing medians such as the sign test, the slippage test, or the rank correlation coefficient (the nonparametric equivalent of the ordinary correlation coefficient). Pearson's Chi square test for comparing an observed set of frequencies with an expected set of frequencies can also be useful.

The present invention provides a number of advantages. For example, the methods described herein allow for use of a determination of a patient's genotype for the timely administration of the most suitable therapy for that particular patient.

The methods of this invention provide a basis for successfully developing and obtaining regulatory approval for a compound even though efficacy or safety of the compound in an unstratified population is not adequate to justify approval. From the point of view of a pharmaceutical or biotechnology company, the information obtained in pharmacogenetic studies of the type described herein could be the basis of a marketing campaign for a drug. For example, a marketing campaign that emphasized the superior efficacy or safety of a compound in a genotype or haplotype restricted patient population, compared to a similar or competing compound used in an undifferentiated population of all patients with the disease. In this respect a marketing campaign could promote the use of a compound in a genetically defined subpopulation, even though the compound was not intrinsically superior to competing compounds when used in the undifferentiated population with the target disease. In fact even a compound with an inferior profile of action in the undifferentiated disease population could become superior when coupled with the appropriate pharmacogenetic test.

By "comprising" is meant including, but not limited to, whatever follows the word "comprising". Thus, use of the term "comprising" indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present. By "consisting of" is meant including, and limited to, whatever follows the phrase "consisting of". Thus, the phrase "consisting of" indicates that the listed elements are required or mandatory, and that no other elements may be present. By "consisting essentially of" is meant including any elements listed after the phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase "consisting essentially of" indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present depending upon whether or not they affect the activity or action of the listed elements.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

Detailed Description of the Preferred Embodiments

First, the content of tables provided in this description is briefly described.

Table 1, the ADME/Toxicology Gene Table, lists genes that may be involved in pharmacological responses involving adsorption, distribution,

metabolism, excretion affecting efficacy or safety of drug response. The table has seven columns. Column 1, headed "Class" provides broad groupings of genes relevant to the pharmacology of absorption, distribution, metabolism, or excretion of drugs. The categories are: adsorption and distribution, Phase I drug metabolism, Phase II drug metabolism, excretion, oxidative stress, and immune response. Column 2, headed "Pathway", provides a more detailed categorization of the different classes of genes by indicating the overall purpose of large groups of genes. These pathways contain genes implicated in the etiology or treatment response of the various patient outcomes detailed in Table 2. Column 3, headed "Function", further categorizes the pathways listed in column 2.

Column 4, headed "Name", lists the genes belonging to the class, pathway and function shown to the left (in columns 1 – 3). The gene names given are generally those used in the OMIM database or in GenBank, however one skilled in the art will recognize that many genes have more than one name, and that it is a straightforward task to identify synonymous names. For example, many alternate gene names are provided in the OMIM record for a gene.

In column 5, headed "OMIM", the Online Mendelian Inheritance in Man (OMIM) record number is listed for each gene in column 4. This record number can be entered next to the words: "Enter one or more search keywords:" at the OMIM world wide web site. The url is:
<http://www3.ncbi.nlm.nih.gov/Omim/searchomim.html>. An OMIM record exists for most characterized human genes. The record often has useful information on the chromosome location, function, alleles, and human diseases or disorders associated with each gene.

Column 6, headed "GID", provides the GenBank identification number (hence GID) of a genomic, cDNA, or partial sequence of the gene named in column 4. Usually the GID provides the record of a cDNA sequence. Many genes have multiple Genbank accession numbers, representing different versions of a sequence obtained by different research groups, or corrected or updated versions of a sequence. As with the gene name, one skilled in the art will recognize that alternative GenBank records related to the named record can be obtained easily. All other GenBank records listing sequences that are alternate versions of the sequences named in the table are equally suitable for the inventions described in this application. (One straightforward way to obtain additional GenBank records for a gene is on the internet. General instructions can be found at the NCBI web site at:
<http://www3.ncbi.nlm.nih.gov>. More specifically, the GenBank record number in column 6 can be entered at the url:

<http://www3.ncbi.nlm.nih.gov/Entrez/nucleotide.html>. Once the GenBank record

has been retrieved one can click on the "nucleotide neighbors" link and additional GenBank records from the same gene will be listed.

Column 7, headed "locus", provides the chromosome location of the gene listed on the same row. The chromosome location helps confirm the identity of the named gene if there is any ambiguity.

Table 2 is a matrix showing the intersection of genes and patient outcomes – that is, which categories of genes are most likely to account for interpatient variation in response to treatments. Column 1 is similar to the 'Class' column in Table 1, while column 2 is a combination of the 'Pathway' and 'Function' columns in Table 1. It is intended that the summary terms listed in columns 1 and 2 be read as referring to all the genes in the corresponding sections of Table 1. The remaining columns in Table 2 lists potential effects on efficacy or on eight patient outcomes. The information in the Table lies in the shaded boxes at the intersection of various 'Pathways' (the rows) and the patient outcomes (the nine columns). An intersection box is shaded when a row corresponding to a particular pathway (and by extension all the genes listed in that pathway in Table 1) intersects a column for a specific effect on patient outcome in response to a candidate therapeutic intervention such that the pathway and genes are of possible use in explaining interpatient differences in response (patient outcomes) to candidate therapeutic interventions. Thus the Table enables one skilled in the art to identify therapeutically relevant genes in patients with one of the nine patient outcomes for the purposes of stratification of these patients based upon genotype and subsequent correlation of genotype with drug response. The shaded intersections indicate preferred sets of genes for understanding the basis of interpatient variation in response to therapy of the indicated disease indication, and in that respect are exemplary. Any of the genes in the table may account for interpatient variation in response to treatments for any of the diseases listed. Thus, the shaded boxes indicate the gene pathways that one skilled in the art would first investigate in trying to understand interpatient variation in response to a candidate therapeutic indications with the listed patient outcomes.

Table 3 is a partial list of DNA sequence variances in genes relevant to the methods described in the present invention. These variances were identified by the inventors in studies of selected genes listed in Table 1, and are provided here as useful for the methods of the present invention. The variances in Table 3 were discovered by one or more of the methods described below in the Detailed Description or Examples. Table 3 has eight columns. Column 1, the "Name" column, contains the Human Genome Organization (HUGO) identifier for the gene. Column 2, the "GID" column provides the GenBank accession number of a genomic, cDNA, or partial sequence of a particular gene. Column 3, the

“OMIM_ID” column contains the record number corresponding to the Online Mendelian Inheritance in Man database for the gene provided in columns 1 and 2. This record number can be entered at the world wide web site <http://www3.ncbi.nlm.nih.gov/Omim/searchomim.html> to search the OMIM record on the gene. Column 4, the VGX_Symbol column, provides an internal identifier for the gene. Column 5, the “Description” column provides a descriptive name for the gene, when available. Column 6, the “Variance_Start” column provides the nucleotide location of a variance with respect to the first listed nucleotide in the GenBank accession number provided in column 2. That is, the first nucleotide of the GenBank accession is counted as nucleotide 1 and the variant nucleotide is numbered accordingly. Column 7, the “variance” column provides the nucleotide location of a variance with respect to an ATG codon believed to be the authentic ATG start codon of the gene, where the A of ATG is numbered as one (1) and the immediately preceding nucleotide is numbered as minus one (-1). This reading frame is important because it allows the potential consequence of the variant nucleotide to be interpreted in the context of the gene anatomy (5’ untranslated region, protein coding sequence, 3’ untranslated region). Column 7 also provides the identity of the two variant nucleotides at the indicated position. For example, in the first entry in Table 3, DG90040, the variance is 191G>A, indicating the presence of a G or an A at nucleotide 232 of GenBank sequence DG90040. Column 8, the “CDS_Context” column indicates whether the variance is in a coding region but silent (S); in a coding region and results in an amino acid change (e.g., R347C, where the letters are one letter amino acid abbreviations and the number is the amino acid residue in the encoded amino acid sequence which is changed); in a sequence 5’ to the coding region (5); or in a sequence 3’ to the coding region (3). As indicated above, interpreting the location of the variance in the gene depends on the correct assignment of the initial ATG of the encoded protein (the translation start site). It should be recognized that assignment of the correct ATG may occasionally be incorrect in GenBank, but that one skilled in the art will know how to carry out experiments to definitively identify the correct translation initiation codon (which is not always an ATG). In the event of any potential question concerning the proper identification of a gene or part of a gene, due for example, to an error in recording an identifier or the absence of one or more of the identifiers, the priority for use to resolve the ambiguity is GenBank accession number, OMIM identification number, HUGO identifier, common name identifier.

05648123-030586

I. Pharmacokinetic Parameters and Effects on Efficacy

The pharmacokinetic parameters with potential effects on efficacy are absorption, distribution, metabolism, and excretion. These parameters affect efficacy broadly by modulating the availability of a compound at the site(s) of action. Interpatient variation in the availability of a compound drug, agent, or candidate therapeutic intervention can result in a reduction of the available compound or more compound at the site of action with a corresponding altered clinical effect. Differences in these parameters, therefore, can be a potential foundation of interpatient variability to drug response.

A. Pharmacokinetic Parameters that Result in a Reduction of Available Drug

1. Absorption- Depending on the solubility of the drug, and its ability to passively cross membranes is fundamental to the ability of the drug, agent, or candidate therapeutic intervention to effectively enter the circulation and gain access to the principle site of action. For enteral delivery or administration, absorption is a critical first step in the pharmacologic process. Within the gastrointestinal tract, absorption of a drug, agent, or candidate therapeutic intervention can be affected by the pH of the contents, speed of gastric emptying, and presence of chelating or binding molecules to the drug, agent or candidate therapeutic intervention. Each of these parameters can effectively reduce the rate of passive absorption of the drug across the gastrointestinal mucosal membrane.
2. Distribution- Once absorbed, the drug, agent or candidate therapeutic intervention must be delivered or distributed to the primary site of pharmacologic action. Although distribution is dependent on regional blood flow and cardiac output; distribution may be further affected by the rate and extent of sequestration of the drug into biological spaces that render the product unavailable to the principle or primary site of pharmacologic site of action. For example, many drugs are actively transported into biological compartments. These processes, if over- or under active may affect the availability and hence reduce the efficacy of the product. Further, only unbound drug may be effective to a cell, tissue, or physiological process, and bound product may be transported to a space that is physiologically unrelated to the pharmacologic mechanism of action or may be of deleterious adverse or toxic consequence.

3. Metabolism- Induction of metabolic enzymes to covalently modify the parent drug, agent or candidate therapeutic intervention may reduce the ability of the parent drug to elicit a pharmacologic action. Metabolism may affect the target active site binding, rate and extent of distribution and excretion, and overall availability of the active molecule.
4. Excretion- If the excretion of the drug or drug metabolite is rapid, less drug is available to elicit a pharmacologic effect.

B. Pharmacokinetic Parameters that Result in More Available Drug.

1. Absorption- Enhanced absorption of drugs, agents or candidate therapeutic interventions may result in increased drug availability. For example, in some cases of decreased gastric emptying, there is an enhanced degree of absorption by prolonging contact with gastrointestinal mucosal membranes. In others, a change in the solubility of the drug may enhance the passive transport across the gastrointestinal mucosal membrane.
2. Distribution- Since free drug is the form that renders pharmacologic action and is metabolized and excreted, drug binding may serve to protect the drug from mechanisms of inactivation. The rate and extent of drug binding affects the free drug concentration relative to the total concentration.
3. Metabolism- If drug metabolism induction is occurring and the inducer is rapidly removed without adjustment in the dose of the drug, drug metabolism may be decreased and adverse effects or toxicities may occur.
4. Excretion- If inhibition of active transport of the parent drug or metabolite across the bile cannicula or the renal tubule, there is a net result of enhanced drug availability.

II. Impaired Drug Tolerability and Drug-Induced Disease, Disorder, Dysfunction or Toxicity

In response to chemical substances, drugs, or xenobiotics, drug-induced disease, disorder, dysfunction, or toxicity manifests as cellular damage or organ physiologic dysfunction, with one potentially leading to the other.

Adverse drug reactions can be categorized as 1) mechanism based reactions which are exaggerations of pharmacologic effects and 2) idiosyncratic, unpredictable effects unrelated to the primary pharmacologic action. Although some

side effects appear shortly after administration of a drug, some side effects appear long after drug administration or after cessation of the drug. Furthermore, these reactions can be categorized by reversible or irreversible manifestations of the drug-induced toxicity referring to whether the clinical symptomology subsides or persists upon withdrawal of the offending agent.

In the first category, excessive drug effects may result from alterations of pharmacokinetic parameters by either drug-drug interactions, pathophysiologic disease mediated alterations in the organs or processes involved in absorption, distribution, metabolism, or excretion, or genetic predisposition to heightened pharmacodynamic effect of the drug. The excessive or heightened response may be receptor or drug target or non-receptor or non-drug target mediated.

There are a large number of adverse events that are suspected and or known to occur as a result of administration of a drug, agent, or candidate therapeutic intervention. For example, many antineoplastic agents act by prevention of cell division in dividing cells or promoting cytotoxicity via disruption of DNA synthesis, transcription, and formation of mitotic spindles. These agents, unfortunately, do not distinguish between normal and cancerous cells, e.g. normally dividing cells and cancer cells are equally killed. Therefore, adverse events of antineoplastic agents include bone marrow suppression leading to anemia, leukopenia, and thrombocytopenia; immunosuppression rendering the patient susceptible and vulnerable to infectious agents; and initiation of mutagenesis and the formation of alternate forms of cancer, in many cases, acute myeloid leukemia.

In another example of predictable adverse events related to drug therapy is immunosuppression as a result of therapy to reduce or ablate immune response. This therapy includes but is not exclusive to prevention of graft vs. host or autoimmune disease. These agents, e.g. corticosteroids, cyclosporine, and azathioprine, all suppress humoral or cell-mediated immunity. Patients taking these agents are rendered susceptible to microbial infections, particular opportunistic infections such as cytomegalovirus, pneumocystis carinii, Candida, and sperigillus. Furthermore, long-term immunosuppressive therapy is associated with increased risk of developing lymphoma. Individual drugs are associated with renal injury (cyclosporine) and interstitial pneumonitis (azathioprine).

In the second category of adverse events, idiosyncratic reactions arise often by unpredictable, unknown mechanisms or reactions that evoke immunologic reactions or unanticipated cytotoxicity.

Adverse reactions in this category are often found together, because often it is difficult to ascertain the etiology of the offending reaction. These toxic events can be specific for a target organ, e.g. ototoxicity, nephrotoxicity, hepatotoxicity,

neurotoxicity, etc. or are caused by reactive metabolic intermediates and are toxic or create local damage usually near the site of metabolism.

Immunologic reactions to drugs are thought or result from the combination of the drug or agent with a protein to form an antigenic protein-drug complex that stimulates the immune system response. Without the formation of a complex, most small molecular drugs are unable, alone, to elicit an immunological response. First exposure to the offending drug produces a latent reaction, subsequent exposures usually results in heightened and rapid immunological response. These allergic reactions, characterized by immunohypersensitivity, are most dramatic in anaphylaxis. There are other immune responses that result in adverse reactions or toxicities. They include but are not limited to : 1) immune response mediated cytotoxicity which occurs when the drug-protein complex binds to the surface of a cell and this cell-complex is then recognized by circulating antibodies; 2) serum sickness which occurs when immune complexes of drug and antibody are found in the circulation; and 3) lupus syndromes in which the drug or reactive intermediate interact with nuclear material to stimulate the formation of antinuclear antibodies.

In addition to the immune phenomena described above, there are other drug reactions that are syndromes involving allergic reactions. These reactions include, but are not limited to, skin e rashes, drug induced fever, pulmonary reactions, hepatocellular or cholestatic reactions, interstitial nephritis, and lymphadenopathy. Further, there are some drug reactions that mimic allergic reactions but are not immune related. For example, such reactions are due to direct release of mediators by drugs and are called anaphylactoid reactions. An example of this type of adverse event is reaction to radiocontrast dye.

These are common adverse drug reactions that may prevent a candidate therapeutic intervention from use, continued development, and marketing rights. Some of these reactions are reversible, others are not.

Adverse drug reactions include, but are not limited to, the following organs systems: a) hemostasis which encompass blood dyscrasias (feature of over half of all drug-related deaths) which are bone marrow aplasia, granulocytopenia, aplastic anemia, leukopenia, pancytopenia, lymphoid hyperplasia, hemolytic anemia, and thrombocytopenia; b) cutaneous which encompass urticaria, macules, papules, angioedema, morbilliform-maculopapular rash, toxic epidermal necrolysis, erythema multiforme, erythema nodosum, contact dermatitis, vesicles, petechiae, exfoliative dermatitis, fixed drug eruptions, and severe skin rash (Stevens-Johnson syndrome); c) cardiovascular which includes arrhythmias, QT prolongation, cardiomyopathy, hypotension, or hypertension; d) renal which includes glomerulonephritis and tubular necrosis; e) pulmonary which includes asthma, acute pneumonitis,

eosinophilic pneumonitis, fibrotic and pleural reactions, and interstitial fibrosis; f) hepatic which includes steatosis, hepatocellular damage and cholestasis; g) systemic which includes anaphylaxis, vasculitis, fever, lupus erythematosus syndrome; and h) the central nervous system which includes tinnitus and dizziness, acute dystonic reactions, parkinsonian syndrome, coma, convulsions, depression and psychosis, and respiratory depression.

In the cases whereby severe, fatal reactions occur after drug administration, there may be a warning label in the product insert.

For example, tricyclic antidepressants can cause central nervous system depression, seizures, respiratory arrest, cardiac arrhythmias and arrest. The mechanism for the injury is a result of the increased synaptic concentrations of biogenic amines and inhibition of postsynaptic receptors.

Acetaminophen can cause hepatic necrosis as a result of prolonged high dose usage or overdose. In the hepatocyte, acetaminophen is converted to a toxic metabolite that binds to glutathione. As the concentration of acetaminophen increases the levels of glutathione are depleted and the toxic acetaminophen metabolite then binds liver macromolecules. Aggregation of polymorphonuclear neutrophils in hepatic microcirculation may cause ischemia and foster necrotic events.

Halothane can cause hepatic necrosis as well as prodrome fever and jaundice. Interestingly, the liver effects of halothane are usually after a first time exposure. The hepatic reaction is thought to occur via a genetic predisposition to deranged metabolism with the formation of toxic metabolites.

III. Pharmacokinetic Parameters as Potential Mechanisms of Drug-Induced Adverse Reactions Leading to Disease, Disorder, Dysfunction or Toxicities

A. Absorption

Absorption is the pharmacokinetic parameter that describes the rate and extent of the drug, agent, or candidate therapeutic intervention leaves the site of administration. Although absorption is critical for the drug, agent, or candidate therapeutic intervention to ultimately reach the site of physiologic action, the term bioavailability is the parameter that is clinically relevant. Bioavailability is the term used to define the extent to which the active component of the drug, agent, or candidate therapeutic intervention reaches its site of physiologic action or a biological fluid to which has access to the site of biological action. Although bioavailability is related to all pharmacokinetic parameters, e.g. absorption, distribution, metabolism, and excretion, bioavailability is primarily dependent on the

first ability of the drug, agent, or candidate therapeutic intervention to be absorbed from the site of delivery, i.e. cross cellular membranes.

There are many factors that influence absorption of a drug, agent, or candidate therapeutic intervention. For example, compound solubility, conditions of absorption, and route of administration. In the present invention, we concern ourselves with genes that are involved in the active or passive process of drug, agent, or candidate therapeutic intervention absorption through a biological membrane.

The absorption surface is dependent on the route of administration. For example, absorption of drugs can occur via 1) oral (enteral); 2) sublingual; 3) injections (parenteral, i.e., intravenous, intramuscular, intraarterial, intrathecal, intraperitoneal, or subcutaneous); 4) rectal; 5) inhalation (pulmonary); 6) topical application (skin and eye). In each of these routes of administration, the adsorption rate and extent is dependent on the concentration of the drug at the site, the patency of the epithelial cells, local biological conditions, and function of the active or passive transport.

Absorption can affect both the efficacy and safety of a drug, agent, or candidate therapeutic intervention. For example, for a compound to achieve full pharmacologic potential, it must be available at the target site, be active, and be unbound. In regards to safety, absorption affects safety in one or more of the following: site of delivery pain, necrosis, or irritation; rate of administration; and erratic available concentrations.

B. Distribution

The distribution of the drug, agent, or candidate therapeutic intervention is dependent on the rate and extent the compound enters the bloodstream. Once in the bloodstream, the compound may be distributed to the interstitial and cellular fluids. The distribution of drugs to target tissues can be categorized into two phases. The first distribution phase, is dependent on cardiac output and regional blood flow, both of which are dependent on the health and status of the cardiovascular system. In a second distribution phase, diffusion into tissues is dependent on the level and extent that the drug, agent, or candidate therapeutic intervention is bound. Drug binding by proteins found in the blood can serve to protect the compound from modifications by enzymes, proteins, or compounds in the circulation and or limit the bioavailability of the compound to enter target tissues or individual cells.

Drug entry into tissues requires free drug, and drug binding proteins may limit this active or passive transport. Once distributed into tissues, the drug may be

sequestered within that tissue, to render full pharmacologic activity or to prevent that drug from reaching the appropriate target tissue.

Distribution can affect both the efficacy and safety of a drug, agent, or candidate therapeutic intervention. For example, for a compound to achieve full pharmacologic potential, it must be available at the target site, be active, and be unbound. In regards to safety, distribution affects safety in one or more of the following: distribution to a tissue that is more or less affected by the pharmacologic action of the compound, erratic available concentrations, and tissue specific distribution characteristics.

C. Metabolism

Drugs or xenobiotics, are usually found in the circulation bound to plasma proteins, generally but not exclusive to serum albumin. It is the bound form of the drug that is taken up by the hepatocyte. Bile salts in the circulation are taken up via organic anion transporters. Once inside the hepatocyte, the drug or bile salt is a substrate for a series of reactions that are either oxidative or reductive or reactions that are conjugative steps in the metabolism of the substrate. Generally these chemical modifications are a refined process to render the substrate more hydrophilic, or polar, to be more likely excreted in the bile (via the intestinal tract) or urine (via the kidneys). However, there are exceptions whereby the redox reactions produce reactive intermediates or products that retard elimination. Except for their role in detoxification, there is little in common among the enzymes involved in the redox detoxification reactions. For certain enzymes there are specific groups that will act as substrates, for others there are general classes of chemical compounds that will be suitable substrates for a given enzyme or enzymes.

In the mammalian liver these mechanisms to detoxify and/or enhance the excretion of metabolic by-products, endogenous substrates, and exogenous molecules. The ability to determine whether hepatic function is inadequate is based upon clinical observation, e.g., the presence of jaundice, right upper quadrant abdominal discomfort or pain, pruritis, or by clinical laboratory analyses, e.g., aspartate transaminase (AST or SGOT) or alanine transferase (ALT or SGPT). The hepatic metabolic and excretory mechanisms are critical for short- and long-term survival and are inheritable characteristics. These hepatic biotransformations mechanisms have broad substrate specificity that have been evolutionarily inherited for the host protection from environmental, biological, and chemical substances.

There are two categories of drug, agent, or candidate therapeutic intervention biotransformation (metabolism). In the first, phase I, functionalization reactions occur. Phase I reactions introduce or expose a functional group to the parent

compound. In general, phase I reactions render the parent compound pharmacologically inactive, however there are examples of phase I reaction activation or retention of activity. In phase II reactions, biosynthetic reactions occur. Phase II conjugation reactions leads to a covalent linkage between a functional group on the parent compound with glucuronic acid, sulfate, glutathione, amino acids, or acetate. The metabolic conversion of drugs is the liver, however, all tissues have enzymatic activity.

Factors affecting drug biotransformation are 1) induction of metabolizing enzymes, 2) inhibition of enzymatic reactions, and 3) genetic polymorphisms. It is the interplay of these factors and the health and well being of the patient or subject that determines the fate of parent drug molecules in the body.

The first factor affecting drug biotransformation is induction of metabolizing enzyme activity. The metabolic processes that modify drugs or chemicals (oxidation, reduction, or conjugation) can be induced to significant enzymatic activity. Under physiological conditions, the induction process is in place to coordinately metabolize excess substrates. The induction process can be both at the level of enzymatic activity and increased protein levels of the pertinent enzyme or enzymes. Induction may include one or several of the enzymatic pathways or processes in response to the presence of drugs, xenobiotics, endogenous substrates, or metabolic by-products. There may or may not be increased toxicity as a result of increased concentrations of metabolites. Further, induction of phase I reactive processes (oxidation or reduction reactions) may or may not induce the phase II reactive processes (conjugation reactions).

The second factor affecting drug biotransformation is the inhibition of metabolic enzymes. Enzymatic inhibition can occur via 1) competition of two or more substrates for the enzymatic active site, 2) suicide inhibitors, or 3) depletion of required cofactors for the enzymatic pathways or processes in phase I or phase II reactions.

In competitive inhibition, two or more drugs, xenobiotics, or substrates present can interact with the active site of the enzyme. If one drug binds specifically to the enzymatic active site or to an other intracellular regulatory protein molecule, other compounds are blocked from binding and remain unbound. In this case, unmetabolized parent drug or xenobiotic remains in the circulation, potentially for extended periods of time. Competitive inhibition is dependent on the relative specificity of the substrates for the enzymatic active site and the concentration of the drugs or substrates. An example of competitive drug biotransformation inhibition are cimetidine and ketoconazole which inhibit oxidative drug metabolism by forming a tight complex with the heme iron complex of cytochrome P450, and

macrolide antibiotics such as erythromycin and troleandomycin are metabolized to products bind to heme groups on the cytochrome P450 molecules.

In the second case, the inhibition of enzymes involved in the drug biotransformation process may also occur by suicide inactivation. In these cases, the drug or xenobiotic may interact and covalently modify or render inactive the enzyme involved in the metabolic pathway. In this way, the parent drug compound or molecule is not metabolized, nor is it free to interact with another molecule. Examples of suicide inactivators are secobarbital and synthetic steroids (norethindrone or ethinyl estradiol) which bind to cytochrome P450 and destroy the heme portion of the enzyme unit.

In the third case, inhibition of the enzymes involved in the drug biotransformation pathway can also occur by agents or compounds or physiological status that deplete NADPH or other cofactors required for the enzymatic reactions to occur. In the cases of phase I oxidation or reduction, lack of oxygen or NADPH, may reduce the efficiency and activity of a particular enzyme. In phase II reactions, cofactors provide specific groups for the enzymatic covalent modification of the drug or xenobiotic. These phase II cofactors are required for conjugation biotransformation reactions to occur and depletion of these cofactors would be rate limiting.

The third factor that can affect drug biotransformation is genetic polymorphism. Differences among individuals to metabolize drugs have long been known. Observed phenotypic differences, as determined by amount of drug excreted, through polymorphically controlled pathway/s has lead to a generalized classification of slow (poor) metabolizers and fast (rapid or extensive) metabolizers. In general, poor metabolizers are those with impaired metabolism of a drug via a polymorphic pathway have been associated with an increased incidence of adverse effects. In addition, to date all major deficiencies in drug metabolizing activity are inherited as autosomal recessive traits. Fast or rapid metabolizers are those individuals with processes that extensively metabolize a drug via a polymorphic pathway. The fast or rapid metabolizers have been associated with an increased incidence of ineffective treatment. In these individuals active drug is rapidly metabolized to less active or inactive metabolites such that a reassessment of the pharmacokinetic parameters and dosing regimen may require analysis or readjustment, respectively, for appropriate therapy to occur.

The first observed and catalogued genetic polymorphism associated with drug metabolism was described for isoniazid. Isoniazid is a primary drug prescribed for the chemotherapy of tuberculosis. Marked interindividual variation in the elimination of this drug was observed and genetic studies of families revealed that

005280-000000

1005230" 62134960

this variation was genetically controlled. Isoniazid is predominantly metabolized via N-acetylation. In the analysis of the phenotypically distinct individuals, it was shown that slow acetylators were homozygous for a recessive gene and fast acetylators were homozygous or heterozygous for the wild type gene. It has been determined that the incidence of the slow acetylator phenotype is approximately 50% for U.S. caucasians and blacks, 60-70% of Northern Europeans, and 5-10% in Asians. Other drugs have been shown to be polymorphically acetylated, e.g. sulfonamides (sulfadiazine, sulfamethazine, sulfapyridine, sulfameridine, and sulfadoxine), aminogluthethimide, amonafide, amrinone, dapsone, dipyrone, endralazine, hydralazine, prizidilol, and procainamide. Other drugs that first undergo metabolism and then polymorphically acetylated are clonazepam and caffeine.

Another common genetic polymorphism associated with oxidative metabolism is exemplified by the drug debrisoquine (a sympatholytic antihypertensive). It was discovered that variable inter-patient hypotensive response was due to differing metabolic rates of debrisoquine 4-hydroxylase. Further analysis of family studies revealed that oxidative metabolic reactions are under monogenic control. A cytochrome P450 enzyme, CYP2D6, was determined to be the target gene for debrisoquine 4-hydroxylase activity. Poor metabolizers of desbrisoquine are homozygous for a recessive CYP2D6 allele and rapid or fast metabolizers are homozygous or heterozygous for the wild type CYP2D6 allele. Urinary metabolic ratio can be determined after administration of a probe drug and phenotypic assignments (poor or extensive metabolizer) can be identified. The extent of debrisoquine metabolic analysis achieved clinical importance as it was determined that other drugs were poorly metabolized in individuals that poorly metabolized debrisoquine. For example, anti-arrhythmics such as flecainide, propafenone, and mexiletine; antidepressants such as amitriptyline, clomipramine, desipramine, fluoxetine, imipramine, maprotiline, mianserin, paroxetine, and nortriptyline; neuroleptics such as haloperidol, perphenazine, and thioridazine; antianginals such as perhexilene; opioids such as dextromethorphan and codeine; and amphetamines such as methylenedioxymethamphetamine. Further, many β -adrenergic antagonists are metabolized and are subject to polymorphic influence in elimination patterns.

Another example of a genetic polymorphism affecting oxidative metabolism was described for mephenytoin, a drug prescribed for epilepsy. It was shown that a deficiency in the 4'-hydroxylation of S-mephenytoin is inherited as an autosomal recessive trait. The other main metabolic pathway, N-methylation of R-mephenytoin to 5-phenyl-5-ethylhydantoin remains unaffected. Individuals with poor metabolic rate of mephenytoin are subject to adverse central effects, i.e.

sedation. Other drugs can be grouped into the poor mephenytoin metabolizers are mephobarbital, hexobarbital, side-chain oxidization of propanolol, the demethylation of imipramine, and the metabolism of diazepam and desmethyldiazepam. Further analysis of other drugs such as the metabolism of antidepressant drugs (citalopram), the proton pump inhibitor omeprazol, the antimalarial drugs pantoprazole and lansoprazole cosegregate with mephenytoin metabolites.

Because the majority of metabolic enzymes for the conduct of drug biotransformation occurs in the liver, impairment of liver function as a result of hepatic pathological conditions or other disease states can lead to alterations of hepatic or other organ metabolic drug biotransformation. Liver disease pathologies such as hepatitis, alcoholic liver disease, fatty liver disease, biliary cirrhosis, and hepatocarcinomas can impair function of normal physiological metabolic pathways. Further, decreases in hepatic circulation as a result of cardiac insufficiency, hypertension, vascular obstruction, or vascular insult can affect the rate and extent of drug biotransformation. For example drugs with a high hepatocyte extraction ratio would have different metabolism rates affected by alterations of hepatic circulation. Changes in liver blood flow can affect the rate and extent of the metabolism and the clearance of the parent drug. In all cases of hepatic pathological conditions, the affect on drug biotransformation and clearance of parent drugs or metabolized products will be dependent on the severity and extent of the liver organ and hepatocellular damage.

Although hepatic damage may affect the metabolism and clearance of a parent drug or metabolic by-product, residual concentrations of parent drug or metabolic by-products may be deleterious to the liver and its metabolic functions. Following nonparenteral (enteral) administration of a drug, a significant portion of the drug will be metabolized by intestinal or hepatic enzymes before it reaches the general circulation. This first pass effect may generate active drug (administered drug was a prodrug), inactive drug, or toxic drug. Prior to circulation of the metabolized product, circulation to the kidney, the major organ for excretion of the hydrophilic moiety, and excretion via the urine will occur. Therefore, a metabolic product of hepatic metabolic pathways can affect the liver, kidney, and other organs of the body prior to excretion.

1. Phase I Drug Biotransformation: Oxidation and Reduction Reactions

Enzymatic Oxidation of Drugs

In oxidative metabolism, oxidases catalyze the transfer of electrons from substrate to oxygen, generating either hydrogen peroxide or superoxide anions. There are two oxidases present in hepatocytes; they are aldehyde oxidases and

Xanthine oxidase in intact tissues is present as a NAD-dependent dehydrogenase, and is converted to an oxidase when there is disruption of the tissue, for example during hepatic cellular damage.

Monoamine oxidase is present in two forms, A and B. They are dimeric proteins consisting of identical subunits and FAD is covalently linked to the protein through a cysteinyl residue. Catalytic cycles of monoamine oxidases A or B occur in discrete steps that take an amine and convert it to an aldehyde, while in the process creating hydrogen peroxide and ammonia. These oxidases have a broad specificity; they protect mitochondrial proteins from xenobiotic amines and hydrazines. Further neurotransmitters are metabolized through this route, e.g. serotonin, dopamine, and catecholamines. Primary alkylamines containing unsubstituted methylene group or groups adjacent to the nitrogen exhibits activity. Activity increases as the length of a side chain, with optimal side length being C6. These enzymes also catalyze the oxidation of secondary and tertiary amines and acyclic amines. Hydrazines can be oxidized by these oxidases. Substrates for monoamine oxidases include but are not exclusive to the following amines: benzylamine, dopamine, tyramine, epinephrine, N-methylbenzylamine, and N,N-dimethylbenzylamine; and the following hydrazines: procarbazine 1,2-dimethylhydrazine.

The liver microsomal P-450 system consists of a flavoprotein, and a family of related, but distinct, hemoproteins. The flavoprotein catalyzes the transfer of the electrons from NADPH to the hemoprotein, and is the mono-oxygenase. The reaction also requires phosphatidylcholine. The reductase is a monomeric flavoprotein that contains both FAD and FMN. The reductase is specific for NADPH as a reductant, but other oxidants can be substituted. In addition to cytochrome P-450, the flavoprotein catalyzes reduction of quinones, nitro, and azo compounds.

There are many P450 gene families. Subsequent cloning and sequence determination has afforded the ability to divide this gene family into three main groups, CYP1, CYP2, and CYP3, that are responsible for the majority of drug biotransformation. There are further subdivisions in each of these families, examples being CYP2D6, CYP3A4, CYP2E1, as well as others.

Examples of enzymatic inductive processes that affect biotransformation reactions involve the P450 gene family. Specifically, glucocorticoids and anticonvulsants induce CYP3A4; isoniazid, acetone, and chronic ethanol consumption for CYP2E1. Many inducers of the cytochrome P450 enzymes also induce conjugation metabolic enzymes, e.g. glucuronosyltransferases.

In contrast to the monooxygenases, multiple forms of the terminal oxidase (P-450) are present in the hepatocyte. There are many distinct isoforms characterized in different species including humans. It should be noted that mitochondrial P-450 exhibit little or no activity in the metabolism of drugs, xenobiotics, biological compounds, or chemicals. Representative functional groups oxidated by the microsomal P-450 system are as follows: alkanes (hexane, decane, hexadecane); alkenes (vinyl chloride, aflatoxin-B1, dieldrin); aromatic hydrocarbons (naphthylene, bromobenzene, benzo(a)pyrene, biphenyl); aliphatic amines (aminopyrine, benzphetamine, ethylmorphine); heterocyclic amines (3-acetylpyridine, 4,4'-bipyridine, quinoline); amides (N-acetylaminofluorene, urethane); ethers (indemethacin, pheancetin, p-nitroanisole); and sulfides (chlorpromazine, thioanisole).

There are many P450s that have been identified in human liver. Substrate specificities vary among these P-450 dependent mono-oxygenases. For example, P4501A1 prefers polycyclic aromatic hydrocarbons; P-4501A2 prefers arylamines, arylamides; P-450A26 prefers coumarin, 7-ethoxycoumarin; P-450 2C8, 2C9, 2C10 prefers tolbutamide, hexobarbital; P-450 2C18 prefers mephentyoin; P-450 mp-1, mp-2 prefers debrisoquine and related amines; P450 2E1 prefers ethanol, N-nitrosoalkylamines, vinyl monomers; P-450 3A3, 3A4, 3A5, 3A7 prefers dihydropyridines, cyclosporin, lovastatin, aflatoxins.

The effect of genetic polymorphism of the P450s has been known for some time. For example, debrisoquine and related drugs; alfentanil, tolbutamide; (S)mephentyoin. Because the P450s can be induced by xenobiotics, an enhanced metabolic rate or efficiency can lead to one drug affecting the potency, efficacy, dosing of another. For example, women taking rifampicin or barbiturates can lead to metabolic inactivation of synthetic oral contraceptives.

The flavin-containing mono-oxygenases are the principle enzymes catalyzing the N-oxidation of tertiary amine drugs to N-oxides. The N-oxides are found in

abundance in serum. Although isoforms have been identified and the catalytic cycle is similar to the cytochrome P450 system, flavin-containing mono-oxygenases substrate specificity differs. Unlike the other flavin-bearing mono-oxygenases, these flavin-containing mono-oxygenases are present in the cell as very reactive oxygen-activated form. It is believed that particular protein structure stabilizes the nucleophilic molecule. Since the molecule is so highly reactive, precise substrate-to-enzyme fit is unnecessary. The following lists substrate types and examples oxidized by the flavin-containing mono-oxygenases: tertiary amines (trifluoperazine, bromopheniramine, morphine, nicotine, pargyline); secondary amines (desipramine, methamphetamine, propanolol); hydrazines (1,1-demethylhydrazine, N-aminopiperidine, 1-methyl-1-phenylhydrazine); thiols and disulfides (dithiothreitol, β -mercaptomethanol, thiophenol); thiocarbamides (thiourea, methimazole, propylthiouracil); sulfides (dimethylsulfide, sulindac sulfide).

Examples of drugs that undergo oxidative reactions are: N-dealkylation (imipramine, diazepam, codeine, erythromycin, morphine, tamoxifen, theophylline); O-dealkylation (codeine, indomethacin, dextromethorphan); aliphatic hydroxylation (tolbutamide, ibuprofen, pentobarbital, meprobamate, cyclosporin, midazolam); aromatic hydroxylation (phenytoin, phenobarbital, propanolol, phenylbutazone, ethinyl estradiol); N-oxidation (chlorpheniramine, dapsone); S-oxidation (cimetidine, chlorpromazine, thioridazine); deamination (diazepam, amphetamine).

Enzymatic Reduction of Drugs

The reductases are a class of enzymes that are involved in the metabolic reduction of xenobiotics. This class of enzymes includes the aldehyde and ketone reductases, the quinone reductases, the nitro and nitroso reductases, the azoreductases, the N-oxide reductases, and the sulfoxide reductases. These classes of enzymes are involved in sequential one-electron reduction of some functional groups and produce radicals that can produce damage cellular components directly or indirectly.

The dehydrogenases consist of alcohol dehydrogenases, aldehyde dehydrogenases, or dihydrodiol dehydrogenases. This class of enzymes is involved in the catalysis of hydrogen transfer to a hydrogen acceptor, usually a pyridine nucleotide.

Hydrolysis of Drugs

Alternative reactions of detoxification and metabolism of drugs and xenobiotics are initial steps of hydrolysis. Esters, amides, imides, or other

functional groups that are generated as a result of a hydrolysis reaction can alter the hydrophilicity of a molecule and enhance urinary excretion. Hydrolysis occurs both enzymatically and nonenzymatically. Hydrolysis of proteins before they are degraded has been suggested as a step in the process of the aging of intracellular proteins. Antibodies with an affinity for certain esters and certain proteases e.g. 3-phosphoglyceraldehyde dehydrogenase and carbonic anhydrase, have been shown to have esterase activity.

Enzymatic hydrolysis of drugs and xenobiotics include the following enzymes: esterases, amidases, imidases, and epoxide hydratases. Examples of drugs undergoing hydrolysis reactions are: procaine, aspirin, clofibrate, lidocaine, procainamide, indomethacin.

Other hydrolytic processes include reactions owing to both enzymes in tissues, circulation, and those elaborated by microorganisms in the lower bowel; for example, sulfatases, glucuronidases, and phosphatases.

2. Phase II Drug Biotransformation: Conjugation Reactions

In addition, to the redox reactions of the hepatocyte to detoxify or metabolize xenobiotics, there are a series of conjugation reactions. The substrates for these reactions are generally the products from the redox reactions described above. These conjugation reactions involve donation of a suitable hydrophilic molecular group to an accepting xenobiotic or its metabolite. The major function of these covalent modifications is to render the parent compound pharmacologically inactive. The covalent addition of such a group to a parent drug or compound not only inactivates the substrate but also renders the recipient molecule more polar and is more readily excreted via the bile ducts into the intestinal tract or via the urine.

Lipophilic compounds that have one of the functional groups that can serve as an acceptor undergo enzymatic catalysis with a second, donor substrate. The conjugation reactions include the following broad categories: glucuronidation, sulfation, methylation, N-acetylation, and conjugation with amino acids. The enzymes involved in these reactions are as follows: UDP-glucuronyltransferase, alcohol sulfotransferase, amine N-sulfotransferase, phenol sulfotransferase, glutathione transferase, catechol O-methyltransferase, amine N-methyltransferase, histamine N-methyltransferase, thiol S-methyltransferase, benzoyl-CoA glycine acyltransferase, acetyltransacetylase, cysteine S-conjugate N-acetyltransferase, cysteine S-conjugate N-acetyltransferase, cysteine conjugate β -lyase, thioltransferase, and rhodanese. Each of these enzymes has donor and acceptor specificities. The importance of these reactions in the detoxification and metabolism of drugs and xenobiotics are discussed in the examples

Examples of drugs that are known to be conjugated are: glucuronidation (acetaminophen, morphine, diazepam); sulfation (acetaminophen, steroids, methyldopa); acetylation (sulfonamides, isoniazid, dapsone, clonazepam).

5 D. Excretion

Excretion of parent drugs and metabolites can occur in the excretory organs, namely the kidneys, liver, lungs, skin, and breasts (milk). The kidneys are the most important organs for the excretion of drugs and metabolites. Renal excretion involves glomerular filtration, active tubular absorption, and passive tubule
10 reabsorption. The more hydrophilic the compound is the more readily excreted via urine. In addition, many drugs and metabolites are excreted via the bile into the intestinal tract. These metabolites may be excreted in the feces, or may be reabsorbed by the gastrointestinal epithelial cell lining. Organic anions and cations, steroids, fatty acids, and other drugs may be specifically transported into the bile
15 canniculus.

In all of the metabolism and excretion routes, the physiologic goal is to detoxify and rid the body of drugs, xenobiotics, endogenous or exogenous chemicals, or compounds that may or may not be deleterious to the major organs of the body. In principle the detoxification mechanisms function to attain this goal,
20 however there are many cases of major organ toxicity upon exposure to drugs or metabolites of drugs. Although drugs and drug metabolites predominantly affect the liver and kidneys due to the circulatory and physiological processes, other organs can be affected. In the present invention, we address specific genes that may have polymorphic sites affecting metabolic rates to ultimately affect these major organ
25 functions.

1. Excretion of Drugs and Drug Metabolites via the Bile

After parent drugs or xenobiotics are metabolized by redox and or conjugation reactions, the modified products can then be actively transported into
30 the bile cannicula. The transport occurs in an energy dependent fashion requiring ATP. It has been shown that the transporters involved in the active transport from the basolateral (sinusoidal) to the apical (canalicular) surfaces of hepatocytes are members of the ATP binding cassette (ABC) family. The transmembrane electrical potential required to maintain the chemical and electrical potentials required for this
35 active transport is provided by the Na⁺/K⁺ ATPases located on the basolateral membrane. Other ion transporters are the potassium channel, sodium-bicarbonate symporter, chloride-bicarbonate anion exchanger, and the chloride channel. In the cholangiocyte there are other ion transporters, for example chloride-bicarbonate

anion exchanger, isoform 2, and other organic-solute transporters. Bile acids, phosphatidyl choline, organic anions, organic cations, and cholesterol are actively transported. Approximately 5% of the transporters is multi-drug resistance protein 1 (MDR1) and the remaining are the phospholipid transporter multi-drug resistance protein 3 (MDR3), alicular multispecific organic- anion transporter (multi-drug resistance associated protein (MRP2 or cMOAT), canalicular bile-salt-export pump (BSEP or SPGP(sister of p-glycoprotein)), sodium-taurocholate cotransporter, organic anion-transporting polypeptide, glutathione transporter, and a chloride-bicarbonate anion exchanger are also involved in the transport.

These transporters have been identified to move specific molecules or compounds across biological membranes. For example, the MDR1 protein mediates the canicular excretion of bulky lipophilic cations, e.g. anticancer drugs, calcium channel blockers, cyclosporine A, and various other drugs. In contrast, the MDR3 protein transports phosphatidyl choline from the inner leaflet to the outer leaflet of the canicular membrane. Phosphatidyl choline then can be selectively extracted by intracanicular bile salts and secreted into bile as vesicles or mixed micelles. MRP2 is involved in the transport of amphipathic anionic substrates e.g. leukotriene C4, glutathione-S conjugates, glucuronides (bilirubin diglucuronide and estradiol-17 β -glucuronide), sulfate conjugates, and is responsible for the generation of bile flow independent of bile salts within the bile canicula. SPGP is the canicular bile salt export pump in the mammalian liver.

The hepatocyte has the ability to recruit the ATP-requiring transporters when faced with excessive metabolites. After synthesis, these transporters are stored in compartments that, in response to cAMP, can be actively moved through the cell to the membrane and fused to the canicula. The active movement from the intracellular compartment to the membrane requires microtubules, cytoplasmic kinesin, cytoplasmic dynein, and calcium. It has been shown that peptides activate phosphoinositide 3 kinase, and increased turnover of phosphoinositides drives the formation of 3'-phosphoinositol, which can activate the transporter in the membrane and ultimately increases movement to the canicular membrane. Signaling pathways via the activation of rab5 stimulate the active movement of the transporters to the internal compartment.

2. Excretion of Drugs and Drug Metabolites via the Kidney

Excretion of drugs or drug metabolites via the kidney and into the urine involves three processes: 1) glomerular filtration, 2) active tubular secretion, and 3) passive tubular reabsorption. The amount of drug or metabolites entering the tubular lumen is dependent on its fractional plasma protein binding and glomerular filtration

rate. In the proximal renal tubule anions and cations are actively transported by carrier mediated tubular secretion and bases are transported by a separate system that secretes choline, histamine, and other endogenous bases. In the proximal and distal tubules there is passive reabsorption of these molecules. The concentration
5 gradient for back-diffusion is created by sodium and other inorganic ions and water.

IV. Identification of interpatient variation in response; identification of genes and variances relevant to drug action; development of diagnostic tests; and use of variance status to determine treatment

10 Development of therapeutics in man follows a course from compound discovery and analysis in a laboratory (preclinical development) to testing the candidate therapeutic intervention in human subjects (clinical development). The preclinical development of candidate therapeutic interventions for use in the
15 treatment of human diseases, disorders, or conditions begins at the discovery stage whereby a candidate therapy is tested *in vitro* to achieve a desired biochemical alteration of a biochemical or physiological event. If successful, the candidate is generally tested in animals to determine toxicity, adsorption, distribution, metabolism and excretion in a living species. Occasionally, there are available
20 animal models that mimic human diseases, disorders, and conditions in which testing the candidate therapeutic intervention can provide supportive data to warrant proceeding to test the compound in humans. It is widely recognized that preclinical data is imperfect in predicting response to a compound in man. Both safety and efficacy have to ultimately be demonstrated in humans. Therefore, given economic
25 constraints, and considering the complexities of human clinical trials, any technical advance that increases the likelihood of successfully developing and registering a compound, or getting new indications for a compound, or marketing a compound successfully against competing compounds or treatment regimens, will find immediate use. Indeed, there has been much written about the potential of
30 pharmacogenetics to change the practice of medicine. In this application we provide descriptions of the methods one skilled in the art would use to advance compounds through clinical trials using genetic stratification as a tool to circumvent some of the difficulties typically encountered in clinical development, such as poor efficacy or toxicity. We also provide specific genes, variation in which may account for
35 interpatient variation in treatment response, and further we provide specific exemplary variances in those genes that may account for variation in treatment response.

The study of sequence variation in genes that mediate and modulate the

005280" EETB4960

action of drugs may provide advances at virtually all stages of drug development. For example, identification of amino acid variances in a drug target during preclinical development would allow development of non-allele selective agents. During early clinical development, knowledge of variation in a gene related to drug
5 action could be used to design a clinical trial in which the variances are taken account of by, for example, including secondary endpoints that incorporate an analysis of response rates in genetic subgroups. In later stages of clinical development the goal might be to first establish retrospectively whether a particular problem, such as liver toxicity, can be understood in terms of genetic subgroups, and
10 thereby controlled using a genetic test to screen patients. Thus genetic analysis of drug response can aid successful development of therapeutic products at any stage of clinical development. Even after a compound has achieved regulatory approval its commercialization can be aided by the methods of this invention, for example by allowing identification of genetically defined responder subgroups in new
15 indications (for which approval in the entire disease population could not be achieved) or by providing the basis for a marketing campaign that highlights the superior efficacy and/or safety of a compound coupled with a genetic test to identify preferential responders. Thus the methods of this invention will provide medical, economic and marketing advantages for products, and over the longer term increase
20 therapeutic alternatives for patients.

As indicated in the Summary above, certain aspects of the present invention typically involve the following process, which need not occur separately or in the order stated. Not all of these described processes must be present in a particular method, or need be performed by a single entity or organization or person. Additionally, if certain of
25 the information is available from other sources, that information can be utilized in the present invention. The processes are as follows: a) variability between patients in the response to a particular treatment is observed; b) at least a portion of the variable response is correlated with the presence or absence of at least one variance in at least one gene; c) an analytical or diagnostic test is provided to determine the presence or absence
30 of the at least one variance in individual patients; d) the presence or absence of the variance or variances is used to select a patient for a treatment or to select a treatment for a patient, or the variance information is used in other methods described herein.

A. Identification of Interpatient Variability in Response to a Treatment

35 Interpatient variability is the rule, not the exception, in clinical therapeutics. One of the best sources of information on interpatient variability is the nurses and physicians supervising the clinical trial who accumulate a body of first hand

observations of physiological responses to the drug in different normal subjects or patients. Evidence of interpatient variation in response can also be measured statistically, and may be best assessed by descriptive statistical measures that examine variation in response (beneficial or adverse) across a large number of subjects, including in different patient subgroups (men vs. women; whites vs. blacks; Northern Europeans vs. Southern Europeans, etc.).

In accord with the other portions of this description, the present invention concerns DNA sequence variances that can affect one or more of:

i. The susceptibility of individuals to a disease;

ii. The course or natural history of a disease;

iii. The response of a patient with a disease to a medical intervention, such as, for example, a drug, a biologic substance, physical energy such as radiation therapy, or a specific dietary regimen. (The terms 'drug', 'compound' or 'treatment' as used herein may refer to any of the foregoing medical interventions.) The ability to predict either beneficial or detrimental responses is medically useful.

Thus variation in any of these three parameters may constitute the basis for initiating a pharmacogenetic study directed to the identification of the genetic sources of interpatient variation. The effect of a DNA sequence variance or variances on disease susceptibility or natural history (i and ii, above) are of particular interest as the variances can be used to define patient subsets which behave differently in response to medical interventions such as those described in (iii). The methods of this invention are also useful in a clinical development program where there is not yet evidence of interpatient variation (perhaps because the compound is just entering clinical trials) but such variation in response can be reliably anticipated. It is more economical to design pharmacogenetic studies from the beginning of a clinical development program than to start at a later stage when the costs of any delay are likely to be high given the resources typically committed to such a program.

In other words, a variance can be useful for customizing medical therapy at least for either of two reasons. First, the variance may be associated with a specific disease subset that behaves differently with respect to one or more therapeutic interventions (i and ii above); second, the variance may affect response to a specific therapeutic intervention (iii above). Consider for exemplary purposes pharmacological therapeutic interventions. In the first case, there may be no effect

of a particular gene sequence variance on the observable pharmacological action of a drug, yet the disease subsets defined by the variance or variances differ in their response to the drug because, for example, the drug acts on a pathway that is more relevant to disease pathophysiology in one variance-defined patient subset than in another variance-defined patient subset. The second type of useful gene sequence variance affects the pharmacological action of a drug or other treatment. Effects on pharmacological responses fall generally into two categories; pharmacokinetic and pharmacodynamic effects. These effects have been defined as follows in Goodman and Gilman's Pharmacologic Basis of Therapeutics (ninth edition, McGraw Hill, New York, 1986): "Pharmacokinetics" deals with the absorption, distribution, biotransformations and excretion of drugs. The study of the biochemical and physiological effects of drugs and their mechanisms of action is termed "pharmacodynamics."

Useful gene sequence variances for this invention can be described as variances which partition patients into two or more groups that respond differently to a therapy or that correlate with differences in disease susceptibility or progression, regardless of the reason for the difference, and regardless of whether the reason for the difference is known. The latter is true because it is possible, with genetic methods, to establish reliable associations even in the absence of a pathophysiological hypothesis linking a gene to a phenotype, such as a pharmacological response, disease susceptibility or disease prognosis.

B. Identification of Specific Genes and Correlation of Variances in Those Genes with Response to Treatment of Diseases or Conditions

It is useful to identify particular genes which do or are likely to mediate the efficacy or safety of a treatment method for a disease or condition, particularly in view of the large number of genes which have been identified and which continue to be identified in humans. As is further discussed in section C below, this correlation can proceed by different paths. One exemplary method utilizes prior information on the pharmacology or pharmacokinetics or pharmacodynamics of a treatment method, e.g., the action of a drug, which indicates that a particular gene is, or is likely to be, involved in the action of the treatment method, and further suggests that variances in the gene may contribute to variable response to the treatment method. For example if a compound is known to be glucuronidated then a glucuronyltransferase is likely involved. If the compound is a phenol, the likely glucuronyltransferase is UGT1 (either the UGT1*1 or UGT1*6 transcripts, both of which catalyze the conjugation

of planar phenols with glucuronic acid). Similar inferences can be made for many other biotransformation reactions.

Alternatively, if such information is not known, variances in a gene can be correlated empirically with treatment response. In this method, variances in a gene which exist in a population can be identified. The presence of the different variances or haplotypes in individuals of a study group, which is preferably representative of a population or populations of known geographic, ethnic and/or racial background, is determined. This variance information is then correlated with treatment response of the various individuals as an indication that genetic variability in the gene is at least partially responsible for differential treatment response. It may be useful to independently analyze variances in the different geographic, ethnic and/or racial groups as the presence of different genetic variances in these groups (i.e. different genetic background) may influence the effect of a specific variance. That is, there may be a gene x gene interaction involving one unstudied gene, however the indicated demographic variables may act as a surrogate for the unstudied allele. Statistical measures known to those skilled in the art are preferably used to measure the fraction of interpatient variation attributable to any one variance, or to measure the response rates in different subgroups defined genetically or defined by some combination of genetic, demographic and clinical criteria.

Useful methods for identifying genes relevant to the pharmacological action of a drug or other treatment are known to those skilled in the art, and include review of the scientific literature combined with inferential or deductive reasoning that one skilled in the art of molecular pharmacology and molecular biology would be capable of; large scale analysis of gene expression in cells treated with the drug compared to control cells; large scale analysis of the protein expression pattern in treated vs. untreated cells, or the use of techniques for identification of interacting proteins or ligand-protein interactions, such as yeast two-hybrid systems.

C. Development of a Diagnostic Test to Determine Variance Status

In accordance with the description in the Summary above, the present invention generally concerns the identification of variances in genes which are indicative of the effectiveness of a treatment in a patient. The identification of specific variances, in effect, can be used as a diagnostic or prognostic test. Correlation of treatment efficacy and/or toxicity with particular genes and gene families or pathways is provided in Stanton et al., U.S. Provisional Application 60/093,484, filed July 20, 1998, entitled GENE SEQUENCE VARIANCES WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE (concerns the

safety and efficacy of compounds active on folate or pyrimidine metabolism or action) and Stanton, U.S. Provisional Application No. 60/121,047, filed February 22, 1999, entitled GENE SEQUENCE VARIANCES WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE (concerning Alzheimer's disease and other dementias and cognitive disorders), which are hereby incorporated by reference in their entireties including drawings.

Genes identified in the examples below and in the Tables and Figures can be used in the methods of the present invention. A variety of genes which the inventors realize may account for interpatient variation in patient outcome response to candidate therapeutic interventions are listed in Tables 1 and 3. Gene sequence variances in said genes are particularly useful for aspects of the present invention.

Methods for diagnostic tests are well known in the art. Generally in this invention, the diagnostic test involves determining whether an individual has a variance or variant form of a gene that is involved in the disease or condition or the action of the drug or other treatment or effects of such treatment. Such a variance or variant form of the gene is preferably one of several different variances or forms of the gene that have been identified within the population and are known to be present at a certain frequency. In an exemplary method, the diagnostic test involves determining the sequence of at least one variance in at least one gene after amplifying a segment of said gene using a DNA amplification method such as the polymerase chain reaction (PCR). In this method DNA for analysis is obtained by amplifying a segment of DNA or RNA (generally after converting the RNA to cDNA) spanning one or more variances in the gene sequence. Preferably, the amplified segment is <500 bases in length, in an alternative embodiment the amplified segment is <100 bases in length, most preferably <45 bases in length.

In some cases it will be desirable to determine a haplotype instead of a genotype. In such a case the diagnostic test is performed by amplifying a segment of DNA or RNA (cDNA) spanning more than one variance in the gene sequence and preferably maintaining the phase of the variances on each allele. The term "phase" refers to the relationship of variances on a single chromosomal copy of the gene, such as the copy transmitted from the mother (maternal copy or maternal allele) or the father (paternal copy or paternal allele). The haplotyping test may take part in two phases, where first genotyping tests at two or more variant sites reveal which sites are heterozygous in each patient or normal subject. Subsequently the phase of the two or more variant sites can be determined. In performing a haplotyping test preferably the amplified segment is >500 bases in length, more preferably it is >1,000 bases in length, and most preferably it is >2,500 bases in length. One way of preserving phase is to amplify one strand in the PCR reaction. This can be done

using one or a pair of oligonucleotide primers that terminate (i.e. have a 3' end that stops) opposite the variant site, such that one primer is perfectly complementary to one variant form and the other primer is perfectly complementary to the other variant form. Other than the difference in the 3' most nucleotide the two primers are identical (forming an allelic primer pair). Only one of the allelic primers is used in any PCR reaction, depending on which strand is being amplified. The primer for the opposite strand may also be an allelic primer, or it may prime from a non-polymorphic region of the template. This method exploits the requirement of most polymerases for perfect complementarity at the 3' terminus of the primer in a primer-template complex. See, for example: Lo YM, Patel P, Newton CR, Markham AF, Fleming KA and JS Wainscoat. (1991) Direct haplotype determination by double ARMS: specificity, sensitivity and genetic applications. *Nucleic Acids Res* July 11;19(13):3561-7.

It is apparent that such diagnostic tests are performed after initial identification of variances within the gene, which allows selection of appropriate allele specific primers.

Diagnostic genetic tests useful for practicing this invention belong to two types: genotyping tests and haplotyping tests. A genotyping test simply provides the status of a variance or variances in a subject or patient. For example suppose nucleotide 150 of hypothetical gene X on an autosomal chromosome is an adenine (A) or a guanine (G) base. The possible genotypes in any individual are AA, AG or GG at nucleotide 150 of gene X.

In a haplotyping test there is at least one additional variance in gene X, say at nucleotide 810, which varies in the population as cytosine (C) or thymine (T). Thus a particular copy of gene X may have any of the following combinations of nucleotides at positions 150 and 810: 150A-810C, 150A-810T, 150G-810C or 150G-810T. Each of the four possibilities is a unique haplotype. If the two nucleotides interact in either RNA or protein, then knowing the haplotype can be important. The point of a haplotyping test is to determine the haplotypes present in a DNA or cDNA sample (e.g. from a patient). In the example provided there are only four possible haplotypes, but, depending on the number of variances in the gene and their distribution in human populations there may be three, four, five, six or more haplotypes at a given gene. The most useful haplotypes for this invention are those which occur commonly in the population being treated for a disease or condition. Preferably such haplotypes occur in at least 5% of the population, more preferably in at least 10%, still more preferably in at least 20% of the population and most preferably in at least 30% or more of the population. Conversely, when the goal of a pharmacogenetic program is to identify a relatively rare population that has

an adverse reaction to a treatment, the most useful haplotypes may be rare haplotypes, which may occur in less than 5%, less than 2%, or even in less than 1% of the population. One skilled in the art will recognize that the frequency of the adverse reaction provides a useful guide to the likely frequency of salient causative haplotypes.

Based on the identification of variances or variant forms of a gene, a diagnostic test utilizing methods known in the art can be used to determine whether a particular form of the gene, containing specific variances or haplotypes, or combinations of variances and haplotypes, is present in at least one copy, one copy, or more than one copy in an individual. Such tests are commonly performed using DNA or RNA collected from blood, cells, tissue scrapings or other cellular materials, and can be performed by a variety of methods including, but not limited to, PCR based methods, hybridization with allele-specific probes, enzymatic mutation detection, chemical cleavage of mismatches, mass spectrometry or DNA sequencing, including minisequencing. Methods for haplotyping are described above. In particular embodiments, hybridization with allele specific probes can be conducted in two formats: (1) allele specific oligonucleotides bound to a solid phase (glass, silicon, nylon membranes) and the labeled sample in solution, as in many DNA chip applications, or (2) bound sample (often cloned DNA or PCR amplified DNA) and labeled oligonucleotides in solution (either allele specific or short – e.g. 7mers or 8mers - so as to allow sequencing by hybridization). Preferred methods for diagnostic testing of variances are described in four patent applications Stanton et al, entitled A METHOD FOR ANALYZING POLYNUCLEOTIDES, serial numbers 09/394,467; 09/394,457; 09/394,774; and 09/394,387; all filed September 10, 1999. The application of such diagnostic tests is possible after identification of variances that occur in the population. Diagnostic tests may involve a panel of variances from one or more genes, often on a solid support, which enables the simultaneous determination of more than one variance in one or more genes.

D. Use of Variance Status to Determine Treatment

The present disclosure describes exemplary gene sequence variances in genes identified in a gene table herein (e.g., Table 3), and variant forms of these gene that may be determined using diagnostic tests. As indicated in the Summary, such a variance-based diagnostic test can be used to determine whether or not to

administer a specific drug or other treatment to a patient for treatment of a disease or condition. Preferably such diagnostic tests are incorporated in texts such as are described in Clinical Diagnosis and Management by Laboratory Methods (19th Ed) by John B. Henry (Editor) W B Saunders Company, 1996; Clinical Laboratory
5 Medicine : Clinical Application of Laboratory Data, (6th edition) by R. Ravel, Mosby-Year Book, 1995, or other medical textbooks including, without limitation, textbooks of medicine, laboratory medicine, therapeutics, pharmacy, pharmacology, nutrition, allopathic, homeopathic, and osteopathic medicine; preferably such a test is developed as a 'home brew' method by a certified diagnostic laboratory; most
10 preferably such a diagnostic test is approved by regulatory authorities, e.g., by the U.S. Food and Drug Administration, and is incorporated in the label or insert for a therapeutic compound, as well as in the Physicians Desk Reference.

In such cases, the procedure for using the drug is restricted or limited on the basis of a diagnostic test for determining the presence of a variance or variant form
15 of a gene. Alternatively the use of a genetic test may be advised as best medical practice, but not absolutely required, or it may be required in a subset of patients, e.g. those using one or more other drugs, or those with impaired liver or kidney function. The procedure that is dictated or recommended based on genotype may include the route of administration of the drug, the dosage form, dosage, schedule of
20 administration or use with other drugs; any or all of these may require selecting or determination consistent with the results of the diagnostic test or a plurality of such tests. Preferably the use of such diagnostic tests to determine the procedure for administration of a drug is incorporated in a text such as those listed above, or medical textbooks, for example, textbooks of medicine, laboratory medicine,
25 therapeutics, pharmacy, pharmacology, nutrition, allopathic, homeopathic, and osteopathic medicine. As previously stated, preferably such a diagnostic test or tests are required by regulatory authorities and are incorporated in the label or insert as well as the Physicians Desk Reference.

Variances and variant forms of genes useful in conjunction with treatment
30 methods may be associated with the origin or the pathogenesis of a disease or condition. In many useful cases, the variant form of the gene is associated with a specific characteristic of the disease or condition that is the target of a treatment, most preferably response to specific drugs or other treatments. Examples of diseases or conditions ameliorable by the methods of this invention are identified in the
35 Examples and tables below; in general treatment of disease with current methods, particularly drug treatment, always involves some unknown element (involving efficacy or toxicity or both) that can be reduced by appropriate diagnostic methods.

Alternatively, the gene is involved in drug action, and the variant forms of the gene are associated with variability in the action of the drug. For example, in some cases, one variant form of the gene is associated with the action of the drug such that the drug will be effective in an individual who inherits one or two copies of that form of the gene. Alternatively, a variant form of the gene is associated with the action of the drug such that the drug will be toxic or otherwise contra-indicated in an individual who inherits one or two copies of that form of the gene.

In accord with this invention, diagnostic tests for variances and variant forms of genes as described above can be used in clinical trials to demonstrate the safety and efficacy of a drug in a specific population. As a result, in the case of drugs which show variability in patient response correlated with the presence or absence of a variance or variances, it is preferable that such drug is approved for sale or use by regulatory agencies with the recommendation or requirement that a diagnostic test be performed for a specific variance or variant form of a gene which identifies specific populations in which the drug will be safe and/or effective. For example, the drug may be approved for sale or use by regulatory agencies with the specification that a diagnostic test be performed for a specific variance or variant form of a gene which identifies specific populations in which the drug will be toxic. Thus, approved use of the drug, or the procedure for use of the drug, can be limited by a diagnostic test for such variances or variant forms of a gene; or such a diagnostic test may be considered good medical practice, but not absolutely required for use of the drug.

As indicated, diagnostic tests for variances as described in this invention may be used in clinical trials to establish the safety and efficacy of a drug. Methods for such clinical trials are described below and/or are known in the art and are described in standard textbooks. For example, diagnostic tests for a specific variance or variant form of a gene may be incorporated in the clinical trial protocol as inclusion or exclusion criteria for enrollment in the trial, to allocate certain patients to treatment or control groups within the clinical trial or to assign patients to different treatment cohorts. Alternatively, diagnostic tests for specific variances may be performed on all patients within a clinical trial, and statistical analysis performed comparing and contrasting the efficacy or safety of a drug between individuals with different variances or variant forms of the gene or genes. Preferred embodiments involving clinical trials include the genetic stratification strategies, phases, statistical analyses, sizes, and other parameters as described herein.

Similarly, diagnostic tests for variances can be performed on groups of patients known to have efficacious responses to the drug to identify differences in the frequency of variances between responders and non-responders. Likewise, in

other cases, diagnostic tests for variance are performed on groups of patients known to have toxic responses to the drug to identify differences in the frequency of the variance between those having adverse events and those not having adverse events. Such outlier analyses may be particularly useful if a limited number of patient samples are available for analysis. It is apparent that such clinical trials can be or are performed after identifying specific variances or variant forms of the gene in the population. In defining outliers it is useful to examine the distribution of responses in the placebo group; outliers should preferably have responses that exceed in magnitude the extreme responses in the placebo group.

The identification and confirmation of genetic variances is described in certain patents and patent applications. The description therein is useful in the identification of variances in the present invention. For example, a strategy for the development of anticancer agents having a high therapeutic index is described in Housman, International Application PCT/US/94 08473 and Housman, INHIBITORS OF ALTERNATIVE ALLELES OF GENES ENCODING PROTEINS VITAL FOR CELL VIABILITY OR CELL GROWTH AS A BASIS FOR CANCER THERAPEUTIC AGENTS, U.S. Patent 5,702,890, issued December 30, 1997, which are hereby incorporated by reference in their entireties. Also, a number of gene targets and associated variances are identified in Housman et al., U.S. Patent Application 09/045,053, entitled TARGET ALLELES FOR ALLELE-SPECIFIC DRUGS, filed March 19, 1998, which is hereby incorporated by reference in its entirety, including drawings.

The described approach and techniques are applicable to a variety of other diseases, conditions, and/or treatments and to genes associated with the etiology and pathogenesis of such other diseases and conditions and the efficacy and safety of such other treatments.

Useful variances for this invention can be described generally as variances which partition patients into two or more groups that respond differently to a therapy (a therapeutic intervention), regardless of the reason for the difference, and regardless of whether the reason for the difference is known.

III. From Variance List to Clinical Trial: Identifying Genes and Gene Variances that Account for Variable Responses to Treatment

There are a variety of useful methods for identifying a subset of genes from a large set of candidate genes that should be prioritized for further investigation with respect to their influence on inter-individual variation in disease predisposition or response to a particular drug. These methods include for example, (1) searching the

biomedical literature to identify genes relevant to a disease or the action of a drug,
(2) screening the genes identified in step 1 for variances. A large set of exemplary
variances are provided in Table 3. Other methods include (3) using computational
tools to predict the functional effects of variances in specific genes, (4) using *in vitro*
or *in vivo* experiments to identify genes which may participate in the response to a
drug or treatment, and to determine the variances which affect gene, RNA or protein
function, and may therefore be important genetic variables affecting disease
manifestations or drug response, and (5) retrospective or prospective clinical trials.
Computational tools are described in U.S. Patent Application, Stanton et al., serial
number 09/300,747, filed April 26, 1999, entitled GENE SEQUENCE
VARIANCES WITH UTILITY IN DETERMINING THE TREATMENT OF
DISEASE, and in Stanton et al., serial number 09/419,705, filed October 14, 1999,
entitled VARIANCE SCANNING METHOD FOR IDENTIFYING GENE
SEQUENCE VARIANCES, which are hereby incorporated by reference in their
entireties, including drawings. Other methods are considered below in some detail.

(1) To begin, one preferably identifies, for a given treatment, a set of candidate
genes that are likely to affect disease phenotype or drug response. This can be
accomplished most efficiently by first assembling the relevant medical,
pharmacological and biological data from available sources (e.g., public
databases and publications). One skilled in the art can review the literature
(textbooks, monographs, journal articles) and online sources (databases) to
identify genes most relevant to the action of a specific drug or other treatment,
particularly with respect to its utility for treating a specific disease, as this
beneficially allows the set of genes to be analyzed ultimately in clinical trials to
be reduced from an initial large set. Specific strategies for conducting such
searches are described below. In some instances the literature may provide
adequate information to select genes to be studied in a clinical trial, but in other
cases additional experimental investigations of the sort described below will be
preferable to maximize the likelihood that the salient genes and variances are
moved forward into clinical studies. Specific genes relevant to understanding
interpatient variation in patient outcome response to candidate therapeutic
interventions are listed in Table 1. In Table 2 preferred sets of genes for analysis
of variable therapeutic response in specific diseases are highlighted. These
genes are exemplary; they do not constitute a complete set of genes that may
account for variation in clinical response. Experimental data are also useful in
establishing a list of candidate genes, as described below.

(2) Having assembled a list of candidate genes generally the second step is to screen for variances in each candidate gene. Experimental and computational methods for variance detection are described in this invention, and tables of exemplary variances are provided (Table 3) as well as methods for identifying additional variances and a written description of such possible additional variances in the cDNAs of genes that may affect drug action (see Stanton & Adams, Application No. 09/300,747, application number 09/300,747, filed April 26, 1999, entitled GENE SEQUENCE VARIANCES WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE, incorporated in its entirety.

(3) Having identified variances in candidate genes the next step is to assess their likely contribution to clinical variation in patient response to therapy, preferably by using informatics-based approaches such as DNA and protein sequence analysis and protein modeling. The literature and informatics-based approaches provide the basis for prioritization of candidate genes, however it may in some cases be desirable to further narrow the list of candidate genes, or to measure experimentally the phenotype associated with specific variances or sets of variances (e.g. haplotypes).

(4) Thus, as a third step in candidate gene analysis, one skilled in the art may elect to perform *in vitro* or *in vivo* experiments to assess the functional importance of gene variances, using either biochemical or genetic tests. (Certain kinds of experiments – for example gene expression profiling and proteome analysis - may not only allow refinement of a candidate gene list but may also lead to identification of additional candidate genes.) Combination of two or all of the three above methods will provide sufficient information to narrow and prioritize the set of candidate genes and variances to a number that can be studied in a clinical trial with adequate statistical power.

(5) The fourth step is to design retrospective or prospective human clinical trials to test whether the identified allelic variance, variances, or haplotypes or combination thereof influence the efficacy or toxicity profiles for a given drug or other therapeutic intervention. It should be recognized that this fourth step is the crucial step in producing the type of data that would justify introducing a diagnostic test for at least one variance into clinical use. Thus while each of the above four steps are useful in particular instances of the invention, this final step is indispensable. Further guidance and examples of how to perform these five steps are provided below.

(6) A fifth (optional) step entails methods for using a genotyping test in the promotion and marketing of a treatment method. It is widely appreciated that there is a tendency in the pharmaceutical industry to develop many compounds for well established therapeutic targets. Examples include beta adrenergic blockers, hydroxymethylglutaryl (HMG) CoA reductase inhibitors (statins), dopamine D2 receptor antagonists and serotonin transporter inhibitors. Frequently the pharmacology of these compounds is quite similar in terms of efficacy and side effects. Therefore the marketing of one compound vs. other members of the class is a challenging problem for drug companies, and is reflected in the lesser success that late products typically achieve compared to the first and second approved products. It occurred to the inventors that genetic stratification can provide the basis for identifying a patient population with a superior response rate or improved safety to one member of a class of drugs, and that this information can be the basis for commercialization of that compound. Such a commercialization campaign can be directed at caregivers, particularly physicians, or at patients and their families, or both.

1. Identification of Candidate Genes Relevant to the Action of a Drug

Practice of this invention will often begin with identification of a specific pharmaceutical product, for example a drug, that would benefit from improved efficacy or reduced toxicity or both, and the recognition that pharmacogenetic investigations as described herein provide a basis for achieving such improved characteristics. The question then becomes which genes and variances, such as those provided in this application in Tables 1 and 3, would be most relevant to interpatient variation in response to the drug. As discussed above, the set of relevant genes includes both genes involved in the disease process and genes involved in the interaction of the patient and the treatment – for example genes involved in pharmacokinetic and pharmacodynamic action of a drug. The biological and biomedical literature and online databases provide useful guidance in selecting such genes. Specific guidance in the use of these resources is provided below.

Review the literature and online sources

One way to find genes that affect response to a drug in a particular disease setting is to review the published literature and available online databases regarding the pathophysiology of the disease and the pharmacology of the drug. Literature or online sources can provide specific genes involved in the disease process or drug

response, or describe biochemical pathways involving multiple genes, each of which may affect the disease process or drug response.

Alternatively, biochemical or pathological changes characteristic of the disease may be described; such information can be used by one skilled in the art to infer a set of genes that can account for the biochemical or pathologic changes. For example, to understand variation in response to a drug that modulates serotonin levels in a central nervous system (CNS) disorder associated with altered levels of serotonin one would preferably study, at a minimum, variances in genes responsible for serotonin biosynthesis, release from the cell, receptor binding, presynaptic reuptake, and degradation or metabolism. Genes responsible for each of these functions should be examined for variation that may account for interpatient differences in drug response or disease manifestations. As recognized by those skilled in the art, a comprehensive list of such genes can be obtained from textbooks, monographs and the literature.

There are several types of scientific information, described in some detail below, that are valuable for identifying a set of candidate genes to be investigated with respect to a specific disease and therapeutic intervention. First there is the medical literature, which provides basic information on disease pathophysiology and therapeutic interventions. A subset of this literature is devoted to specific description of pathologic conditions. Second there is the pharmacology literature, which will provide additional information on the mechanism of action of a drug (pharmacodynamics) as well as its principal routes of metabolic transformation (pharmacokinetics) and the responsible proteins. Third there is the biomedical literature (principally genetics, physiology, biochemistry and molecular biology), which provides more detailed information on metabolic pathways, protein structure and function and gene structure. Fourth, there are a variety of online databases that provide additional information on metabolic pathways, gene families, protein function and other subjects relevant to selecting a set of genes that are likely to affect the response to a treatment.

30

Medical Literature

A good starting place for information on molecular pathophysiology of a specific disease is a general medical textbook such as Harrison's Principles of Internal Medicine, 14th edition, (2 Vol Set) by A.S. Fauci, E. Braunwald, K.J. Isselbacher, et al. (editors), McGraw Hill, 1997, or Cecil Textbook of Medicine

35

(20th Ed) by R. L. Cecil, F. Plum and J. C. Bennett (Editors) W B Saunders Co., 1996. For pediatric diseases texts such as Nelson Textbook of Pediatrics (15th edition) by R.E. Behrman, R.M. Kliegman, A.M. Arvin and W.E. Nelson (Editors), W B Saunders Co., 1995 or Oski's Principles and Practice of Pediatrics (3rd Edition) by J.A. Mamillan & F.A. Oski Lippincott-Raven, 1999 are useful introductions. For obstetrical and gynecological disorders texts such as Williams Obstetrics (20th Ed) by F.G. Cunningham, N.F. Gant, P.C. McDonald et al. (Editors), Appleton & Lange, 1997 provide general information on disease pathophysiology. For psychiatric disorders texts such as the Comprehensive Textbook of Psychiatry, VI (2 Vols) by H.I. Kaplan and B.J. Sadock (Editors), Lippincott, Williams & Wilkins, 1995, or The American Psychiatric Press Textbook of Psychiatry (3rd edition) by R.E. Hales, S.C. Yudofsky and J.A. Talbott (Editors) Amer Psychiatric Press, 1999 provide an overview of disease nosology, pathophysiological mechanisms and treatment regimens.

In addition to these general texts, there are a variety of more specialized medical texts that provide greater detail about specific disorders which can be utilized in developing a list of candidate genes and variances relevant to interpatient variation in response to a treatment. For example, within the field of medicine there are standard textbooks for each of the subspecialties. Some specific examples include:

Heart Disease: A Textbook of Cardiovascular Medicine (2 Volume set) by E. Braunwald (Editor), W B Saunders Co., 1996.
Hurst's the Heart, Arteries and Veins (9th Ed) (2 Vol Set) by R.W. Alexander, R.C. Schlant, V. Fuster, W. Alexander and E.H. Sonnenblick (Editors) McGraw Hill, 1998.
Principles of Neurology (6th edition) by R.D. Adams, M. Victor (editors), and A.H. Ropper (Contributor), McGraw Hill, 1996.
Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management (6th edition) by M. Feldman, B.F. Scharschmidt and M. Sleisenger (Editors), W B Saunders Co., 1997.
Textbook of Rheumatology (5th edition) by W.N. Kelley, S. Ruddy, E.D. Harris Jr. and C.B. Sledge (Editors) (2 volume set) W B Saunders Co., 1997.
Williams Textbook of Endocrinology (9th edition) by J.D. Wilson, D.W. Foster, H. M. Kronenberg and Larsen (Editors), W B Saunders Co., 1998.
Wintrobe's Clinical Hematology (10th Ed) by G.R. Lee, J. Foerster (Editor) and J. Lukens (Editors) (2 Volumes) Lippincott, Williams & Wilkins, 1998.

Cancer: Principles & Practice of Oncology (5th edition) by V.T. Devita, S.A.

Rosenberg and S. Hellman (editors), Lippincott-Raven Publishers, 1997.

Principles of Pulmonary Medicine (3rd edition) by S.E. Weinberger & J Fletcher (Editors), W B Saunders Co., 1998.

- 5 Diagnosis and Management of Renal Disease and Hypertension (2nd edition) by A.K. Mandal & J.C. Jennette (Editors), Carolina Academic Press, 1994. Massry & Glassock's Textbook of Nephrology (3rd edition) by S.G. Massry & R.J. Glassock (editors) Williams & Wilkins, 1995.

The Management of Pain by J.J. Bonica, Lea and Febiger, 1992

- 10 Ophthalmology by M. Yanoff & J.S. Duker, Mosby Year Book, 1998

Clinical Ophthalmology: A Systemic Approach by J.J. Kanski, Butterworth-

Heineman, 1994. Essential Otolaryngology by J.K. Lee Appleton and Lange 1998.

- In addition to these subspecialty texts there are many textbooks and
15 monographs that concern more restricted disease areas, or specific diseases. Such books provide more extensive coverage of pathophysiologic mechanisms and therapeutic options. The number of such books is too great to provide examples for all but a few diseases, however one skilled in the art will be able to readily identify relevant texts. One simple way to search for relevant titles is to use the search
20 engine of an online bookseller such as <http://www.amazon.com> or <http://www.barnesandnoble.com> using the disease or drug (or the group of diseases or drugs to which they belong) as search terms. For example a search for asthma would turn up titles such as Asthma : Basic Mechanisms and Clinical Management (3rd edition) by P.J. Barnes, I.W. Rodger and N.C. Thomson (Editors), Academic
25 Press, 1998 and Airways and Vascular Remodelling in Asthma and Cardiovascular Disease : Implications for Therapeutic Intervention, by C. Page & J. Black (Editors), Academic Press, 1994.

Pathology Literature

- In addition to medical texts there are texts that specifically address disease
30 etiology and pathologic changes associated with disease. A good general pathology text is Robbins Pathologic Basis of Disease (6th edition) by R.S. Cotran, V. Kumar, T. Collins and S.L. Robbins, W B Saunders Co., 1998. Specialized pathology texts exist for each organ system and for specific diseases, similar to medical texts. These texts are useful sources of information for one skilled in the art for developing lists
35 of genes that may account for some of the known pathologic changes in disease tissue. Exemplary texts are as follows:

09648123 092500

There are also both general and specialized texts and monographs on pharmacology that provide data on pharmacokinetics and pharmacodynamics of drugs. The discussion of pharmacodynamics (mechanism of action of the drug) in such texts is often supported by a review of the biochemical pathway or pathways that are affected by the drug. Also, proteins related to the target protein are often listed; it is important to account for variation in such proteins as the related proteins may be involved in drug pharmacology. For example, there are 14 known serotonin receptors. Various pharmacological serotonin agonists or antagonists have different affinities for these different receptors. Variation in a specific receptor may affect the pharmacology not only of drugs targeted to that receptor, but also drugs that are principally agonists or antagonists of different receptors. Such compounds may produce different effects on two allelic forms of a non-targeted receptor; for example on variant form may bind the compound with higher affinity than the other, or a compound that is principally an antagonist for one allele may be a partial agonist for another allele. Thus genes encoding proteins structurally related to the target protein should be screened for variance in order to successfully realize the methods of the present invention. A good general pharmacology text is Goodman & Gilman's the Pharmacological Basis of Therapeutics (9th Ed) by J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon and A.G. Gilman (Editors) McGraw Hill, 1996. There are also texts that focus on the pharmacology of drugs for specific

disease areas, or specific classes of drugs (e.g. natural products) or adverse drug interactions, among other subjects. Specific examples include:

The American Psychiatric Press Textbook of Psychopharmacology (2nd edition) by A.F. Schatzberg & C.B. Nemeroff (Editors), American Psychiatric Press, 1998.

5 Essential Psychopharmacology : Neuroscientific Basis and Practical Applications by N. Muntner and S.M. Stahl, Cambridge Univ Press, 1996.

There are also texts on pharmacogenetics which are particularly useful for identifying genes which may contribute to variable pharmacokinetic response. In addition there are texts on some of the major xenobiotic metabolizing proteins, such
10 as the cytochrome P450 genes.

Pharmacogenetics of Drug Metabolism (International Encyclopedia of Pharmacology and Therapeutics) by Werner Kalow (Editor) Pergamon Press, 1992.

Genetic Factors in Drug Therapy : Clinical and Molecular Pharmacogenetics by D.A Price Evans, Cambridge Univ Press, 1993.

15 Pharmacogenetics (Oxford Monographs on Medical Genetics, 32) by W.W. Weber, Oxford Univ Press, 1997.

Cytochrome P450 : Structure, Mechanism, and Biochemistry by P.R. Ortiz de Montellano (Editor), Plenum Publishing Corp, 1995.

20 Appleton & Lange's Review of Pharmacy, 6th edition, (Appleton & Lange's Review Series) by G.D. Hall & B.S. Reiss, Appleton & Lange, 1997.

Genetics, Biochemistry and Molecular Biology Literature

In addition to the medical, pathology, and pharmacology texts listed above there are several information sources that one skilled in the art will turn to for
25 information on the genetic, physiologic, biochemical, and molecular biological aspects of the disease, disorder or condition or the effect of the therapeutic intervention on specific physiologic processes. The biomedical literature may include information on nonhuman organisms that is relevant to understanding the likely disease or pharmacological pathways in man.

30 Also provided below are illustrative texts which will aid in the identification of a pathway or pathways, and a gene or genes that may be relevant to interindividual variation in response to a therapy. Textbooks of biochemistry, genetics and physiology are often useful sources for such pathway information. In order to ascertain the appropriate methods to analyze the effects of an allelic
35 variance, variances, or haplotypes in vitro, one skilled in the art will review existing

information on molecular biology, cell biology, genetics, biochemistry; and physiology. Such texts are useful sources for general and specific information on the genetic and biochemical processes involved in disease and in drug action, as well as experimental procedures that may be useful in performing in vitro research on an allelic variance, variances, or haplotype.

Texts on gene structure and function and RNA biochemistry will be useful in evaluating the consequences of variances that do not change the coding sequence (silent variances). Such variances may alter the interaction of RNA with proteins or other regulatory molecules affecting RNA processing, polyadenylation, or export.

Molecular and Cellular Biology

Molecular Cell Biology by H. Lodish, D. Baltimore, A. Berk, L. Zipurksy & J. Darnell, W H Freeman & Co., 1995.

Essentials of Molecular Biology, D. Freifelder and Malacinski Jones and Bartlett, 1993.

Genes and Genomes: A Changing Perspective, M. Singer and P. Berg, 1991. University Science Books

Gene Structure and Expression, J.D. Hawkins, 1996. Cambridge University Press
Molecular Biology of the Cell, 2nd edition, B. Alberts et al., Garland Publishing, 1994.

Molecular Genetics

The Metabolic and Molecular Bases of Inherited Disease by C. R. Scriver, A.L. Beaudet, W.S. Sly (Editors), 7th edition, McGraw Hill, 1995

Genetics and Molecular Biology, R. Schleif, 1994. 2nd edition, Johns Hopkins University Press

Genetics, P.J. Russell, 1996. 4th edition, Harper Collins

An Introduction to Genetic Analysis, Griffiths et al. 1993. 5th edition, W.H. Freeman and Company

Understanding Genetics: A molecular approach, Rothwell, 1993. Wiley-Liss

General Biochemistry

Biochemistry, L. Stryer, 1995. W.H. Freeman and Company

Biochemistry, D. Voet and J.G. Voet, 1995. John Wiley and Sons

Principles of Biochemistry, A.L. Lehninger, D.L. Nelson, and M.M. Cox, 1993.

Worth Publishers

Biochemistry, G. Zubay, 1998. Wm. C. Brown Communications

Biochemistry, C.K. Mathews and K.E. van Holde, 1990. Benjamin/Cummings

005280 "EAT 960

OMIM record number is provided for many of the genes in Table 1 and 3 (see

column 3), and constitutes an excellent entry point for identification of references that point to the broader literature. Another useful site at NCBI is the Entrez browser, located at <http://www3.ncbi.nlm.nih.gov/Entrez/>. One can search genomes, polynucleotides, proteins, 3D structures, taxonomy or the biomedical literature (PubMed) via the Entrez site. More generally links to a number of useful sites with biomedical or genetic data are maintained at sites such as Med Web at the Emory University Health Sciences Center Library:

<http://WWW.MedWeb.Emory.Edu/MedWeb/>; Riken, a Japanese web site at: <http://www.rtc.riken.go.jp/othersite.html> with links to DNA sequence, structural, molecular biology, bioinformatics, and other databases; at the Oak Ridge National Laboratory web site: <http://www.ornl.gov/hgmis/links.html>; or at the Yahoo website of Diseases and Conditions: http://dir.yahoo.com/health/diseases_and_conditions/index.html. Each of the indicated web sites has additional useful links to other sites.

Another type of database with utility in selecting the genes on a biochemical pathway that may affect the response to a drug are databases that provide information on biochemical pathways. Examples of such databases include the Kyoto Encyclopedia of Genes and Genomes (KEGG), which can be found at: <http://www.genome.ad.jp/kegg/kegg.html>. This site has pictures of many biochemical pathways, as well as links to other metabolic databases such as the well known Boehringer Mannheim biochemical pathways charts: <http://www.expasy.ch/cgi-bin/search-biochem-index>. The metabolic charts at the latter site are comprehensive, and excellent starting points for working out the salient enzymes on any given pathway.

Each of the web sites mentioned above has links to other useful web sites, which in turn can lead to additional sites with useful information. *Research Libraries*

Those skilled in the art will often require information found only at large libraries. The National Library of Medicine (<http://www.nlm.nih.gov/>) is the largest medical library in the world and its catalogs can be searched online. Other libraries, such as university or medical school libraries are also useful to conduct searches. Biomedical books such as those referred to above can often be obtained from online bookstores as described above.

Biomedical Literature

To obtain up to date information on drugs and their mechanism of action and biotransformation; disease pathophysiology; biochemical pathways relevant to drug

action and disease pathophysiology; and genes that encode proteins relevant to drug action and disease one skilled in the art will consult the biomedical literature . A widely used, publicly accessible web site for searching published journal articles is PubMed (<http://www.ncbi.nlm.nih.gov/PubMed/>). At this site, one can search for the most recent articles (within the last 1-2 months) or older literature (back to 1966). Many Journals also have their own sites on the world wide web and can be searched online. For example see the IDEAL web site at:

<http://www.apnet.com/www/ap/aboutid.html>. This site is an online library, featuring full text journals from Academic Press and selected journals from W.B. Saunders and Churchill Livingstone. The site provides access (for a fee) to nearly 2000 scientific, technical, and medical journals.

Experimental methods for identification of genes involved in the action of a drug

There are a number of experimental methods for identifying genes and gene products that mediate or modulate the effects of a drug or other treatment. They encompass analyses of RNA and protein expression as well as methods for detecting protein – protein interactions and protein – ligand interactions. Two preferred experimental methods for identification of genes that may be involved in the action of a drug are (1) methods for measuring the expression levels of many mRNA transcripts in cells or organisms treated with the drug (2) methods for measuring the expression levels of many proteins in cells or organisms treated with the drug.

RNA transcripts or proteins that are substantially increased or decreased in drug treated cells or tissues relative to control cells or tissues are candidates for mediating the action of the drug. Preferably the level of an mRNA is at least 30% higher or lower in drug treated cells, more preferably at least 50% higher or lower, and most preferably two fold higher or lower than levels in non-drug treated control cells. The analysis of RNA levels can be performed on total RNA or on polyadenylated RNA selected by oligodT affinity. Further, RNA from different cell compartments can be analyzed independently – for example nuclear vs. cytoplasmic RNA. In addition to RNA levels, RNA kinetics can be examined, or the pool of RNAs currently being translated can be analyzed by isolation of RNA from polysomes. Other useful experimental methods include protein interaction methods such as the yeast two hybrid system and variants thereof which facilitate the detection of protein – protein interactions. Preferably one of the interacting proteins is the drug target or another protein strongly implicated in the action of the compound being assessed.

09645123 "082500

The pool of RNAs expressed in a cell is sometimes referred to as the transcriptome. Methods for measuring the transcriptome, or some part of it, are known in the art. A recent collection of articles summarizing some current methods appeared as a supplement to the journal *Nature Genetics*. (The Chipping Forecast. Nature Genetics supplement, volume 21, January 1999.) A preferred method for measuring expression levels of mRNAs is to spot PCR products corresponding to a large number of specific genes on a nylon membrane such as Hybond N Plus (Amersham-Pharmacia). Total cellular mRNA is then isolated, labeled by random oligonucleotide priming in the presence of a detectable label (e.g. alpha 33P labeled radionucleotides or dye labeled nucleotides), and hybridized with the filter containing the PCR products. The resulting signals can be analyzed by commercially available software, such as can be obtained from Clontech/Molecular Dynamics or Research Genetics, Inc.

Experiments have been described in model systems that demonstrate the utility of measuring changes in the transcriptome before and after changing the growth conditions of cells, for example by changing the nutrient environment. The changes in gene expression help reveal the network of genes that mediate physiological responses to the altered growth condition. Similarly, the addition of a drug to the cellular or in vivo environment, followed by monitoring the changes in gene expression can aid in identification of gene networks that mediate pharmacological responses.

The pool of proteins expressed in a cell is sometimes referred to as the proteome. Studies of the proteome may include not only protein abundance but also protein subcellular localization and protein-protein interaction. Methods for measuring the proteome, or some part of it, are known in the art. One widely used method is to extract total cellular protein and separate it in two dimensions, for example first by size and then by isoelectric point. The resulting protein spots can be stained and quantitated, and individual spots can be excised and analyzed by mass spectrometry to provide definitive identification. The results can be compared from two or more cell lines or tissues, at least one of which has been treated with a drug. The differential up or down modulation of specific proteins in response to drug treatment may indicate their role in mediating the pharmacologic actions of the drug. Another way to identify the network of proteins that mediate the actions of a drug is to exploit methods for identifying interacting proteins. By starting with a protein known to be involved in the action of a drug – for example the drug target – one can use systems such as the yeast two hybrid system and variants thereof (known to those skilled in the art; see Ausubel et al., Current Protocols in Molecular

005280 "E2T34560"

Biology, op. cit.) to identify additional proteins in the network of proteins that mediate drug action. The genes encoding such proteins would be useful for screening for DNA sequence variances, which in turn may be useful for analysis of interpatient variation in response to treatments. For example, the protein 5-lipoxygenase (5LO) is an enzyme which is at the beginning of the leukotriene biosynthetic pathway and is a target for anti-inflammatory drugs used to treat asthma and other diseases. In order to detect proteins that interact with 5-lipoxygenase the two-hybrid system was recently used to isolate three different proteins, none previously known to interact with 5LO. (Provost et al., Interaction of 5-lipoxygenase with cellular proteins. *Proc. Natl. Acad. Sci. U.S.A.* 96: 1881-1885, 1999.) A recent collection of articles summarizing some current methods in proteomics appeared in the August 1998 issue of the journal *Electrophoresis* (volume 19, number 11). Other useful articles include: Blackstock WP, et al. Proteomics: quantitative and physical mapping of cellular proteins. *Trends Biotechnol.* 17 (3): p. 121-7, 1999, and Patton W.F., Proteome analysis II. Protein subcellular redistribution: linking physiology to genomics via the proteome and separation technologies involved. *J Chromatogr B Biomed Sci App.* 722(1-2):203-23. 1999.

Since many of these methods can also be used to assess whether specific polymorphisms are likely to have biological effects, they are also relevant in section 3, below, concerning methods for assessing the likely contribution of variances in candidate genes to clinical variation in patient responses to therapy.

2. Screen for Variances in Genes that may be Related to Therapeutic Response

Having identified a set of genes that may affect response to a drug the next step is to screen the genes for variances that may account for interindividual variation in response to the drug. There are a variety of levels at which a gene can be screened for variances, and a variety of methods for variance screening. The two main levels of variance screening are genomic DNA screening and cDNA screening. Genomic variance detection may include screening the entire genomic segment spanning the gene from 2 kb to 10 kb upstream of the transcription start site to the polyadenylation site, or 2 to 10 kb beyond the polyadenylation site. Alternatively genomic variance detection may (for intron containing genes) include the exons and some region around them containing the splicing signals, for example, but not all of the intronic sequences. In addition to screening introns and exons for variances it is generally desirable to screen regulatory DNA sequences for variances. Promoter, enhancer, silencer and other regulatory elements have been described in human

genes. The promoter is generally proximal to the transcription start site, although there may be several promoters and several transcription start sites. Enhancer, silencer and other regulatory elements may be intragenic or may lie outside the introns and exons, possibly at a considerable distance, such as 100 kb away.

5 Variances in such sequences may affect basal gene expression or regulation of gene expression. In either case such variation may affect the response of an individual patient to a therapeutic intervention, for example a drug, as described in the examples. Thus in practicing the present invention it is useful to screen regulatory sequences as well as transcribed sequences, in order to identify variances that may
10 affect gene transcription. Frequently the genomic sequence of a gene can be found in the sources above, particularly by searching GenBank or Medline (PubMed). The name of the gene can be entered at a site such as Entrez:
<http://www.ncbi.nlm.nih.gov/Entrez/nucleotide.html>. Using the genomic sequence and information from the biomedical literature one skilled in the art can perform a
15 variance detection procedure such as those described in examples 15, 16 and 17.

Variance detection is often first performed on the cDNA of a gene for several reasons. First, available data on functional sequence variances suggests that variances in the transcribed portion of a gene may be most likely to have functional consequences as they can affect the interaction of the transcript with a wide variety
20 of cellular factors during the complex processes of RNA transcription, processing and translation, with consequent effects on RNA splicing, stability, translational efficiency or other processes. Second, as a practical matter the cDNA sequence of a gene is often available before the genomic structure is known, although the reverse will be true in the future as the sequence of the human genome is determined. Third,
25 the cDNA is often compact compared to the genomic locus, and can be screened for variances with much less effort. If the genomic structure is not known then only the cDNA sequence can be scanned for variances. Methods for preparing cDNA are described in Example 14. Methods for variance detection on cDNA are described below and in the examples.

30 In general it is preferable to catalog genetic variation at the genomic DNA level because there are an increasing number of well documented instances of functionally important variances that lie outside of transcribed sequence. Also, to properly use optimal genetic methods to assess the contribution of a candidate gene to variation in a phenotype of interest it is desirable to understand the character of
35 sequence variation in the candidate gene: what is the nature of linkage disequilibrium between different variances in the gene; are there sites of recombination within the gene; what is the extent of homoplasmy in the gene (i.e.

005260" E2F4960

occurrence of two variant sites that are identical by state but not identical by descent because the same variance arose at least twice in human evolutionary history on two different haplotypes); what are the different haplotypes and how can they be grouped to increase the power of genetic analysis?

5 Methods for variance screening have been described, including DNA sequencing. See for example: US5698400: Detection of mutation by resolvase cleavage; US5217863: Detection of mutations in nucleic acids; and US5750335: Screening for genetic variation, as well as the examples and references cited therein for examples of useful variance detection procedures. Detailed variance detection
10 procedures are also described in examples 15, 16 and 17. One skilled in the art will recognize that depending on the specific aims of a variance detection project (number of genes being screened, number of individuals being screened, total length of DNA being screened) one of the above cited methods may be preferable to the others, or yet another procedure may be optimal. A preferred method of variance
15 detection is chain terminating DNA sequencing using dye labeled primers, cycle sequencing and software for assessing the quality of the DNA sequence as well as specialized software for calling heterozygotes. The use of such procedures has been described by Nickerson and colleagues. See for example: Rieder M.J., et al. Automating the identification of DNA variations using quality-based fluorescence
20 re-sequencing: analysis of the human mitochondrial genome. *Nucleic Acids Res.* 26 (4):967-73, 1998, and: Nickerson D.A., et al. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. *Nucleic Acids Res.* 25 (14):2745-51, 1997. Although the variances provided in Table 3, consist principally of cDNA variances, it is an aspect of this
25 invention that detection of genomic variances is also a useful method for identification of variances that may account for interpatient variation in response to a therapy.

 Another important aspect of variance detection is the use of DNA from a panel of human subjects that represents a known population. For example, if the
30 subjects are being screened for variances relevant to a specific drug development program it is desirable to include both subjects with the target disease and healthy subjects in the panel, because certain variances may occur at different frequencies in the healthy and disease populations and can only be reliably detected by screening both populations. Also, for example, if the drug development program is taking
35 place in Japan, it is important to include Japanese individuals in the screening population. In general, it is always desirable to include subjects of known geographic, racial or ethnic identity in a variance screening experiment so the results

can be interpreted appropriately for different patient populations, if necessary. Also, in order to select optimal sets of variances for genetic analysis of a gene locus it is desirable to know which variances have occurred recently – perhaps on multiple different chromosomes - and which are ancient. Inclusion of one or more apes or monkeys in the variance screening panel is one way of gaining insight into the evolutionary history of variances. Chimpanzees are preferred subjects for inclusion in a variance screening panel.

3. Assess the Likely Contribution of Variances in Candidate Genes to Clinical Variation in Patient Responses to Therapy

Once a set of genes likely to affect disease pathophysiology or drug action has been identified, and those genes have been screened for variances, said variances (e.g., provided in Table 3) can be assessed for their contribution to variation in the pharmacological or toxicological phenotypes of interest. Such studies are useful for reducing a large number of candidate variances to a smaller number of variances to be tested in clinical trials. There are several methods which can be used in the present invention for assessing the medical and pharmaceutical implications of a DNA sequence variance. They range from computational methods to *in vitro* and/or *in vivo* experimental methods, to prospective human clinical trials, and also include a variety of other laboratory and clinical measures that can provide evidence of the medical consequences of a variance. In general, human clinical trials constitute the highest standard of proof that a variance or set of variances is useful for selecting a method of treatment, however, computational and *in vitro* data, or retrospective analysis of human clinical data may provide strong evidence that a particular variance will affect response to a given therapy, often at lower cost and in less time than a prospective clinical trial. Moreover, at an early stage in the analysis when there are many possible hypotheses to explain interpatient variation in treatment response, the use of informatics-based approaches to evaluate the likely functional effects of specific variances is an efficient way to proceed.

Informatics-based approaches to the prediction of the likely functional effects of variances include DNA and protein sequence analysis (phylogenetic approaches and motif searching) and protein modeling (based on coordinates in the protein database, or pdb; see <http://www.rcsb.org/pdb/>). See, for example: Kawabata et al. The Protein Mutant Database. Nucleic Acids Research 27: 355-357, 1999; also available at: <http://pmd.ddbj.nig.ac.jp>. Such analyses can be performed quickly and inexpensively, and the results may allow selection of certain genes for more extensive *in vitro* or *in vivo* studies or for more variance detection or both.

1997-1998		1998-1999		1999-2000		2000-2001		2001-2002		2002-2003		2003-2004		2004-2005		2005-2006		2006-2007		2007-2008		2008-2009		2009-2010		2010-2011		2011-2012		2012-2013		2013-2014		2014-2015		2015-2016		2016-2017		2017-2018		2018-2019		2019-2020		2020-2021		2021-2022		2022-2023		2023-2024		2024-2025		2025-2026		2026-2027		2027-2028		2028-2029		2029-2030		2030-2031		2031-2032		2032-2033		2033-2034		2034-2035		2035-2036		2036-2037		2037-2038		2038-2039		2039-2040		2040-2041		2041-2042		2042-2043		2043-2044		2044-2045		2045-2046		2046-2047		2047-2048		2048-2049		2049-2050		2050-2051		2051-2052		2052-2053		2053-2054		2054-2055		2055-2056		2056-2057		2057-2058		2058-2059		2059-2060		2060-2061		2061-2062		2062-2063		2063-2064		2064-2065		2065-2066		2066-2067		2067-2068		2068-2069		2069-2070		2070-2071		2071-2072		2072-2073		2073-2074		2074-2075		2075-2076		2076-2077		2077-2078		2078-2079		2079-2080		2080-2081		2081-2082		2082-2083		2083-2084		2084-2085		2085-2086		2086-2087		2087-2088		2088-2089		2089-2090		2090-2091		2091-2092		2092-2093		2093-2094		2094-2095		2095-2096		2096-2097		2097-2098		2098-2099		2099-2100		2100-2101		2101-2102		2102-2103		2103-2104		2104-2105		2105-2106		2106-2107		2107-2108		2108-2109		2109-2110		2110-2111		2111-2112		2112-2113		2113-2114		2114-2115		2115-2116		2116-2117		2117-2118		2118-2119		2119-2120		2120-2121		2121-2122		2122-2123		2123-2124		2124-2125		2125-2126		2126-2127		2127-2128		2128-2129		2129-2130		2130-2131		2131-2132		2132-2133		2133-2134		2134-2135		2135-2136		2136-2137		2137-2138		2138-2139		2139-2140		2140-2141		2141-2142		2142-2143		2143-2144		2144-2145		2145-2146		2146-2147		2147-2148		2148-2149		2149-2150		2150-2151		2151-2152		2152-2153		2153-2154		2154-2155		2155-2156		2156-2157		2157-2158		2158-2159		2159-2160		2160-2161		2161-2162		2162-2163		2163-2164		2164-2165		2165-2166		2166-2167		2167-2168		2168-2169		2169-2170		2170-2171		2171-2172		2172-2173		2173-2174		2174-2175		2175-2176		2176-2177		2177-2178		2178-2179		2179-2180		2180-2181		2181-2182		2182-2183		2183-2184		2184-2185		2185-2186		2186-2187		2187-2188		2188-2189		2189-2190		2190-2191		2191-2192		2192-2193		2193-2194		2194-2195		2195-2196		2196-2197		2197-2198		2198-2199		2199-2200		2200-2201		2201-2202		2202-2203		2203-2204		2204-2205		2205-2206		2206-2207		2207-2208		2208-2209		2209-2210		2210-2211		2211-2212		2212-2213		2213-2214		2214-2215		2215-2216		2216-2217		2217-2218		2218-2219		2219-2220		2220-2221		2221-2222		2222-2223		2223-2224	
-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--	-----------	--

30

35

including consensus binding domains for all transcription factor binding domains. See, for example, the databases cited in: Burks, C. Molecular Biology Database List. *Nucleic Acids Research* 27: 1-9, 1999, and links to useful databases on the internet at:

5 http://www.oup.co.uk/nar/Volume_27/issue_01/summary/gkc105_gml.html. In particular see the Transcription Factor Database (Heinemeyer, T., et al. (1999) Expanding the TRANSFAC database towards an expert system of regulatory molecular mechanisms. *Nucleic Acids Res.* 27: 318-322, or on the internet at: <http://193.175.244.40/TRANSFAC/index.html>). Any sequence variances in
10 transcriptional regulatory sequences can be assessed for their effects on mRNA levels using standard methods, either by making plasmid constructs with the different allelic forms of the sequence, transfecting them into cells and measuring the output of a reporter transcript, or by assays of cells with different endogenous alleles of variances. One example of a polymorphism in a transcriptional regulatory
15 element that has a pharmacogenetic effect is described by Drazen et al. (1999) Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. *Nature Genetics* 22: 168-170. Drazen and co-workers found that a polymorphism in an Sp1-transcription factor binding domain, which varied among subjects from 3-6 tandem copies, accounted for varied expression
20 levels of the 5-lipoxygenase gene when assayed in vitro in reporter construct assays. This effect would have been flagged by an informatics analysis that surveyed the 5-lipoxygenase candidate promoter region for transcriptional regulatory sequences (resulting in discovery of polymorphism in the Sp1 motif).

25 4. Perform *in vitro* or *in vivo* Experiments to Assess the Functional Importance of Gene Variances

There are two broad types of studies useful for assessing the likely importance of variances: analysis of RNA or protein abundance (as described above in the context of methods for identifying candidate genes for explaining interpatient
30 variation in treatment response) or analysis of functional differences in different variant forms of a gene, mRNA or protein. Studies of functional differences may involve direct measurements of biochemical activity of different variant forms of an mRNA or protein, or may involve assaying the influence of a variance or variances on various cell properties, including both tissue culture and *in vivo* studies.

35 The selection of an appropriate experimental program for testing the medical consequences of a variance may differ depending on the nature of the variance, the gene, and the disease. For example if there is already evidence that a protein is involved in the pharmacologic action of a drug, then the *in vitro* or *in vivo*

09648133.082500

demonstration that an amino acid variance in the protein affects its biochemical activity is strong evidence that the variance will have an effect on the pharmacology of the drug in patients, and therefore that patients with different variant forms of the gene may have different responses to the same dose of drug. If the variance is silent with respect to protein coding information, or if it lies in a noncoding portion of the gene (e.g., a promoter, an intron, or a 5'- or 3'-untranslated region) then the appropriate biochemical assay may be to assess mRNA abundance, half life, or translational efficiency. If, on the other hand, there is no substantial evidence that the protein encoded by a particular gene is relevant to drug pharmacology, but instead is a candidate gene on account of its involvement in disease pathophysiology, then the optimal test may be a clinical study addressing whether two patient groups distinguished on the basis of the variance respond differently to a therapeutic intervention. This approach reflects the current reality that biologists do not sufficiently understand gene regulation, gene expression and gene function to consistently make accurate inferences about the consequences of DNA sequence variances for pharmacological responses.

In summary, if there is a plausible hypothesis regarding the effect of a protein on the action of a drug, then *in vitro* and *in vivo* approaches, including those described below, will be useful to predict whether a given variance is therapeutically consequential. If, on the other hand, there is no evidence of such an effect, then the preferred test is an empirical clinical measure of the impact to the variance on efficacy or toxicity *in vivo* (which requires no evidence or assumptions regarding the mechanism by which the variance may exert an effect on a therapeutic response). However, given the expense and statistical constraints of clinical trials, it is preferable to limit clinical testing to variances for which there is at least some experimental or computational evidence of a functional effect.

In another aspect of the invention a powerful, high throughput approach to the genetics of drug response is to study variation in drug response phenotypes among cell lines derived from related individuals. Consider a cellular drug response phenotype that is readily measured, and that varies among cell lines. The demonstration of Mendelian transmission of the drug response phenotype in cell lines from related individuals would constitute evidence of a genetic component to the drug response phenotype. The expected pattern of segregation depends on making an assumption about the genetic model: recessive, dominant or co-dominant alleles will produce different proportions in the progeny of a cross. The value of studying cell lines as surrogates for people is that experiments can be performed for a small fraction of the cost. The value of studying cell lines from related individuals is that genetic effects on drug response are likely to be much easier to identify when

genetic background among the subjects is substantially similar. In particular, in cell lines from a pedigree it is known that only four parental alleles are segregating in the children, and that any two children are on average 50% genetically identical. In a more heterogeneous genetic background (i.e. cell lines from unrelated subjects) the effect of allelic variation at multiple genes that modulate the measured drug response phenotypes is more likely to create a nearly continuous distribution of responses (except in cases where the product of one gene accounts for most of the measured drug response phenotype).

Many cell lines have been derived from groups of related individuals, or pedigrees. A commercial source of such cell lines is the Human Genetic Cell Repository, supported by the National Institute of General Medical Sciences (NIGMS) and housed at the Coriell Cell Repository, Camden, New Jersey. A directory of these cell lines is available on the world wide web:

<http://locus.umdnc.edu/nigms/>. One preferred set of cell lines for pharmacogenetic studies, available from the Coriell Cell Repository, is the set of cell lines used by the Centre d'Etudes du Polymorphisme Humain (CEPH) consortium (Paris, France) to establish a detailed genetic map of man. See, for example: Gyapay, G., Morissette, J., Vignal, A., et al. (1994) The 1993-94 Genethon human genetic linkage map. *Nature Genetics* 7(2 Spec No):246-339. More current data on the CEPH genetic linkage map can be found on the world wide web at: <http://landru.cephb.fr/cephdb/>. Lymphoblastoid cell lines from 57 CEPH families are available from the Coriell Repository. In most cases the families consist of four grandparents, two parents and between four and twelve children.

The principal attraction of the CEPH cell lines for pharmacogenetic studies is that a detailed genetic map of nearly 12,000 polymorphic markers has been established via an international effort, and the map data are freely available on the world wide web. In other words the genotypes of thousands of polymorphic markers are known in most of the CEPH cell lines (not all markers were studied in all cell lines). As a result, one skilled in the art can determine the chromosomal location of any locus that controls a Mendelian trait in these cell lines, using software for linkage analysis such as the programs LINKAGE, CRIMAP and MAPMAKER. (See, for example: Lander, E.S., Green, P., Abrahamson, J., et al. (1987) MAPMAKER: an interactive computer package for constructing primary genetic linkage maps of experimental and natural populations. *Genomics* 1(2):174-81. See also: Terwilliger, J. and J. Ott (1994), Handbook of Human Linkage Analysis. John Hopkins University Press, Baltimore for a more exhaustive description of linkage analysis methods.)

One set of interesting Mendelian traits to study using the CEPH cell lines (or similar cell lines from pedigrees) and the genetic approach just described are drug response phenotypes. Consider, for example, a G protein coupled receptor that exists in two allelic forms that behave differently in the presence of a compound being developed for human clinical use (e.g. one receptor binds the compound with higher affinity than the other). Methods for assaying G protein mediated signal transduction are well known in the art. By adding the compound (either at a fixed concentration or at a series of different concentrations) to a family-derived set of lymphoblastoid cell lines (which of course must express the G protein coupled receptor) and measuring the signal produced it should be possible to detect the segregation of the grandparental alleles in the parents and the segregation of parental alleles in the children. For example, consider two alleles of the receptor: if allele A produces a greater signal than allele B at a given concentration of the compound, and if one parent is an AB heterozygote while the other parent is a BB heterozygote then the levels of signal in the children should be medium (in AB heterozygotes) or low (in BB homozygotes). The detection of such a pattern in cell lines of the family would constitute evidence that the G protein coupled receptor polymorphism was responsible for intersubject differences in response to the compound. (More generally, the detection of any discrete partitioning of responses in the data – high and low, or high medium and low - is suggestive of genetic control, with the genetic model to be inferred from the pattern of inheritance, and support for the hypothesis to come from the analysis of multiple families.) It is not necessary to know the identify of the variant gene in advance (as in the G protein coupled receptor example just provided). The pattern of segregation of the drug response phenotype in the cell lines of the various members of the CEPH families can be compared to the pattern of segregation of the thousands of polymorphic markers already typed in the same cell lines.

Those polymorphic markers that co-segregate with the drug response phenotype are candidates for marking the location of the locus responsible for the drug response phenotype. By performing the same experiment in cell lines from multiple (e.g. from two up to 57 CEPH) families the list of candidate polymorphic markers generally narrows to a few, all of which (or nearly all of which) are from the same chromosomal region – viz. the region harboring the gene responsible for the drug response phenotype. Knowing (i) the chromosomal location of the gene (or genes) implicated by the linkage analysis, together with (ii) information about the location and function of genes in that chromosomal region (available from online databases, for example, those at the US National Center for Biotechnology Information; see <http://www.ncbi.nlm.nih.gov/LocusLink/>), and further (iii)

knowing something of the pharmacology of the compound and consequently the metabolic and regulatory pathways likely to influence its action, should constrain the list of candidate genes likely to be responsible for the observed variation to a small number of genes. These genes (if there is more than one) can be systematically
5 evaluated for pharmacogenetic impact by identifying polymorphisms and testing whether they cosegregate with drug response phenotypes in the pedigrees, in new pedigrees, in cells from unrelated individuals, or *in vivo* in a population of nonrelated individuals, for example in a clinical trial.

Some drug response phenotypes may not behave as Mendelian traits, but
10 may rather be continuous (quantitative) traits under the control of several genes. Variation at any of the relevant gene loci could affect drug response, often to different extents. Robust methods for mapping quantitative trait loci (QTL) are known in the art. For example, see: Shugart, Y.Y. and Goldgar, D.E. (1999) Multipoint genomic scanning for quantitative loci: effects of map density, sibship
15 size and computational approach. *Eur J Hum Genet* 7(2):103-9. It is worth emphasizing that in the approach described (using the CEPH cell lines) there is no need for genotyping in order to map the drug response traits in the cell lines; the effort already expended to produce a human linkage map in the CEPH cell lines can be exploited.

Cell responses that could be usefully characterized by the above methods
20 include for example the level of signaling in a pathway that mediates the response to a compound (as in the G protein coupled receptor assays where levels of a second messenger are measured), compound uptake, compound metabolism, levels of metabolites affected by a compound, levels of proteins (including enzymes in
25 biochemical pathways related to the action of the compound), levels of an inhibitory complex formed by a compound, and other assays known to those skilled in the art of pharmacology and assay development. For example, a study of the genetic basis of variation in response to the antineoplastic drug 5-fluorouracil might include measurement of cell uptake of 5-FU, conversion of 5-FU to inactive metabolites
30 such as 5, 6- dihydrofluorouridine or fluoro-beta alanine, conversion of 5-FU to active metabolites such as 5-fluorodeoxyuridine, levels of thymidylate synthetase (an enzyme inhibited by 5-FU), levels of 5, 10 methylenetetrahydrofolate (a folate co-factor essential for 5-FU mediated inhibition of thymidylate synthetase) and the enzymes that produce it, or levels of nucleotide pools or the enzymes that produce
35 them. All of the relevant transporters and enzymes are expressed in lymphoblastoid cells, even though 5-FU is not routinely used in the therapy of lymphoid malignancies.

However, a limitation of lymphoblastoid cell lines for the methods described above is that they are not suitable for all of the different types of assays one might wish to perform. One alternative is to use fibroblast cell lines, which have already been derived from multiple different families. Fibroblasts are not available from the CEPH pedigrees, however a set of fibroblasts from known pedigrees could be genotyped at a set of highly polymorphic markers to produce a genetic map. Another approach is to treat lymphoblastoid cells with a procedure or agent that induces differentiation to a different cell type, such as an adipocyte or a myocyte. For example, there are genes which effectively control differentiation programs (e.g. peroxisome proliferator activated receptor [PPAR] gamma mediates adipocyte differentiation, myoD mediates myocyte differentiation); introduction of such a gene into a cell line of one type can alter its differentiated state to another cell type. Alternatively, stimulation of the gene product of such a regulatory gene (e.g. treatment of cells with the PPAR gamma agonist troglitazone) can be used to induce differentiation to a different cell type. Such procedures are known in the art, and may be effectively applied to human lymphoblasts.

In preferred embodiments of the above methods the cells used are from the CEPH pedigrees. Preferably at least one pedigree is studied, more preferably two pedigrees, still more preferably five pedigrees and most preferably eight pedigrees or more. It is useful to perform a statistical calculation to determine how many pedigrees and cell lines should be studied to achieve a given power to detect an effect, making assumptions about the magnitude of the effect.

In another aspect, described below, the methods described above can be used to identify mRNAs that vary in levels between cell lines as a result of genetically controlled regulatory factors, such as, for example, polymorphisms in promoters that affect the binding or action of transcriptional regulatory factors. Such variation in mRNA levels may be responsible for intersubject variation in drug response.

Experimental Methods: Genomic DNA Analysis

Variances in DNA may affect the basal transcription or regulated transcription of a gene locus. Such variances may be located in any part of the gene but are most likely to be located in the promoter region, the first intron, or in 5' or 3' flanking DNA, where enhancer or silencer elements may be located. Methods for analyzing transcription are well known to those skilled in the art and exemplary methods are briefly described above and in some of the texts cited elsewhere in this application. Transcriptional run off assay is one useful method. Detailed protocols can be found in texts such as: Current Protocols in Molecular Biology edited by: F.M. Ausubel, et al. John Wiley & Sons, Inc, 1999, or: Molecular Cloning: A

Laboratory Manual by J. Sambrook, E.F. Fritsch and T Maniatis. 1989. 3 vols, 2nd edition, Cold Spring Harbor Laboratory Press

Experimental Methods: RNA Analysis

5 RNA variances may affect a wide range of processes including RNA splicing, polyadenylation, capping, export from the nucleus, interaction with translation initiation, elongation or termination factors, or the ribosome, or interaction with cellular factors including regulatory proteins, or factors that may affect mRNA half life. However, the effect of most RNA sequence variances on
10 RNA function, if any, should ultimately be measurable as an effect on RNA or protein levels – either basal levels or regulated levels or levels in some abnormal cell state, such as cells from patients with a disease. Therefore, one preferred method for assessing the effect of RNA variances on RNA function is to measure the levels of RNA produced by different alleles in one or more conditions of cell or tissue
15 growth. Said measuring can be done by conventional methods such as Northern blots or RNAase protection assays (kits available from Ambion, Inc.), or by methods such as the Taqman assay (developed by the Applied Biosystems Division of the Perkin Elmer Corporation), or by using arrays of oligonucleotides or arrays of cDNAs attached to solid surfaces. Systems for arraying cDNAs are available
20 commercially from companies such as Nanogen and General Scanning. Complete systems for gene expression analysis are available from companies such as Molecular Dynamics. For recent reviews of systems for high throughput RNA expression analysis see the supplement to volume 21 of Nature Genetics entitled “The Chipping Forecast”, especially articles beginning on pages 9, 15, 20 and 25.

25 Additional methods for analyzing the effect of variances on RNA include secondary structure probing, and direct measurement of half life or turnover. Secondary structure can be determined by techniques such as enzymatic probing (using enzymes such as T1, T2 and S1 nuclease), chemical probing or RNAase H probing using oligonucleotides. Most RNA structural assays are performed *in vitro*,
30 however some techniques can be performed on cell extracts or even in living cells, using fluorescence resonance energy transfer to monitor the state of RNA probe molecules.

In another aspect the methods described above (relating to the use of cell lines from pedigrees to genetically map phenotypes that can be studied in tissue
35 culture cells) can be used to identify mRNAs that vary in levels between individuals as a result of genetically controlled factors. Genetic factors include both cis-acting polymorphisms, such as might be present in promoters (e.g. polymorphisms that affect the binding or action of transcription factors) as well as trans-acting factors

such as might be present in transcription factors (e.g. an amino acid polymorphism that affects the interaction of a transcription factor with a promoter element, or that might affect levels of the transcription factor itself). Variation in mRNA levels may contribute to intersubject variation in drug response, disease susceptibility or disease manifestations. (See above for example of promoter polymorphism in 5-lipoxygenase and its effect on response to anti-asthma medications.)

The methods for identifying mRNAs which vary in abundance as a consequence of genetic mechanisms are similar to those described above for drug response phenotypes. First, by examining whether levels of an mRNA segregate in one or more pedigrees it is possible to infer whether there is a genetic component to the variation. Second, by inspecting the CEPH genotype data it is possible to identify genetic markers that cosegregate with the mRNA expression levels (either increased or decreased) and thereby map the chromosomal location of the locus or loci that control mRNA levels. Third, by inspection of the genes at the chromosomal locus controlling mRNA levels it should be possible to identify one or a few genes that are likely responsible for the effect. These genes can then be definitively evaluated by discovering variances and testing if they predict mRNA levels (or other phenotypes) in the pedigree cell lines, in cell lines from unrelated individuals, or in vivo. Fourth, the above analysis can be performed on cell lines subjected to various pharmacological or nutritional manipulations. For example cell lines from one or more pedigrees can be treated with a drug, or deprived of an amino acid and mRNA levels measured at various times after treatment. Any variable differences in mRNA levels in response to the treatment, if they segregate in pedigrees, can be subjected to steps 1-3. Fifth, this analysis can be performed at very large scale using arrays of gridded cDNAs, PCR products or oligonucleotides corresponding to an unlimited number of genes. In each experiment the RNA from the pedigree cell lines (treated or not) is isolated, labeled using standard methods and hybridized to the grids containing the nucleic acids corresponding to the genes being investigated. Current commercial methods permit up to 400,000 oligonucleotides (more than the total number of human genes) to be queried in one experiment, although lower density formats are also well suited to the methods described. Thus, in a comparatively modest number of experiments the entire transcript population of lymphoblasts (probably <25,000 unique transcripts) can be queried for genetically controlled variation in mRNA abundance. Other types of cell lines can be subjected to similar analysis.

The variation in mRNA levels due to gene polymorphisms is likely to be of small magnitude (generally two-fold differences or less are expected). Therefore a key aspect of experimental systems used to measure mRNA levels is their accuracy.

Preferably a system capable of resolving mRNAs that differ in abundance (measured in molecules per cell, or relative to a standard such as total mRNA or one or more specific RNAs such as actin or clathrin or glucose-6-phosphare dehydrogenase) is sufficiently sensitive to detect differences as small as 50%, more preferably as small as 30%, and most preferably as small as 20%.

There are 757 individuals in the 57 CEPH cell lines. Thus all the CEPH cell lines could fit in eight 96 well microtiter plates. Microtiter plates provide a convenient format for growing cells and for performing cell manipulations, such as those described above, using multichannel pipettes or automated pipetting robots. By growing cells in large volume flasks, counting them (by hemocytometer or Coulter counter or other means) and then aliquoting them robotically to 96 well plates it is possible to assure that each well has nearly the same number of cells. A large number of plates can be prepared in this way and then stored frozen in appropriate medium until needed for experiments.

15

Experimental Methods: Protein Analysis

There are a variety of experimental methods for investigating the effect of an amino acid variance on response of a patient to a treatment. The preferred method will depend on the availability of cells expressing a particular protein, and the feasibility of a cell-based assay vs. assays on cell extracts, on proteins produced in a foreign host, or on proteins prepared by *in vitro* translation.

For example, the methods and systems listed below can be utilized to demonstrate differential expression, stability and/or activity of different variant forms of a protein, or in phenotype/genotype correlations in a model system.

For the determination of protein levels or protein activity a variety of techniques are available. The *in vitro* protein activity can be determined by transcription or translation in bacteria, yeast, baculovirus, COS cells (transient), Chinese Hamster Ovary (CHO) cells, or studied directly in human cells, or other cell systems can be used. Further, one can perform pulse chase experiments to determine if there are changes in protein stability (half-life).

One skilled in the art can construct cell based assays of protein function, and then perform the assays in cells with different genotypes or haplotypes. For example, identification of cells with different genotypes, e.g., cell lines established from families and subsequent determination of relevant protein phenotypes (e.g., expression levels, post translational modifications, activity assays) may be performed using standard methods.

Assays of protein levels or function can also be performed on cell lines (or extracts from cell lines) derived from pedigrees in order to determine whether there

is a genetic component to variation in protein levels or function. The experimental analysis is as above for RNAs, except the assays are different. Experiments can be performed on naive cells or on cells subjected to various treatments, including pharmacological treatments.

5 In another approach to the study of amino acid variances one can express genes corresponding to different alleles in experimental organisms and examine effects on disease phenotype (if relevant in the animal model), or on response to the presence of a compound. Such experiments may be performed in animals that have disrupted copies of the homologous gene (e.g. gene knockout animals engineered to be deficient in a target gene), or variant forms of the human gene may be introduced into germ cells by transgenic methods, or a combination of approaches may be used. To create animal strains with targeted gene disruptions a DNA construct is created (using DNA sequence information from the host animal) that will undergo homologous recombination when inserted into the nucleus of an embryonic stem cell. The targeted gene is effectively inactivated due to the insertion of non-natural sequence – for example a translation stop codon or a marker gene sequence that interrupts the reading frame. Well known PCR based methods are then used to screen for those cells in which the desired homologous recombination event has occurred. Gene knockouts can be accomplished in worms, drosophila, mice or other organisms. Once the knockout cells are created (in whatever species) the candidate therapeutic intervention can be administered to the animal and pharmacological or biological responses measured, including gene expression levels. If variant forms of the gene are useful in explaining interpatient variation in response to the compound in man, then complete absence of the gene in an experimental organism should have a major effect on drug response. As a next step various human forms of the gene can be introduced into the knockout organism (a technique sometimes referred to as a knock-in). Again, pharmacological studies can be performed to assess the impact of different human variances on drug response. Methods relevant to the experimental approaches described above can be found in the following exemplary texts:

General Molecular Biology Methods

Molecular Biology: A project approach, S.J. Karcher, Fall 1995. Academic Press

DNA Cloning: A Practical Approach, D.M. Glover and B.D. Hayes (eds). 1995.

IRL/Oxford University Press. Vol. 1 - Core Techniques; Vol 2 - Expression Systems; Vol. 3 - Complex Genomes; Vol. 4 -Mammalian Systems.

Short Protocols in Molecular Biology, Ausubel et al. October 1995. 3rd edition, John Wiley and Sons

Current Protocols in Molecular Biology Edited by: F.M. Ausubel, R.Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, K. Struhl, (Series Editor: V.B. Chanda), 1988
Molecular Cloning: A laboratory manual, J. Sambrook, E.F. Fritsch. 1989. 3 vols, 2nd edition, Cold Spring Harbor Laboratory Press

5

Polymerase chain reaction (PCR)

PCR Primer: A laboratory manual, C.W. Diffenbach and G.S. Dveksler (eds.). 1995. Cold Spring Harbor Laboratory Press.

The Polymerase Chain Reaction, K.B. Mullis et al. (eds.), 1994. Birkhauser

10

PCR Strategies, M.A. Innis, D.H. Gelf, and J.J. Sninsky (eds.), 1995. Academic Press

General procedures for discipline specific studies

Current Protocols in Neuroscience Edited by: J. Crawley, C. Gerfen, R. McKay, M. Rogawski, D. Sibley, P. Skolnick, (Series Editor: G. Taylor), 1997.

15

Current Protocols in Pharmacology Edited by: S. J. Enna / M. Williams, J.W. Ferkany, T. Kenakin, R.E. Porsolt, J.P. Sullivan, (Series Editor: G. Taylor), 1998.

Current Protocols in Protein Science Edited by: J.E. Coligan, B.M. Dunn, H.L. Ploegh, D.W. Speicher, P.T. Wingfield, (Series Editor: Virginia Benson Chanda), 1995.

20

Current Protocols in Cell Biology Edited by: J.S. Bonifacino, M. Dasso, J. Lippincott-Schwartz, J.B. Harford, K.M. Yamada, (Series Editor: K. Morgan) 1999.

Current Protocols in Cytometry Managing Editor: J.P. Robinson, Z. Darzynkiewicz (ed) / P. Dean (ed), A. Orfao (ed), P. Rabinovitch (ed), C. Stewart (ed), H. Tanke (ed), L. Wheelless (ed), (Series Editor: J. Paul Robinson), 1997.

25

Current Protocols in Human Genetics Edited by: N.C. Dracopoli, J.L. Haines, B.R. Korf, et al., (Series Editor: A. Boyle), 1994.

Current Protocols in Immunology Edited by: J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, (Series Editor: R. Coico), 1991.

IV. Clinical Trials

30

A clinical trial is the definitive test of the utility of a variance or variances for the selection of optimal therapy. A clinical trial in which an interaction of gene variances and clinical outcomes (desired or undesired) is explored will be referred to herein as a "pharmacogenetic clinical trial". Pharmacogenetic clinical trials require no knowledge of the biological function of the gene containing the variance or

35 variances to be assessed, nor any knowledge of how the therapeutic intervention to be assessed works at a biochemical level. The pharmacogenetics effects of a variance can be addressed at a purely statistical level: either a particular variance or set of variances is consistently associated with a significant difference in a salient

drug response parameter (e.g. response rate, effective dose, side effect rate, etc.) or not. On the other hand, if there is information about either the biochemical basis of a therapeutic intervention or the biochemical effects of a variance, then a pharmacogenetic clinical trial can be designed to test a specific hypothesis. In preferred embodiments of the methods of this application the mechanism of action of the compound to be genetically analyzed is at least partially understood.

Methods for performing clinical trials are well known in the art. (see e.g. Guide to Clinical Trials by Bert Spilker, Raven Press, 1991; The Randomized Clinical Trial and Therapeutic Decisions by Niels Tygstrup (Editor), Marcel Dekker; Recent Advances in Clinical Trial Design and Analysis (Cancer Treatment and Research, Ctar 75) by Peter F. Thall (Editor) Kluwer Academic Pub, 1995. Clinical Trials: A Methodologic Perspective by Steven Piantadosi, Wiley Series in Probability and Statistics, 1997). However, performing a clinical trial to test the genetic contribution to interpatient variation in drug response entails additional design considerations, including (i) defining the genetic hypothesis or hypotheses, (ii) devising an analytical strategy for testing the hypothesis, including determination of how many patients will need to be enrolled to have adequate statistical power to measure an effect of a specified magnitude (power analysis), (iii) definition of any primary or secondary genetic endpoints, and (iv) definition of methods of statistical genetic analysis, as well as other aspects. In the outline below some of the major types of genetic hypothesis testing, power analysis and statistical testing and their application in different stages of the drug development process are reviewed. One skilled in the art will recognize that certain of the methods will be best suited to specific clinical situations, and that additional methods are known and can be used in particular instances.

A. Performing a Clinical Trial: Overview

As used herein, a "clinical trial" is the testing of a therapeutic intervention in a volunteer human population for the purpose of determining whether it is safe and/or efficacious in the treatment of a disease, disorder, or condition. The present invention describes methods for achieving superior efficacy and/or safety in a genetically defined subgroup defined by the presence or absence of at least one gene sequence variance, compared to the effect that could be obtained in a conventional trial (without genetic stratification).

[illegible]

For a clinical study to commence enrollment and proceed to treat subjects at an institution that receives any federal support (most medical institutions in the US), an application that describes in detail the scientific premise for the therapeutic intervention and the procedures involved in the study, including the endpoints and analytical methods to be used in evaluating the data, must be reviewed and accepted by a review panel, often termed an Institutional Review Board (IRB). Similarly any clinical study that will ultimately be evaluated by the FDA as part of a new drug or product application (or other application as described below), must be reviewed and approved by an IRB. The IRB is responsible for determining that the trial protocol is safe, conforms to established ethical principles and guidelines, has risks proportional to any expected benefits, assures equitable selection of patients, provides sufficient information to patients (via a consent form) to insure that they can make an informed decision about participation, and insures the privacy of participants and the confidentiality of any data collected. (See the report of the National Commission for Protection of Human Subjects of Biomedical and Behavioral Research (1978). The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, D.C.: DHEW Publication Number (OS) 78-0012. For a recent review see: Coughlin, S.S. (ed.) (1995) Ethics in Epidemiology and Clinical Research. Epidemiology Resources, Newton, MA.) The European counterpart of the US FDA is the European Medicines Evaluation Agency (EMEA). Similar agencies exist in other

countries and are responsible for insuring, via the regulatory process, that clinical trials conform to similar standards as are required in the US. The documents reviewed by an IRB include a clinical protocol containing the information described above, and a consent form.

5 It is also customary, but not required, to prepare an investigator's brochure which describes the scientific hypothesis for the proposed therapeutic intervention, the preclinical data, and the clinical protocol. The brochure is made available to any physician participating in the proposed or ongoing trial.

10 The supporting preclinical data is a report of all the *in vitro*, *in vivo* animal or previous human trial or other data that supports the safety and/or efficacy of a given therapeutic intervention. In a pharmacogenetic clinical trial the preclinical data may also include a description of the effect of a specific genetic variance or variances on biochemical or physiologic experimental variables *in vitro* or *in vivo*, or on treatment outcomes, as determined by *in vivo* studies in animals or humans (for example in an
15 earlier trial), or by retrospective genetic analysis of clinical trial or other medical data (see below) used to formulate or strengthen a pharmacogenetic hypothesis. For example, case reports of unusual pharmacological responses in individuals with rare alleles (e.g. mutant alleles), or the observation of clustering of pharmacological responses in family members may provide the rationale for a pharmacogenetic
20 clinical trial.

The clinical protocol provides the relevant scientific and therapeutic introductory information, describes the inclusion and exclusion criteria for human subject enrollment, including genetic criteria if relevant (e.g. if genotype is to be among the enrollment criteria), describes in detail the exact procedure or procedures
25 for treatment using the candidate therapeutic intervention, describes laboratory analyses to be performed during the study period, and further describes the risks (both known and possible) involving the use of the experimental candidate therapeutic intervention. In a clinical protocol for a pharmacogenetic clinical trial, the clinical protocol will further describe the genetic variance and/or variances
30 hypothesized to account for differential responses in the normal human subjects or patients and supporting preclinical data, if any, a description of the methods for genotyping, genetic data collection and data handling as well as a description of the genetic statistical analysis to be performed to measure the interaction of the variance or variances with treatment response. Further, the clinical protocol for a
35 pharmacogenetic clinical trial will include a description of the genetic study design. For example patients may be stratified by genotype and the response rates in the different groups compared, or patients may be segregated by response and the genotype frequencies in the different responder or nonresponder groups measured.

005230" E2T B4 960

One or more gene sequence variances or a combination of variances and/or haplotypes may be studied.

5 The informed consent document is a description of the therapeutic intervention and the clinical protocol in simple language (e.g. third grade level) for the patient to read, understand, and, if willing, agree to participate in the study by signing the document. In a pharmacogenetic clinical study the informed consent document will describe, in simple language, the use of a genetic test or a limited set of genetic tests to determine the subject or patient's genotype at a particular gene variance or variances, and to further ascertain whether, in the study population,
10 particular variances are associated with particular clinical or physiological responses. The consent form should also describe procedures for assuring privacy and confidentiality of genetic information.

15 The US FDA reviews proposed clinical trials through the process of an Investigational New Drug Application (IND). The IND is composed of the investigator's brochure, the supporting *in vitro* and *in vivo* animal or previous human data, the clinical protocol, and the informed consent forms. In each of the sections of the IND, a specific description of a single allelic variance or a number of variances to be tested in the clinical study will be included. For example, in the investigator's brochure a description of the gene or genes hypothesized to account,
20 at least in part, for differential responses will be included as well as a description of a genetic variance or variances in one or more candidate genes. Further, the preclinical data may include a description of *in vivo*, *in vitro* or *in silico* studies of the biochemical or physiologic effects of a variance or variances (e.g., haplotype) in a candidate gene or genes, as well as the predicted effects of the variance or
25 variances on efficacy or toxicology of the candidate therapeutic intervention. The results of retrospective genetic analysis of response data in patients treated with the candidate therapy may be the basis for formulating the genetic hypotheses to be tested in the prospective trial. The US FDA reviews applications with particular attention to safety and toxicological data to ascertain whether candidate compounds
30 should be tested in humans.

The established phases of clinical development are Phase I, II, III, and IV. The fundamental objectives for each phase become increasingly complex as the stages of clinical development progress. In Phase I, safety in humans is the primary focus. In these studies, dose-ranging designs establish whether the candidate
35 therapeutic intervention is safe in the suspected therapeutic concentration range. However, it is common practice to obtain information about surrogate markers of efficacy even in phase I clinical trials. In a pharmacogenetic clinical trial there may be an analysis of the effect of a variance or variances on Phase I safety or surrogate

efficacy parameters. At the same time, evaluation of pharmacokinetic parameters (e.g., adsorption, distribution, metabolism, and excretion) may be a secondary objective; again, in a pharmacogenetic clinical study there may be an analysis of the effect of sequence variation in genes that affect absorption, distribution, metabolism and excretion of the candidate compound on pharmacokinetic parameters such as peak blood levels, half life or tissue distribution of the compound. As clinical development stages progress, trial objectives focus on the appropriate dose and method of administration required to elicit a clinically relevant therapeutic response. In a pharmacogenetic clinical trial, there may be a comparison of the effectiveness of several doses of a compound in patients with different genotypes, in order to identify interactions between genotype and optimal dose. For this purpose the doses selected for late stage clinical testing may be greater, equal or less than those chosen based upon preclinical safety and efficacy determinations. Data on the function of different alleles of genes affecting pharmacokinetic parameters could provide the basis for selecting an optimal dose or range or doses of a compound or biological. Genes involved in drug metabolism may be particularly useful to study in relation to understanding interpatient variation in optimal dose. Genes involved in drug metabolism include the cytochrome P450s, especially 2D6, 3A4, 2C9, 2E1, 2A6 and 1A1; the glucuronyltransferases; the acetyltransferases; the methyltransferases; the sulfotransferases; the glutathione system; the flavine monooxygenases and other enzymes known in the art.

An additional objective in the latter stages of clinical development is demonstration of the effect of the therapeutic intervention on a broad population. In phase III trials, the number of individuals enrolled is dictated by a power analysis. The number of patients required for a given pharmacogenetic clinical trial will be determined by prior knowledge of variance or haplotype frequency in the study population, likely response rate in the treated population, expected magnitude of pharmacogenetic effect (for example, the ratio of response rates between a genetic subgroup and the unfractionated population, or between two different genetic subgroups); nature of the genetic effect, if known (e.g. dominant effect, codominant effect, recessive effect); and number of genetic hypotheses to be evaluated (including number of genes and/or variances to be studied, number of gene or variance interactions to be studied). Other considerations will likely arise in the design of specific trials.

Clinical trials should be designed to blind both human subjects and study coordinators from biasing that may otherwise occur during the testing of a candidate therapeutic invention. Often the candidate therapeutic intervention is compared to best medical treatment, or a placebo (a compound, agent, device, or procedure that

appears identical to the candidate therapeutic intervention but is therapeutically inert). The combination of a placebo group and blind controls for potentially confounding factors such as prejudice on the part of study participants or investigators, insures that real, rather than perceived or expected, effects of the candidate therapeutic intervention are measured in the trials. Ideally blinding extends not only to trial subjects and investigators but also to data review committees, ancillary personnel, statisticians, and clinical trial monitors.

In pharmacogenetic clinical studies, a placebo arm or best medical control group may be required in order to ascertain the effect of the allelic variance or variances on the efficacy or toxicology of the candidate therapeutic intervention as well as placebo or best medical therapy. It will be important to assure that the composition of the control and test populations are matched, to the degree possible, with respect to genetic background and allele frequencies. This is particularly true if the variances being investigated may have an effect on disease manifestations (in addition to a hypothesized effect on response to treatment). It is likely that standard clinical trial procedures such as insuring that treatment and control groups are balanced for race, sex and age composition and other non-genetic factors relevant to disease will be sufficient to assure that genetic background is controlled, however a preferred practice is to explicitly test for genetic stratification between test and control groups. Methods for minimizing the possibility of spurious results attributable to genetic stratification between two comparison groups include the use of surrogate markers of geographic, racial and/or ethnic background, such as have been described by Rannala and coworkers. (See, for example: Rannala B, and JL Mountain. 1997 Detecting immigration by using multilocus genotypes. *Proc Natl Acad Sci U S A* Aug 19;94(17):9197-201.) One procedure would be to assure that surrogate markers of genetic background (such as those described by Rannala and Mountain) occur at comparable frequency in two comparison groups.

Open label trials are unblinded; in single blind trials patients are kept unaware of treatment assignments; in double blind trials both patients and investigators are unaware of the treatment groups; a combination of these procedures may be instituted during the trial period. Pharmacogenetic clinical trial design may include one or a combination of open label, single blind, or double blind clinical trial designs. Reduction of biases attributable to the knowledge of either the type of treatment or the genotype of the normal subjects or patients is an important aspect of study design. So, for example, even in a study that is single blind with respect to treatment, it should be possible to keep both patients and caregivers blinded to genotype during the study.

In designing a clinical trial it is important to include termination endpoints

such as adverse clinical events, inadequate study participation either in the form of lack of adherence to the clinical protocol or loss to follow up, (e.g. such that adequate power is no longer assured), lack of adherence on the part of trial investigators to the trial protocol, or lack of efficacy or positive response within the test group. In a pharmacogenetic clinical trial these considerations obtain not only in the entire treatment group, but also in the genetically defined subgroups. That is, if a dangerous toxic effect manifests itself predominantly or exclusively in a genetically defined subpopulation of the total treatment population it may be deemed inappropriate to continue treating that genetically defined subgroup. Such decisions are typically made by a data safety monitoring committee, a group of experts not including the investigators, and generally not blinded to the analysis, who review the data from an ongoing trial on a regular basis.

It is important to note that medicine is a conservative field, and clinicians are unlikely to change their behavior on the basis of a single clinical trial. Thus it is likely that, in most instances, two or more clinical trials will be required to convince physicians that they should change their prescribing habits in view of genetic information. Large scale trials represent one approach to providing increased data supporting the utility of a genetic stratification. In such trials the stringent clinical and laboratory data collection characteristic of traditional trials is often relaxed in exchange for a larger patient population. Important goals in large scale pharmacogenetic trials will include establishing whether a pharmacogenetic effect is detectable in all segments of a population. For example, in the North American population one might seek to demonstrate a pharmacogenetic effect in people of African, Asian, European and Hispanic (i.e. Mexican and Puerto Rican) origin, as well as in native American people. (It generally will not be practical to segment patients by geographical origin in a standard clinical trial, due to loss of power.) Another goal of a large scale clinical trial may be to measure more precisely, and with greater confidence, the magnitude of a pharmacogenetic effect first identified in a smaller trial. Yet another undertaking in a large scale clinical trial may be to examine the interaction of an established pharmacogenetic variable (e.g. a variance in gene A, shown to affect treatment response in a smaller trial) with other genetic variances (either in gene A or in other candidate genes). A large scale trial provides the statistical power necessary to test such interactions.

In designing all of the above stages of clinical testing investigators must be attentive to the statistical problems raised by testing multiple different hypotheses, including multiple genetic hypotheses, in subsets of patients. Bonferroni's correction or other suitable statistical methods for taking account of multiple hypothesis testing will need to be judiciously applied. However, in the early stages

of clinical testing, when the main goal is to reduce the large number of potential hypotheses that could be tested to a few that will be tested, based on limited data, it may be impractical to rigidly apply the multiple testing correction.

5 B. Phase I Clinical Trials

1. Introduction

Phase I of clinical development is generally focused on safety, although drug companies are increasingly obtaining information on pharmacokinetics and surrogate pharmacodynamic markers in early trials. Phase I studies are typically performed with a small number (< 60) of normal, healthy volunteers usually at single institutions. The primary endpoints in these studies usually relate to pharmacokinetic parameters (i.e. adsorption, distribution, metabolism and bioavailability), and dose-related side effects. In a Phase I pharmacogenetic clinical trial, stratification based upon allelic variance or variances of a candidate gene or genes related to pharmacokinetic parameters may allow early assessment of potential genetic interactions with treatment.

Phase I studies of some diseases (e.g. cancer or other medically intractable diseases for which no effective medical alternative exists) may include patients who satisfy specified inclusion criteria. These safety/limited-efficacy studies can be conducted at multiple institutions to ensure rapid enrollment of patients. In a pharmacogenetic Phase I study that includes patients, or a mixture of patients and normals, the status of a variance or variances suspected to affect the efficacy of the candidate therapeutic intervention may be used as part of the inclusion criteria. Alternatively, analysis of variances or haplotypes in patients with different treatment responses may be among the endpoints. It is not unusual for such a Phase I study design to include a double-blind, balanced, random-order, crossover sequence (separated by washout periods), with multiple doses on separate occasions and both pharmacokinetic and pharmacodynamic endpoints.

30 2. Phase I trials with subjects drawn from large populations and/or from related volunteer subjects: the Pharmacogenetic Phase I Unit concept

In general it is useful to be able to assess the contribution of genetic variation to treatment response at the earliest possible stage of clinical development. Such an assessment, if accurate, will allow efficient prioritization of candidate compounds for subsequent detailed pharmacogenetic studies; only those treatments where there is early evidence of a significant interaction of genetic variation with treatment response would be advanced to pharmacogenetic studies in later stages of development. In this invention we describe methods for achieving early insight – in

Phase I - into the contribution of genetic variation to variation in surrogate treatment response variables. It occurred to the inventors that this can be accomplished by bringing the power of genetic linkage analysis and outlier analysis to Phase I testing via the recruitment of a very large Phase I population including a large number of individuals who have consented in advance to genetic studies (occasionally referred to hereinafter as a Pharmacogenetic Phase I Unit). In one embodiment of a Pharmacogenetic Phase I Unit many of the subjects are related to each other by blood. (Currently Phase I trials are performed in unrelated individuals, and there is no consideration of genetic recruitment criteria, or of genetic analysis of surrogate markers.) There are several novel ways in which a large population, or a population comprised at least in part of related individuals, could be useful in early clinical trials. Some of the most attractive applications depend on the availability of surrogate markers for pharmacodynamic drug action which can be used early in clinical development, preferably in normal subjects in Phase I. Such surrogate markers are increasingly used in Phase I, as drug development companies seek to make early yes/no decisions about compounds.

Recruitment of a population optimized for clinical genetic investigation may entail utilization of methods in statistical genetics to select the size and composition of the population. For example powerful methods for detecting and mapping quantitative trait loci in sibpairs have been developed. These methods can provide some estimate of the statistical power derived from a given number of groups of closely related individuals. Ideally subjects in the pharmacogenetic Phase I unit are of known ethnic/racial/geographic background and willing to participate in Phase I studies, for pay, over a period of years. The population is preferably selected to achieve a specified degree of statistical power for genetic association studies, or is selected in order to be able to reliably identify a certain number of individuals with rare genotypes, as discussed below. Family participation could be encouraged by appropriate incentive compensation. For example, individual subjects might be paid \$200 for participation in a study; two sibs participating in the same study might each be paid \$300; if they could encourage another sib (or cousin) to participate the three related individuals might each be paid \$350, and so forth. This type of compensation would encourage subjects to recruit their relatives to participate in Phase I studies. (It would also increase the cost of studies, however the type of data that can be obtained can not be duplicated with conventional approaches.) The optimal location to establish such a Phase I unit is a city with a stable population, many large families, and a positive attitude about gene technology. The Pharmacogenetic Phase I Unit population can then be used to test for the existence of genetic variation in response to any drug as a first step in deciding whether to

proceed with extensive pharmacogenetic studies in later stages of clinical development. Specific uses of a large Phase I unit in which some or all subjects are related include:

5 a. It should be possible, for virtually any compound, to assess the magnitude of the genetic contribution to variation in drug response (if any) by comparing variation in drug response traits among related vs. non-related individuals. The rationale is as follows: if a surrogate drug response trait (i.e., a surrogate marker of pharmacodynamic effect that can be measured in normal subjects) is under strong genetic control then related individuals, who share 25% (cousins) or 50% (sibs) of their alleles, should have less divergent responses (less intragroup variance) than 10 unrelated individuals, who share a much smaller fraction of alleles. That is, individuals who share alleles at the genes that affect drug response should be more similar to each other (i.e. have a narrower distribution of responses, whether measured by variance, standard deviation or other means) than individuals who, on average, share very few alleles. By using statistical methods known in the art the degree of variation in a set of data from related individuals (each individual would only be compared with his/her relatives, but such comparisons would be performed within each group of relatives and a summary statistic developed) could be compared to the degree of variation in a set of unrelated individuals (the same 15 subjects could be used, but the second comparison would be across related groups). Account would be taken of the degree of similarity expected between related individuals, based on the fraction of the genome they shared by descent. Thus the extent of variation in the surrogate response marker between identical twins should be less than between sibs, which should be less than between first cousins, which 20 should be less than that between second cousins, and so forth, *if* there is a genetic component to the variation. It is well known from twin studies (in which, for example, variation between identical twins is compared to variation between fraternal twins) that pharmacokinetic variables (e.g. compound half life, peak concentration) are frequently over 90% heritable; the type of study proposed here (comparison of variation within groups of sibs and cousins to variation between 25 unrelated subjects) would also show this genetic effect, without requiring the recruitment of monozygotic twins. For a summary of pharmacokinetic studies in twins see: Propping, Paul (1978) Pharmacogenetics. *Rev. Physiol. Biochem. Pharmacol.* 83: 123-173.

35 It may be that the pattern of drug responses that distinguishes related individuals from non-related individuals is more complex than, for example, variance or standard deviation. For example, there may be two discrete phenotypes characteristic of intrafamilial variation (a bimodal distribution) that are not a feature

09546133 "082500

of variation between unrelated individuals (where, for example, variation might be more nearly continuous). Such a pattern could be attributable to Mendelian inheritance operating on a restricted set of alleles in a family (or families) with, for example, AA homozygotes giving one phenotype and AB heterozygotes and BB homozygotes giving a second phenotype, all in the context of a relatively homogeneous genetic background. In contrast, variation among non-related subjects would be less discrete due to a greater degree of variation in genetic background and the presence of additional alleles C, D and E at the candidate locus. Statistical measures of the significance of such differences in distribution, including nonparametric methods such as chi square and contingency tables, are known in the art.

The methods described herein for measuring whether pharmacodynamic traits are under genetic control, using surrogate markers of drug efficacy in phase I studies which include groups of related individuals, will be useful in obtaining an early assessment of the extent of genetically determined variation in drug response for a given therapeutic compound. Such information provides an informed basis for either stopping development at the earliest possible stage or, preferably, continuing with development but with a plan for identifying and controlling for genetic variation so as to allow rapid progression through the regulatory approval process.

For example, it is well known that Alzheimer's trials are long and expensive, and most drugs are only effective in a fraction of patients. Using surrogate measures of response in normals drawn from a population of related individuals would help to assess the contribution of genetic variation to variation in treatment response. For an acetylcholinesterase inhibitor, relevant surrogate pharmacodynamic measures could include testing erythrocyte membrane acetylcholinesterase levels in drug treated normal subjects, or performing psychometric tests that are affected by treatment (and ideally that correlate with clinical efficacy) and measuring the effect of treatment. As another example, antidepressant drugs can produce a variety of effects on mood in normal subjects – or no effect at all. Careful monitoring and measurement of such responses in related vs. unrelated normal subjects, and statistical comparison of the degree of variation in each group, could provide an early readout on whether there is a genetic component to drug response (and hence clinical efficacy). The observation of similar effects in family members, and comparatively dissimilar effects in unrelated subjects would provide compelling evidence of a pharmacogenetic effect and justify the substantial expenditure necessary for a full pharmacogenetic drug development program. Conversely, the absence of any significant family influence on drug response would provide an early termination point for pharmacogenetic studies. *Note that the proposed studies do*

not require any knowledge of candidate genes, nor is DNA collection or genotyping required – simply a reliable surrogate pharmacodynamic assay and small groups of related normal individuals. Refined statistical methods should permit the magnitude of the pharmacogenetic effect to be measured, which could be a further criteria for deciding whether to proceed with pharmacogenetic analysis. The greater the differential in magnitude or pattern of variance between the related and the unrelated subjects, the greater the extent of genetic control of the trait.

Not all drug response traits are under the predominant control of one locus. Many such traits are under the control of multiple genes, and may be referred to as quantitative trait loci. It is then desirable to identify the major loci contributing to variation in the drug response trait. This can be done for example, to map quantitative trait loci in a population of drug treated related normals. Either a candidate gene approach or a genome wide scanning approach can be used. (For review of some relevant methods see: Hsu L, Aragaki C, Quiaoit F. (1999) A genome-wide scan for a simulated data set using two newly developed methods. *Genet Epidemiol* 17 Suppl 1:S621-6; Zhao LP, Aragaki C, Hsu L, Quiaoit F. (1998) Mapping of complex traits by single-nucleotide polymorphisms. *Am J Hum Genet* 63(1):225-40; Stoesz MR, Cohen JC, Mooser V, et al. (1997) Extension of the Haseman-Elston method to multiple alleles and multiple loci: theory and practice for candidate genes. *Ann Hum Genet* 61 (Pt 3):263-74.)) However, this method would require at least 100 patients (preferably 200, and still more preferably >300) to have adequate statistical power, and each patient would have to be genotyped at a few polymorphic loci (candidate gene approach) or hundreds of polymorphic loci (genome scanning approach).

b. With a large Phase I population of normal subjects that need not be related (a second type of Pharmacogenetic Phase I Unit) it is possible to efficiently identify and recruit for any Phase I trial a set of individuals comprising virtually any combination of genotypes present in a population (for example, all common genotypes, or a group of genotypes expected to represent outliers for a drug response trait of interest). This method preferably entails obtaining blood or other tissue (e.g. buccal smear) in advance from a large number of the subjects in the Phase I unit. Ideally consent for genotyping would be obtained at the same time. It would be most efficient if blanket consent for genotyping any polymorphic site or sites could be obtained. Second best would be consent for testing any site relevant to any customer project (not specific at the time of initial consent). Third best would be consent to genotype polymorphic sites relevant to specific disease areas. Another, less desirable, solution would be to obtain consent for genotyping on a project by

project basis (for example by mailing out reply cards), after the specific polymorphic sites to be genotyped are known.

One useful way to screen for pharmacogenetic effects in Phase I is to recruit homozygotes for a variance or variances of interest in one or more candidate genes.

5 For example, consider a compound for which there are two genes that are strong candidates for influencing response to treatment. Gene X has alleles A and A', while gene Y has alleles B and B'. If these genes do in fact contribute significantly to response then one would expect that, regardless of the mode of inheritance (recessive, codominant, dominant, polygenic) homozygotes would exhibit the most

10 extreme responses. One would also expect epistatic interactions, if any, to be most extreme in double homozygotes. Thus one would ideally perform a surrogate drug response test in Phase I volunteers doubly homozygous at both X and Y. That is, test AA/BB, A'A'/BB, AA/B'B' and A'A'/B'B' subjects. If the allele frequencies for A and A' are .15 and .85, and for B and B' .2 and .8 then the frequency of AA homozygotes is expected to be 2.25% and BB homozygotes 4%. In the absence of

15 any linkage between the genes, the frequency of AA/BB double homozygotes is expected to be $0.0225 \times 0.04 = 0.0009$ or .09%, or about 1 subject in 1000. Ideally at least 5 subjects of each genotype are recruited for the Phase I study, and preferably at least 10 subject. Thus, even for variances of moderately low allele

20 frequency (15%, 20%), the identification of potential outliers (i.e. homozygotes) for the candidate genes of interest will require a large population. Preferably the Phase I unit has enrolled at least 1,000 normal individuals, more preferably 2,000, still more preferably 5,000 and most preferably 10,000 or more. In another application of the large, genotyped Phase I population it may be useful to identify individuals

25 with rare variances in candidates genes (either homozygous or heterozygous), in order to determine whether those variances are predisposing to extreme pharmacological responses to the compound. For example, variances occurring at 5% allele frequency are expected to occur in homozygous form in 0.25% of the population (0.05×0.05), and therefore may rarely, if ever, be encountered in early

30 clinical development. Yet it may be serious adverse effects occurring in just such a small group that create problems in later stages of drug development. In yet another application of the large genotyped Phase I population, subjects may be selected to represent the known common variances in one or more genes that are candidates for influencing the response to treatment. By insuring that all common genotypes are

35 represented in a Phase I trial the likelihood of misleading results due to genetic stratification (resulting in discrepancy with results of later, larger trials can be reduced.

It would be useful to prospectively genotype the large Phase I population for variances that are commonly the source of interpatient variation in drug response, since demand for genotyped groups of such patients can be anticipated from pharmaceutical companies and contract research organizations (CROs). For
5 example, genotyping might initially focus on common pharmacological targets such as estrogen receptors, adrenergic receptors, or serotonin receptors. The pre-genotyped Phase I population could be part of a package of services (along with genotyping assay development capability, high throughput genotyping capacity and software and expertise in statistical genetics) designed to accelerate
10 pharmacogenetic Phase I studies. Eventually, as the databank of genotypes built up, individuals with virtually any genotype or combination of genotypes could be called in for precisely designed physiological or toxicological studies designed to test for pharmacogenetic effects.

One of the most useful aspects of the Pharmacogenetic Phase I Unit is that
15 subjects with rare genotypes can be pharmacologically assessed in a small study. This addresses a serious limitation of conventional clinical trials with respect to the investigation of polygenic traits or the effect of rare alleles. Unfortunately even Phase III studies, as currently performed, are often barely powered to address simple one variance hypotheses about efficacy or toxicity. The problem, of course, is that
20 each time a new genetic variable is introduced the comparison groups are cut in halves or thirds (or even smaller groups if there are multiple haplotypes at each gene). It is therefore a challenging problem to test the interaction of several genes in determining drug response. Yet the character of drug response data in populations – there is often a continuous distribution of responses among different individuals –
25 suggests that drug responses may often be mediated by several genes. (On the other hand, there are an increasing number of well documented single gene, or even single variance, pharmacogenetic effects in the literature, showing that it is possible to detect the effect of a single variance.) One approach to identifying pharmacogenetic effects is to focus on finding the single gene variances that have the largest effects.
30 This approach can be undertaken within the scale of current clinical trials. However, in order to develop a test which predicts a large fraction of the quantitative variation in a drug response trait it may be desirable to test the effect of multiple genes, including the interaction of variances at different genes, which may be non-additive (referred to as epistasis). The Pharmacogenetic Phase I Unit provides a way to
35 efficiently test for gene interactions or multigene effects by, for example, allowing easy identification of individuals who, on account of being homozygous at several loci of interest, should be outliers for the drug response phenotypes of interest if there is a gene x gene interaction. Testing drug response in a small number of such

individuals will provide a quick read on gene interaction. Obtaining genetic data on the pharmacodynamic action of a compound in Phase I should also provide a crude measure of allele effects – which variances or haplotypes increase pharmacological responses and which decrease them. This information is of great value in designing subsequent trials, as it constrains the number of hypotheses to be tested, thereby enabling powerful statistical designs. This is because when the effect of variances on drug response measures is unknown one is forced to statistically test all the possible effects of each allele (e.g. two tailed tests). As the number of genetically defined groups increases (e.g. as a result of multiple variances or haplotypes) there is a loss of statistical power due to multiple testing correction. On the other hand, if the relative phenotypic effect of each allele at a locus is known (or can be hypothesized) from Phase I data then each individual in a subsequent clinical trial contributes useful information – there is a specific prediction of response based on that individuals combination of genotypes or haplotypes, and testing the fit of the actual data to those predictions provides for powerful statistical designs. (It is also possible to measure allele effects biochemically, of course, to establish which alleles have positive and which negative effects, but at considerable cost.)

It is important to note that Phase I trials can provide useful information at almost any stage of clinical development. It is not unusual, for example, for a product in Phase II or even Phase III testing to be remanded to Phase I in order to clarify some aspect of toxicology or physiology. In this context a Pharmacogenetic Phase I Unit would be extremely useful to a drug development company. Phase I studies in defined genetic subgroups drawn from a large genotyped population, or in groups of related individuals, would be the most economical and efficient way to clarify the existence of pharmacogenetic effects, if any, paving the way for future rational development of the product.

C. Phase II Clinical Trials

Phase II studies generally include a limited number of patients (<100) who satisfy a set of predefined inclusion criteria and do not satisfy any predefined exclusion criteria of the trial protocol. Phase II studies can be conducted at single or multiple institutions. Inclusion/exclusion criteria may include historical, clinical and laboratory parameters for a disease, disorder, or condition; age; gender; reproductive status (i.e. pre- or postmenopausal); coexisting medical conditions; psychological, emotional or cognitive state, or other objective measures known to those skilled in the art. In a pharmacogenetic Phase II trial the inclusion/exclusion criteria may include one or more genotypes or haplotypes. Alternatively, genetic analysis may

be performed at the end of the trial. The primary goals in Phase II testing may include (i) identification of the optimal medical indication for the compound, (ii) definition of an optimal dose or range or doses, balancing safety and efficacy considerations (dose-finding studies), (iii) extended safety studies (complementing Phase I safety studies), (iv) evaluation of efficacy in patients with the targeted disease or condition, either in comparison to placebo or to current best therapy. To some extent these goals may be achieved by performing multiple trials with different goals. Likewise, Phase II trials may be designed specifically to evaluate pharmacogenetic aspects of the drug candidate. Primary efficacy endpoints typically focus on clinical benefit, while surrogate endpoints may measure treatment response variables such as clinical or laboratory parameters that track the progress or extent of disease, often at lesser time, cost or difficulty than the definitive endpoints. A good surrogate marker must be convincingly associated with the definitive outcome. Examples of surrogate endpoints include tumor size as a surrogate for survival in cancer trials, and cholesterol levels as a surrogate for heart disease (e.g. myocardial infarction) in trials of lipid lowering cardiovascular drugs. Secondary endpoints supplement the primary endpoint and may be selected to help guide further clinical studies.

In a pharmacogenetic Phase II clinical trial, retrospective or prospective design will include the stratification of patients based upon a variance or variances in a gene or genes suspected of affecting treatment response. The gene or genes may be involved in mediating pharmacodynamic or pharmacokinetic response to the candidate therapeutic intervention. The parameters evaluated in the genetically stratified trial population may include primary, secondary or surrogate endpoints. Pharmacokinetic parameters - for example, dosage, absorption, toxicity, metabolism, or excretion - may also be evaluated in genetically stratified groups.. Other parameters that may be assessed in parallel with genetic stratification include gender, race, ethnic or geographic origin (population history) or other demographic factors.

While it is optimal to initiate pharmacogenetic studies in phase I, as described above, it may be the case that pharmacogenetic studies are not considered until phase II, when problems relating either to efficacy or toxicity are first encountered. It is highly desirable to initiate pharmacogenetic studies no later than Phase II of a clinical development plan because (1) phase III studies tend to be large and expensive – not an optimal setting in which to explore untested pharmacogenetic hypotheses; (2) phase III studies are typically designed to test one fairly narrow hypothesis regarding efficacy of one or a few dose levels in a specific disease or condition. Phase II studies are often numerous, and are intended to

provide a broad picture of the pharmacology of the candidate compound. This is a good setting for initial pharmacogenetic studies. Several pharmacogenetic hypotheses may be tested in phase II, with the goal of eliminating all but one or two.

5 D. Phase III Clinical Trials

Phase III studies are generally designed to measure efficacy of a new treatment in comparison to placebo or to an established treatment method. Phase II studies are often performed at multiple sites. The design of this type of trial includes
10 power analysis to ensure the sufficient data will be gathered to demonstrate the anticipated effect, making assumptions about response rate based on earlier trials. As a result Phase III trials frequently include large numbers of patients (up to 5,000). Primary endpoints in Phase III studies may include reduction or arrest of disease progression, improvement of symptoms, increased longevity or increased disease-free longevity, or other clinical measures known in the art. In a pharmacogenetic
15 Phase III clinical study, the endpoints may include determination of efficacy or toxicity in genetically defined subgroups. Preferably the genetic analysis of outcomes will be confined to an assessment of the impact of a small number of variances or haplotypes at a small number of genes, said variances having already
20 been statistically associated with outcomes in earlier trials. Most preferably variances at only one or two genes will be assessed.

After successful completion of one or more Phase III studies, the data and information from all trials conducted to test a new treatment method are compiled into a New Drug Application (NDA) and submitted for review by the US FDA,
25 which has authority to grant marketing approval in the US and its territories. The NDA includes the raw (unanalyzed) clinical data, i.e. the patient by patient measurements of primary and secondary endpoints, a statistical analysis of all of the included data, a document describing in detail any observed side effects, tabulation of all patients who dropped-out of trials and detailed reasons for their termination,
30 and any other available data pertaining to ongoing *in vitro* or *in vivo* studies since the submission of the investigational new drug (IND) application. If pharmacoeconomic objectives are a part of the clinical trial design then data supporting cost or economic analyses are included in the NDA. In a pharmacogenetic clinical study, the pharmacoeconomic analyses may include
35 genetically stratified assessment of the candidate therapeutic intervention in a cost benefit analysis, cost of illness study, cost minimization study, or cost utility analysis. The analysis may also be simultaneously stratified by standard criteria such as race/ethnicity/geographic origin, sex, age or other criteria. Data from a

genetically stratified analysis may be used to support an application for approval for marketing of the candidate therapeutic intervention.

E. Phase IV Clinical Trials

5

Phase IV studies occur after a therapeutic intervention has been approved for marketing, and are typically conducted for surveillance of safety, particularly occurrence of rare side effects. The other principal reason for Phase IV studies is to produce information and relationships useful for marketing a drug. In this regard
10 pharmacogenetic analysis may be very useful in Phase IV trials. Consider, for example, a drug that is the fourth or fifth member of a drug class (say statins, or thiazidinediones or fluoropyrimidines) to obtain marketing approval, and which does not differ significantly in clinical effects – efficacy or safety - from other members of the drug class. The first, second and third drugs in the class will likely have a
15 dominant market position (based on their earlier introduction into the marketplace) that is difficult to overcome, particularly in the absence of differentiating clinical effects. However, it is possible that the new drug produces a superior clinical effect – for example, higher response rate, greater magnitude of response or fewer side effects - in a genetically defined subgroup. The genetic subgroup with superior
20 response may constitute a larger fraction of the total patient population than the new drug would likely achieve otherwise. In this instance, there is a clear rationale for performing a Phase IV pharmacogenetic trial to identify a variance or variances that mark a patient population with superior clinical response. Subsequently a marketing campaign can be designed to alert patients, physicians, pharmacy managers,
25 managed care organizations and other parties that, with the use of a rapid and inexpensive genetic test to identify eligible patients, the new drug is superior to other members of the class (including the market leading first, second and third drugs introduced). The high responder subgroup defined by a variance or variances may also exhibit a superior response to other drugs in the class (a class
30 pharmacogenetic effect), or the superior efficacy in the genetic subgroup may be specific to the drug tested (a compound-specific pharmacogenetic effect).

In a Phase IV pharmacogenetic clinical trial, both retrospective and prospective analysis can be performed. In both cases, the key element is genetic stratification based on a variance or variances or haplotype. Phase IV trials will
35 often have adequate sample size to test more than one pharmacogenetic hypothesis in a statistically sound way.

F. Unconventional Clinical Development

Although the above listed phases of clinical development are well-established, there are cases where strict Phase I, II, III development does not occur, for example, in the clinical development of candidate therapeutic interventions for debilitating or life threatening diseases, or for diseases where there is presently no available treatment. Some of the mechanisms established by the FDA for such studies include Treatment INDs, Fast-Track or Accelerated reviews, and Orphan Drug Status. In a clinical development program for a candidate therapeutic of this type there is a useful role for pharmacogenetic analysis, in that the candidate therapeutic may not produce a sufficient benefit in all patients to justify FDA approval, however analysis of outcome in genetic subgroups may lead to identification of a variance or variances that predict a response rate sufficient for FDA approval.

As used herein, "supplemental applications" are those in which a candidate therapeutic intervention is tested in a human clinical trial in order to gain an expanded label indication, expanding recommended use to new medical indications. In these applications, previous clinical studies of the therapeutic intervention, i.e. preclinical safety and Phase I human safety studies can be used to support the testing of the therapeutic intervention in a new indication. Pharmacogenetic analysis is also useful in the context of clinical trials to support supplemental applications. Since these are, by definition, focused on diseases not selected for initial development the overall efficacy may not be as great as for the leading indication(s). The identification of genetic subgroups with high response rates may enable the rapid approval of supplemental applications for expanded label indications. In such instances part of the label indication may be a description of the variance or variances that define the group with superior response.

As used herein, "outcomes" or "therapeutic outcomes" describe the results and value of healthcare intervention. Outcomes can be multi-dimensional, and may include improvement of symptoms; regression of a disease, disorder, or condition; prevention of a disease or symptom; cost savings or other measures.

Pharmacoeconomics is the analysis of a therapeutic intervention in a population of patients diagnosed with a disease, disorder, or condition that includes at least one of the following studies: cost of illness study (COI); cost benefit analysis (CBA), cost minimization analysis (CMA), or cost utility analysis (CUA), or an analysis comparing the relative costs of a therapeutic intervention with one or a group of other therapeutic interventions. In each of these studies, the cost of the treatment of a disease, disorder, or condition is compared among treatment groups. Costs have both direct (therapeutic interventions, hospitalization) and indirect (loss of productivity) components. Pharmacoeconomic factors may provide the

motivation for pharmacogenetic analysis, particularly for expensive therapies that benefit only a fraction of patients. For example, interferon alpha is the only treatment that can cure hepatitis C virus infection, however viral infection is completely and permanently eliminated in less than a quarter of patients. Nearly
5 half of patients receive virtually no benefit from alfa interferon, but may suffer significant side effects. Treatment costs are ~\$10,000 per course. A pharmacogenetic test that could predict responders would save much of the cost of treating patients not able to benefit from interferon alpha therapy, and could provide the rationale for treating a population in a cost efficient manner, where treatment
10 would otherwise be unaffordable.

As used herein, "health-related quality of life" is a measure of the impact of a disease, disorder, or condition on a patient's activities of daily living. An analysis of the health-related quality of life is often included in pharmacoeconomic studies.

As used herein, the term "stratification" refers to the partitioning of patients
15 into groups on the basis of clinical or laboratory characteristics of the patient. "Genetic stratification" refers to the partitioning of patients or normal subjects into groups based on the presence or absence of a variance or variances in one or more genes. The stratification may be performed at the end of the trial, as part of the data analysis, or may come at the beginning of a trial, resulting in creation of distinct
20 groups for statistical or other purposes.

G. Power analysis in pharmacogenetic clinical trials

The basic goal of power calculations in clinical trial design is to insure that trials have adequate patients and controls to fairly assess, with statistical
25 significance, whether the candidate therapeutic intervention produces a clinically significant benefit.

Power calculations in clinical trials are related to the degree of variability of the drug response phenotypes measured and the treatment difference expected between comparison groups (e.g. between a treatment group and a control group).
30 The smaller the variance within each group being compared, and the greater the difference in response between the two groups, the fewer patients are required to produce convincing evidence of an effect of treatment. These two factors (variance and treatment difference) determine the degree of precision required to answer a specific clinical question.

35 The degree of precision may be expressed in terms of the maximal acceptable standard error of a measurement, the magnitude of variation in which the 95% confidence interval must be confined or the minimal magnitude of difference in

a clinical or laboratory value that must be detectable (at a statistically significant level, and with a specified power for detection) in a comparison to be performed at the end of the trial (hypothesis test). The minimal magnitude is generally set at the level that represents the minimal difference that would be considered of clinical importance.

In pharmacogenetic clinical trials there are two countervailing effects with respect to power. First, the comparison groups are reduced in size (compared to a conventional trial) due to genetic partitioning of both the treatment and control groups into two or more subgroups. However, it is reasonable to expect that variability for a trait is smaller within groups that are genetically homogeneous with respect to gene variances affecting the trait. If this is the case then power is increased as a function of the reduction in variability within (genetically defined) groups.

In general it is preferable to power a pharmacogenetic clinical trial to see an effect in the largest genetically defined subgroups. For example, for a variance with allele frequencies of 0.7 and 0.3 the common homozygote group will comprise 49% of all patients ($0.7 \times 0.7 \times 100$). It is most desirable to power the trial to observe an effect (either positive or a negative) in this group. If it is desirable to measure an effect of therapy in a small genetic group (for example, the 9% of patients homozygous for the rare allele) then genotyping should be considered as an enrollment criterion to insure a sufficient number of patients are enrolled to perform an adequately powered study.

Statistical methods for powering clinical trials are known in the art. See, for example: Shuster, J.J. (1990) Handbook of Sample Size Guidelines for Clinical Trials. CRC Press, Boca Raton, FL; Machin, D. and M.J. Campbell (1987) Statistical Tables for the Design of Clinical Trials. Blackwell, Oxford, UK; Donner, A. (1984) Approaches to Sample Size Estimation in the Design of Clinical Trials – A Review. *Statistics in Medicine* 3: 199-214.

H. Statistical analysis of clinical trial data

There are a variety of statistical methods for measuring the difference between two or more groups in a clinical trial. One skilled in the art will recognize that different methods are suited to different data sets. In general, there is a family of methods customarily used in clinical trials, and another family of methods customarily used in genetic epidemiological studies. Methods in quantitative and population genetics designed to measure the association between genotypes and phenotypes, and to map and measure the effect of quantitative trait loci are also

relevant to the task of measuring the impact of a variance on response to a treatment. Methods from any of these disciplines may be suitable for performing statistical analysis of pharmacogenetic clinical trial data, as is known to those skilled in the art.

Conventional clinical trial statistics include hypothesis testing and
 5 descriptive methods, as elaborated below. Guidance in the selection of appropriate statistical tests for a particular data set is provided in texts such as: Biostatistics: A Foundation for Analysis in the Health Sciences, 7th edition (Wiley Series in Probability and Mathematical Statistics, Applied Probability and statistics) by Wayne W. Daniel, John Wiley & Sons, 1998; Bayesian Methods and Ethics in a
 10 Clinical Trial Design (Wiley Series in Probability and Mathematical Statistics. Applied Probability Section) by J. B. Kadane (Editor), John Wiley & Sons, 1996. Examples of specific hypothesis testing and descriptive statistical procedures that may be useful in analyzing clinical trial data are listed below.

15 A. Hypothesis testing statistical procedures

- (1) One-sample procedures (binomial confidence interval, Wilcoxon signed rank test, permutation test with general scores, generation of exact permutational distributions)
- (2) Two-sample procedures (*t*-test, Wilcoxon-Mann-Whitney test,
 20 Normal score test, Median test, Van der Waerden test, Savage test, Logrank test for censored survival data, Wilcoxon-Gehan test for censored survival data, Cochran-Armitage trend test, permutation test with general scores, generation of exact permutational distributions)
- (3) R x C contingency tables (Fisher's exact test, Pearson's chi-squared
 25 test, Likelihood ratio test, Kruskal-Wallis test, Jonckheere-Terpstra test, Linear-by-linear association test, McNemar's test, marginal homogeneity test for matched pairs)
- (4) Stratified 2 x 2 contingency tables (test of homogeneity for odds ratio, test of unity for the common odds ratio, confidence interval for the common
 30 odds ratio)
- (5) Stratified 2 x C contingency tables (all two-sample procedures listed above with stratification, confidence intervals for the odds ratios and trend, generation of exact permutational distributions)
- (6) General linear models (simple regression, multiple regression,
 35 analysis of variance -ANOVA-, analysis of covariance, response-surface models, weighted regression, polynomial regression, partial correlation, multiple analysis of variance -MANOVA-, repeated measures analysis of variance).

005280 "E2T84950

(7) Analysis of variance and covariance with a nested (hierarchical) structure.

(8) Designs and randomized plans for nested and crossed experiments (completely randomized design for two treatment, split-plot design, hierarchical design, incomplete block design, latin square design)

(9) Nonlinear regression models

(10) Logistic regression for unstratified or stratified data, for binary or ordinal response data, using the logit link function, the normit function or the complementary log-log function.

(11) Probit, logit, ordinal logistic and gompit regression models.

(12) Fitting parametric models to failure time data that may be right-, left-, or interval-censored. Tested distributions can include extreme value, normal and logistic distributions, and, by using a log transformation, exponential, Weibull, lognormal, loglogistic and gamma distributions.

(13) Compute non-parametric estimates of survival distribution with right-censored data and compute rank tests for association of the response variable with other variables.

B. Descriptive statistical methods

- Factor analysis with rotations
- Canonical correlation
- Principal component analysis for quantitative variables.
- Principal component analysis for qualitative data.
- Hierarchical and dynamic clustering methods to create tree structure,

dendrogram or phenogram.

- Simple and multiple correspondence analysis using a contingency table as input or raw categorical data.

Specific instructions and computer programs for performing the above calculations can be obtained from companies such as: SAS/STAT Software, SAS Institute Inc., Cary, NC, USA; BMDP Statistical Software, BMDP Statistical Software Inc., Los Angeles, CA, USA; SYSTAT software, SPSS Inc., Chicago, IL, USA; StatXact & LogXact, CYTEL Software Corporation, Cambridge, MA, USA.

C. Statistical Genetic Methods Useful for Analysis of Pharmacogenetic Data

A wide spectrum of mathematical and statistical tools may be useful in the analysis of data produced in pharmacogenetic clinical trials, including methods employed in molecular, population, and quantitative genetics, as well as genetic

epidemiology. Methods developed for plant and animal breeding may be useful as well, particularly methods relating to the genetic analysis of quantitative traits.

Analytical methods useful in the analysis of genetic variation among individuals, populations and species of various organisms are described in the following texts: Molecular Evolution, by W- H. Li, Sinauer Associates, Inc., 1997; Principles of Population Genetics, by D. L. Hartl and A. G. Clark, 1996; Genetics and Analysis of Quantitative Traits, By M. Lynch and B. Walsh, Sinauer Associates, Inc., Principles of Quantitative Genetics, by D. S. Falconer and T.F.C. Mackay, Longman, 1996; Genetic Variation and Human Disease, by K. M. Weiss, Cambridge University Press, 1993; Fundamentals of Genetic Epidemiology, by M. J. Khoury, T. H. Beaty, and B. H. Cohen, Oxford University Press, 1993; Handbook of Genetic Linkage, by J. Terwilliger J. Ott, Johns Hopkins University Press, 1994.

The types of statistical analysis performed in different branches of genetics are outlined below as a guide to the relevant literature and publicly available software, some of which is cited.

Molecular evolutionary genetics

- Patterns of nucleotide variation among individuals, families/populations and across species and genera,
- Alignment of sequences and description of variation/polymorphisms among the aligned sequences, amounts of similarities and dissimilarities,
- Measurement of molecular variation among various regions of a gene, testing of neutrality models,
- Rates of nucleotide changes among coding and the non-coding regions within and among populations,
- Construction of phylogenetic trees using methods such as neighborhood joining and maximum parsimony; estimation of ages of variances using coalescent models,

Population genetics

- Patterns of distribution of genes among genotypes and populations. Hardy-Weinberg equilibrium, departures from the equilibrium
- Genotype and haplotype frequencies, levels of heterozygosities, polymorphism information contents of genes, estimation of haplotypes from genotypes; the E-M algorithm, and parsimony methods
- Estimation of linkage disequilibrium and recombination
- Hierarchical structure of populations, the F-statistics, estimation of inbreeding, selection and drift
- Genetic admixture/migration and mutation frequencies
- Spatial distribution of genotypes using spatial autocorrelation methods
- Kin-structured maintenance of variation and migration

Quantitative genetics

- Phenotype as the product of the interaction between genotype and environment

- Additive, dominance and epistatic variance on the phenotype
- Effects of homozygosity, heterozygosity and developmental homeostasis
- Estimation of heritability: broad sense and narrow sense
- Determination of number of genes governing a character
- 5 • Determination of quantitative trait loci (QTLs) using family information or population information, and using linkage and/or association studies
- Determination of quantitative trait nucleotide (QTN) using a combination linkage disequilibrium methods and cladistic approaches
- 10 • Determination of individual causal nucleotide in the diploid or haploid state on the phenotype using the method of measured genotype approaches, and combined effects or synergistic interaction of the causal mutations on the phenotype
- Determination of relative importance of each of the mutations on a given phenotype using multivariate methods, such as discriminant function, principal component and step-wise regression methods
- 15 • Determination of direct and indirect effect of polymorphisms on a complex phenotype using path analysis (partial regression) methods
- Determination of the effects of specific environment on a given genotype – genotype x environment interactions using joint regression and additive and multiplicative parameter methods.
- 20

Genetic epidemiology

- Determination of sample size based on the disease and the marker frequency in the “case” and in the “control” populations
- 25 • Stratification of study population based on gender, ethnic, socio-economic variation
- Establishing a “causal relationship” between genotype and disease, using , using various association and linkage approaches – viz., case-control designs, family studies (if available), transmission disequilibrium tests etc.,
- 30 • Linkage analysis between markers and a candidate locus using two-point and multipoint approaches.

Computer programs used for genetic analysis are: Dna SP version 3.0, by Juilo Rozas, University of Barcelona, Spain. <http://www.bio.ub.es/-Julio>; Arlequin 1.1 by S. Schnieder, J-M Kueffer, D. Roessli and L. Excoffier. University of Geneva, Switzerland, <http://anthropologie.unige.ch/arlequin>. PAUP*4, by D. L. Swofford, Sinauer Associates, Inc., 1999. SYSTAT software, SPSS Inc., Chicago, Il., 1998; . Linkage User's Guide, by J. Ott, Rockefeller University, <http://Linkage.rockefeller.edu/soft/linkage>

40

Guidance in the selection of appropriate genetic statistical tests for analysis of data can be obtained from texts such as: Fundamentals of Genetic Epidemiology (Monographs in Epidemiology and Biostatistics, Vol 22) by M. J. Khoury, B. H. Cohen & T. H. Beaty, Oxford Univ Press, 1993; Methods in Genetic Epidemiology by Newton E. Morton, S. Karger Publishing, 1983; Methods in Observational

45

Epidemiology, 2nd edition (Monographs in Epidemiology and Biostatistics, V. 26) by J. L. Kelsey (Editor), A. S. Whittemore & A. S. Evans, 1996; Clinical Trials : Design, Conduct, and Analysis (Monographs in Epidemiology and Biostatistics, Vol 8) by C. L. Meinert & S. Tonascia, 1986)

5

I. Retrospective clinical trials.

In general the goal of retrospective clinical trials is to test and refine hypotheses regarding genetic factors that are associated with drug responses. The best supported hypotheses can subsequently be tested in prospective clinical trials, and data from the prospective trials will likely comprise the main basis for an application to register the drug and predictive genetic test with the appropriate regulatory body. In some cases, however, it may become acceptable to use data from retrospective trials to support regulatory filings. Exemplary strategies and criteria for stratifying patients in a retrospective clinical trial are provided below.

15

Clinical trials to study the effect of one gene locus on drug response

A. Stratify patients by genotype at one candidate variance in the candidate gene locus.

20

1. Genetic stratification of patients can be accomplished in several ways, including the following (where 'A' is the more frequent form of the variance being assessed and 'a' is the less frequent form):

25

(a) AA vs. aa

(b) AA vs. Aa vs. aa

(c) AA vs. (Aa + aa)

(d) (AA + Aa) vs. aa.

2. The effect of genotype on drug response phenotype may be affected by a variety of nongenetic factors. Therefore it may be beneficial to measure the effect of genetic stratification in a subgroup of the overall clinical trial population.

30

Subgroups can be defined in a number of ways including, for example, biological, clinical, pathological or environmental criteria. For example, the predictive value of genetic stratification can be assessed in a subgroup or subgroups defined by:

a. Biological criteria:

i. gender (males vs. females)

35

ii. age (for example above 60 years of age). Two, three or more age groups may be useful for defining subgroups for the genetic analysis.

iii. hormonal status and reproductive history, including pre- vs. post-menopausal status of women, or multiparous vs. nulliparous women

iv. ethnic, racial or geographic origin, or surrogate markers of ethnic, racial or geographic origin. (For a description of genetic markers that serve as surrogates of racial/ethnic origin see, for example: Rannala, B. and J.L. Mountain, Detecting immigration by using multilocus genotypes. *Proc Natl Acad Sci U S A*, 94 (17): 9197-9201, 1997. Other surrogate markers could be used, including biochemical markers.)

b. Clinical criteria:

i. Disease status. There are clinical grading scales for many diseases. For example, the status of Alzheimer's Disease patients is often measured by cognitive assessment scales such as the mini-mental status exam (MMSE) or the Alzheimer's Disease Assessment Scale (ADAS), which includes a cognitive component (ADAS-COG). There are also clinical assessment scales for many other diseases, including cancer.

ii. Disease manifestations (clinical presentation).

iii. Radiological staging criteria.

c. Pathological criteria:

i. Histopathologic features of disease tissue, or pathological diagnosis. (For example there are many varieties of lung cancer: squamous cell carcinoma, adenocarcinoma, small cell carcinoma, bronchoalveolar carcinoma, etc., each of which may – which, in combination with genetic variation, may correlate with

ii. Pathological stage. A variety of diseases, particularly cancer, have pathological staging schemes

iii. Loss of heterozygosity (LOH)

iv. Pathology studies such as measuring levels of a marker protein

v. Laboratory studies such as hormone levels, protein levels, small molecule levels

3. Measure frequency of responders in each genetic subgroup. Subgroups may be defined in several ways.

i. more than two age groups

ii. reproductive status such as pre or post-menopausal

4. Stratify by haplotype at one candidate locus where the haplotype is made up of two variances, three variances or greater than three variances.

Data from already completed clinical trials can be retrospectively reanalyzed. Since the questions are new, the data can be treated as if it were a prospective trial, with identified variances or haplotypes as stratification criteria or endpoints in clinically

stratified data (e.g. what is the frequency of a particular variance in a response group compared to nonresponders). Care should be taken to in studying a population in which there may be a link between drug-related genes and disease-related genes.

5 Retrospective pharmacogenetic trials can be conducted at each of the phases of clinical development, if sufficient data is available to correlate the physiologic effect of the candidate therapeutic intervention and the allelic variance or variances within the treatment population. In the case of a retrospective trial, the data collected from the trial can be re-analyzed by imposing the additional stratification
10 on groups of patients by specific allelic variances that may exist in the treatment groups. Retrospective trials can be useful to ascertain whether a hypothesis that a specific variance has a significant effect on the efficacy or toxicity profile for a candidate therapeutic intervention.

15 A prospective clinical trial has the advantage that the trial can be designed to ensure the trial objectives can be met with statistical certainty. In these cases, power analysis, which includes the parameters of allelic variance frequency, number of treatment groups, and ability to detect positive outcomes can ensure that the trial objectives are met.

20 In designing a pharmacogenetic trial, retrospective analysis of Phase II or Phase III clinical data can indicate trial variables for which further analysis is beneficial. For example, surrogate endpoints, pharmacokinetic parameters, dosage, efficacy endpoints, ethnic and gender differences, and toxicological parameters may result in data that would require further analysis and re-examination through the design of an additional trial. In these cases, analysis involving statistics, genetics,
25 clinical outcomes, and economic parameters may be considered prior to proceeding to the stage of designing any additional trials. Factors involved in the consideration of statistical significance may include Bonferroni analysis, permutation testing, with multiple testing correction resulting in a difference among the treatment groups that has occurred as a result of a chance of no greater than 20%, i.e. $p < 0.20$. Factors
30 included in determining clinical outcomes to be relevant for additional testing may include, for example, consideration of the target indication, the trial endpoints, progression of the disease, disorder, or condition during the trial study period, biochemical or pathophysiologic relevance of the candidate therapeutic intervention, and other variables that were not included or anticipated in the initial study design or
35 clinical protocol. Factors to be included in the economic significance in determining additional testing parameters include sample size, accrual rate, number of clinical sites or institutions required, additional or other available medical or therapeutic interventions approved for human use, and additional or other available medical or

therapeutic interventions concurrently or anticipated to enter human clinical testing. Further, there may be patients within the treatment categories that present data that fall outside of the average or mean values, or there may be an indication of multiple allelic loci that are involved in the responses to the candidate therapeutic intervention. In these cases, one could propose a prospective clinical trial having an objective to determine the significance of the variable or parameter and its effect on the outcome of the parent Phase II trial. In the case of a pharmacogenetic difference, i.e. a single or multiple allelic difference, a population could be selected based upon the distribution of genotypes. The candidate therapeutic intervention could then be tested in this group of volunteers to test for efficacy or toxicity. The repeat prospective study could be a Phase I limited study in which the subjects would be healthy human volunteers, or a Phase II limited efficacy study in which patients which satisfy the inclusion criteria could be enrolled. In either case, the second, confirmatory trial could then be used to systematically ensure an adequate number of patients with appropriate phenotype is enrolled in a Phase III trial.

A placebo controlled pharmacogenetics clinical trial design will be one in which target allelic variance or variances will be identified and a diagnostic test will be performed to stratify the patients based upon presence, absence, or combination thereof of these variances. In the Phase II or Phase III stage of clinical development, determination of a specific sample size of a prospective trial will be described to include factors such as expected differences between a placebo and treatment on the primary or secondary endpoints and a consideration of the allelic frequencies.

The design of a pharmacogenetics clinical trial will include a description of the allelic variance impact on the observed efficacy between the treatment groups. Using this type of design, the type of genetic and phenotypic relationship display of the efficacy response to a candidate therapeutic intervention will be analyzed. For example, a genotypically dominant allelic variance or variances will be those in which both heterozygotes and homozygotes will demonstrate a specific phenotypic efficacy response different from the homozygous recessive genotypic group. A pharmacogenetic approach is useful for clinicians and public health professionals to include or eliminate small groups of responders or non-responders from treatment in order to avoid unjustified side-effects. Further, adjustment of dosages when clear clinical difference between heterozygous and homozygous individuals may be beneficial for therapy with the candidate therapeutic intervention

In another example, a recessive allelic variance or variances will be those in which only the homozygote recessive for that or those variances will demonstrate a specific phenotypic efficacy response different from the heterozygotes or homozygous dominants. An extension of these examples may include allelic

variance or variances organized by haplotypes from additional gene or genes.

V. Variance Identification and Use

A. Initial Identification of variances in genes

5 *Selection of population size and composition*

Prior to testing to identify the presence of sequence variances in a particular gene or genes, it is useful to understand how many individuals should be screened to provide confidence that most or nearly all pharmacogenetically relevant variances will be found. The answer depends on the frequencies of the phenotypes of interest and what assumptions we make about heterogeneity and magnitude of genetic effects. Prior to testing to identify the presence of sequence variances in a particular gene or genes, it is useful to understand how many individuals should be screened to provide confidence that most or nearly all pharmacogenetically relevant variances will be found. The answer depends on the frequencies of the phenotypes of interest and what assumptions we make about heterogeneity and magnitude of genetic effects. At the beginning we only know phenotype frequencies (e.g. responders vs. nonresponders, frequency of various side effects, etc.).

The most conservative assumption (resulting in the lowest estimate of allele frequency, and consequently the largest suggested screening population) is (i) that the phenotype (e.g. toxicity or efficacy) is multifactorial (i.e. can be caused by two or more variances or combinations of variances), (ii) that the variance of interest has a high degree of penetrance (i.e. is consistently associated with the phenotype), and (iii) that the mode of transmission is Mendelian dominant. Consider a pharmacogenetic study designed to identify predictors of efficacy for a compound that produces a 15% response rate in a nonstratified population. If half the response is substantially attributable to a given variance, and the variance is consistently associated with a positive response (in 80% of cases) and the variance need only be present in one copy to produce a positive result then ~10% of the subjects are likely heterozygotes for the variance that produces the response. The Hardy-Weinberg equation can be used to infer an allele frequency in the range of 5% from these assumptions (given allele frequencies of 5%/95% then: $2 \times .05 \times .95 = .095$, or 9.5% heterozygotes are expected, and $0.05 \times 0.05 = 0.0025$, or 0.25% homozygotes are expected. They sum to $9.5\% + 0.25\% = 9.75\%$ likely responders, 80% of whom, or 7.6%, are likely real responders due to presence of the positive response allele. Thus about half of the 15% responders are accounted for.). From the Table it can be seen that, in order to have a 99% chance of detecting an allele present at a frequency of

5% nearly 50 subjects should be screened for variances, assuming that the variances occur in the screening population at the same frequency as they occur in the patient population. Similar analyses can be performed for other assumptions regarding likely magnitude of effect, penetrance and mode of genetic transmission.

At the beginning we only know phenotype frequencies (e.g. responders vs. nonresponders, frequency of various side effects, etc.). As an example, the occurrence of serious 5-FU/FA toxicity - e.g. toxicity requiring hospitalization is often >10%. The occurrence of life threatening toxicity is in the 1-3% range (Buroker et al. 1994). The occurrence of complete remissions is on the order of 2-8%. The lowest frequency phenotypes are thus on the order of ~2%. If we assume that (i) homogeneous genetic effects are responsible for half the phenotypes of interest and (ii) for the most part the extreme phenotypes represent recessive genotypes, then we need to detect alleles that will be present at ~10% frequency ($.1 \times .1 = .01$, or 1% frequency of homozygotes) if the population is at Hardy-Weinberg equilibrium. To have a ~99% chance of identifying such alleles would require searching a population of 22 individuals (see Table below). If the major phenotypes are associated with heterozygous genotypes then we need to detect alleles present at ~.5% frequency ($2 \times .005 \times .995 = .00995$, or ~1% frequency of heterozygotes). A 99% chance of detecting such alleles would require ~40 individuals (Table below). Given the heterogeneity of the North American population we cannot assume that all genotypes are present in Hardy-Weinberg proportions, therefore a substantial oversampling may be done to increase the chances of detecting relevant variances: For our initial screening, usually, 62 individuals of known race/ethnicity are screened for variance. Variance detection studies can be extended to outliers for the phenotypes of interest to cover the possibility that important variances were missed in the normal population screening.

Table 4

Allele frequencies	Number of subjects genotyped							
	n = 5	n = 10	n = 15	n = 20	n = 25	n = 30	n = 35	n = 50
p=.99,	9.56	18.21	26.03	33.10	39.50	45.28	50.52	63.40
p=.97,	26.26	45.62	59.90	70.43	78.19	83.92	88.14	95.24
p=.95,	40.13	64.15	78.53	87.15	92.30	95.39	97.24	99.65
p=.93,	51.60	76.58	88.66	94.51	97.34	98.71	99.38	99.93
p=.9, q =	65.13	87.84	95.76	98.52	99.48	99.82	99.94	>99.9
p=.8, q =	89.26	98.84	99.88	99.99	>99.9	>99.9	>99.9	>99.9

p=.7, q=	97.17	99.92	99.99	>99.9	>99.9	>99.9	>99.9	>99.9
----------	-------	-------	-------	-------	-------	-------	-------	-------

Likelihood of Detecting Polymorphism in a Population as a Function of Allele Frequency & Number of Individuals Genotyped

5 Table 4 shows the probability (expressed as percent) of detecting both alleles (i.e. detecting heterozygotes) at a biallelic locus as a function of (i) the allele frequencies and (ii) the number of individuals genotyped. The chances of detecting heterozygotes increases as the frequencies of the two alleles approach 0.5 (down a column), and as the number of individuals genotyped increases (to the right along a row). The numbers in the table are given by the formula: $1 - (p)^{2n} - (q)^{2n}$. Allele frequencies are designated p and q and the number of individuals tested is designated n. (Since humans are diploid, the number of alleles tested is twice the number of individuals, or 2n.)

15 While it is preferable that numbers of individuals, or independent sequence samples, are screened to identify variances in a gene, it is also very beneficial to identify variances using smaller numbers of individuals or sequence samples. For example, even a comparison between the sequences of two samples or individuals can reveal sequence variances between them. Preferably, 5, 10, or more samples or individuals are screened.

20 *Source of nucleic acid samples*

Nucleic acid samples, for example for use in variance identification, can be obtained from a variety of sources as known to those skilled in the art, or can be obtained from genomic or cDNA sources by known methods. For example, the Coriell Cell Repository (Camden, N.J.) maintains over 6,000 human cell cultures, mostly fibroblast and lymphoblast cell lines comprising the NIGMS Human Genetic Mutant Cell Repository. A catalog (<http://locus.umdj.edu/nigms>) provides racial or ethnic identifiers for many of the cell lines. It is preferable to perform polymorphism discovery on a population that mimics the population to be evaluated in a clinical trial, both in terms of racial/ethnic/geographic background and in terms of disease status. Otherwise, it is generally preferable to include a broad population sample including, for example, (for trials in the United States): Caucasians of Northern, Central and Southern European origin, Africans or African-Americans, Hispanics or Mexicans, Chinese, Japanese, American Indian, East Indian, Arabs and Koreans.

Source of human DNA, RNA and cDNA samples

PCR based screening for DNA polymorphism can be carried out using either genomic DNA or cDNA produced from mRNA. For many genes, only cDNA sequences have been published, therefore the analysis of those genes is, at least initially, at the cDNA level since the determination of intron-exon boundaries and the isolation of flanking sequences is a laborious process. However, screening genomic DNA has the advantage that variances can be identified in promoter, intron and flanking regions. Such variances may be biologically relevant. Therefore preferably, when variance analysis of patients with outlier responses is performed, analysis of selected loci at the genomic level is also performed. Such analysis would be contingent on the availability of a genomic sequence or intron-exon boundary sequences, and would also depend on the anticipated biological importance of the gene in connection with the particular response.

When cDNA is to be analyzed it is very beneficial to establish a tissue source in which the genes of interest are expressed at sufficient levels that cDNA can be readily produced by RT-PCR. Preliminary PCR optimization efforts for 19 of the 29 genes in Table 2 reveal that all 19 can be amplified from lymphoblastoid cell mRNA. The 7 untested genes belong on the same pathways and are expected to also be PCR amplifiable.

PCR Optimization

Primers for amplifying a particular sequence can be designed by methods known to those skilled in the art, including by the use of computer programs such as the PRIMER software available from Whitehead Institute/MIT Genome Center. In some cases it is preferable to optimize the amplification process according to parameters and methods known to those skilled in the art; optimization of PCR reactions based on a limited array of temperature, buffer and primer concentration conditions is utilized. New primers are obtained if optimization fails with a particular primer set.

Variance detection using T4 endonuclease VII mismatch cleavage method

Any of a variety of different methods for detecting variances in a particular gene can be utilized, such as those described in the patents and applications cited in section A above. An exemplary method is a T4 EndoVII method. The enzyme T4 endonuclease VII (T4E7) is derived from the bacteriophage T4. T4E7 specifically cleaves heteroduplex DNA containing single base mismatches, deletions or insertions. The site of cleavage is 1 to 6 nucleotides 3' of the mismatch. This

activity has been exploited to develop a general method for detecting DNA sequence variances (Youil et al. 1995; Mashal and Sklar, 1995). A quality controlled T4E7 variance detection procedure based on the T4E7 patent of R.G.H. Cotton and co-workers. (Del Tito et al., in press) is preferably utilized. T4E7 has the advantages of being rapid, inexpensive, sensitive and selective. Further, since the enzyme pinpoints the site of sequence variation, sequencing effort can be confined to a 25 - 30 nucleotide segment.

The major steps in identifying sequence variations in candidate genes using T4E7 are: (1) PCR amplify 400-600 bp segments from a panel of DNA samples; (2) mix a fluorescently-labeled probe DNA with the sample DNA; (3) heat and cool the samples to allow the formation of heteroduplexes; (4) add T4E7 enzyme to the samples and incubate for 30 minutes at 37°C, during which cleavage occurs at sequence variance mismatches; (5) run the samples on an ABI 377 sequencing apparatus to identify cleavage bands, which indicate the presence and location of variances in the sequence; (6) a subset of PCR fragments showing cleavage are sequenced to identify the exact location and identity of each variance.

The T4E7 Variance Imaging procedure has been used to screen particular genes. The efficiency of the T4E7 enzyme to recognize and cleave at all mismatches has been tested and reported in the literature. One group reported detection of 81 of 81 known mutations (Youil et al. 1995) while another group reported detection of 16 of 17 known mutations (Mashal and Sklar, 1995). Thus, the T4E7 method provides highly efficient variance detection.

DNA sequencing

A subset of the samples containing each unique T4E7 cleavage site is selected for sequencing. DNA sequencing can, for example, be performed on ABI 377 automated DNA sequencers using BigDye chemistry and cycle sequencing. Analysis of the sequencing runs will be limited to the 30-40 bases pinpointed by the T4E7 procedure as containing the variance. This provides the rapid identification of the altered base or bases.

In some cases, the presence of variances can be inferred from published articles which describe Restriction Fragment Length Polymorphisms (RFLP). The sequence variances or polymorphisms creating those RFLPs can be readily determined using convention techniques, for example in the following manner. If the RFLP was initially discovered by the hybridization of a cDNA, then the molecular sequence of the RFLP can be determined by restricting the cDNA probe into fragments and separately hybridizing to a Southern blot consisting of the restriction digestion with the enzyme which reveals the polymorphic site, identifying

the sub-fragment which hybridizes to the polymorphic restriction fragment, obtaining a genomic clone of the gene (e.g., from commercial services such as Genome Systems (Saint Louis, Missouri) or Research Genetics (Alabama) which will provide appropriate genomic clones on receipt of appropriate primer pairs).

5 Using the genomic clone, restrict the genomic clone with the restriction enzyme which revealed the polymorphism and isolate the fragment which contains the polymorphism, e.g., identifying by hybridization to the cDNA which detected the polymorphism. The fragment is then sequenced across the polymorphic site. A copy of the other allele can be obtained by PCT from addition samples.

10 *Variance detection using sequence scanning*

In addition to the physical methods, e.g., those described above and others known to those skilled in the art (see, e.g., Housman, U.S. Patent 5,702,890; Housman et al., U.S. Patent Application 09/045,053), variances can be detected using computational methods, involving computer comparison of sequences from
15 two or more different biological sources, which can be obtained in various ways, for example from public sequence databases. The term "variance scanning" refers to a process of identifying sequence variances using computer-based comparison and analysis of multiple representations of at least a portion of one or more genes. Computational variance detection involves a process to distinguish true variances
20 from sequencing errors or other artifacts, and thus does not require perfectly accurate sequences. Such scanning can be performed in a variety of ways, preferably, for example, as described in Stanton et al., filed October 14, 1999, serial number 09/419,705.

While the utilization of complete cDNA sequences is highly preferred, it is
25 also possible to utilize genomic sequences. Such analysis may be desired where the detection of variances in or near splice sites is sought. Such sequences may represent full or partial genomic DNA sequences for a gene or genes. Also, as previously indicated, partial cDNA sequences can also be utilized although this is less preferred. As described below, the variance scanning analysis can simply
30 utilize sequence overlap regions, even from partial sequences. Also, while the present description is provided by reference to DNA, e.g., cDNA, some sequences may be provided as RNA sequences, e.g., mRNA sequences. Such RNA sequences may be converted to the corresponding DNA sequences, or the analysis may use the RNA sequences directly.

35 B. Determination of Presence or Absence of Known Variances

005230 034960

The identification of the presence of previously identified variances in cells of an individual, usually a particular patient, can be performed by a number of different techniques as indicated in the Summary above. Such methods include methods utilizing a probe which specifically recognizes the presence of a particular nucleic acid or amino acid sequence in a sample. Common types of probes include nucleic acid hybridization probes and antibodies, for example, monoclonal antibodies, which can differentially bind to nucleic acid sequences differing in one or more variance sites or to polypeptides which differ in one or more amino acid residues as a result of the nucleic acid sequence variance or variances. Generation and use of such probes is well-known in the art and so is not described in detail herein.

Preferably, however, the presence or absence of a variance is determined using nucleotide sequencing of a short sequence spanning a previously identified variance site. This will utilize validated genotyping assays for the polymorphisms previously identified. Since both normal and tumor cell genotypes can be measured, and since tumor material will frequently only be available as paraffin embedded sections (from which RNA cannot be isolated), it will be necessary to utilize genotyping assays that will work on genomic DNA. Thus PCR reactions will be designed, optimized, and validated to accommodate the intron-exon structure of each of the genes. If the gene structure has been published (as it has for some of the listed genes), PCR primers can be designed directly. However, if the gene structure is unknown, the PCR primers may need to be moved around in order to both span the variance and avoid exon-intron boundaries. In some cases one-sided PCR methods such as bubble PCR (Ausubel et al. 1997) may be useful to obtain flanking intronic DNA for sequence analysis.

Using such amplification procedures, the standard method used to genotype normal and tumor tissues will be DNA sequencing. PCR fragments encompassing the variances will be cycle sequenced on ABI 377 automated sequencers using Big Dye chemistry

30

C. Correlation of the Presence or Absence of Specific Variances with Differential Treatment Response

Prior to establishment of a diagnostic test for use in the selection of a treatment method or elimination of a treatment method, the presence or absence of one or more specific variances in a gene or in multiple genes is correlated with a differential treatment response. (As discussed above, usually the existence of a variable response and the correlation of such a response to a particular gene is performed first.) Such a differential response can be determined using prospective

35

and/or retrospective data. Thus, in some cases, published reports will indicate that the course of treatment will vary depending on the presence or absence of particular variances. That information can be utilized to create a diagnostic test and/or incorporated in a treatment method as an efficacy or safety determination step.

5 Usually, however, the effect of one or more variances is separately determined. The determination can be performed by analyzing the presence or absence of particular variances in patients who have previously been treated with a particular treatment method, and correlating the variance presence or absence with the observed course, outcome, and/or development of adverse events in those
10 patients. This approach is useful in cases in which observation of treatment effects was clearly recorded and cell samples are available or can be obtained. Alternatively, the analysis can be performed prospectively, where the presence or absence of the variance or variances in an individual is determined and the course, outcome, and/or development of adverse events in those patients is subsequently or
15 concurrently observed and then correlated with the variance determination.

Analysis of Haplotypes Increases Power of Genetic Analysis

In some cases, variation in activity due to a single gene or a single genetic variance in a single gene may not be sufficient to account for a clinically significant
20 fraction of the observed variation in patient response to a treatment, e.g., a drug, there may be other factors that account for some of the variation in patient response. Drug response phenotypes may vary continuously, and such (quantitative) traits may be influenced by a number of genes (Falconer and Mackay, Quantitative Genetics, 1997). Although it is impossible to determine *a priori* the number of genes
25 influencing a quantitative trait, potentially only one or a few loci have large effects, where a large effect is 5-20% of total variation in the phenotype (Mackay, 1995).

Having identified genetic variation in enzymes that may affect action of a specific drug, it is useful to efficiently address its relation to phenotypic variation.
30 The sequential testing for correlation between phenotypes of interest and single nucleotide polymorphisms may be adequate to detect associations if there are major effects associated with single nucleotide changes; certainly it is useful to this type of analysis. However there is no way to know in advance whether there are major phenotypic effects associated with single nucleotide changes and, even if there are,
35 there is no way to be sure that the salient variance has been identified by screening cDNAs. A more powerful way to address the question of genotype-phenotype correlation is to assort genotypes into haplotypes. (A haplotype is the cis

Table 1. Demographic characteristics of the study population	
Age (years)	65.8 ± 1.2
Gender (male/female)	10/10
Education (years)	12.5 ± 0.5
Occupation (white/blue)	10/10
Marital status (married/divorced/widowed)	10/10/0
Smoking status (smoker/nonsmoker)	10/10
Alcohol consumption (yes/no)	10/10
Comorbidities (hypertension/diabetes/cholesterol)	10/10/10
Medication (antihypertensive/antidiabetic/anticholesterol)	10/10/10
Physical activity (yes/no)	10/10
Stress level (low/high)	10/10
Sleep quality (good/poor)	10/10
Depression score (0-10)	2.5 ± 0.5
Life satisfaction score (0-10)	7.5 ± 0.5
Overall health status (good/fair/poor)	10/10/0

(1) Of all the possible haplotypes at a locus (2^n haplotypes are theoretically possible at a locus with n binary polymorphic sites) only a small fraction will generally occur at a significant frequency in human populations. Thus, association studies of haplotypes and phenotypes will involve testing fewer hypotheses. As a result there is a smaller probability of Type I errors, that is, false inferences that a particular variant is associated with a given phenotype.

(2) The biological effect of each variance at a locus may be different both in magnitude and direction. For example, a polymorphism in the 5' UTR may affect translational efficiency, a coding sequence polymorphism may affect protein activity, a polymorphism in the 3' UTR may affect mRNA folding and half life, and so on. Further, there may be interactions between variances: two neighboring polymorphic amino acids in the same domain - say cys/arg at residue 29 and met/val at residue 166 - may, when combined in one sequence, for example, 29cys-166val, have a deleterious effect, whereas 29cys-166met, 29arg-166met and 29arg-166val proteins may be nearly equal in activity. Haplotype analysis is the best method for assessing the interaction of variances at a locus.

(3) Templeton and colleagues have developed powerful methods for assorting haplotypes and analyzing haplotype/phenotype associations (Templeton et al., 1987). Alleles which share common ancestry are arranged into a tree structure (cladogram) according to their (inferred) time of origin in a population (that is, according to the principle of parsimony). Haplotypes that are evolutionarily ancient will be at the center of the branching structure and new ones (reflecting recent mutations) will be represented at the periphery, with the links representing intermediate steps in evolution. The cladogram defines which haplotype-phenotype association tests should be performed to most efficiently exploit the available degrees of freedom, focusing attention on those comparisons most likely to define functionally different haplotypes (Haviland et al., 1995). This type of analysis has been used to define interactions between heart disease and the apolipoprotein gene cluster (Haviland et al 1995) and Alzheimer's Disease and the Apo-E locus (Templeton 1995) among other studies, using populations as small as 50 to 100 individuals. The methods of Templeton have also been applied to measure the genetic determinants of variation in the angiotensin-I converting enzyme gene.

(Keavney, B., McKenzie, C. A., Connoll, J.M.C., et al. Measured haplotype analysis of the angiotensin-I converting enzyme gene. *Human Molecular Genetics* 7: 1745-1751.)

5 *Methods for determining haplotypes*

 The goal of haplotyping is to identify the common haplotypes at selected loci that have multiple sites of variance. Haplotypes are usually determined at the cDNA level. Several general approaches to identification of haplotypes can be employed. Haplotypes may also be estimated using computational methods or determined
10 definitively using experimental approaches. Computational approaches generally include an expectation maximization (E-M) algorithm (see, for example: Excoffier and Slatkin, *Mol. Biol. Evol.* 1995) or a combination of Parsimony (see below) and E-M methods.

 Haplotypes can be determined experimentally without requirement of a
15 haplotyping method by genotyping samples from a set of pedigrees and observing the segregation of haplotypes. For example families collected by the Centre d'Etude du Polymorphisme Humaine (CEPH) can be used. Cell lines from these families are available from the Coriell Repository. This approach will be useful for cataloging common haplotypes and for validating methods on samples with known haplotypes.
20 The set of haplotypes determined by pedigree analysis can be useful in computational methods, including those utilizing the E-M algorithm.

 Haplotypes can also be determined directly from cDNA using the T4E7 procedure. T4E7 cleaves mismatched heteroduplex DNA at the site of the mismatch. If a heteroduplex contains only one mismatch, cleavage will result in the
25 generation of two fragments. However, if a single heteroduplex (allele) contains two mismatches, cleavage will occur at two different sites resulting in the generation of three fragments. The appearance of a fragment whose size corresponds to the distance between the two cleavage sites is diagnostic of the two mismatches being present on the same strand (allele). Thus, T4E7 can be used to determine haplotypes
30 in diploid cells.

 An alternative method, allele specific PCR, may be used for haplotyping. The utility of allele specific PCR for haplotyping has already been established (Michalatos-Beloin et al., 1996; Chang et al. 1997). Opposing PCR primers are designed to cover two sites of variance (either adjacent sites or sites spanning one or
35 more internal variances). Two versions of each primer are synthesized, identical to each other except for the 3' terminal nucleotide. The 3' terminal nucleotide is designed so that it will hybridize to one but not the other variant base. PCR

09648133-082500

amplification is then attempted with all four possible primer combinations in separate wells. Because Taq polymerase is very inefficient at extending 3' mismatches, the only samples which will be amplified will be the ones in which the two primers are perfectly matched for sequences on the same strand (allele). The presence or absence of PCR product allows haplotyping of diploid cell lines. At most two of four possible reactions should yield products. This procedure has been successfully applied, for example, to haplotype the DPD amino acid polymorphisms.

Parsimony methods are also useful for classifying DNA sequences, haplotypes or phenotypic characters. Parsimony principle maintains that the best explanation for the observed differences among sequences, phenotypes (individuals, species) etc., is provided by the smallest number of evolutionary changes. Alternatively, simpler hypotheses are preferable to explain a set of data or patterns, than more complicated ones, and *ad hoc* hypotheses should be avoided whenever possible (Molecular Systematics, Hillis et al., 1996). Parsimony methods thus operate by minimizing the number of evolutionary steps or mutations (changes from one sequence/character) required to account for a given set of data.

For example, supposing we want to obtain relationships among a set of sequences and construct a structure (tree/topology), we first count the minimum number of mutations that are required for explaining the observed evolutionary changes among a set of sequences. A structure (topology) is constructed based on this number. When once this number is obtained, another structure is tried. This process is continued for all reasonable number of structures. Finally, the structure that required the smallest number of mutational steps is chosen as the likely structure/evolutionary tree for the sequences studied.

For haplotypes identified herein, haplotypes were identified by examining genotypes from each cell line. This list of genotypes was optimized to remove variance sites/individuals with incomplete information, and the genotype from each remaining cell line was examined in turn. The number of heterozygotes in the genotype were counted, and those genotypes containing more than one heterozygote were discarded, and the rest were gathered in a list for storage and display. For haplotypes identified herein, haplotypes were identified by examining genotypes from each cell line. This list of genotypes was optimized to remove variance sites/individuals with incomplete information, and the genotype from each remaining cell line was examined in turn. The number of heterozygotes in the genotype were counted, and those genotypes containing more than one heterozygote were discarded, and the rest were gathered in a list for storage and display.

D. Selection of Treatment Method Using Variance Information

1. General

Once the presence or absence of a variance or variances in a gene or genes is shown to correlate with the efficacy or safety of a treatment method, that information can be used to select an appropriate treatment method for a particular patient. In the case of a treatment which is more likely to be effective when administered to a patient who has at least one copy of a gene with a particular variance or variances (in some cases the correlation with effective treatment is for patients who are homozygous for a variance or set of variances in a gene) than in patients with a different variance or set of variances, a method of treatment is selected (and/or a method of administration) which correlates positively with the particular variance presence or absence which provides the indication of effectiveness. As indicated in the Summary, such selection can involve a variety of different choices, and the correlation can involve a variety of different types of treatments, or choices of methods of treatment. In some cases, the selection may include choices between treatments or methods of administration where more than one method is likely to be effective, or where there is a range of expected effectiveness or different expected levels of contra-indication or deleterious effects. In such cases the selection is preferably performed to select a treatment which will be as effective or more effective than other methods, while having a comparatively low level of deleterious effects. Similarly, where the selection is between method with differing levels of deleterious effects, preferably a method is selected which has low such effects but which is expected to be effective in the patient.

Alternatively, in cases where the presence or absence of the particular variance or variances is indicative that a treatment or method of administration is more likely to be ineffective or contra-indicated in a patient with that variance or variances, then such treatment or method of administration is generally eliminated for use in that patient.

2. Diagnostic Methods

Once a correlation between the presence and absence of at least one variance in a gene or genes and an indication of the effectiveness of a treatment, the determination of the presence or absence of that at least one variance provides diagnostic methods, which can be used as indicated in the Summary above to select methods of treatment, methods of administration of a treatment, methods of selecting a patient or patients for a treatment and others aspects in which the determination of the presence or absence of those variances provides useful information for selecting or designing or preparing methods or materials for medical

use in the aspects of this invention. As previously stated, such variance determination or diagnostic methods can be performed in various ways as understood by those skilled in the art.

5 In certain variance determination methods, it is necessary or advantageous to amplify one or more nucleotide sequences in one or more of the genes identified herein. Such amplification can be performed by conventional methods, e.g., using polymerase chain reaction (PCR) amplification. Such amplification methods are well-known to those skilled in the art and will not be specifically described herein. For most applications relevant to the present invention, a sequence to be amplified
10 includes at least one variance site, which is preferably a site or sites which provide variance information indicative of the effectiveness of a method of treatment or method of administration of a treatment, or effectiveness of a second method of treatment which reduces a deleterious effect of a first treatment method, or which enhances the effectiveness of a first method of treatment. Thus, for PCR, such
15 amplification generally utilizes primer oligonucleotides which bind to or extend through at least one such variance site under amplification conditions.

For convenient use of the amplified sequence, e.g., for sequencing, it is beneficial that the amplified sequence be of limited length, but still long enough to allow convenient and specific amplification. Thus, preferably the amplified
20 sequence has a length as described in the Summary.

Also, in certain variance determination, it is useful to sequence one or more portions of a gene or genes, in particular, portions of the genes identified in this disclosure. As understood by persons familiar with nucleic acid sequencing, there are a variety of effective methods. In particular, sequencing can utilize dye
25 termination methods and mass spectrometric methods. The sequencing generally involves a nucleic acid sequence which includes a variance site as indicated above in connection with amplification. Such sequencing can directly provide determination of the presence or absence of a particular variance or set of variances, e.g., a haplotype, by inspection of the sequence (visually or by computer). Such
30 sequencing is generally conducted on PCR amplified sequences in order to provide sufficient signal for practical or reliable sequence determination.

Likewise, in certain variance determinations, it is useful to utilize a probe or probes. As previously described, such probes can be of a variety of different types.

35 **VI. Pharmaceutical Compositions, Including Pharmaceutical Compositions Adapted to be Preferentially Effective in Patients Having Particular Genetic Characteristics**

A. General

The methods of the present invention, in many cases will utilize conventional pharmaceutical compositions, but will allow more advantageous and beneficial use of those compositions due to the ability to identify patients who are likely to benefit from a particular treatment or to identify patients for whom a particular treatment is less likely to be effective or for whom a particular treatment is likely to produce undesirable or intolerable effects. However, in some cases, it is advantageous to utilize compositions which are adapted to be preferentially effective in patients who possess particular genetic characteristics, i.e., in whom a particular variance or variances in one or more genes is present or absent (depending on whether the presence or the absence of the variance or variances in a patient is correlated with an increased expectation of beneficial response). Thus, for example, the presence of a particular variance or variances may indicate that a patient can beneficially receive a significantly higher dosage of a drug than a patient having a different

B. Regulatory Indications and Restrictions

The sale and use of drugs and the use of other treatment methods usually are subject to certain restrictions by a government regulatory agency charged with ensuring the safety and efficacy of drugs and treatment methods for medical use, and approval is based on particular indications. In the present invention it is found that variability in patient response or patient tolerance of a drug or other treatment often correlates with the presence or absence of particular variances in particular genes. Thus, it is expected that such a regulatory agency may indicate that the approved indications for use of a drug with a variance-related variable response or toleration include use only in patients in whom the drug will be effective, and/or for whom the administration of the drug will not have intolerable deleterious effects, such as excessive toxicity or unacceptable side-effects. Conversely, the drug may be given for an indication that it may be used in the treatment of a particular disease or condition where the patient has at least one copy of a particular variance, variances, or variant form of a gene. Even if the approved indications are not narrowed to such groups, the regulatory agency may suggest use limited to particular groups or excluding particular groups or may state advantages of use or exclusion of such groups or may state a warning on the use of the drug in certain groups. Consistent with such suggestions and indications, such an agency may suggest or recommend the use of a diagnostic test to identify the presence or absence of the relevant variances in the prospective patient. Such diagnostic methods are described in this description. Generally, such regulatory suggestion or indication is provided in a product insert or label, and is generally reproduced in references such as the

Physician's Desk Reference (PDR). Thus, this invention also includes drugs or pharmaceutical compositions which carry such a suggestion or statement of indication or warning or suggestion for a diagnostic test, and which may also be packaged with an insert or label stating the suggestion or indication or warning or suggestion for a diagnostic test.

In accord with the possible variable treatment responses, an indication or suggestion can specify that a patient be heterozygous, or alternatively, homozygous for a particular variance or variances or variant form of a gene. Alternatively, an indication or suggestion may specify that a patient have no more than one copy, or zero copies, of a particular variance, variances, or variant form of a gene.

A regulatory indication or suggestion may concern the variances or variant forms of a gene in normal cells of a patient and/or in cells involved in the disease or condition. For example, in the case of a cancer treatment, the response of the cancer cells can depend on the form of a gene remaining in cancer cells following loss of heterozygosity affecting that gene. Thus, even though normal cells of the patient may contain a form of the gene which correlates with effective treatment response, the absence of that form in cancer cells will mean that the treatment would be less likely to be effective in that patient than in another patient who retained in cancer cells the form of the gene which correlated with effective treatment response. Those skilled in the art will understand whether the variances or gene forms in normal or disease cells are most indicative of the expected treatment response, and will generally utilize a diagnostic test with respect to the appropriate cells. Such a cell type indication or suggestion may also be contained in a regulatory statement, e.g., on a label or in a product insert.

C. Preparation and Administration of Drugs and Pharmaceutical Compositions Including Pharmaceutical Compositions Adapted to be Preferentially Effective in Patients Having Particular Genetic Characteristics

A particular compound useful in this invention can be administered to a patient either by itself, or in pharmaceutical compositions where it is mixed with suitable carriers or excipient(s). In treating a patient exhibiting a disorder of interest, a therapeutically effective amount of a agent or agents such as these is administered. A therapeutically effective dose refers to that amount of the compound that results in amelioration of one or more symptoms or a prolongation of survival in a patient.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀

(the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD_{50}/ED_{50} . Compounds which exhibit large therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED_{50} with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.

For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. For example, a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC_{50} as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by HPLC.

The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See *e.g.* Fingl et. al., in The Pharmacological Basis of Therapeutics, 1975, Ch. 1 p.1). It should be noted that the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity, or to organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an administered dose in the management of disorder of interest will vary with the severity of the condition to be treated and the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, will also vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine.

Depending on the specific conditions being treated, such agents may be formulated and administered systemically or locally. Techniques for formulation and administration may be found in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Co., Easton, PA (1990). Suitable routes may include oral, rectal, transdermal, vaginal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections, just to name a few.

For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For such transmucosal

administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

Use of pharmaceutically acceptable carriers to formulate the compounds herein disclosed for the practice of the invention into dosages suitable for systemic administration is within the scope of the invention. With proper choice of carrier and suitable manufacturing practice, the compositions of the present invention, in particular, those formulated as solutions, may be administered parenterally, such as by intravenous injection. The compounds can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration. Such carriers enable the compounds of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.

Agents intended to be administered intracellularly may be administered using techniques well known to those of ordinary skill in the art. For example, such agents may be encapsulated into liposomes, then administered as described above. Liposomes are spherical lipid bilayers with aqueous interiors. All molecules present in an aqueous solution at the time of liposome formation are incorporated into the aqueous interior. The liposomal contents are both protected from the external microenvironment and, because liposomes fuse with cell membranes, are efficiently delivered into the cell cytoplasm. Additionally, due to their hydrophobicity, small organic molecules may be directly administered intracellularly.

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. The preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions. The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, *e.g.*, by means of conventional mixing, dissolving, granulating, dragee-making, levitating, emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or

synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which
5 increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to
10 obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired,
15 disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and
20 suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a
25 plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition,
30 stabilizers may be added.

The invention described herein features methods for determining the appropriate identification of a patient diagnosed with a neurological disease or neurological dysfunction based on an analysis of the patient's allele status for a gene
35 listed in Tables 1 and 3. Specifically, the presence of at least one allele indicates that a patient will respond to a candidate therapeutic intervention aimed at treating a neurological clinical symptoms. In a preferred approach, the patient's allele status is rapidly diagnosed using a sensitive PCR assay and a treatment protocol is rendered.

The invention also provides a method for forecasting patient outcome and the suitability of the patient for entering a clinical drug trial for the testing of a candidate therapeutic intervention for a neurological disease, condition, or dysfunction.

5 The findings described herein indicate the predictive value of the target allele in identifying patients at risk for neurologic disease or neurologic dysfunction. In addition, because the underlying mechanism influenced by the allele status is not disease-specific, the allele status is suitable for making patient predictions for diseases not affected by the pathway as well.

10 The following examples, which describe exemplary techniques and experimental results, are provided for the purpose of illustrating the invention, and should not be construed as limiting.

005280" E2T84950

Example 1**Effect of Pharmacokinetic parameters on Efficacy of Drugs and Candidate Therapeutic Interventions**

5 The efficacy of a compound is determined by a combination of pharmacodynamic and pharmacokinetic effects. Both types of effect are under genetic control. In the present invention, the genetic determinants of efficacy are discussed in terms of variation in the genes that encode proteins responsible for absorption, distribution, metabolism, and excretion of compounds, i.e. pharmacokinetic parameters.

10 The pharmacokinetic parameters with potential effects on efficacy include absorption, distribution, metabolism, and excretion. These parameters affect efficacy broadly by controlling the availability of a compound at the site(s) of action. Interpatient variability in the availability of a compound can result in
15 undertreatment or overtreatment, or in adverse reactions due to levels of a compound or its metabolite(s). Differences in the genes responsible for pharmacokinetic variation, therefore, can be a potential source of interpatient variability in drug response.

20 *Impact of Stratification Based Upon Genotype in Drug Development for Drugs, Compounds, or Candidate Therapeutic Interventions that may Efficacy*

 Clozapine induced agranulocytosis has been associated in some reports with specific HLA haplotypes or with HSP70 variants. These reports suggest that a gene within the HLA region is associated with agranulocytosis in response to clozapine
25 therapy. In a recent study, two ethnic groups were analyzed for genetic markers for agranulocytosis. Tumor necrosis factor microsatellites d3 and b4 were found in higher frequencies in patients that experience clozapine-induced agranulocytosis. These data, while they need to be confirmed by additional studies, are suggestive that tumor necrosis factor polymorphisms may also be associated with clozapine-
30 induced agranulocytosis.

 In this invention we provide additional genes and gene sequence variances that may account for variability in toxic responses. The Detailed Description above demonstrates how identification of a candidate gene or genes (e.g. gene pathways), genetic stratification, clinical trial design, and diagnostic genotyping can lead to
35 improved medical management of a disease and/or approval of a drug, or broader use of an already approved drug. Gene pathways including, but not limited to, those that are outlined in the gene pathway, Table 1, are useful in identifying the sources of interpatient variation in efficacy as well as in the adverse events summarized in

005280" E2T84950

the column headings of Table 2, Discussed in detail below are exemplary candidate genes for the analysis of pharmacokinetic variability in clinical development, using the methods described above.

5 Advantages of Inclusion of Pharmacogenetic Stratification in Clinical Development of Agents: Impact on Efficacy

10 The advantages of a clinical research and drug development program that includes the use of polymorphic genotyping for the stratification of patients for the appropriate selection of candidate therapeutic intervention includes 1) identification of patients that may respond earlier and show signs and symptoms of efficacious therapy, 2) identification of the primary gene and relevant polymorphic variance that directly affects efficacy endpoints, 3) identification of pathophysiologic relevant variance or variances and potential therapies affecting those allelic genotypes or haplotypes, and 4) identification of allelic variances or haplotypes in genes that indirectly affects efficacy, safety or both.

15 By identifying subsets of patients, based upon genotype, that experience efficacious therapeutic benefit in response to the administration of a drug, agent or candidate therapeutic intervention, optimal selection may reduce level and extent of the appearance or manifestation of a side effect or toxicity. Appropriate genotyping and correlation to dosing regimen, or selection of optimal therapy would be beneficial to the patient, caregivers, medical personnel, and the patient's loved ones.

20 As an example of identification of the primary gene and relevant polymorphic variance that directly affects efficacy, safety, or both one could select an gene pathway as described in the Detailed Description, and determine the effect of genetic polymorphism and therapy efficacy, safety, or both within that given pathway. For example, referring to Table 2, genes involved in absorption and distribution, phase I and phase II metabolism, and excretion the optimization of therapy of by an agent known to have an efficacious effect by determining whether the patient has a predisposing genotype in which the selected agents are more effective and or are more safe. In considering an optimization protocol, one could potentially predetermine the genotypic profile of these genes involved in the manifestation of the adverse effect, or those genes preeminently responsible for drug response. By embarking on the previously described gene pathway approach, it is technical feasibility to determine the relevant genes within such a targeted drug development program.

Identification of pathophysiologic relevant variance or variances and potential therapies affecting those allelic genotypes or haplotypes may speed drug development for therapeutic alternatives. There is a need for therapies that are targeted to a disease and symptom management with limited or no undesirable side effects. Identification of a specific variance or variances within genes involved in the manifestation of clinical efficacious endpoints or therapeutic benefit and specific genetic polymorphisms of these critical genes may assist the development of novel agents and the identification of those patients that may best benefit from therapy of these candidate therapeutic alternatives.

By identifying allelic variances or haplotypes in genes that indirectly affects efficacy, safety of any class of drugs, one could target specific secondary drug or agent therapeutic actions that affect the overall therapeutic action of these agents.

Pharmacogenomics studies for these drugs, or other agent, compound, drug, or candidate therapeutic intervention, could be performed by identifying genes that are involved in the function of a drug including, but not limited to absorption, distribution, metabolism, or elimination, the interaction of the drug with its target as well as potential alternative targets, the response of the cell to the binding of a drug to a target, the metabolism (including synthesis, biodistribution or elimination) of natural compounds which may alter the activity of the drug by complementary, competitive or allosteric mechanisms that potentiate or limit the effect of the drug, and genes involved in the etiology of the disease that alter its response to a particular class of therapeutic agents. It will be recognized to those skilled in the art that this broadly includes proteins involved in pharmacokinetics as well as genes involved in pharmacodynamics. This also includes genes that encode proteins homologous to the proteins believed to carry out the above functions are also worth evaluation as they may carry out similar functions. Together the foregoing proteins constitute the candidate genes for affecting response of a patient to the therapeutic intervention. Using the methods described above, variances in these genes can be identified, and research and clinical studies can be performed to establish an association between a drug response or toxicity and specific variances.

Example 2

Drug-Induced Toxicity: Blood Dyscrasias

I. Description of Blood Dyscrasias

Blood dyscrasias are a feature of over half of all drug-related deaths and include, but are not limited to, bone marrow aplasia, granulocytopenia, aplastic

anemia, leukopenia, lymphoid hyperplasia, hemolytic anemia, and thrombocytopenia. All of these syndromes include pancytopenia to some degree.

Bone marrow aplasia- is defined as a profound loss of bone marrow resulting in pancytopenia. Drugs known to cause bone marrow aplasia include, but are not limited to, chloramphenicol, gold salts, mephenytoin, penicillamine, phenylbutazone, and trimethadione. In general these drugs are not first line therapy due to the rare occurrence of marrow aplasia. Specific forms of aplasia include:

Granulocytopenia- is defined as a loss of polymorphonuclear neutrophils to a count lower than 500. Granulocytopenia primarily predisposes the patient to bacterial and fungal infections. Drugs known to cause granulocytopenia include, but are not limited to, captopril, cephalosporins, choral hydrate, chlorpropamide, penicillins, phenothiazines, phenylbutazone, phenytoin, procainamide, propranolol, and tolbutamide.

Aplastic anemia- is a disorder involving an inability of the hematologic cells to regenerate and thus there is a dramatic depletion of one or more of the following cell types: neutrophils, platelets, or reticulocytes. Drugs associated with producing aplastic anemia are: 1) agents or compounds that produce bone marrow depression, for example cytotoxic drugs used in cancer chemotherapy; 2) agents or compounds that frequently, but inevitably, produce marrow aplasia, for example benzene; 3) agents or compounds that are associated with aplastic anemia, for example chloramphenicol, antiprotozoals, and sulfonamides.

Aplastic anemia is almost always a result of damage to the hematopoietic stem cells. There are two possible routes for the destruction of these cells: 1) direct damage to the stem cell DNA, and 2) cell cycle dependant depletion of later stage progenitor cells. In the first case, drugs or agents bind to and randomly damage the genetic material. This type of aplasia is associated with both early aplasia (immediate or direct cytotoxicity) or later myelodysplasia and leukemia. In the latter case, mitotically and metabolically active progenitor cells are preferentially affected and progenitor cell depletion may lead to unregulated proliferation of spared stem cells.

Leukopenia- is defined when the circulating peripheral white cell count falls below $5-10 \times 10^9$ cells per liter. Circulating leukocytes consist of neutrophils, monocytes, basophils, eosinophils, and lymphocytes.

Neutropenia is defined when the peripheral neutrophil count falls below 2×10^9 cells per liter. There are a number of drugs families that can cause neutropenia including, but not exclusive to, antiarrhythmics (procainamide, propranolol, quinidine), antibiotics (chloramphenicol, penicillins, sulfonamides, trimethoprim-methoxazole, para-aminosalicylic acid, rifampin, vancomycin, isoniazid,

nitrofurantoin), antimalarials (dapson, quinine, pyrimethamine), anticonvulsants (phenytoin, mephenytoin, trimethadione, ethosuximide, carbamazepine), hypoglycemic agents (tolbutamide, chlorpropamide), antihistamines (cimetadine, brompheniramine, tripeleminamine), antihypertensives (methyldopa, captopril),
5 antiinflammatory agents (aminopyrine, phenylbutazone, gold salts, ibuprofen, indomethacin), diuretics (acetazolamide, hydrochlorothiazide, chlorthalidone), phenothiazines (chlorpormazine, promazine, prochlorperazine), antimetabolite immunosuppressive agents, cytotoxic agents (alkylating agents, antimetabolites, anthracyclines, vinca alkyls, cis-platinum, hydroxyurea, actinomycin D), and
10 other agents (alpha and gamma interferon, allopurinol, ethanol, levamisole, penicillamine).

Lymphoid hyperplasia- is characterized by reactive changes within the T-cell regions of the lymph node that encroach on, and at times appear to efface, the germinal follicles. In these regions, the T-cells undergo progressive transformation
15 to immunoblasts. These reactions are encountered particularly in response to drug-induced immunoreactivity. Drugs known to cause lymphoid hyperplasia are phenytoin, and mephenytoin.

Hemolytic anemia- is characterized by the premature destruction of red cells, accumulation of hemoglobin metabolic by-products, and a marked increase in erythropoiesis within the bone marrow. Drugs known to cause hemolytic anemia
20 include, but are not excluded to, methyldopa, penicillin, sulfonamides, and vitamin E deficiency.

Thrombocytopenia- is characterized by a marked reduction in the number of circulating platelets to a level below 100,000/mm³. Drug-induced thrombocytopenia
25 may result from decreased production of platelets or decreased platelet survival or both. Drugs known to cause thrombocytopenia include, but are not excluded to, ethanol, acetaminophen, acetazolamide, acetylsalicylic acid, 5-aminosalicylic acid, carbamazepine, chlorpheniramine, cimetadine, digitoxin, diltiazem, ethchlorvynol, gold salts, heparin, hydantoins, isoniazid, levodopa, meprobamate, methyldopa,
30 penicillamine, phenylbutazone, procainamide, quinidine, quinine, ranitidine, Rauwolfia alkaloids, rifampin, sulfonamides, sulfonylureas, cytotoxic drugs, and thiazide diuretics.

II. Impact of Stratification Based Upon Genotype in Drug Development for
35 Drugs, Compounds, or Candidate Therapeutic Interventions that may Induce Blood Dyscrasias

Clozapine induced agranulocytosis is associated with differing HLA types and HSP70 variants in patients for whom responded to clozapine therapy but developed agranulocytosis. This is suggestive that a gene within the MHC region is

005230 030586

associated with the manifestation of agranulocytosis in response to clozapine therapy. In a recent study, two ethnic groups were analyzed for genetic markers for the agranulocytosis. Tumor necrosis factor microsatellites d3 and b4 were found in higher frequencies in patients that experience clozapine-induced agranulocytosis.

5 These data are suggestive that there is an involvement of tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis.

There is evidence to suggest that there are safety response differences to drug therapy in reference to development of blood dyscrasias which may be attributable to genotypic differences between individuals. There is provided in this invention
10 examples of gene pathways that are implicated in the disease process or its therapy and those that potentially cause this variability. The Detailed Description above demonstrates how identification of a candidate gene or genes and gene pathways, stratification, clinical trial design, and implementation of genotyping for appropriate medical management of a given disease can be used to identify the genetic cause of
15 variations in clinical response to therapy, new diagnostic tests, new therapeutic approaches for treating this disorder, and new pharmaceutical products or formulations for therapy. Gene pathways including, but not limited to, those that are outlined in the gene pathway Table 1, and pathway matrix Table 2 and discussed below are candidates for the genetic analysis and product development using the
20 methods described above.

Advantages of Inclusion of Pharmacogenetic Stratification in Clinical Development of Agents that May Cause Blood Dyscrasias

The advantages of a clinical research and drug development program that
25 includes the use of polymorphic genotyping for the stratification of patients for the appropriate selection of candidate therapeutic intervention includes 1) identification of patients that may respond earlier and show signs and symptoms of blood dyscrasias, 2) identification of the primary gene and relevant polymorphic variance that directly affects manifestation of a blood disorder, 3) identification of
30 pathophysiologic relevant variance or variances and potential therapies affecting those allelic genotypes or haplotypes, and 4) identification of allelic variances or haplotypes in genes that indirectly affects efficacy, safety or both.

By identifying subsets of patients, based upon genotype, that experience blood dyscrasias in response to the administration of a drug, agent or candidate
35 therapeutic intervention, optimal selection may reduce level and extent of the hemostatic damage. Appropriate genotyping and correlation to dosing regimen, or

selection of optimal therapy would be beneficial to the patient, caregivers, medical personnel, and the patient's loved ones.

As an example of identification of the primary gene and relevant polymorphic variance that directly affects efficacy, safety, or both one could select an gene pathway as described in the Detailed Description, and determine the effect of genetic polymorphism and therapy efficacy, safety, or both within that given pathway. For example, referring to Table 2, genes involved in drug transport, phase I and phase II metabolism, protection from reactive intermediate damage, and immune responsiveness the optimization of therapy of by an agent known to have a blood dyscrasia side effect by determining whether the patient has a predisposing genotype in which the selected agents are more effective and or are more safe. In considering an optimization protocol, one could potentially predetermine the genotypic profile of these genes involved in the manifestation of the adverse effect, or those genes preeminently responsible for drug response. By embarking on the previously described gene pathway approach, it is technical feasibility to determine the relevant genes within such a targeted drug development program.

Identification of pathophysiologic relevant variance or variances and potential therapies affecting those allelic genotypes or haplotypes may speed drug development for therapeutic alternatives. There is a need for therapies that are targeted to a disease and symptom management with limited or no undesirable side effects. Identification of a specific variance or variances within genes involved in the pathophysiologic manifestation of blood dyscrasias and specific genetic polymorphisms of these critical genes may assist the development of novel agents and the identification of those patients that may best benefit from therapy of these candidate therapeutic alternatives.

By identifying allelic variances or haplotypes in genes that indirectly affects efficacy, safety of any class of drugs that has an effect on the prevention, progression, or symptoms of blood dyscrasias, one could target specific secondary drug or agent therapeutic actions that affect the overall therapeutic action of hemoprotective agents.

Pharmacogenomics studies for these drugs, or other agent, compound, drug, or candidate therapeutic intervention, could be performed by identifying genes that are involved in the function of a drug including, but not limited to absorption, distribution, metabolism, or elimination, the interaction of the drug with its target as well as potential alternative targets, the response of the cell to the binding of a drug to a target, the metabolism (including synthesis, biodistribution or elimination) of

natural compounds which may alter the activity of the drug by complementary, competitive or allosteric mechanisms that potentiate or limit the effect of the drug, and genes involved in the etiology of the disease that alter its response to a particular class of therapeutic agents. It will be recognized to those skilled in the art that this broadly includes proteins involved in pharmacokinetics as well as genes involved in pharmacodynamics. This also includes genes that encode proteins homologous to the proteins believed to carry out the above functions are also worth evaluation as they may carry out similar functions. Together the foregoing proteins constitute the candidate genes for affecting response of a patient to the therapeutic intervention. Using the methods described above, variances in these genes can be identified, and research and clinical studies can be performed to establish an association between a drug response or toxicity and specific variances.

Example 3

Drug-Induced Toxicity: Cutaneous Toxicity

Drug-induced cutaneous toxicity includes, but is not excluded to, eczematous: photodermatitis (phototoxic and photoallergic), exfoliative dermatitis; maculopapular eruption; papulosquamous reactions: psoriaform, lichus planus, or pityriasis rosea-like; vesiculobullous reactions; toxic epidermal necrolysis; pustular-acneform reactions; urticaria and erythemas: urticaria, erythema multiforme; nodular lesions: erythema nodosum, vasculitis reaction; telangiectatic and LE reactions; pigmentary reaction; other cutaneous reactions: fixed drug reactions, alopecia, hypertrichosis, macules, papules, angioedema, morbilliform-maculopapular rash, toxic epidermal necrolysis, erythema multiforme, erythema nodosum, contact dermatitis, vesicles, petechiae, exfoliative dermatitis, fixed drug eruptions, and severe skin rash (Stevens-Johnson syndrome).

Drugs known to be associated with cutaneous toxicities include, but are not exclusive of, antineoplastic agents, sulfonamides, hydantoins and others listed for each type of toxicity.

Uticaria and angioedema- is defined as the transient appearance of elevated, erythematous pruritic wheals (hives) or serpiginous exanthem. The appearance of uticaria is perceived as ongoing immediate hypersensitivity reaction. Angioedema is defined as uticaria, but involving deeper dermal and subdermal sites. Uticaria and angioedema appear to result from dilation of local postcapillary venules.

Degranulation of cutaneous mast cells may be involved.

Drugs associated with uticaria and angioedema include, but are not excluded to, antimicrobials include, but not exclusive of, 5-aminosalicylic acid, aminoglycosides, cephalosporins, ethambutol, isoniazid, metronidazole, miconazole,

nalidixic acid, penicillins, quinine, rifampin, spectinomycin, sulfonamides, and other drugs: asparaginase, aspirin and other non-steroidal antiinflammatory agenets, calcitonin, chloral hydrate, chlorambucil, cimetidine, cyclophosphamide, daunorubicin, ergotamine, ethchlorvynol, doxorubicin, ethosuximide, ethylenediamine, glucocorticoids, melphalan, penicillamine, phenothiazines, procainamide, procarbazine, quinidine, tartazine, thiazide diuretics, thiotepa.

Morbilliform-maculopapular rash- are rashes that result in eruptions or are morbilliform in nature.

Drugs associated with rashes include, but are not limited to, 5-aminosalicylic acid, cephalosporins, erythromycin, gentamicin, penicillins, streptomycin, sulfonamides, allopurinol, barbiturates, captopril, coumarin, gold salts, hydantoins, thiazide diuretics.

Toxic epidermal necrolysis and erythroderma and exfoliative dermatitis-

Cutaneous erythroderma, edema, scaling, and fissuring may occur in response to certain drugs. Drugs associated with these types of cutaneous reactions include, but are limited to, allopurinol, amikacin, captopril, carbamazepine, chloral hydrate, chlorambucil, chloroquine, chlorpromazine, cyclosporine, diltiazem, ethambutol, ethylenediamine, glutethimide, gold salts, griseofulvin, hydantoins, hydroxychloroquine, minoxidil, nifedipine, nonsteroid antiinflammatory agents, penicillin, phenobarbital, rifampin, spironolactone, sulfonamides, trimethadione, trimethoprim, tocainamide, tocainide, vancomycin, verpamil.

Erythema mutliforme- is characterized by a hypersensitivity reaction in blood vessels of the dermis. The hypersensitivity is the result of immune complexes formed by small molecules interacting with proteinaceous components of the blood vessels. In cases whereby the mucosal membranes of the mouth and eye are involved, is referred to as Stevens-Johnson syndrome. Typically the cutaneous lesions, blisters and painful erosions occur in the mout and eye.

Drugs associated with erythema mulitforme include, but are not limited to, allopurinol, acetaminophen, amikacin, barbiturates, carbamazepine, chloroquine, chlorporamide, clindamycin, ethambutol, ethosuximide, gold salts, glucocorticoids, hydantoins, hydralazine, hydroxyurea, mechllorethamine, meclofenamate, penicillins, phenothiazides, phenophthalein, phenylbutazone, rifampin, streptomycin, sulfonamides, sulfonylureas, sulindac, vaccines.

Fixed drug eruptions-

Drug associated with fixed drug eruptions include, but are not excluded to, acetaminophen, 5-aminosalicylic acid, aspirin, barbiturates, benzodiazepines, barbiturates, chloroquine, dapsone, dimethylhydrinate, gold salts, hydralazine, hyoscine, ibuprofen, iodides, meprobamate, methanamine, metronidazole,

005280 22 030586

penicillins, phenobarbital, phenolphthalein, phenothiazides, phenylbutazone, procabazine, pseudoephedrine, quinine, saccharin, streptomycin, sulfonamides, and tetracyclines.

5 *Erythema nodosum*- is an inflammatory reaction in subcutaneous fat which represents a hypersensitivity reaction to a number of antigenic stimuli. Multiple red, painful nodules do not ulcerate but involute and leave a yellow-purple bruises. Small molecules interacting with proteinaceous components form a sensitizing antigen.

10 Drugs associated with producing erythema nodosum include, but are not excluded to, bromides, oral contraceptives, penicillins, and sulfonamides.

15 *Contact dermatitis*- is characterized by eruptions on histological analysis to epidermal intercellular edema (spongiosis). Contact dermatitis can be caused by allergic or irritant mechanisms. Allergic contact dermatitis is a delayed hypersensitivity reaction that can occur in response to a variety of small molecules that when bound to proteinaceous components of the skin form a sensitizing antigen. The antigen is processed by Langerhans' cells in the epidermis, presenting the antigen to the circulating T lymphocytes. Irritant dermatitis is produced by substances that irritate or have a direct toxic effect on the skin.

20 Drugs associated with contact dermatitis side effects include, but are not limited to, ambroxol, amikacin, antihistamines, bacitracin, benzalkonium chloride, benzocaine, benzyl chloride, cetl alcohol, chloramphenicol, chlorpormazine, clioquinol, colophony, ethylenediamine, fluorouracil, formaldehyde, gentamycin, glucocorticoids, glutaraldehyde, heparin, hexachlorophene, iodochlorhydroxyquin, lanolin, local anesthetics, minoxidil, naftin, neimycin, nitrofurazone, opiates, para-aminobenzoic acid, parabens, penicillins, phenothiazines, proflavine, propylene glycol, streptomycin, sulfonamides, thimerosal, timolol.

30 *Impact of Stratification Based Upon Genotype in Drug Development for Drugs, Compounds, or Candidate Therapeutic Interventions that May Induce Cutaneous Reactions*

35 Recently, it has been described that there is a deletion polymorphism in the B2 bradykinin receptor gene (B2BKR). It was revealed that there is a 9 base pair deletion in exon 1 of the B2BKR gene and upon inspection of patients experiencing angioedema, patients with immunochemical evidence of angioedema were homozygous for no deletion at that site. These results were suggestive of B2BKR genotype influence on the clinical status and manifestation angioedema.

There is evidence to suggest that there are safety response differences to drug therapy in reference to development of cutaneous reactions which may be attributable to genotypic differences between individuals. There is provided in this

invention examples of gene pathways that are implicated in the disease process or its therapy and those that potentially cause this variability. The Detailed Description above demonstrates how identification of a candidate gene or genes and gene pathways, stratification, clinical trial design, and implementation of genotyping for appropriate medical management of a given disease can be used to identify the genetic cause of variations in clinical response to therapy, new diagnostic tests, new therapeutic approaches for treating this disorder, and new pharmaceutical products or formulations for therapy. Gene pathways including, but not limited to, those that are outlined in the gene pathway Table 1, and pathway matrix Table 2 and discussed below are candidates for the genetic analysis and product development using the methods described above.

Advantages of Inclusion of Pharmacogenetic Stratification in Clinical Development of Agents that May Cause Cutaneous Reactions

The advantages of a clinical research and drug development program that includes the use of polymorphic genotyping for the stratification of patients for the appropriate selection of candidate therapeutic intervention includes 1) identification of patients that may respond earlier and show signs and symptoms of cutaneous reactions, 2) identification of the primary gene and relevant polymorphic variance that directly affects manifestation of a cutaneous disorder, 3) identification of pathophysiologic relevant variance or variances and potential therapies affecting those allelic genotypes or haplotypes, and 4) identification of allelic variances or haplotypes in genes that indirectly affects efficacy, safety or both.

By identifying subsets of patients, based upon genotype, that experience cutaneous reactions in response to the administration of a drug, agent or candidate therapeutic intervention, optimal selection may reduce level and extent of the skin damage. Appropriate genotyping and correlation to dosing regimen, or selection of optimal therapy would be beneficial to the patient, caregivers, medical personnel, and the patient's loved ones.

As an example of identification of the primary gene and relevant polymorphic variance that directly affects efficacy, safety, or both one could select an gene pathway as described in the Detailed Description, and determine the effect of genetic polymorphism and therapy efficacy, safety, or both within that given pathway. For example, referring to Table 2, genes involved in drug transport, phase I and phase II metabolism, protection from reactive intermediate damage, and

immune responsiveness, the optimization of therapy of by an agent known to have a cutaneous side effect by determining whether the patient has a predisposing genotype in which the selected agents are more effective and or are more safe. In considering an optimization protocol, one could potentially predetermine the genotypic profile of these genes involved in the manifestation of the adverse effect, or those genes preeminently responsible for drug response. By embarking on the previously described gene pathway approach, it is technical feasibility to determine the relevant genes within such a targeted drug development program.

Identification of pathophysiologic relevant variance or variances and potential therapies affecting those allelic genotypes or haplotypes may speed drug development for therapeutic alternatives. There is a need for therapies that are targeted to a disease and symptom management with limited or no undesirable side effects. Identification of a specific variance or variances within genes involved in the pathophysiologic manifestation of cutaneous reactions and specific genetic polymorphisms of these critical genes may assist the development of novel agents and the identification of those patients that may best benefit from therapy of these candidate therapeutic alternatives.

By identifying allelic variances or haplotypes in genes that indirectly affects efficacy, safety of any class of drugs that has an effect on the prevention, progression, or symptoms of cutaneous reactions, one could target specific secondary drug or agent therapeutic actions that affect the overall therapeutic action.

Pharmacogenomics studies for these drugs, or other agents, compounds, or candidate therapeutic interventions, could be performed by identifying genes that are involved in the the function of a drug including, but not limited to absorption, distribution, metabolism, or elimination , the interaction of the drug with its target as well as potential alternative targets, the response of the cell to the binding of a drug to a target, the metabolism (including synthesis, biodistribution or elimination) of natural compounds which may alter the activity of the drug by complementary, competitive or allosteric mechanisms that potentiate or limit the effect of the drug, and genes involved in the etiology of the disease that alter its response to a particular class of therapeutic agents. It will be recognized to those skilled in the art that this broadly includes proteins involved in pharmacokinetics as well as genes involved in pharmacodynamics. This also includes genes that encode proteins homologous to the proteins believed to carry out the above functions are also worth evaluation as they may carry out similar functions. Together, the foregoing proteins constitute the candidate genes for affecting response of a patient to the therapeutic intervention. Using the methods described above, variances in these genes can be identified, and

research and clinical studies can be performed to establish an association between a drug response or toxicity and specific variances.

5 **Example 5**

Drug-Induced CNS Toxicity

Drug-induced central nervous system toxicity includes CNS stimulation or CNS depression. Characteristics of CNS toxicity include, but are not limited to, tinnitus and dizziness, acute dystonic reactions, parkinsonian syndrome, coma,
10 convulsions, depression and psychosis, sweating, mydriasis, hyperpyrexia, centrally mediated cardiovascular involvement (hypertension, tachycardia, extrasystoles, arrhythmias, circulatory collapse) and respiratory depression or tachypnea. Drugs known to be associated with CNS toxicity include, but are not exclusive of, salicylates, antipsychotics, sedatives, cholinergics,

15 *Impact of Stratification Based Upon Genotype in Drug Development for Drugs, Compounds, or Candidate Therapeutic Interventions that May Induce CNS Toxicity*

There is evidence to suggest that there are safety response differences to drug therapy in reference to development of CNS toxicities which may be attributable to
20 genotypic differences between individuals. There is provided in this invention examples of gene pathways that are implicated in the disease process or its therapy and those that potentially cause this variability. The Detailed Description above demonstrates how identification of a candidate gene or genes and gene pathways, stratification, clinical trial design, and implementation of genotyping for appropriate
25 medical management of a given disease can be used to identify the genetic cause of variations in clinical response to therapy, new diagnostic tests, new therapeutic approaches for treating this undesirable adverse effect, and new pharmaceutical products or formulations for therapy. Gene pathways including, but not limited to, those that are outlined in the gene pathway Table 1, and pathway matrix Table 2 and
30 discussed below are candidates for the genetic analysis and product development using the methods described above.

Advantages of Inclusion of Pharmacogenetic Stratification in Clinical Development of Agents that May Cause CNS Toxicities

35 The advantages of a clinical research and drug development program that includes the use of polymorphic genotyping for the stratification of patients for the appropriate selection of candidate therapeutic intervention includes 1) identification

of patients that may respond earlier and show signs and symptoms of CNS toxicities, 2) identification of the primary gene and relevant polymorphic variance that directly affects manifestation of a CNS toxicity, 3) identification of pathophysiologic relevant variance or variances and potential therapies affecting those allelic
5 genotypes or haplotypes, and 4) identification of allelic variances or haplotypes in genes that indirectly affects efficacy, safety or both.

By identifying subsets of patients, based upon genotype, that experience CNS toxicity in response to the administration of a drug, agent or candidate therapeutic intervention, optimal selection may reduce level and extent of the
10 neurologic damage. Appropriate genotyping and correlation to dosing regimen, or selection of optimal therapy would be beneficial to the patient, caregivers, medical personnel, and the patient's loved ones.

As an example of identification of the primary gene and relevant polymorphic variance that directly affects efficacy, safety, or both one could select
15 an gene pathway as described in the Detailed Description, and determine the effect of genetic polymorphism and therapy efficacy, safety, or both within that given pathway. For example, referring to Table 2, genes involved in drug transport, phase I and phase II metabolism, protection from reactive intermediate damage, the optimization of therapy of by an agent known to impart CNS toxic or undesirable
20 side effect or effects by determining whether the patient has a predisposing genotype in which the selected agents are more effective and or are more safe. In considering an optimization protocol, one could potentially predetermine the genotypic profile of these genes involved in the manifestation of the adverse effect, or those genes preeminently responsible for drug response. By embarking on the previously
25 described gene pathway approach, it is technical feasibility to determine the relevant genes within such a targeted drug development program.

Identification of pathophysiologic relevant variance or variances and potential therapies affecting those allelic genotypes or haplotypes may speed drug development for therapeutic alternatives. There is a need for therapies that are
30 targeted to a disease and symptom management with limited or no undesirable side effects. Identification of a specific variance or variances within genes involved in the pathophysiologic manifestation of CNS toxicities and specific genetic polymorphisms of these critical genes may assist the development of novel agents and the identification of those patients that may best benefit from therapy of these
35 candidate therapeutic alternatives.

By identifying allelic variances or haplotypes in genes that indirectly affects efficacy, safety of any class of drugs that has an effect on the prevention, progression, or symptoms of CNS toxicities, one could target specific secondary drug or agent therapeutic actions that affect the overall therapeutic action of neuroprotective agents.

Pharmacogenomics studies for these drugs, or other agent, compound, drug, or candidate therapeutic intervention, could be performed by identifying genes that are involved in the the function of a drug including, but not limited to absorption, distribution, metabolism, or elimination , the interaction of the drug with its target as well as potential alternative targets, the response of the cell to the binding of a drug to a target, the metabolism (including synthesis, biodistribution or elimination) of natural compounds which may alter the activity of the drug by complementary, competitive or allosteric mechanisms that potentiate or limit the effect of the drug, and genes involved in the etiology of the disease that alter its response to a particular class of therapeutic agents. It will be recognized to those skilled in the art that this broadly includes proteins involved in pharmacokinetics as well as genes involved in pharmacodynamics. This also includes genes that encode proteins homologous to the proteins believed to carry out the above functions are also worth evaluation as they may carry out similar functions. Together the foregoing proteins constitute the candidate genes for affecting response of a patient to the therapeutic intervention. Using the methods described above, variances in these genes can be identified, and research and clinical studies can be performed to establish an association between a drug response or toxicity and specific variances.

Example 6

Drug-Induced Liver Toxicity

Drug-induced liver disease or drug-induced liver toxicity can manifest as zonal necrosis, nonspecific focal hepatitis, viral hepatitis-like reactions, inflammatory or noninflammatory cholestasis, small or large droplet fatty liver, granulomas, chronic hepatitis, fibrosis, tumors, or vascular lesions.

In the majority of the cases of known drug-induced liver toxicity, the drug is metabolized to a form that is deleterious to hepatic, or extrahepatic function. There are many endogenous or exogenous compounds that may be considered to attenuate or ablate toxic hepatocyte-produced metabolite mechanisms or effects of hepatic or extrahepatic damage.

In hepatocellular damage, free oxygen radicals may be generated in the hepatic metabolic processes that are deleterious to intracellular organelles, DNA, or metabolic pathways. There are endogenous cytoprotective agents that may prevent

free radical-mediated damage such as retinoids, flavins, reduced glutathione, vitamin E, S-adenylylmethionine, and the enzyme superoxide dismutase (SOD). In animal models in which SOD activity is diminished or absent, the liver function was normal, but the sensitivity to toxin challenge was heightened.

5 In cholestatic damage, the bile salt uptake, metabolism, secretion, or transport is compromised and the residual increased bile salt concentrations are deleterious to hepatocyte function. The increase in bile salts is the main metabolic disturbance that initially leads to jaundice and pruritis and can progress to pancreatitis, hyperbilirubinemia, biliary cirrhosis, and hepatic encephalopathy.

10 In both cases of drug-induced liver toxicity, the drug must first be absorbed and enter in the hepatic circulation. Further, clinically it is often difficult to determine whether cholestatic damage leads to hepatocellular damage or whether hepatocellular damage leads to cholestatic damage. In many cases, until the patient is symptomatic, the underlying damage mechanisms may be clinically overlooked.
15 By the time the drug-induced liver disease is symptomatic, the damage, be it hepatocellular or cholestatic or both, may be irreversible.

Identification of Genes involved in Drug-Induced Liver Toxicity

20 Thus, in the process of identifying drug- or xenobiotic-induced liver toxicity, one skilled in the art would identify key metabolic enzymes or bile cannicula transport processes that would be linked with either hepatocellular damage or cholestasis or combination of hepatocellular damage or cholestasis.

Hepatocellular damage may be the result of direct chemical mediated effects, may be severe, and usually is associated with damage within organelles, DNA and
25 membranes. Clinically there is a marked elevation of SGOT and SGPT as well as other enzymes. In cases of cholestasis there is jaundice, pruritis, a marked elevation of bile salts and alkaline phosphatase activity, but not an elevation of SGOT or SGPT. In cases of toxic liver disease there is difficulty, at least initially to determine the underlying etiology. Clinically, symptoms may not appear as clear as described
30 above. Further, depending on the rate and extent of the damage, hepatocellular damage may be masked or asymptomatic until liver impairment has induced cholestasis.

Potentially hepatotoxic agents can be divided broadly into two groups: intrinsic hepatotoxins and idiosyncratic hepatotoxins. Intrinsic hepatotoxins produce
35 acute liver damage in a predictable, dose-dependent fashion shortly after ingestion or exposure. Generally, all subjects exposed will uniformly exhibit signs and symptoms. In this category, the effects seen in humans can be mimicked in animal models. Examples of intrinsic hepatotoxins are carbon tetrachloride, 2-nitropropane,

trichloroethane, the octapeptide toxins of the Amanita mushroom species, and the antipyretic, acetaminophen. In some of these cases, toxic metabolites result in covalent modification of hepatocyte macromolecules or reactive oxygen intermediates leads to peroxidation of cell membrane lipids or other intracellular molecules.

In contrast, idiosyncratic hepatotoxins produce liver damage in an unpredictable, dose-independent manner after a latent period of ingestion or exposure. Animal models or experimental data is generally incapable of predicting the effect in humans. Further, idiosyncratic hepatotoxins do not uniformly affect a population; a subset of the group exposed may or may not exhibit signs or symptoms. Range of symptoms are from mild to severe and is thought to coincide with differences in the pathways of drug or xenobiotic biotransformation or immune-mediated drug sensitivity (drug allergy). In idiosyncratic drug-induced liver disease, fever, arthralgias, rash, eosinophilia, are often prominent and indicate a hypersensitivity reaction.

Impact of Stratification Based Upon Genotype in Drug Development for Drugs, Compounds, or Candidate Therapeutic Interventions that may Induce Hepatotoxicity

Genes encoding proteins with catalytic function that are involved in the metabolism of drugs or xenobiotics are listed in Tables 1 and 2 below. Further listed are those proteins that are involved in the uptake, transport, or secretion into the bile cannicula. Below are further specific example of drug-specific effects on the liver.

Acetaminophen-Induced Liver Disease

Acetaminophen is a readily available, easy to administer analgesic that is an example of a intrinsic hepatotoxin. This hepatotoxin causes zonal necrosis and acute liver failure and is associated with renal failure. Although a high dose (10-15 grams) is required for significant liver injury to occur, the onset of initial symptoms does not occur until hours after ingestion. The progression of symptoms occurs including progressive liver failure with hepatic encephalopathy, prolongation of prothrombin time, hypoglycemia, and lactic acidosis. The liver injury is caused by a toxic metabolite of acetaminophen via the P450 metabolizing system. This toxic intermediate at low concentrations is conjugated with glutathione. However, in toxic doses, the conjugating enzymes stores are exhausted and the reactive intermediate reacts with intracellular proteins and results in cellular dysfunction and ultimately death. The rate of metabolism is dependent on the concentrations of both P450 and glutathione. Speeding this toxic pathway may include increasing the available P450 or reducing the availability of glutathione, e.g. using known

inducers of P450 such as ethanol and phenobarbital; and known inhibitors of glutathione concentrations, e.g., ethanol and fasting. Acetaminophen toxicity is completely reversed if the drug is removed. Chronic ingestion may produce subclinical liver injury, centrilobular necrosis, or chronic hepatitis; however all reversible if the drug is removed.

Amiodarone-Induced Liver Disease

Amiodarone is used in treatment of refractory arrhythmias. In some patients amiodarone produces mild to moderate increases of serum transaminases which are generally accompanied by engorgement of lysosomes with phospholipid. In a fraction of the patients, a more severe liver injury develops which histologically resembles alcoholic hepatitis: fat infiltration of hepatocytes, focal necrosis, fibrosis, polymorphonuclear leukocyte infiltrates, and Mallory bodies. The lesion may progress to micronodular cirrhosis, with portal hypertension and liver failure. Hepatomegaly is seen, but jaundice is rare.

Amiodarone accumulates in lysosomes and inhibits lysosomal phospholipases, however the connection between this mechanism and alcoholic hepatitis histopathology is unknown. Unfortunately, rapid discontinuation of amiodarone increases the risk of cardiac arrhythmias.

Chlorpromazine-Induced Liver Disease

Chlorpromazine is an anti-psychotic agent which, in a small portion of the patient population can produce a cholestatic reaction. Symptoms include fever, anorexia, arthralgias, pruritis, jaundice, and eosinophilia is common. This idiosyncratic type of liver toxicity suggests a hypersensitivity type reaction. The symptoms subside over a period of weeks following discontinuation. Rarely, residual cholestatic disease occurs, treatment for pruritis and fat-soluble vitamin supplementation may be required, but eventual recovery almost always occurs.

Erythromycin-Induced Liver Disease

Erythromycin, a broad spectrum antibiotic, can be accompanied by a cholestatic reaction. Inflammatory cell infiltration and liver cell necrosis may occur. The hepatotoxicity presents as right upper quadrant pain, fever, and variable cholestatic symptoms. The prognosis is uniform and will occur after readministration of the drug. The mechanism of action is unknown.

Halothane-Induced Liver Disease

Halothane is a gaseous anesthetic and can, in rare instances, cause a viral-like hepatitis syndrome. In severe cases, this hepatotoxicity, may cause fatal massive hepatic necrosis. Severe reactions seem to appear after previous or multiple exposure to halothane. It is known that the P450 metabolites of this xenobiotic are responsible for the mechanism of hepatic injury.

Isoniazid (INH)-Induced Liver Disease

Isoniazid is used as a single drug in the prophylaxis of tuberculosis. In 10-20% of the persons taking INH, subclinical liver injury occurs. The conversion of INH to acetylhydrazine is via acetylation. In slow acetylators, INH is more hepatotoxic. The conversion of INH to acetylhydrazine to diacetylhydrazine is impaired. In slow acetylators, the acetylhydrazine is not well metabolized and is further oxidized by one of the P450 enzymes to a toxic, reactive molecule that is responsible for the liver disease. Discontinuation of the drug returns the enzymatic levels to normal and the liver is able to restore activity.

Sodium Valproate-Induced Liver Disease

Sodium valproate is an anti-epileptic agent that is routinely prescribed for petit mal epilepsy and in some cases produces severe hepatotoxicity. Similar to INH, sodium valproate is accompanied by a high incidence of transient, slight and asymptomatic increases in serum transaminases. Usually the increased enzyme activity appears after weeks of treatment. In rare cases of severe liver toxicity, the nonspecific systemic and digestive symptoms are followed by jaundice, evidence of liver failure, as well as encephalopathy and coagulopathy. The mechanism of hepatotoxicity is unknown, however there are theories that there is impairment of mitochondrial oxidation of long-chain fatty acids by a metabolite of the parent drug. Symptoms subside with little to no residual liver dysfunction after discontinuing the drug.

Oral Contraceptive Induced Liver Disease

Estrogen, progesterone, and combination oral contraceptives can produce several adverse effects on the hepatobiliary system. They are 1) hepatocellular cholestasis, 2) liver cell neoplasias, 3) increased predisposition to cholesterol and gall stone formation, 4) hepatic vein thrombosis. These cholestatic hepatotoxic effects are attributed to estrogen's direct effect on bile formation. The mechanism of action is unknown.

There is evidence to suggest that there are safety response differences to drug therapy in reference to development of drug-induced liver toxicity which may be

attributable to genotypic differences between individuals. There is provided in this invention examples of gene pathways that are implicated in the disease process or its therapy and those that potentially cause this variability. The Detailed Description above demonstrates how identification of a candidate gene or genes and gene pathways, stratification, clinical trial design, and implementation of genotyping for appropriate medical management of a given disease can be used to identify the genetic cause of variations in clinical response to therapy, new diagnostic tests, new therapeutic approaches for treating this disorder, and new pharmaceutical products or formulations for therapy. Gene pathways including, but not limited to, those that are outlined in the gene pathway Table 1, and pathway matrix Table 2 and discussed below are candidates for the genetic analysis and product development using the methods described above.

Advantages of Inclusion of Pharmacogenetic Stratification in Clinical Development of Agents that May Cause Liver Toxicity

The advantages of a clinical research and drug development program that includes the use of polymorphic genotyping for the stratification of patients for the appropriate selection of candidate therapeutic intervention includes 1) identification of patients that may respond earlier and show signs and symptoms of liver toxicity, 2) identification of the primary gene and relevant polymorphic variance that directly affects manifestation of a liver disorder, 3) identification of pathophysiologic relevant variance or variances and potential therapies affecting those allelic genotypes or haplotypes, and 4) identification of allelic variances or haplotypes in genes that indirectly affects efficacy, safety or both.

By identifying subsets of patients, based upon genotype, that experience drug-induced liver toxicity in response to the administration of a drug, agent or candidate therapeutic intervention, optimal selection may reduce level and extent of the hepatic damage. Appropriate genotyping and correlation to dosing regimen, or selection of optimal therapy would be beneficial to the patient, caregivers, medical personnel, and the patient's loved ones.

As an example of identification of the primary gene and relevant polymorphic variance that directly affects efficacy, safety, or both one could select an gene pathway as described in the Detailed Description, and determine the effect of genetic polymorphism and therapy efficacy, safety, or both within that given pathway. For example, referring to Table 2, genes involved in drug transport, phase

I and phase II metabolism, excretion, hepatic cannicular uptake and concentration, and protection from reactive intermediate damage the optimization of therapy by an agent known to have a hepatic side effect by determining whether the patient has a predisposing genotype in which the selected agents are more effective and or are more safe. In considering an optimization protocol, one could potentially predetermine the genotypic profile of these genes involved in the manifestation of the adverse effect, or those genes preeminently responsible for drug response. By embarking on the previously described gene pathway approach, it is technical feasibility to determine the relevant genes within such a targeted drug development program.

Identification of pathophysiologic relevant variance or variances and potential therapies affecting those allelic genotypes or haplotypes may speed drug development for therapeutic alternatives. There is a need for therapies that are targeted to a disease and symptom management with limited or no undesirable side effects. Identification of a specific variance or variances within genes involved in the pathophysiologic manifestation of drug-induced liver toxicity and specific genetic polymorphisms of these critical genes may assist the development of novel agents and the identification of those patients that may best benefit from therapy of these candidate therapeutic alternatives.

By identifying allelic variances or haplotypes in genes that indirectly affects efficacy, safety of any class of drugs that has an effect on the prevention, progression, or symptoms of drug induced liver toxicity, one could target specific secondary drug or agent therapeutic actions that affect the overall therapeutic action of hepatoprotective agents.

Pharmacogenomics studies for these drugs, or other agent, compound, drug, or candidate therapeutic intervention, could be performed by identifying genes that are involved in the the function of a drug including, but not limited to absorption, distribution, metabolism, or elimination , the interaction of the drug with its target as well as potential alternative targets, the response of the cell to the binding of a drug to a target, the metabolism (including synthesis, biodistribution or elimination) of natural compounds which may alter the activity of the drug by complementary, competitive or allosteric mechanisms that potentiate or limit the effect of the drug, and genes involved in the etiology of the disease that alter its response to a particular class of therapeutic agents. It will be recognized to those skilled in the art that this broadly includes proteins involved in pharmacokinetics as well as genes involved in pharmacodynamics. This also includes genes that encode proteins homologous to the proteins believed to carry out the above functions are also worth evaluation as

they may carry out similar functions. Together the foregoing proteins constitute the candidate genes for affecting response of a patient to the therapeutic intervention. Using the methods described above, variances in these genes can be identified, and research and clinical studies can be performed to establish an association between a drug response or toxicity and specific variances.

Example 7

Drug-Induced Cardiovascular Toxicity

Drug induced cardiovascular toxicities include but are not excluded to arrhythmias, tachycardia, extrasystoles, circulatory collapse, QT prolongation, cardiomyopathy, hypotension, or hypertension. Drugs known to elicit these type of responses include but are not excluded to theophylline, hydantoins, doxorubicin, daunorubicin.

Arrhythmias-If the normal sequence of electrical impulse and propagation through myocardial tissue is perturbed, an arrhythmia occurs. Broadly, arrhythmias fall into one of three categories: bradyarrhythmias (slowing or failure of the initiating impulse), heart block (an impaired propagation through node tissue or atrial or ventricular muscle), and tachyarrhythmias (abnormal rapid heart rhythms).

Subcategories include: sinus bradycardia, atrioventricular block (AV block), sinus tachycardia, ventricular tachycardia, atrial flutter, multifocal atrial tachycardia, polymorphic ventricular tachycardia with or without QT prolongation, frequent or difficult to terminate ventricular tachycardia, atrial tachycardia with or without AV block, ventricular bigeminy, and ventricular fibrillation. Drugs known to induce these types of arrhythmias include, but are not excluded to, digitalis, verapamil, diltiazem, b-adrenergic blockers, clonidine, methyldopa, quinidine, flecainide, propafenone, theophylline, sotalol, procainamide, disopyramide, certain non-cardioactive drugs (), and amiodarone.

Heart Rate, Tachycardia-Heart rate is under both sympathetic and parasympathic control. The influence of heart rate on cardiac output is paramount. Drugs affecting heart rate include, but are not limited to, sympathomimetics, parasympathomimetics, and agents or compounds affecting these two central inputs.

Extrasystoles- is defined as premature myocardial excitation. Extrasystoles can include atrial, nodal, or ventricular. Other asynchronous pathologies may result from these systoles. Drugs known to be associated with extra systoles include, but are not excluded to, agents that prolong the depolarization time, agents that leave a residual available intracellular calcium, or agents that alter the function of the K⁺ or Na⁺ channel activity.

QT Prolongation- is the interval on an electrocardiogram that indicates ventricular action potential duration. QT prolongation can lead to uncoordinated atrial and ventricular action potentials. In these circumstances of delayed or prolonged polymorphic ventricular afterdepolarizations, resultant abnormal triggering of secondary, uncoordinated depolarizations can occur. Two of these conditions are explained as follows and may be associated with underlying rapid or slow heart rate: 1) under conditions of residual excess intracellular calcium (myocardial ischemia, adrenergic stress, digitalis intoxication), and 2) under conditions of marked prolongation of cardiac action potential (agents (antiarrhythmics or others) that prolong action potential duration).

Cardiomyopathy-There are broadly three categories of cardiomyopathies: dilated, hypertrophic, and restrictive. These cardiac muscular diseases can be of mechanical or acquired origin.

Dilated cardiomyopathies are generally caused by myocardial injury that results in depressed systolic function and progressive ventricular dilatation. Drug induced dilated cardiomyopathy can occur in the presence of, but are not excluded to, ethanol, chemotherapeutic agents, elemental compounds, and catecholamimetics.

Hypertrophic cardiomyopathy is the presentation of grossly asymmetric (eccentric) or symmetric (concentric) hypertrophy of the left ventricle in the absence of another cardiac or systemic disease capable of producing the disproportionate increase in ventricle mass. In drug induced hypertrophic cardiomyopathy, there may be compensatory hypertrophy of the left ventricle in response to inordinate and or sustained hypertension or prolonged reduced or insufficient cardiac output as a result of myocardial injury or noncardiac mediated physiological events.

Restrictive cardiomyopathies are the result of a primary abnormality of diastolic function (impaired filling). Impaired diastolic function can occur as a result of morphologically detectable myocardial or endomyocardial disease, interstitial deposition of abnormal substances (infiltrative), intracellular accumulation of abnormal substances (storage diseases), or as a result of endomyocardial disease. In the last category, anthracyclines have been associated with both dilated and restrictive cardiomyopathies.

Blood Pressure-Blood pressure is regulated in a complex interplay of neural and endocrine mechanisms. These mechanisms are aimed at the physiologic control of cardiac output, delivery of blood components to the tissues, and removal of metabolic by-products from the tissues.

Hypertension is defined as the elevated arterial blood pressure either an increase of systolic or diastolic pressure or both. Secondary hypertension can be associated with drugs and chemicals including, but not limited to, cyclosporine, oral

contraceptives, glucocorticoids, mineralocorticoids, sympathomimetics, tyramine, and MAO inhibitors.

Hypotension is defined as the reduction in blood pressure that is associated with orthostatic hypotension, syncope, head injury, hepatic failure, antidiuresis, myocardial infarction and cardiogenic shock. Drug-induced hypotension is associated drugs including, but not exclusive of, parasympathomimetics, diuretics, and direct acting cardiac agents.

Impact of Stratification Based Upon Genotype in Drug Development for Drugs, Compounds, or Candidate Therapeutic Interventions that may Induce Cardiovascular Toxicity

There is evidence to suggest that there are safety response differences to drug therapy in reference to development of cardiovascular toxicity which may be attributable to genotypic differences between individuals. There is provided in this invention examples of gene pathways that are implicated in the disease process or its therapy and those that potentially cause this variability. The Detailed Description above demonstrates how identification of a candidate gene or genes and gene pathways, stratification, clinical trial design, and implementation of genotyping for appropriate medical management of a given disease can be used to identify the genetic cause of variations in clinical response to therapy, new diagnostic tests, new therapeutic approaches for treating this disorder, and new pharmaceutical products or formulations for therapy. Gene pathways including, but not limited to, those that are outlined in the gene pathway Table 1, and pathway matrix Table 2 and discussed below are candidates for the genetic analysis and product development using the methods described above.

Advantages of Inclusion of Pharmacogenetic Stratification in Clinical Development of Agents that May Cause Cardiovascular Toxicity

The advantages of a clinical research and drug development program that includes the use of polymorphic genotyping for the stratification of patients for the appropriate selection of candidate therapeutic intervention includes 1) identification of patients that may respond earlier and show signs and symptoms of cardiovascular toxicity, 2) identification of the primary gene and relevant polymorphic variance that directly affects manifestation of a cardiovascular disorder, 3) identification of pathophysiologic relevant variance or variances and potential therapies affecting those allelic genotypes or haplotypes, and 4) identification of allelic variances or haplotypes in genes that indirectly affects efficacy, safety or both.

By identifying subsets of patients, based upon genotype, that experience cardiovascular toxicities in response to the administration of a drug, agent or candidate therapeutic intervention, optimal selection may reduce level and extent of the cardiovascular damage. Appropriate genotyping and correlation to dosing regimen, or selection of optimal therapy would be beneficial to the patient, caregivers, medical personnel, and the patient's loved ones.

As an example of identification of the primary gene and relevant polymorphic variance that directly affects efficacy, safety, or both one could select an gene pathway as described in the Detailed Description, and determine the effect of genetic polymorphism and therapy efficacy, safety, or both within that given pathway. For example, referring to Table 2, genes involved in drug transport, phase I and phase II metabolism, and protection from reactive intermediate damage the optimization of therapy of by an agent known to have a cardiovascular side effect by determining whether the patient has a predisposing genotype in which the selected agents are more effective and or are more safe. In considering an optimization protocol, one could potentially predetermine the genotypic profile of these genes involved in the manifestation of the adverse effect, or those genes preeminently responsible for drug response. By embarking on the previously described gene pathway approach, it is technical feasibility to determine the relevant genes within such a targeted drug development program.

Identification of pathophysiologic relevant variance or variances and potential therapies affecting those allelic genotypes or haplotypes may speed drug development for therapeutic alternatives. There is a need for therapies that are targeted to a disease and symptom management with limited or no undesirable side effects. Identification of a specific variance or variances within genes involved in the pathophysiologic manifestation of cardiovascular toxicities and specific genetic polymorphisms of these critical genes may assist the development of novel agents and the identification of those patients that may best benefit from therapy of these candidate therapeutic alternatives.

By identifying allelic variances or haplotypes in genes that indirectly affects efficacy, safety of any class of drugs that has an effect on the prevention, progression, or symptoms of cardiovascular toxicities, one could target specific secondary drug or agent therapeutic actions that affect the overall therapeutic action of cardiovascular protective agents.

Pharmacogenomics studies for these drugs, or other agent, compound, drug, or candidate therapeutic intervention, could be performed by identifying genes that

are involved in the the function of a drug including, but not limited to absorption, distribution, metabolism, or elimination , the interaction of the drug with its target as well as potential alternative targets, the response of the cell to the binding of a drug to a target, the metabolism (including synthesis, biodistribution or elimination) of natural compounds which may alter the activity of the drug by complementary, competitive or allosteric mechanisms that potentiate or limit the effect of the drug, and genes involved in the etiology of the disease that alter its response to a particular class of therapeutic agents. It will be recognized to those skilled in the art that this broadly includes proteins involved in pharmacokinetics as well as genes involved in pharmacodynamics. This also includes genes that encode proteins homologous to the proteins believed to carry out the above functions are also worth evaluation as they may carry out similar functions. Together the foregoing proteins constitute the candidate genes for affecting response of a patient to the therapeutic intervention. Using the methods described above, variances in these genes can be identified, and research and clinical studies can be performed to establish an association between a drug response or toxicity and specific variances.

Example 8

Drug-Induced Pulmonary Toxicity

Drug induced pulmonary toxicity includes, but is not excluded to, asthma, acute pneumonitis, eosinophilic pneumonitis, fibrotic and pleural reactions, and interstitial fibrosis. Drug know to elicit pulmonary toxicity include, but are not excluded to, salicylates, nitrofurantoin, busulfan, nitrofurantoin, and bleomycin.

Impact of Stratification Based Upon Genotype in Drug Development for Drugs, Compounds, or Candidate Therapeutic Interventions that may Induce Pulmonary Toxicities

There is evidence to suggest that there are safety response differences to drug therapy in reference to development of pulmonary toxicities which may be attributable to genotypic differences between individuals. There is provided in this invention examples of gene pathways that are implicated in the disease process or its therapy and those that potentially cause this variability. The Detailed Description above demonstrates how identification of a candidate gene or genes and gene pathways, stratification, clinical trial design, and implementation of genotyping for appropriate medical management of a given disease can be used to identify the genetic cause of variations in clinical response to therapy, new diagnostic tests, new therapeutic approaches for treating this disorder, and new pharmaceutical products or formulations for therapy. Gene pathways including, but not limited to, those that

are outlined in the gene pathway Table 1, and pathway matrix Table 2 and discussed below are candidates for the genetic analysis and product development using the methods described above.

5 Advantages of Inclusion of Pharmacogenetic Stratification in Clinical Development of Agents that May Cause Pulmonary Toxicities

10 The advantages of a clinical research and drug development program that includes the use of polymorphic genotyping for the stratification of patients for the appropriate selection of candidate therapeutic intervention includes 1) identification of patients that may respond earlier and show signs and symptoms of pulmonary toxicity, 2) identification of the primary gene and relevant polymorphic variance that directly affects manifestation of a pulmonary disorder, 3) identification of pathophysiologic relevant variance or variances and potential therapies affecting those allelic genotypes or haplotypes, and 4) identification of allelic variances or haplotypes in genes that indirectly affects efficacy, safety or both.

15 By identifying subsets of patients, based upon genotype, that experience pulmonary toxicities in response to the administration of a drug, agent or candidate therapeutic intervention, optimal selection may reduce level and extent of the pulmonary damage. Appropriate genotyping and correlation to dosing regimen, or selection of optimal therapy would be beneficial to the patient, caregivers, medical personnel, and the patient's loved ones.

20 As an example of identification of the primary gene and relevant polymorphic variance that directly affects efficacy, safety, or both one could select an gene pathway as described in the Detailed Description, and determine the effect of genetic polymorphism and therapy efficacy, safety, or both within that given pathway. For example, referring to Table 2, genes involved in drug transport, phase I and phase II metabolism, excretion, protection from reactive intermediate damage, and immune responsiveness, the optimization of therapy of by an agent known to have a pulmonary side effect by determining whether the patient has a predisposing genotype in which the selected agents are more effective and or are more safe. In considering an optimization protocol, one could potentially predetermine the genotypic profile of these genes involved in the manifestation of the adverse effect, or those genes preeminently responsible for drug response. By embarking on the previously described gene pathway approach, it is technical feasibility to determine the relevant genes within such a targeted drug development program.

25

30

35

Identification of pathophysiologic relevant variance or variances and potential therapies affecting those allelic genotypes or haplotypes may speed drug development for therapeutic alternatives. There is a need for therapies that are targeted to a disease and symptom management with limited or no undesirable side effects. Identification of a specific variance or variances within genes involved in the pathophysiologic manifestation of pulmonary toxicity and specific genetic polymorphisms of these critical genes may assist the development of novel agents and the identification of those patients that may best benefit from therapy of these candidate therapeutic alternatives.

By identifying allelic variances or haplotypes in genes that indirectly affects efficacy, safety of any class of drugs that has an effect on the prevention, progression, or symptoms of pulmonary toxicity, one could target specific secondary drug or agent therapeutic actions that affect the overall therapeutic action of pulmonary protective agents.

Pharmacogenomics studies for these drugs, or other agent, compound, drug, or candidate therapeutic intervention, could be performed by identifying genes that are involved in the the function of a drug including, but not limited to absorption, distribution, metabolism, or elimination , the interaction of the drug with its target as well as potential alternative targets, the response of the cell to the binding of a drug to a target, the metabolism (including synthesis, biodistribution or elimination) of natural compounds which may alter the activity of the drug by complementary, competitive or allosteric mechanisms that potentiate or limit the effect of the drug, and genes involved in the etiology of the disease that alter its response to a particular class of therapeutic agents. It will be recognized to those skilled in the art that this broadly includes proteins involved in pharmacokinetics as well as genes involved in pharmacodynamics. This also includes genes that encode proteins homologous to the proteins believed to carry out the above functions are also worth evaluation as they may carry out similar functions. Together the foregoing proteins constitute the candidate genes for affecting response of a patient to the therapeutic intervention. Using the methods described above, variances in these genes can be identified, and research and clinical studies can be performed to establish an association between a drug response or toxicity and specific variances.

Example 9

Drug-Induced Renal Toxicity

Drug-induced renal toxicity includes, but is not exclusived to, glomerulonephritis and tubular necrosis. Drugs associated with eliciting renal toxicity include, but are not excluded to, penicillamine, aminoglycoside antibiotics, cyclosporine, amphotericin B, phenacetin, and salicylates.

Impact of Stratification Based Upon Genotype in Drug Development for Drugs, Compounds, or Candidate Therapeutic Interventions that may Induce Renal Toxicity

There is evidence to suggest that there are safety response differences to drug therapy in reference to development of renal toxicity which may be attributable to genotypic differences between individuals. There is provided in this invention examples of gene pathways that are implicated in the disease process or its therapy and those that potentially cause this variability. The Detailed Description above demonstrates how identification of a candidate gene or genes and gene pathways, stratification, clinical trial design, and implementation of genotyping for appropriate medical management of a given disease can be used to identify the genetic cause of variations in clinical response to therapy, new diagnostic tests, new therapeutic approaches for treating this disorder, and new pharmaceutical products or formulations for therapy. Gene pathways including, but not limited to, those that are outlined in the gene pathway Table 1, and pathway matrix Table 2 and discussed below are candidates for the genetic analysis and product development using the methods described above.

Advantages of Inclusion of Pharmacogenetic Stratification in Clinical Development of Agents that May Cause or are Associated with Renal Toxicity

The advantages of a clinical research and drug development program that includes the use of polymorphic genotyping for the stratification of patients for the appropriate selection of candidate therapeutic intervention includes 1) identification of patients that may respond earlier and show signs and symptoms of renal toxicity, 2) identification of the primary gene and relevant polymorphic variance that directly affects manifestation of a renal disorder, 3) identification of pathophysiologic relevant variance or variances and potential therapies affecting those allelic genotypes or haplotypes, and 4) identification of allelic variances or haplotypes in genes that indirectly affects efficacy, safety or both.

By identifying subsets of patients, based upon genotype, that experience renal toxicities in response to the administration of a drug, agent or candidate therapeutic intervention, optimal selection may reduce level and extent of the renal

damage. Appropriate genotyping and correlation to dosing regimen, or selection of optimal therapy would be beneficial to the patient, caregivers, medical personnel, and the patient's loved ones.

As an example of identification of the primary gene and relevant polymorphic variance that directly affects efficacy, safety, or both one could select an gene pathway as described in the Detailed Description, and determine the effect of genetic polymorphism and therapy efficacy, safety, or both within that given pathway. For example, referring to Table 2, genes involved in drug transport, phase I and phase II metabolism, and renal tubular uptake and concentration the optimization of therapy of by an agent known to have a renal side effect by determining whether the patient has a predisposing genotype in which the selected agents are more effective and or are more safe. In considering an optimization protocol, one could potentially predetermine the genotypic profile of these genes involved in the manifestation of the adverse effect, or those genes preeminently responsible for drug response. By embarking on the previously described gene pathway approach, it is technical feasibility to determine the relevant genes within such a targeted drug development program.

Identification of pathophysiologic relevant variance or variances and potential therapies affecting those allelic genotypes or haplotypes may speed drug development for therapeutic alternatives. There is a need for therapies that are targeted to a disease and symptom management with limited or no undesirable side effects. Identification of a specific variance or variances within genes involved in the pathophysiologic manifestation of renal toxicity and specific genetic polymorphisms of these critical genes may assist the development of novel agents and the identification of those patients that may best benefit from therapy of these candidate therapeutic alternatives.

By identifying allelic variances or haplotypes in genes that indirectly affects efficacy, safety of any class of drugs that has an effect on the prevention, progression, or symptoms of renal toxicity, one could target specific secondary drug or agent therapeutic actions that affect the overall therapeutic action of renal protective agents.

Pharmacogenomics studies for these drugs, or other agent, compound, drug, or candidate therapeutic intervention, could be performed by identifying genes that are involved in the the function of a drug including, but not limited to absorption, distribution, metabolism, or elimination , the interaction of the drug with its target as well as potential alternative targets, the response of the cell to the binding of a drug

to a target, the metabolism (including synthesis, biodistribution or elimination) of natural compounds which may alter the activity of the drug by complementary, competitive or allosteric mechanisms that potentiate or limit the effect of the drug, and genes involved in the etiology of the disease that alter its response to a particular class of therapeutic agents. It will be recognized to those skilled in the art that this broadly includes proteins involved in pharmacokinetics as well as genes involved in pharmacodynamics. This also includes genes that encode proteins homologous to the proteins believed to carry out the above functions are also worth evaluation as they may carry out similar functions. Together the foregoing proteins constitute the candidate genes for affecting response of a patient to the therapeutic intervention. Using the methods described above, variances in these genes can be identified, and research and clinical studies can be performed to establish an association between a drug response or toxicity and specific variances.

15 **Example 10**

Hardy-Weinberg equilibrium

Evolution is the process of change and diversification of organisms through time, and evolutionary change affects morphology, physiology and reproduction of organisms, including humans. These evolutionary changes are the result of changes in the underlying genetic or hereditary material. Evolutionary changes in a group of interbreeding individuals or Mendelian population, or simply populations, are described in terms of changes in the frequency of genotypes and their constituent alleles. Genotype frequencies for any given generation is the result of the mating among members (genotypes) of their previous generation. Thus, the expected proportion of genotypes from a random union of individuals in a given population is essential for describing the total genetic variation for a population of any species. For example, the expected number of genotypes that could form from the random union of two alleles, A and a, of a gene are AA, Aa and aa. The expected frequency of genotypes in a large, random mating population was discovered to remain constant from generation to generation; or achieve Hardy-Weinberg equilibrium, named after its discoverers. The expected genotypic frequencies of alleles A and a (AA, 2Aa, aa) are conventionally described in terms of $p^2 + 2pq + q^2$ in which p and q are the allele frequencies of A and a. In this equation ($p^2 + 2pq + q^2 = 1$), p is defined as the frequency of one allele and q as the frequency of another allele for a trait controlled by a pair of alleles (A and a). In other words, p equals all of the alleles in individuals who are homozygous dominant (AA) and half of the alleles in individuals who are heterozygous (Aa) for this trait. In mathematical terms, this is

$$p = AA + \frac{1}{2}Aa$$

005230 2274960

Likewise, q equals the other half of the alleles for the trait in the population, or

$$q = aa + \frac{1}{2}Aa$$

Because there are only two alleles in this case, the frequency of one plus the frequency of the other must equal 100%, which is to say

5
$$p + q = 1$$

Alternatively,

$$p = 1 - q \text{ OR } q = 1 - p$$

All possible combinations of two alleles can be expressed as:

10
$$(p + q)^2 = 1$$

or more simply,

$$p^2 + 2pq + q^2 = 1$$

In this equation, if p is assumed to be dominant, then p^2 is the frequency of homozygous dominant (AA) individuals in a population, $2pq$ is the frequency of heterozygous (Aa) individuals, and q^2 is the frequency of homozygous recessive (aa) individuals.

15

From observations of phenotypes, it is usually only possible to know the frequency of homozygous dominant or recessive individuals, because both dominant and recessives will express the distinguishable traits. However, the Hardy-Weinberg equation allows us to determine the expected frequencies of all the genotypes, if only p or q is known. Knowing p and q , it is a simple matter to plug these values into the Hardy-Weinberg equation ($p^2 + 2pq + q^2 = 1$). This then provides the frequencies of all three genotypes for the selected trait within the population. This illustration shows Hardy-Weinberg frequency distributions for the genotypes AA, Aa, and aa at all values for frequencies of the alleles, p and q . It should be noted that the proportion of heterozygotes increases as the values of p and q approach 0.5.

20

25

Linkage disequilibrium

Linkage is the tendency of genes or DNA sequences (e.g. SNPs) to be inherited together as a consequence of their physical proximity on a single chromosome. The closer together the markers are, the lower the probability that they will be separated during DNA crossing over, and hence the greater the probability that they will be inherited together. Suppose a mutational event introduces a "new" allele in the close proximity of a gene or an allele. The new allele will tend to be inherited together with the alleles present on the "ancestral," chromosome or haplotype. However, the resulting association, called linkage disequilibrium, will decline over time due to recombination. Linkage disequilibrium has been used to map disease genes. In

30

35

005230 22184960

general, both allele and haplotype frequencies differ among populations. Linkage disequilibrium is varied among the populations, being absent in some and highly significant in others.

5 *Quantification of the relative risk of observable outcomes of a Pharmacogenetics Trial*

Let PlaR be the placebo response rate (0% (PlaR (100%) and TntR be the treatment response rate (0% (TntR (100%) of a classical clinical trial. ObsRR is defined as the relative risk between TntR and PlaR:

$$10 \quad \text{ObsRR} = \text{TntR} / \text{PlaR}.$$

Suppose that in the treatment group there is a polymorphism in relation to drug metabolism such as the treatment response rate is different for each genotypic subgroup of patients. Let q be the allele a frequency of a recessive biallelic locus (e.g. SNP) and $p = 1 - q$ the allele A frequency. Following Hardy-Weinberg equilibrium, the relative frequency of homozygous and heterozygous patients are as follow:

$$AA: p^2 \quad Aa: 2pq \quad aa: q^2$$

with

$$(p^2 + 2pq + q^2) = 1.$$

20 Let's define AAR, AaR, aaR as respectively the response rates of the AA, Aa and aa patients. We have the following relationship:

$$\text{TntR} = \text{AAR} * p^2 + \text{AaR} * 2pq + \text{aaR} * q^2.$$

Suppose that the aa genotypic group of patients has the lowest response rate, i.e. a response rate equal to the placebo response rate (which means that the polymorphism has no impact on natural disease evolution but only on drug action) and let's define ExpRR as the relative risk between AAR and aaR, as

$$\text{ExpRR} = \text{AAR} / \text{aaR}.$$

From the previous equations, we have the following relationships:

$$\text{ObsRR} (\text{ExpRR} (1/\text{PlaR}$$

$$30 \quad \text{TntR} / \text{PlaR} = (\text{AAR} * p^2 + \text{AaR} * 2pq + \text{aaR} * q^2) / \text{PlaR}$$

The maximum of the expected relative risk, $\max(\text{ExpRR})$, corresponding to the case of heterozygous patients having the same response rate as the placebo rate, is such that:

$$\text{ObsRR} = \text{ExpRR} * p^2 + 2pq + q^2 \quad \Leftrightarrow \quad \text{ExpRR} = (\text{ObsRR} - 2pq - q^2) / p^2$$

35 The minimum of the expected relative risk, $\min(\text{ExpRR})$, corresponding to the case of heterozygous patients having the same response rate as the homozygous non-affected patients, is such that:

$$\text{ObsRR} = \text{ExpRR} * (p^2 + 2pq) + q^2 \quad \Leftrightarrow \quad \text{ExpRR} = (\text{ObsRR} - q^2) / (p^2 + 2pq)$$

For example, if $q = 0.4$, $\text{PlaR} = 40\%$ and $\text{ObsRR} = 1.5$ (i.e. $\text{TntR} = 60\%$), then 1.6 (ExpRR) 2.4. This means that the best treatment response rate we can expect in a genotypic subgroup of patients in these conditions would be 95.6% instead of 60%.

5 This can also be expressed in terms of maximum potential gain between the observed difference in response rates ($\text{TntR} - \text{PlaR}$) without any pharmacogenetic hypothesis and the maximum expected difference in response rates ($\text{max}(\text{ExpRR}) * \text{PlaR} - \text{TntR}$) with a strong pharmacogenetic hypothesis:

$$\begin{aligned} 10 \quad & (\text{max}(\text{ExpRR}) * \text{PlaR} - \text{TntR}) = [(\text{ObsRR} - 2pq - q^2) / p^2] * \text{PlaR} - \text{TntR} \\ & \Leftrightarrow (\text{max}(\text{ExpRR}) * \text{PlaR} - \text{TntR}) = [\text{TntR} - \text{PlaR} * (2pq + q^2) - \text{TntR} * p^2] / p^2 \\ & \Leftrightarrow (\text{max}(\text{ExpRR}) * \text{PlaR} - \text{TntR}) = [\text{TntR} * (1 - p^2) - \text{PlaR} * (2pq + q^2)] / p^2 \\ & \Leftrightarrow (\text{max}(\text{ExpRR}) * \text{PlaR} - \text{TntR}) = [(1 - p^2) / p^2] * (\text{TntR} - \text{PlaR}) \end{aligned}$$

15 that is for the previous example,

$$(95.6\% - 60\%) = [(1 - 0.62) / 0.62] * (60\% - 40\%) = 35.6\%$$

Suppose that, instead of one SNP, we have p loci of SNPs for one gene. This means that we have $2p$ possible haplotypes for this gene and $(2p)(2p-1)/2$ possible
20 genotypes. And with 2 genes with p_1 and p_2 SNP loci, we have $[(2p_1)(2p_1-1)/2] * [(2p_2)(2p_2-1)/2]$ possibilities; and so on. Examining haplotypes instead of combinations of SNPs is especially useful when there is linkage disequilibrium enough to reduce the number of combinations to test, but not complete since in this latest case one SNP would be sufficient. Yet the problem of frequency above still
25 remains with haplotypes instead of SNPs since the frequency of a haplotype cannot be higher than the highest SNP frequency involved. Hence cladograms.

Statistical Methods to be used in Objective Analyses

The statistical significance of the differences between variance frequencies
30 can be assessed by a Pearson chi-squared test of homogeneity of proportions with $n-1$ degrees of freedom. Then, in order to determine which variance(s) is(are) responsible for an eventual significance, we can consider each variance individually against the rest, up to n comparisons, each based on a 2×2 table. This should result in chi-squared tests that are individually valid, but taking the most significant of
35 these tests is a form of multiple testing. A Bonferroni's adjustment for multiple testing will thus be made to the P-values, such as $p^* = 1 - (1-p)^n$. Chi square on 3 genotypes, on haplotypes.

The statistical significance of the difference between genotype frequencies associated to every variance can be assessed by a Pearson chi-squared test of homogeneity of proportions with 2 degrees of freedom, using the same Bonferroni's adjustment as above.

5 Testing for unequal haplotype frequencies between cases and controls can be considered in the same framework as testing for unequal variance frequencies since a single variance can be considered as a haplotype of a single locus. The relevant likelihood ratio test compares a model where two separate sets of haplotype frequencies apply to the cases and controls, to one where the entire sample is
10 characterized by a single common set of haplotype frequencies. This can be performed by repeated use of a computer program (Terwilliger and Ott, 1994, Handbook of Human Linkage Analysis, Baltimore, John Hopkins University Press) to successively obtain the log-likelihood corresponding to the set of haplotype frequency estimates on the cases ($\ln L_{case}$), on the controls ($\ln L_{control}$), and on the
15 overall ($\ln L_{combined}$). The test statistic $2((\ln L_{case}) + (\ln L_{control}) - (\ln L_{combined}))$ is then chi-squared with $r-1$ degrees of freedom (where r is the number of haplotypes).

 To test for potentially confounding effects or effect-modifiers, such as sex, age, etc., logistic regression can be used with case-control status as the outcome variable, and genotypes and covariates (plus possible interactions) as predictor
20 variables.

Example 11

Exemplary Pharmacogenetic Analysis Steps

 In accordance with the discussion of distribution frequencies for variances, alleles, and haplotypes, variance detection, and correlation of variances or
25 haplotypes with treatment response variability, the points below list major items which will typically be performed in an analysis of the pharmacogenetic determination of the effects of variances in the treatment of a disease and the selection/optimization of treatment.

- 30
- 1) List candidate gene/genes for a known genetic disease, and assign them to the respective metabolic pathways.
 - 2) Determine their alleles, observed and expected frequencies, and their relative
35 distributions among various ethnic groups, gender, both in the control and in the study (case) groups.

- 3) Measure the relevant clinical/phenotypic (biochemical / physiological) variables of the disease.
- 4) If the causal variance/allele in the candidate gene is unknown, then determine linkage disequilibria among variances of the candidate gene(s).
- 5) Divide the regions of the candidate genes into regions of high linkage disequilibrium and low disequilibrium.
- 6) Develop haplotypes among variances that show strong linkage disequilibrium using the computation methods.
- 7) Determine the presence of rare haplotypes experimentally. Confirm if the computationally determined rare haplotypes agree with the experimentally determined haplotypes.
- 8) If there is a disagreement between the experimentally determined haplotypes and the computationally derived haplotypes, drop the computationally derived rare haplotypes, construct cladograms from these haplotypes using the Templeton (1987) algorithm.
- 9) Note regions of high recombination. Divide regions of high recombination further to see patterns of linkage disequilibria.
- 10) Establish association between cladograms and clinical variables using the nested analysis of variance as presented by Templeton (1995), and assign causal variance to a specific haplotype.
- 11) For variances in the regions of high recombination, use permutation tests for establishing associations between variances and the phenotypic variables.
- 12) If two or more genes are found to affect a clinical variable determine the relative contribution of each of the genes or variances in relation to the clinical variable, using step-wise regression or discriminant function or principal component analysis.

- 13) Determine the relative magnitudes of the effects of any of the two variances on the clinical variable due to their genetic (additive, dominant or epistasis) interaction.
- 5 14) Using the frequency of an allele or haplotypes, as well as biochemical/clinical variables determined in the *in vitro* or *in vivo* studies, determine the effect of that gene or allele on the expression of the clinical variable, according to the measured genotype approach of Boerwinkle et al (Ann. Hum. Genet 1986).
- 10 15) Stratify ethnic/ clinical populations based on the presence or absence of a given allele or a haplotype.
- 16) Optimize drug dosages based on the frequency of alleles and haplotypes as well as their effects using the measured genotype approach as a guide.

15

Example 12Method for Producing cDNA

In order to identify sequence variances in a gene by laboratory methods it is in some instances useful to produce cDNA(s) from multiple human subjects. (In other instances it may be preferable to study genomic DNA.). Methods for producing cDNA are known to those skilled in the art, as are methods for amplifying and sequencing the cDNA or portions thereof. An example of a useful cDNA production protocol is provided below. As recognized by those skilled in the art, other specific protocols can also be used.

25

cDNA Production

** Make sure that all tubes and pipette tips are RNase-free. (Bake them overnight at 100°C in a vacuum oven to make them RNase-free.)

30

1. Add the following to a RNase-free 0.2 ml micro-amp tube and mix gently:

24 ul water (DEPC treated)
12 ul RNA (1ug/ul)
12 ul random hexamers(50 ng/ul)

35

2. Heat the mixture to 70°C for ten minutes.
3. Incubate on ice for 1 minute.

4. Add the following:

- 16 ul 5 X Synthesis Buffer
 8 ul 0.1 M DTT
 4 ul 10 mM dNTP mix (10 mM each dNTP)
 4 ul SuperScript RT II enzyme

Pipette gently to mix.

5. Incubate at 42°C for 50 minutes.

6. Heat to 70°C for ten minutes to kill the enzyme, then place it on ice.

7. Add 160 ul of water to the reaction so that the final volume is 240 ul.

8. Use PCR to check the quality of the cDNA. Use primer pairs that will give a ~800 base pair long piece. See "PCR Optimization" for the PCR protocol.

The following chart shows the reagent amounts for a 20 ul reaction, a 80 ul reaction, and a batch of 39 (which makes enough mix for 36) reactions:

	20 ul X 1 tube	80 ul X 1 tube	80ul X 39 tubes	
water	6 ul	24 ul	936	water
RNA	3 ul	12 ul		RNA
random hexamers	3 ul	12 ul	468	random hexamers
synthesis buffer	4 ul	16 ul	624	synthesis buffer
0.1 M DTT	2 ul	8 ul	312	0.1 M DTT
10mM dNTP	1 ul	4 ul	156	10mM dNTP
SSRT	1 ul	4 ul	156	SSRT

Example 13

Method for Detecting Variances by Single Strand Conformation Polymorphism (SSCP) Analysis

This example describes the SSCP technique for identification of sequence variances of genes. SSCP is usually paired with a DNA sequencing method, since the SSCP method does not provide the nucleotide identity of variances. One useful sequencing method, for example, is DNA cycle sequencing of ³²P labeled PCR products using the Femtomole DNA cycle sequencing kit from Promega (WI) and the instructions provided with the kit. Fragments are selected for DNA sequencing based on their behavior in the SSCP assay.

Single strand conformation polymorphism screening is a widely used technique for identifying an discriminating DNA fragments which differ from each other by as little as a single nucleotide. As originally developed by Orita et al. (Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. *Proc Natl Acad Sci U S A.* 86(8):2766-70, 1989), the technique was used on genomic DNA, however the same group showed that the technique works very well on PCR amplified DNA as well. In the last 10 years the technique has been used in hundreds of published papers, and modifications of the technique have been described in dozens of papers. The enduring popularity of the technique is due to (1) a high degree of sensitivity to single base differences (>90%) (2) a high degree of selectivity, measured as a low frequency of false positives, and (3) technical ease. SSCP is almost always used together with DNA sequencing because SSCP does not directly provide the sequence basis of differential fragment mobility. The basic steps of the SSCP procdure are described below.

When the intent of SSCP screening is to identify a large number of gene variances it is useful to screen a relatively large number of individuals of different racial, ethnic and/or geographic origins. For example, 32 or 48 or 96 individuals is a convenient number to screen because gel electrophoresis apparatus are available with 96 wells (Applied Biosystems Division of Perkin Elmer Corporation), allowing 3 X 32, 2 X 48 or 96 samples to be loaded per gel.

The 32 (or more) individuals screened should be representative of most of the worlds major populations. For example, an equal distribution of Africans, Europeans and Asians constitutes a reasonable screening set. One useful source of cell lines from different populations is the Coriell Cell Repository (Camden, NJ), which sells EBV immortalized lymphoblastoid cells obtained from several thousand subjects, and includes the racial/ethnic/geographic background of cell line donors in its catalog. Alternatively, a panel of cDNAs can be isolated from any specific target population.

SSCP can be used to analyze cDNAs or genomic DNAs. For many genes cDNA analysis is preferable because for many genes the full genomic sequence of the target gene is not available, however, this circumstance will change over the next

few years. To produce cDNA requires RNA. Therefore each cell lines is grown to mass culture and RNA is isolated using an acid/phenol protocol, sold in kit form as Trizol by Life Technologies (Gaithersburg, MD). The unfractionated RNA is used to produce cDNA by the action of a modified Maloney Murine Leukemia Virus Reverse Transcriptase, purchased in kit form from Life Technologies (Superscript II kit). The reverse transcriptase is primed with random hexamer primers to initiate cDNA synthesis along the whole length of the RNAs. This proved useful later in obtaining good PCR products from the 5' ends of some genes. Alternatively, oligodT can be used to prime cDNA synthesis.

Material for SSCP analysis can be prepared by PCR amplification of the cDNA in the presence of one α ^{32}P labeled dNTP (usually α ^{32}P dCTP). Usually the concentration of nonradioactive dCTP is dropped from 200 μM (the standard concentration for each of the four dNTPs) to about 100 μM , and ^{32}P dCTP is added to a concentration of about 0.1-0.3 μM . This involves adding a 0.3- 1 μl (3-10 μCi) of ^{32}P cCTP to a 10 μl PCR reaction. Radioactive nucleotides can be purchased from DuPont/New England Nuclear.

The customary practice is to amplify about 200 base pair PCR products for SSCP, however, an alternative approach is to amplify about 0.8-1.4 kb fragments and then use several cocktails of restriction endonucleases to digest those into smaller fragments of about 0.1-0.4kb, aiming to have as many fragments as possible between .15 and .3 kb. The digestion strategy has the advantage that less PCR is required, reducing both time and costs. Also, several different restriction enzyme digests can be performed on each set of samples (for example 96 cDNAs), and then each of the digests can be run separately on SSCP gels. This redundant method (where each nucleotide is surveyed in three different fragments) reduces both the false negative and false positive rates. For example: a site of variance might lie within 2 bases of the end of a fragment in one digest, and as a result not affect the conformation of that strand; the same variance, in a second or third digest, would likely lie in a location more prone to affect strand folding, and therefore be detected by SSCP.

After digestion, the radiolabelled PCR products are diluted 1:5 by adding formamide load buffer (80% formamide, 1X SSCP gel buffer) and then denatured by heating to 90°C for 10 minutes, and then allowed to renature by quickly chilling on ice. This procedure (both the dilution and the quick chilling) promotes intra- (rather than inter-) strand association and secondary structure formation. The secondary structure of the single strands influences their mobility on nondenaturing gels, presumably by influencing the number of collisions between the molecule and the

gel matrix (i.e., gel sieving). Even single base differences consistently produce changes in intrastrand folding sufficient to register as mobility differences on SSCP.

The single strands were then resolved on two gels, one a 5.5% acrylamide, 0.5X TBE gel, the other an 8% acrylamide, 10% glycerol, 1X TTE gel. (Other gel
5 recipes are known to those skilled in the art.) The use of two gels provides a greater opportunity to recognize mobility differences. Both glycerol and acrylamide concentration have been shown to influence SSCP performance. By routinely analyzing three different digests under two gel conditions (effectively 6 conditions), and by looking at both strands under all 6 conditions, one can achieve a 12-fold
10 sampling of each base pair of cDNA. However, if the goal is to rapidly survey many genes or cDNAs then a less redundant procedure would be optimal.

Example 14

Method for Detecting Variances by T4 endonuclease VII (T4E7) mismatch cleavage
15 method

The enzyme T4 endonuclease VII is derived from the bacteriophage T4. T4 endonuclease VII is used by the bacteriophage to cleave branched DNA intermediates which form during replication so the DNA can be processed and packaged. T4 endonuclease can also recognize and cleave heteroduplex DNA
20 containing single base mismatches as well as deletions and insertions. This activity of the T4 endonuclease VII enzyme can be exploited to detect sequence variances present in the general population.

The following are the major steps involved in identifying sequence variations in a candidate gene by T4 endonuclease VII mismatch cleavage:

- 25 1. Amplification by the polymerase chain reaction (PCR) of 400-600 bp regions of the candidate gene from a panel of DNA samples. The DNA samples can either be cDNA or genomic DNA and will represent some cross section of the world population.
- 30 2. Mixing of a fluorescently labeled probe DNA with the sample DNA. Heating and cooling the mixtures causing heteroduplex formation between the probe DNA and the sample DNA.
3. Addition of T4 endonuclease VII to the heteroduplex DNA samples. T4 endonuclease will recognize and cleave at sequence variance mismatches formed in the heteroduplex DNA.
- 35 4. Electrophoresis of the cleaved fragments on an ABI sequencer to determine the site of cleavage.
5. Sequencing of a subset of PCR fragments identified by T4 endonuclease VI to contain variances to establish the specific base variation at that location.

005230 "E2T84950

A more detailed description of the procedure is as follows:

A candidate gene sequence is downloaded from an appropriate database. Primers for PCR amplification are designed which will result in the target sequence being divided into amplification products of between 400 and 600 bp. There will be a minimum of a 50 bp of overlap not including the primer sequences between the 5' and 3' ends of adjacent fragments to ensure the detection of variances which are located close to one of the primers.

Optimal PCR conditions for each of the primer pairs is determined experimentally. Parameters including but not limited to annealing temperature, pH, MgCl₂ concentration, and KCl concentration will be varied until conditions for optimal PCR amplification are established. The PCR conditions derived for each primer pair is then used to amplify a panel of DNA samples (cDNA or genomic DNA) which is chosen to best represent the various ethnic backgrounds of the world population or some designated subset of that population.

One of the DNA samples is chosen to be used as a probe. The same PCR conditions used to amplify the panel are used to amplify the probe DNA. However, a fluorescently labeled nucleotide is included in the deoxy-nucleotide mix so that a percentage of the incorporated nucleotides will be fluorescently labeled.

The labeled probe is mixed with the corresponding PCR products from each of the DNA samples and then heated and cooled rapidly. This allows the formation of heteroduplexes between the probe and the PCR fragments from each of the DNA samples. T4 endonuclease VII is added directly to these reactions and allowed to incubate for 30 min. at 37 C. 10 ul of the Formamide loading buffer is added directly to each of the samples and then denatured by heating and cooling. A portion of each of these samples is electrophoresed on an ABI 377 sequencer. If there is a sequence variance between the probe DNA and the sample DNA a mismatch will be present in the heteroduplex fragment formed. The enzyme T4 endonuclease VII will recognize the mismatch and cleave at the site of the mismatch. This will result in the appearance of two peaks corresponding to the two cleavage products when run on the ABI 377 sequencer.

Fragments identified as containing sequencing variances are subsequently sequenced using conventional methods to establish the exact location and sequence variance.

Example 15

Method for Detecting Variances by DNA sequencing.

Sequencing by the Sanger dideoxy method or the Maxim Gilbert chemical cleavage method is widely used to determine the nucleotide sequence of genes. Presently, a worldwide effort is being put forward to sequence the entire human genome. The Human Genome Project as it is called has already resulted in the identification and sequencing of many new human genes. Sequencing can not only be used to identify new genes, but can also be used to identify variations between individuals in the sequence of those genes.

The following are the major steps involved in identifying sequence variations in a candidate gene by sequencing:

1. Amplification by the polymerase chain reaction (PCR) of 400-700 bp regions of the candidate gene from a panel of DNA samples. The DNA samples can either be cDNA or genomic DNA and will represent some cross section of the world population.
2. Sequencing of the resulting PCR fragments using the Sanger dideoxy method. Sequencing reactions are performed using fluorescently labeled dideoxy terminators and fragments are separated by electrophoresis on an ABI 377 sequencer or its equivalent.
3. Analysis of the resulting data from the ABI 377 sequencer using software programs designed to identify sequence variations between the different samples analyzed.

A more detailed description of the procedure is as follows:

A candidate gene sequence is downloaded from an appropriate database. Primers for PCR amplification are designed which will result in the target sequence being divided into amplification products of between 400 and 700 bp. There will be a minimum of a 50 bp of overlap not including the primer sequences between the 5' and 3' ends of adjacent fragments to ensure the detection of variances which are located close to one of the primers.

Optimal PCR conditions for each of the primer pairs is determined experimentally. Parameters including but not limited to annealing temperature, pH, $MgCl_2$ concentration, and KCl concentration will be varied until conditions for optimal PCR amplification are established. The PCR conditions derived for each primer pair is then used to amplify a panel of DNA samples (cDNA or genomic DNA) which is chosen to best represent the various ethnic backgrounds of the world population or some designated subset of that population.

PCR reactions are purified using the QIAquick 8 PCR purification kit (Qiagen cat# 28142) to remove nucleotides, proteins and buffers. The PCR reactions are mixed with 5 volumes of Buffer PB and applied to the wells of the QIAquick strips. The liquid is pulled through the strips by applying a vacuum. The wells are then washed two times with 1 ml of buffer PE and allowed to dry for 5 minutes under vacuum. The PCR products are eluted from the strips using 60 ul of elution buffer.

The purified PCR fragments are sequenced in both directions using the Perkin Elmer ABI Prism™ Big Dye™ terminator Cycle Sequencing Ready Reaction Kit (Cat# 4303150). The following sequencing reaction is set up: 8.0 ul Terminator Ready Reaction Mix, 6.0 ul of purified PCR fragment, 20 picomoles of primer, deionized water to 20 ul. The reactions are run through the following cycles 25 times: 96°C for 10 second, annealing temperature for that particular PCR product for 5 seconds, 60°C for 4 minutes.

The above sequencing reactions are ethanol precipitated directly in the PCR plate, washed with 70% ethanol, and brought up in a volume of 6 ul of formamide dye. The reactions are heated to 90°C for 2 minutes and then quickly cooled to 4°C. 1 ul of each sequencing reaction is then loaded and run on an ABI 377 sequencer.

The output for the ABI sequencer appears as a series of peaks where each of the different nucleotides, A, C, G, and T appear as a different color. The nucleotide at each position in the sequence is determined by the most prominent peak at each location. Comparison of each of the sequencing outputs for each sample can be examined using software programs to determine the presence of a variance in the sequence. One example of heterozygote detection using sequencing with dye labeled terminators is described by Kwok *et. al.* (Kwok, P.-Y.; Carlson, C.; Yager, T.D., Ankener, W., and D. A. Nickerson, *Genomics* 23, 138-144, 1994). The software compares each of the normalized peaks between all the samples base by base and looks for a 40% decrease in peak height and the concomitant appearance of a new peak underneath. Possible variances flagged by the software are further analyzed visually to confirm their validity.

Example 16**Exemplary Pharmacogenetic Analysis Steps - biological function analysis**

In many cases when a gene which may affect drug action is found to exhibit variances in the gene, RNA, or protein sequence, it is preferable to perform biological experiments to determine the biological impact of the variances on the structure and function of the gene or its expressed product and on drug action. Such experiments may be performed *in vitro* or *in vivo* using methods known in the art.

The points below list major items which may typically be performed in an analysis of the effects of variances in the treatment of a disease and the selection/optimization of treatment using biological studies to determine the structure and function of variant forms of a gene or its expressed product..

- 1) List candidate gene/genes for a known genetic disease, and assign them to the respective metabolic pathways.
- 2) Identify variances in the gene sequence, the expressed mRNA sequence or expressed protein sequence.
- 3) Match the position of variances to regions of the gene, mRNA, or protein with known biological functions. For example, specific sequences in the promotor of a gene are known to be responsible for determining the level of expression of the gene; specific sequences in the mRNA are known to be involved in the processing of nuclear mRNA into cytoplasmic mRNA including splicing and polyadenylation; and certain sequences in proteins are known to direct the trafficking of proteins to specific locations within a cell and to constitute active sites of biological functions including the binding of proteins to other biological constituents or catalytic functions. Variances in sites such as these, and others known in the art, are candidates for biological effects on drug action.
- 4) Model the effect of the variance on mRNA or protein structure. Computational methods for predicting the structure of mRNA are known and can be used to assess whether a specific variance is likely to cause a substantial change in the structure of mRNA. Computational methods can also be used to predict the structure of peptide sequences enabling predictions to be made concerning the potential impact of the variance on protein function. Most useful are structures of proteins determined by X-ray diffraction, NMR or

other methods known in the art which provide the atomic structure of the protein. Computational methods can be used to consider the effect of changing an amino acid within such a structure to determine whether such a change would disrupt the structure and/or function of the protein. Those skilled in the art will recognize that this analysis can be performed on crystal structures of the protein known to have a variance as well as homologous proteins expressed from different loci in the human genome, or homologous proteins from other species, or non-homologous but analogous proteins with similar functions from humans or other species.

- 5 10 5) Produce the gene, mRNA or protein in amounts sufficient to experimentally characterize the structure and function of the gene, mRNA or protein. It will be apparent to those skilled in the art that by comparing the activity of two genes or their products which differ by a single variance, the effect of the
15 variance can be determined. Methods for producing genes or gene products which differ by one or more bases for the purpose of experimental analysis are known in the art.
- 20 6) Experimental methods known in the art can be used to determine whether a specific variance alters the transcription of a gene and translation into a gene product. This involves producing amounts of the gene by molecular cloning sufficient for in vitro or in vivo studies. Methods for producing genes and gene products are known in the art and include cloning of segments of
25 genetic material in prokaryotes or eukaryotic hosts, run off transcription and cell-free translation assays that can be performed in cell free extracts, transfection of DNA into cultured cells, introduction of genes into live animals or embryos by direct injection or using vehicles for gene delivery including transfection mixtures or viral vectors.
- 30 7) Experimental methods known in the art can be used to determine whether a specific variance alters the ability of a gene to be transcribed into RNA. For example, run off transcription assays can be performed in vitro or expression can be characterized in transfected cells or transgenic animals.
- 35 8) Experimental methods known in the art can be used to determine whether a specific variance alters the processing, stability, or translation of RNA into protein. For example, reticulocyte lysate assays can be used to study the production of protein in cell free systems, transfection assays can be

designed to study the production of protein in cultured cells, and the production of gene products can be measured in transgenic animals.

- 5 9) Experimental methods known in the art can be used to determine whether a specific variant alters the activity of an expressed protein product. For example, protein can be produced by reticulocyte lysate systems or by introducing the gene into prokaryotic organisms such as bacteria or lower eukaryotic organisms such as yeast or fungus), or by introducing the gene into cultured cells or transgenic animals. Protein produced in such systems can be extracted or purified and subjected to bioassays known to those in the art as measures of the action of that particular protein. Bioassays may involve, but are not limited to, binding, inhibition, or catalytic functions.
- 10 10) Those skilled in the art will recognize that it is sometimes preferred to perform the above experiments in the presence of a specific drug to determine whether the drug has differential effects on the activity being measured. Alternatively, studies may be performed in the presence of an analogue or metabolite of the drug.
- 15 11) Using methods described above, specific variances which alter the biological function of a gene or its gene product that could have an impact on drug action can be identified. Such variances are then studied in clinical trial populations to determine whether the presence or absence of a specific variance correlates with observed clinical outcomes such as efficacy or toxicity.
- 20 12) It will be further recognized that there may be more than one variance within a gene that is capable of altering the biological function of the gene or gene product. These variances may exhibit similar, synergistic effects, or may have opposite effects on gene function. In such cases, it is necessary to consider the haplotype of the gene, namely the combination of variances that are present within a single allele, to assess the composite function of the gene or gene product.
- 25 13) Perform clinical trials with stratification of patients based on presence or absence of a given variance, allele or haplotype of a gene. Establish associations between observed drug responses such as toxicity, efficacy, drug
- 30
- 35

00586.0009CIP2

response, or dose toleration and the presence or absense of a specific variance, allele, or haplotype.

14) Optimize drug dosage or drug usage based on the presence of the variant.

Example 17**Stratification of patients by genotype in prospective clinical trials.**

In a prospective clinical trial, patients will be stratified by genotype to determine whether the observed outcomes are different in patients having different genotypes. A critical issue is the design of such trials to assure that a sufficient number of patients are studied to observe genetic effects.

The number of patients required to achieve statistical significance in a conventional clinical trial is calculated from:

$$1.1 \quad N = 2(z_{\alpha} + z_{2\beta})^2 / (\delta/\sigma)^2 \text{ (two tailed test)}$$

From this equation it may be inferred that the size of a genetically defined subgroup N_i required to achieve statistical significance for an observed outcome associated with variance or haplotype “i” can be calculated as:

$$1.2 \quad N_i = 2(z_{\alpha} + z_{2\beta})^2 / (\delta_i/\sigma_i)^2$$

If P_i is the prevalence of the genotype “i” in the population, the total number of patients that need to be incorporated in a clinical trial N_g to identify a population with haplotype “i” of size N_i is given by:

$$1.3 \quad N_g = N_i / P_i$$

It should be noted that N_g describes the total number of patients that need to be genotyped in order to identify a subset of N_i patients with genotype “i”.

If genotyping is used as means for statistical stratification of patients, N_g represents the number of patients that would need to be enrolled in a trial to achieve statistical significance for subgroup “i”. If genotyping is used as a means for inclusion, it represents the number of patients that need to be screened to identify a population of N_i individuals for an appropriately powered clinical trial. Thus, N_g is a critical determinant of the scope of the clinical trial as well as N_i .

A clinical trial can also be designed to test associations for multiple genetic subgroups “j” defined by a single allele in which case:

$$1.4 \quad N_g = \max (N_{gi}) \text{ for } i=1 \dots j$$

If more than one subgroup is tested, but there is no overlap in the patients contained within the subgroups, these can be considered to be independent hypotheses and no multiple testing correction should be required. If consideration of more than one subgroup constitutes multiple testing, or if individual patients are included in multiple subgroups, then statistical corrections may be required in the values of z_{α} or $z_{2\beta}$ which would increase the number of patients required.

It should be emphasized that a clinical trial of this nature may not provide statistically significant data concerning associations with any genotype other than "i". The total number of patients that would be required in a clinical trial to test more than one genetically defined subgroup would be determined by the maximum value of N_g for any single subgroup.

The power of pharmacogenomics to improve the efficiency of clinical trials arises from the fact it is possible to have $N_g < N$. The goal of pharmacogenomic analysis is to identify a genetically defined subgroup in which the magnitude of the clinical response is greater and the variability in response is reduced. These observations correspond to an increase in the magnitude of the (mean) observed response δ or a decrease the degree of variability σ . Since the value of N_i calculated in equation 1.2 decreases non-linearly as the square of these changes, the total number of patients N_g can also decrease non-linearly, resulting in a clinical trial that requires fewer patients to achieve statistical significance. If δ_i and σ_i are not different than δ and σ , then N_g is greater than N as given by $N_g = N_i / P_i$. Values of δ_i and σ_i that give $N_g < N$ can be calculated:

$$1.5 \quad N_g < N \text{ if: } P_i > [(\delta/\sigma)^2] / [(\delta_i/\sigma_i)^2]$$

It is apparent from this analysis that N_g is not uniformly less than N , even with modest improvements in the values for δ_i and σ_i .

As with a conventional clinical trial, the incorporation of an appropriate control group in the study design is critical for achieving success. In the case of a prospective clinical trial, the control group commonly is selected on the basis of the same inclusion criteria as the treatment group, but is treated with placebo or a standard therapeutic regimen rather than the investigational drug. In the case of a study with subgroups that are defined by haplotype, the ideal control group for a treatment subgroup with haplotype "i" is a placebo-treated subgroup with haplotype

“i”. This is often a critical control, since haplotypes which may be associated with the response to treatment may also affect the natural course of the disease.

A critical issue in considering control groups is that σ for the control group placebo treated population with haplotype “i” may not be equivalent to that of the control population. If so, 1.5 may overestimate the benefits of any reduction in σ_i in the treatment response group if there is not also a reduction in σ_i in the control group.

If σ of the treatment and control groups are not equivalent, δ would be still calculated as the difference in the response of the two groups, but σ would be different in the two groups with values of σ_0 or σ_1 respectively. In this case, the number of patients in the genetically defined subgroup N_i would be defined by:

$$2.1 \quad N_i = (\sigma Z_\alpha + \sigma_i Z_\beta)^2 / \delta^2$$

The total number of patients that would need to be enrolled in such a trial would be the maximum of

$$2.2 \quad N \text{ or } N/P_i$$

It will be apparent that such an analysis remains sensitive to increases in δ , but is less sensitive to changes in σ which are not also reflected in the control group.

Certain analysis may be performed by comparing individuals with one haplotype against the entire normal population. Such an analysis may be used to establish the selectivity of the response associated with a specific haplotype. For example, it may be desirable to establish that the response or toxicity observed in a specific subgroup is greater than that associated observed with the entire population. It may also be of interest to compare the response to treatment between two different subgroups. If σ differs between the groups, then the estimate of the number of patients that need to be enrolled in the trial must be calculated using equations 2.1 with N being the maximum of N_i/P_i for the different subgroups.

Another issue in controls is the relative size of the treatment and control groups. In a prospectively designed clinical trial which selectively incorporates patients with haplotype “i” the number of patients in the control and treatment group will be essentially equivalent. If the control group is different, or if haplotypes are used for

stratification but not inclusion, statistical corrections may need to be made for having populations of different size.

005220 "CFB950

Example 18Stratification of patients by phenotype.

5 The identification of genetic associations in Phase II or retrospective studies can be performed by stratifying patients by phenotype and analyzing the distribution of genotypes/haplotypes in the separate populations. A particularly important aspect of this analysis is that any gene may have only a partial effect on the observed outcome, meaning that there will be an association value (A) corresponding to the fraction of patients in a phenotypically-defined subgroup who exhibit that phenotype
10 due to a specific genotype/phenotype.

It will be recognized to those skilled in the art that the fraction of individuals who exhibit a phenotype due to any specific allele will be less than 1 (i.e. $A < 1$). This is true for several reasons. The observed phenotype may occur by random chance. The observed phenotype may be associated with environmental influences,
15 or the observed phenotype may be due to different genetic effects in different individuals. Furthermore, the construction of haplotypes and analysis of recombination may not group all alleles with phenotypically-significant variances within a single haplotype or haplotype cluster. In this case, causative variances at a single locus may be associated with more than one haplotype or haplotype cluster
20 and the association constant A for the locus would be $A = A_1 + A_2 + \dots + A_n < 1$. It is likely that many phenotypes will be associated with multiple alleles at a given locus, and it is particularly important that statistical methods be sufficiently robust to identify association with a locus even if A_i is reduced by the presence of several causative alleles.

25 Statistical methods can be used to identify genetic effects on an observed outcome in patient groups stratified by phenotype, eg the presence or absence of the observed response. One such method entails determining the allele frequencies in two populations of patients stratified by an observed clinical outcome, for example efficacy or toxicity and performing a maximum likelihood analysis for the
30 association between a given gene and the observed phenotype based on the allele frequencies and a range of values for A (the association constant between a specific allele and the observed outcome used to stratify patients).

This analysis is performed by comparing the observed gene frequencies in a patient population with an observed outcome to gene frequencies in a table in which
35 the predicted frequencies of different alleles of the gene assuming different values of the association constant A for that allele. This table of predicted gene frequencies can be constructed by those skilled in the art based on the frequency of any specific allele in the normal population, the predicted inheritance of the effect (e.g. dominant

or recessive) and the fraction of a subgroup with a specific outcome who would have that allele based on the association constant A.

For example, if a specific outcome was only observed in the presence of a specific allele of a gene, the expected frequency would be 1. If a specific outcome was never observed in the presence of a specific allele of a gene, the expected frequency would be 0. If there was no association between the allele and the observed outcome, the frequency of that allele among individuals with an observed outcome would be the same as in the general population. A statistical analysis can be performed to compare the observed allele frequencies with the predicted allele frequencies and determine the best fit or maximum likelihood of the association. For example, a chi square analysis will determine whether the observed outcome is statistically similar to predicted outcomes calculated for different modes of inheritance and different potential values of A. P values can then be calculated to determine the likelihood that any specific association is statistically significant. A curve can be calculated based on different values of A, and the maximal likelihood of an association determined from the peak of such a curve. Methods for chi square analysis are known to those in the art.

A multidimensional analysis can also be performed to determine whether an observed outcome is associated with more than one allele at a specific genetic locus. An example of this analysis considering the potential effects of two different alleles of a single gene is shown. It will be apparent to those skilled in the art that this analysis can be extended to n dimensions using computer programs.

This analysis can be used to determine the maximum likelihood that one or more alleles at a given locus are associated with a specific clinical outcome.

It will be apparent to those skilled in the art that critical issues in this analysis include the fidelity of the phenotypic association and identification of a control group. In particular, it may be useful to perform an identical analysis in patients receiving a placebo to eliminate other forms of bias which may contribute to statistical errors.

Other Embodiments

The invention described herein provides a method for identifying patients with a risk of developing drug-induced liver disease or hepatic dysfunction by determining the patients allele status for a gene listed in Tables 1 and 2 and providing a forecast of the patients ability to respond to a given drug treatment. In particular, the invention provides a method for determining, based on the presence or absence of a polymorphism, a patient's likely response to drug therapies as drug-

induced liver disease or hepatic dysfunction. Given the predictive value of the described polymorphisms across two different classes of drug, having different mechanisms of action, the candidate polymorphism is likely to have a similar predictive value for other drugs acting through other pharmacological mechanisms. Thus, the methods of the invention may be used to determine a patient's response to other drugs including, without limitation, antihypertensives, anti-obesity, anti-hyperlipidemic, or anti-proliferative, antioxidants, or enhancers of terminal differentiation.

In addition, while determining the presence or absence of the candidate allele is a clear predictor determining the efficacy of a drug on a given patient, other allelic variants of reduced catalytic activity are envisioned as predicting drug efficacy using the methods described herein. In particular, the methods of the invention may be used to treat patients with any of the possible variances, e.g., as described in Table 3 of Stanton & Adams, application number 09/300,747, *supra*.

In addition, while the methods described herein are preferably used for the treatment of human patient, non-human animals (e.g., pets and livestock) may also be treated using the methods of the invention.

All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. All references cited in this disclosure are incorporated by reference to the same extent as if each reference had been incorporated by reference in its entirety individually.

One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The methods, variances, and compositions described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims.

It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. For example, using other compounds, and/or methods of administration are all within the scope of the present invention. Thus, such additional embodiments are within the scope of the present invention and the following claims.

The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the

In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.

In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Absorption and Distribution	Gastrointestinal Drug Metabolism	Glycosidases	sucrase-isomaltase/S1	222900	NM_001041	3q25-q26
			maltase-glucoamylase/alpha-glucosidase/MGAM	154360	NM_004668	Chr.7
			lactase-phlorizin hydrolase/LPH/lactase/LCT	603202	NM_002299	2q21
			salivary amylase A/AMY1A	104700	NM_004038	1p21
			salivary amylase B/AMY1B	104701	*****	1p21
			salivary amylase C/AMY1C	104702	*****	1p22
			pancreatic amylase A/AMY2A	104650	X07057	1p21
			pancreatic amylase B/AMY2B	104660	*****	1p21
			dipeptidylpeptidase IV/CD26/ADA complexing protein 2/DPP4	102720	NM_001935	2q23
			pepsinogen A/PGA/PG	169700	AH001519	11q13
			pepsinogen, group 3/PGA3	169710	*****	11q13
			pepsinogen C/PGC	169740	J04443	6p21.3-p21.1
			kallikrein 1/KLK1	147910	AH002853	19q13.2-q13.4
		Proteases and Peptidases	chymotrypsin-like protease	118888	X71875	16q22.1
			trypsinogen 1/TRY1/protease, serine 1/PRSS1	276000	NM_002769	7q35
			trypsinogen 1/TRY2/protease, serine 2/PRSS2	601564	NM_002770	7q35
			trypsinogen 1/TRY3/protease, serine 3/PRSS3	*****	NM_002771	*****
			enterokinase 1/TRY3/protease, serine7/PRSS7	226200	NM_002772	21q21
			chymotrypsinogen 1/CTRB1	118890	NM_001906	16q23.2-q23.3
			carboxypeptidase A1/CPA1	114850	NM_001868	7q32-qter
			carboxypeptidase A2/CPA2	600688	NM_001869	*****
			carboxypeptidase Z/CPZ	603105	NM_003652	
			elastase 1/ELA1	130120	D00158	12q13

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Absorption and Distribution	Gastrointestinal Drug Metabolism	Proteases and Peptidases	renal microsomal dipeptidase/DPEP1 (b-lactam ring hydrolysis)	179780	NM_004413	16q24.3
			tripeptidyl peptidase II/TPP2	190470	NM_003291	13q32-q33
			protease inhibitor 1/alpha-1-antitrypsin/AAT/PI	107400	NM_000295	14q32.1
			protease inhibitor/alpha-1-antichymotrypsin/AAC1	107280	NM_001085	14q32.1
			protease inhibitor 1 (alpha-1-antitrypsin)-like/PI1	107410	NM_006220	14q32.1
		Lipases	Carboxyl ester lipase (bile salt-stimulated lipase)/CEL	114840	M85201	9q34.3
			Carboxyl ester lipase-like (bile salt-stimulated lipase-like)/CELL	114841	NM_001808	9q34.3
			Pancreatic colipase/CLPS	120105	M95529	6pter-p21.1
			Pancreatic triglyceride lipase/PNLIP	246600	AH003527	10q26.1
			Lipoprotein lipase/LPL	238600	NM_000237	8p22
	Oxidases	Esterases	Hepatic triglyceride lipase/LIPC	151670	AH005429	
			salivary peroxidase/SAPX	170990	U39573	*****
			alcohol dehydrogenases 6/ADH6	103735	NM_000672	15q26
			paraoxonase 2/PON2	602447	L48513	7q21.3
			intestinal alkaline phosphatase/ALPI	171740	NM_001631	2q36.3-q37.1
	Drug Binding	Blood Transport	tissue non-specific alkaline phosphatase/liver alkaline phosphatase/ALPL	171760	NM_000478	1p36.1-p34
			serum albumin/ALB	103600	NM_000477	4q11-q13
			alpha fetoprotein/AFP	104150	NM_001134	4q11-q13
			alpha albumin/afamin/AFM/ALB2	104145	NM_001133	4q11-q13
			vitamin D-binding protein/group-specific component/GC	139200	AH004448	4q12

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Absorption and Distribution	Drug Binding	Blood Transport	orosomucoid 1/alpha 1 acid glycoprotein/ORM1	138600	M13692	9q34.1-q34.3
			orosomucoid 2/alpha 1 acid glycoprotein, type 2/ORM2	138610	NM_000608	9q34.1-q34.3
			transferrin (prealbumin, amyloidosis type I)/TTR	176300	NM_000371	18q11.2-q12.1
			thyroxine-binding globulin/TBG	314200	NM_000354	Xq22.2
			corticosteroid binding globulin precursor/CBG	122500	NM_001756	14q32.1
			sex hormone-binding globulin/SHBG	182205	X16349	17p13-p12
			mannose-binding lectin, soluble/MBL2	154545	NM_000242	10q11.2-q21
			Hepatic fatty acid binding protein/FABP1	134650	*****	2p11
			Intestinal fatty acid binding protein/FABP2	134640	NM_000134	4q28-q31
			Muscle fatty acid binding protein/mammary-derived growth inhibitor/MDGI/FABP3	134651	NM_004102	1p33-p31
	Bile Acid Binders		Adipocyte fatty acid binding protein/FABP4	600434	NM_001442	8q21
			Ileal fatty acid binding protein/FABP6	600422	U19869	5q23-q35
			Brain fatty acid binding protein/FABP7	602965	D88648	6q22-q23
			Adipocyte long chain fatty acid transport protein/FATP	600691	*****	*****
			Retina-specific ATP binding cassette transporter/ABCR	601691	NM_000350	1p21-p13
			ATP binding cassette 1/ABC1	600046	AJ012376	9q22-q31
Drug Uptake	ABC Transporters		ATP binding cassette 2/ABC2	600047	U18235	9q34
			ATP binding cassette 3/ABC3	601615	NM_001089	16p13.3
			ATP binding cassette 7/ABC7	300135	AB005289	Xq13.1-q13.3

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Absorption and Distribution	Drug Uptake	ABC Transporters	ATP binding cassette 8/ABC8	603076	AF038175	21q22.3
			ATP-binding cassette 50/ABC50	603429	AF027302	6p21.33
			Placenta-specific ATP-binding cassette transporter/ABCP	603756	NM_004827	4q22
			cystic fibrosis transmembrane conductance regulator/CFTR	602421	NM_000492	7q31.2
			adrenoleukodystrophy/adrenomyeloneuropathy/ALD	300100	NM_000033	Xq28
			adrenoleukodystrophy related protein/ALDR	601081	U28150	12q11-q12
			sulfonylurea receptor (hyperinsulinemia)/SUR	600509	NM_000352	11p15.1
			peroxisomal membrane protein 1/PXMP1	170995	NM_002858	1p22-p21
			peroxisomal membrane protein 1-like/PXMP1L	603214	NM_005050	14q24.3
			antigen peptide transporter 1/MHC 1/TAP1	170260	NM_000593	6p21.3
			antigen peptide transporter 2/MHC 2/TAP2	170261	NM_000544	6p21.3
			multidrug resistance associated protein MRP1	158343	L05628	16p13.1
			multidrug resistance associated protein MRP2/CMOAT	601107	NM_000392	10q24
			ATP-binding cassette, sub-family C (CFTR/MRP), member 3/CMOAT2	*****	NM_003786	*****
			ATP-binding cassette, sub-family C (CFTR/MRP), member 4/MOATB	*****	NM_005845	*****
			ATP-binding cassette, sub-family C (CFTR/MRP), member 5/SMRP	*****	NM_005688	*****
			ATP-binding cassette, sub-family C (CFTR/MRP), member 9/SUR2	601439	NM_005691	*****
			multidrug resistance protein MDR1	171050	X96395	7q21.1
			multidrug resistance protein MDR3/P-glycoprotein 3/PGY3	602347	X06181	7q21.1

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Absorption and Distribution		ABC Transporters	anthracylcline resistance-related protein/ARA	603234	NM_001171	16p13.1
			bile salt export pump/BSEP	603201	NM_003742	2q24
			familial intrahepatic cholestasis 1/FIC1	602397	NM_005603	18q21
			Human sorcin/SRI	182520	L12387	7q21.1
	Drug Uptake	Solute Antiporters	Solute carrier family 1, member 1/SLC1A1 (glutamate)	133550	U08989	9p24
			Solute carrier family 1, member 2/SLC1A2 (glutamate)	600300	U03505	11p13- p12
			Solute carrier family 1, member 3/SLC1A3 (glutamate)	600111	U03504	5p13
			Solute carrier family 1, member 4/SLC1A4 (glutamate)	600229	NM_003038	2p15-p13
			Solute carrier family 1, member 5/SLC1A5 (neutral AA)	109190	AF105230	19q13.3
			Solute carrier family 1, member 6/SLC1A6 (glutamate)	600637	NM_005071	*****
			Solute carrier family 2, member 1/SLC2A1/SGLT1 (glucose)	182380	NM_006516	22q13.1
			Solute carrier family 2, member 2/SLC2A2/GLUT2 (glucose)	138160	NM_006516	3q26.1- q26.3
			Solute carrier family 2, member 3/SLC2A3/GLUT3 (glucose)	138170	M20681	12p13.3
			Solute carrier family 2, member 4/SLC2A4/GLUT4 (glucose)	138190	*****	17p13
			Solute carrier family 2, member 5/SLC2A5/GLUT5 (glucose)	138230	NM_003039	1p36.2
			Solute carrier family 3 member 1/SLC3A1 (aa transporter)	104614	*****	2p16.3

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Absorption and Distribution	Drug Uptake	Solute Antiporters	Solute carrier family 5 member 1/SLC5A2 (glucose)	182381	*****	16p11.2
			Solute carrier family 5 member 3/SLC5A3 (myoinositol)	600444	L38500	21q22
			Solute carrier family 5 member 6/SLC5A6 (folate, biotin, lipoate)	604024	*****	2p23
			Solute carrier family 6 member 1/SLC6A1 (GABA)	137165	X54673	3p25-p24
			Solute carrier family 6 member 2/SLC6A2 (noradrenalin)	163970	NM_001043	16q12.2
			Solute carrier family 6 member 3/SLC6A3 (dopamine)	126455	L24178	5p15.3
			Solute carrier family 6 member 4/SLC6A4 (serotonin)	182138	X70697	17q11.1-q12
			Solute carrier family 6, member 5/SLC6A5 (glycine)	604159	NM_004211	*****
			Solute carrier family 6, member 6/SLC6A6 (taurine)	186854	U16120	3p25-q24
			Solute carrier family 6, member 8/SLC6A8 (creatine)	300036	NM_005629	300036
			Solute carrier family 6, member 9/SLC6A9 (glycine)	601019	S70612	1p33
			Solute carrier family 6, member 10/SLC6A10 (creatine-testis)	601294	*****	16p11.2
			Solute carrier family 6, member 12/SLC6A12 (GABA-betaine)	603080	NM_003044	12p13
			Solute carrier family 7, member 1/SLC7A1 (cationic AA)	104615	*****	13q12.3
			Solute carrier family 7, member 2/SLC7A2 (cationic AA)	601872	D29990	8p22
			Solute carrier family 7, member 4/SLC7A4 (cationic AA)	603752	*****	22q11.2
			Solute carrier family 7, member 5/SLC7A5 (neutral AA)	600182	M80244	16q24.3

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Absorption and Distribution	Drug Uptake	Solute Antiporters	Solute carrier family 7, member 7/SLC7A7 (dibasic AA)	603593	Y18474	14q11.2
			Solute carrier family 7, member 9/SLC7A9 (neutral AA)	604144	*****	19q13.1
			Solute carrier family 10, member 1/SLC10A1 (taurocholate)	182396	NM_003049	chr. 14
			Solute carrier family 10, member 2/SLC10A2 (taurocholate)	601295	NM_000452	13q33
			Solute carrier family 11, member 1/SLC11A1 (?)	600266	AH002806	2q35
			Solute carrier family 11, member 2/SLC11A2 (iron)	600523	L37347	12q13
			Solute carrier family 13, member 2/SLC13A2 (dicarboxylic acids)	604148	NM_003984	17p11.1-q11.1
			Solute carrier family 14, member 1/SLC14A1 (urea)	111000	*****	18q11-q12
			Solute carrier family 14, member 2/SLC14A2 (urea)	601611	X96969	18q12.1-q21.1
			Solute carrier family 15, member 1/SLC15A1 (peptides)	600544	U13173	13q33-q34
			Solute carrier family 15, member 2/SLC15A2 (peptides)	602339	S78203	*****
			Solute carrier family 16, member 1/SLC16A1 (monocarboxylic acids)	600682	NM_003051	1p13.2-p12
			Solute carrier family 16, member 2/SLC16A2 (monocarboxylic acids)	300095	NM_006517	Xq13.2
			Solute carrier family 16, member 3/SLC16A3 (monocarboxylic acids)	603877	NM_004207	*****
			Solute carrier family 16, member 4/SLC16A4 (monocarboxylic acids)	603878	*****	*****

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Absorption and Distribution	Drug Uptake	Solute Antiporters	Solute carrier family 16, member 5/SLC16A5 (monocarboxylic acids)	603879	NM_004695	*****
			Solute carrier family 16, member 6/SLC16A6 (monocarboxylic acids)	603880	NM_004694	*****
			Solute carrier family 16, member 7/SLC16A7 (monocarboxylic acids)	603654	AF049608	12q13
			Solute carrier family 18, member 1/VAT1/SLC18A1 (monoamines)	193001	L09118	10q25
			Solute carrier family 18, member 2/VAT2/SLC18A2 (monoamines)	193002	*****	8p21.3
			Solute carrier family 18, member 3/VAT3/SLC18A3 (monoamines)	600336	NM_003055	10q11.2
			Solute carrier family 19, member 1/SLC19A1 (reduced folate)	600424	U19720	21q22.3
			Solute carrier family 19, member 2/SLC19A2 (thiamine)	603941	AF160186	1q23.2-q23.3
			Solute carrier family 21, member 2/SLC21A2 (prostaglandin)	601460	NM_005630	3q21
			Solute carrier family 21, member 3/SLC21A3 (organic anion)	602883	NM_005075	12p12
			Solute carrier family 22, member 1/SLC22A1 (organic cation)	602607	NM_003058	6q26
			Solute carrier family 22, member 1-like/SLC22A1L (organic cation)	602631	AF037064	11p15.5
			Solute carrier family 22, member 2/SLC22A2 (organic cation)	602608	NM_003058	6q26
			Solute carrier family 22, member 4/SLC22A4 (organic cation)	604190	NM_003059	Chr. 5

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Absorption and Distribution	Drug Uptake	Solute Antiporters	Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377	NM_003060	5q33.1
			Solute carrier family 25, member 1/SLC25A1 (tricarboxylic acids) (mitochondrial)	190315	X96924	22q11
			Solute carrier family 25, member 11/SLC25A11 (oxoglutarate/malate) (mitochondrial)	604165	NM_003562	17p13.3
			Solute carrier family 25, member 12/SLC25A12 (?) (mitochondrial)	603667	NM_003705	*****
			Solute carrier family 25, member 13/SLC25A13 (?) (mitochondrial)	603859	*****	7q21.3
			Solute carrier family 25, member 15/SLC25A15 (ornithine) (mitochondrial)	603861	*****	13q14
			Solute carrier family 25, member 16/SLC25A16 (ADP/ATP) (mitochondrial)	139080	M31659	10q21.3-q22.1
			Solute carrier family 29, member 1/SLC29A1/ENT1 (nucleoside) (mitochondrial)	602193	NM_004955	6p21.2-p21.1
			Solute carrier family 29, member 2/SLC29A2/ENT2 (nucleoside) (mitochondrial)	602110	X86681	11q13
			Flavin-containing monooxygenase 1/FMO1	136130	NM_002021	1q23-q25
Phase I Drug Metabolism (oxidation and reduction)	Monooxygenases (mixed function oxidases)	Flavin-containing Mono-oxygenases	Flavin-containing monooxygenase 3/FMO3	136132	AH006707	1q23-q25
			Flavin-containing monooxygenase 4/FMO4	136131	NM_001460	1q23-q25
			Flavin-containing monooxygenase 5/FMO5	603957	NM_001461	1q21.1
			Aryl hydrocarbon receptor nuclear translocator/ARNT	126110	NM_001668	1q21
			Aryl hydrocarbon receptor nuclear translocator-like/ARNTL	602550	NM_001178	11p15
		P450 Cytochromes	Aryl hydrocarbon receptor/AHR	600253	NM_001621	7p15

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Phase I Drug Metabolism (oxidation and reduction)	Monooxygenases (mixed function oxidases)	P450 Cytochromes	Nuclear receptor subfamily 1, group I, member 2/NR1I2	603065	NM_003889	*****
			Constitutive androstane receptor, beta/orphan nuclear hormone receptor/CAR	603881	NM_005122	*****
			Nuclear receptor subfamily 1, group H, member 2/NR1H2	600380	U07132	19q13.3
			Retinoic acid receptor, alpha/RARA	180240	NM_000964	17q12
			Retinoic acid receptor, beta/RARB	180220	NM_000965	3p24
			Retinoic acid receptor, gamma/RARG	180190	M57707	12q13
			Retinoid X receptor alpha/RXRA	180245	NM_005693	9q34.3
			Retinoid X receptor beta/RXRB	180246	X66424	6p21.3
			Retinoid X receptor gamma/RXRG	180247	U38480	1q22-q23
			RAR-related orphan receptor A/RORA	600825	NM_002943	15q21- q22
			RAR-related orphan receptor B/RORB	600825	*****	15q21- q22
			RAR-related orphan receptor C/RORC	602943	NM_005060	1q21
			cellular retinoic acid-binding protein, type 2/CRABP2	180231	*****	1q21.3
			glucocorticoid receptor/GRL	138040	NM_000176	5q31
			Peroxisome proliferative activated receptor, alpha/PPARA	170998	NM_005036	22q12- q13.1
			Peroxisome proliferative activated receptor, gamma/PPARG	601487	NM_005037	3p25
			Peroxisome proliferative activated receptor, delta/PPARD	600409	NM_006238	1q21.3
			cytochrome P450, subfamily I, polypeptide 1 (aryl hydrocarbon oxidase)/CYP1A1	108330	NM_000499	15q22- q24

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Phase I Drug Metabolism (oxidation and reduction)	Monooxygenases (mixed function oxidases)	P450 Cytochromes	cytochrome P450, subfamily I, polypeptide 2 (phenacetin metabolism)/CYP1A2	124060	AH002667	15q22-qter
			cytochrome P450, subfamily IB, polypeptide 1 (dioxin inducible)/CYP1B1	601771	NM_000104	2p22-p21
			cytochrome P450, subfamily II, polypeptide 1 (phenobarbital inducible)/CYP2A	123960	X13897	19q13.2
			cytochrome P450, subfamily IIA, polypeptide 6 (coumarin-7-hydroxylase)/CYP2A6	122720	NM_000762	19q13.2
			cytochrome P450, subfamily IIB (phenobarbital inducible)/CYP2B	123930	M29874	19q13.2
			cytochrome P450, subfamily IIC, polypeptide 8/CYP2C8	601129	*****	10q24
			cytochrome P450, subfamily IIC, polypeptide 9 (hydroxylation of tolbutamide)/CYP2C9	601130	*****	10q24
			cytochrome P450, subfamily IIC, polypeptide 18/CYP2C18	601131	*****	10q25
			cytochrome P450, subfamily IIC, polypeptide 19 (mephenytoin 4-hydroxylase)/CYP2C19	124020	NM_000769	10q24.1-q24.3
			cytochrome P450, subfamily IID, polypeptide 6 (debrisoquine hydroxylation)/CYP2D6	124030	NM_000106	22q13.1
			cytochrome P450, subfamily IIE (ethanol inducible)/CYP2E	124040	J02843	10q24.3-qter
			cytochrome P450, subfamily IIF (ethoxycoumarin monooxygenase), polypeptide 1/CYP2F1	124070	NM_000774	19q13.2
			cytochrome P450, subfamily IIJ (arachidonate epooxygenase), polypeptide 2/CYP2J2	601258	NM_000775	1p31.3-p31.2
			cytochrome P450, subfamily IIIA (nifedipine oxidase), polypeptide 3/CYP3A3	124010	NM_000776	7q22.1

Table 1

Class	Pathway	Function	Name	OMIM	GIID	Locus
Phase I Drug Metabolism (oxidation and reduction)	Monooxygenases (mixed function oxidases)	P450 Cytochromes	cytochrome P450, subfamily IVA (fatty acid W- hydroxylase), polypeptide 11/CYP4A11	601310	NM_000778	Chr.1
			cytochrome P450, subfamily IVB, polypeptide 1/CYP4B1	124075	NM_000779	1p34-p12
			cytochrome P450, subfamily IVF (leukotriene B4-W- hydroxylase), polypeptide 3/CYP4F3	601270	NM_000896	19p13.2
			cytochrome P450, subfamily VIIA (cholesterol 7-a- hydroxylase), polypeptide 1/CYP7A1	118455	M89803	8q11-q12
			cytochrome P450, subfamily VIIB (oxysterol 7-a- hydroxylase), polypeptide 1/CYP7B1	603711	AF029403	8q21.3
			cytochrome P450, subfamily VIIB (sterol 12-a- hydroxylase), polypeptide 1/CYP8B1	602172	*****	3p21.3- p22
			cytochrome P450, subfamily XIA (cholesterol side- chain cleavage)/CYP11A	118485	NM_000781	15q23- q24
			cytochrome P450, subfamily XIB, polypeptide 2 (steroid 11-b-hydroxylase)/CYP11B2	124080	NM_000498	8q21
			cytochrome P450, subfamily XIX (androgen aromatase)/CYP19	107910	NM_000103	15q21.1
			cytochrome P450, subfamily XXI (sterol 21-a- hydroxylase)/CYP21	201910	M13936	6p21.3
			cytochrome P450, subfamily XXIV (25- hydroxyvitamin D 24-hydroxylase)/CYP24	600125	S67623	20q13.2- q13.3
			cytochrome P450, subfamily XXVIA, polypeptide 1 (retinoic acid hydroxylase)/CYP26A1	602239	NM_000783	10q23- q24
			cytochrome P450, subfamily XXVIA, polypeptide 1 (25-hydroxyvitamin D-1-a-hydroxylase)/CYP27A1	213700	NM_000105	2q33-qter
			adrenodoxin/ferredoxin 1/FDX1/ADX	103260	NM_004109	11q22
			adrenodoxin reductase/ferredoxin:NADP(+) reductase/FDXR/ADXR	103270	NM_004110	17q24- q25

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Phase I Drug Metabolism (oxidation and reduction)	Monooxygenases (mixed function oxidases)	P450 Cytochromes	cytochrome P450, subfamily XXVIII, polypeptide 1 (2,5-hydroxyvitamin D-1-a-hydroxylase)/CYP27B1	264700	NM_000785	12q14
			cytochrome P450, subfamily XLVI (cholesterol 24-hydroxylase)/CYP46	604087	NM_006668	14q32.1
	General Oxidases	General Oxidases	cytochrome P450, subfamily LI (lanosterol 14-a-demethylase)/CYP51	601637	U51692	7q21.2-q21.3
			Monoamine Oxidase A; MAOA	309850	M69226	Xp11.23
			Monoamine Oxidase B; MAOB	309860	M69177	Xp11.23
			Copper-containing amine oxidase/AOC3	603735	NM_003734	17q21
	Cofactor Synthesis	Cofactor Synthesis	Xanthine dehydrogenase/XDH	278300	NM_000379	2p23-p22
			tryptophan 2,3-dioxygenase/TDO2	191070	NM_005651	4q31-q32
			sulfite oxidase/SUOX	272300	NM_000456	*****
			molybdenum factor synthesis 1/MOCS1	603707	AJ224328	6p21.3
Dehydrogenases	Alcohol Dehydrogenases	Alcohol Dehydrogenases	molybdenum factor synthesis 2/MOCS2	603708	*****	5q11
			alcohol dehydrogenases 1, alpha subunit/ADH1	103700	NM_000667	4q22
			alcohol dehydrogenases 2, beta subunit/ADH2	103720	NM_000668	4q22
			alcohol dehydrogenases 3, gamma subunit/ADH3	103730	M12272	4q22
	Aldehyde Dehydrogenases	Aldehyde Dehydrogenases	alcohol dehydrogenases 4/pi isozyme/ADH4	103740	M15943	4q22
			alcohol dehydrogenases 5/chi isozyme/ADH5	103710	NM_000671	4q21-q25
			alcohol dehydrogenases 6/ADH6	103735	NM_000672	15q26
			alcohol dehydrogenases 7/ADH7	600086	AH006682	4q23-q24
			aldehyde dehydrogenase 1/ALDH1 (liver cytosol)	100640	AH002598	9q21
			aldehyde dehydrogenase 2/ALDH2 (liver mitochondria)	100650	K03001	12q24.2
			aldehyde dehydrogenase 3/acetaldehyde dehydrogenase/ALDH3 (stomach)	100660	M74542	17p11.2
			aldehyde dehydrogenase 5/acetaldehyde dehydrogenase/ALDH5	100670	NM_000692	9p13

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Phase I Drug Metabolism (oxidation and reduction)	Dehydrogenases	Aldehyde Dehydrogenases	aldehyde dehydrogenase 5, member A1/succinic semialdehyde dehydrogenase/ALDH5A1	271980	NM_001080	6p22
			aldehyde dehydrogenase 6/acetalddehyde dehydrogenase/ALDH6	600463	NM_000693	15q26
			aldehyde dehydrogenase 7/acetalddehyde dehydrogenase/ALDH7	600466	NM_000694	11q13
			aldehyde dehydrogenase 8/ALDH8	601917	NM_000695	chr. 11
			aldehyde dehydrogenase 9/g-aminobutyraldehyde dehydrogenase/ALDH9	602733	NM_000696	1q22-q23
			aldehyde dehydrogenase 10/ALDH10	270200	NM_000382	17p11.2
			Dihydropyrimidine dehydrogenase (5-fluorouracil detoxification)	274270	U09178	1p22
		Peroxisome Proliferation	Peroxisome proliferative activated receptor, alpha/PPARA	170998	NM_005036	22q12-q13.1
			Peroxisome proliferative activated receptor, gamma/PPARG	601487	NM_005037	3p25
			Peroxisome proliferative activated receptor, delta/PPARD	180231	NM_006238	1q21.3
Fatty Acid β -Oxidation		Peroxisome Synthesis	peroxisome biogenesis factor 1/PEX1	602136	AB008112	7q21-q22
			peroxisomal membrane protein 3 (35kD, Zellweger syndrome)/PXM3/PEX2	170993	NM_000318	8q21.1
			peroxisomal biogenesis factor 3/PEX3	603164	NM_003630	*****
			peroxisomal biogenesis factor 6/PEX6	601498	NM_000287	6p21.1
			peroxisomal biogenesis factor 7/PEX7	601757	NM_000288	6q22-q24
			peroxisomal biogenesis factor 10/PEX10	602859	*****	*****
			peroxisomal biogenesis factor 11A/PEX11A	603866	NM_003847	*****
			peroxisomal biogenesis factor 11B/PEX11B	603867	NM_003846	*****

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Phase I Drug Metabolism (oxidation and reduction)	Fatty Acid β - Oxidation	Peroxisome Synthesis	peroxisomal biogenesis factor 12/PEX12	601758	NM_000286	
			peroxisomal biogenesis factor 13/PEX13	601789	U71374	2p15
			peroxisomal biogenesis factor 14/PEX14	601791	*****	*****
			peroxisomal farnesylated protein/PXF/peroxisomal biogenesis factor 19/PEX19	600279	NM_002857	1q22
		Coenzyme A Ligases	Fatty acid CoA Ligase, long chain 1/FACL1	152425	*****	3q13
			Fatty acid CoA Ligase, long chain 2/FACL2	152426	*****	4q34-q35
			Fatty acid CoA Ligase, long chain 3/FACL3	602371	NM_004457	2q34-q35
			Fatty acid CoA Ligase, long chain 4/FACL4	300157	NM_004458	Xq22.3
		Oxidation	Fatty acid CoA Ligase, very long chain 1/FACVL1	603247	*****	15q21.2
			Enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase/EHHADH	261515	NM_001966	3q27
			hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase, alpha subunit/HADHA	600890	NM_000182	2p23
			hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase, beta subunit/HADHB	143450	NM_000183	2p23
			acyl-Coenzyme A oxidase 1/ACOX1 (peroxisomal)	264470	NM_004035	17q25
			acyl-Coenzyme A oxidase 2, branched chain/ACOX2 (peroxisomal)	601641	NM_003500	3p14.3
			acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain precursor/ACADS (mitochondrial)	201470	NM_000017	12q22- qter
			acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain/ACADM (mitochondrial)	201450	NM_000016	1p31
			acyl-Coenzyme A dehydrogenase, long chain/ACADL (mitochondrial)	201460	NM_001608	2q34-q35
			hydroxyacyl-Coenzyme A dehydrogenase, type II/HADH2	602057	NM_004493	*****

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Phase I Drug Metabolism (oxidation and reduction)	Fatty Acid β -Oxidation	Oxidation	enoyl-Coenzyme A hydratase 1/ECH1 (peroxisomal)	600696	NM_001398	19q13
	Reduction	Aldo-Keto Reductases	Aldo-keto reductase family 1, member A1/dihydrodiol dehydrogenase/AKR1A1	103830	NM_006066	1p33-p32
			Aldo-keto reductase family 1, member C1/dihydrodiol dehydrogenase/AKR1C1	600449	NM_001353	10p15-p14
			Aldo-keto reductase family 1, member C3/dihydrodiol dehydrogenase/AKR1C3	603966	NM_003739	10p15-p14
			Aldo-keto reductase family 1, member C4/chlorodecone reductase/AKR1C4	600451	*****	10p15-p14
			Aldo-keto reductase family 7, member A2/aflatoxin aldehyde reductase/AKR7A2	603418	NM_003689	*****
			Carbonyl reductase 1/CBR1	114830	NM_001757	21q22.12
			Carbonyl reductase 2/CBR2	*****	*****	chr. 11
			Carbonyl reductase 3/CBR3	603608	NM_001236	21q22.2
			Sepiapterin reductase (7,8-dihydrobiopterin:NADP+ oxidoreductase)/SPR	182125	NM_003124	2p14-p12
		Quinone Oxidoreductases	Z-crystallin/quinone reductase/CRYZ	123691	L31521	1p31-p22
			Z-crystallin-like/quinone reductase-like/CRYZL1	603920	NM_005111	21q22.1
			NAD(P)H menadione oxidoreductase 1, dioxin-inducible/NMOR1/diaphorase 4/DIA4	125860	NM_000903	16q22.1
			NAD(P)H menadione oxidoreductase 2, dioxin-inducible/NMOR2	160998	NM_000904	6pter-q12
Phase II Drug Metabolism (conjugation and catabolism)	Conjugation	Sulfate Unit Activation	3-prime-phosphoadenosine 5-prime-phosphosulfate synthase 1/PAPSS1	603262	NM_005443	4q

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Phase II Drug Metabolism (conjugation and catabolism			Phenol-preferring sulfotransferase, family 1A, member 1/SULT1A1	171150	NM_001055	16p12.1- p11.2
			Phenol-preferring sulfotransferase, family 1A, member 2/SULT1A2	601292	NM_001054	16p12.1- p11.2
			Phenol-preferring sulfotransferase, family 1A, member 3/SULT1A3	600641	L19956	16p11.2
			Sulfotransferase, family 1C, member 3/SULT1C1	602385	U66036	2q11.1- q11.2
			Dehydroepiandrosterone (DHEA)-preferring sulfotransferase, family 2A, member 1/SULT2A1	125263	NM_003167	19q13.3
			Sulfotransferase, family 2B, member 1/SULT2B1	604125	NM_004605	19q13.3
			Estrogen-preferring sulfotransferase/STE	600043	NM_005420	4q13.1
			N-deacetylase/N-sulfotransferase (heparan glucosaminyl)/NDST1	600853	U18918	5q32- q33.3
			N-deacetylase/N-sulfotransferase (heparan glucosaminyl)/NDST2	603268	NM_003635	10q22
			N-deacetylase/N-sulfotransferase (heparan glucosaminyl)/NDST3	603950	NM_004784	*****
			Carbohydrate sulfotransferase 1 (chondroitin 6/keratan)/CHST1	603797	NM_003654	11p11.2- p11.1
			Carbohydrate sulfotransferase 2 (chondroitin 6/keratan)/CHST2	603798	*****	7q31
			Carbohydrate sulfotransferase 3 (chondroitin 6/keratan)/CHST3	603799	NM_004273	*****
			Cerebroside sulfotransferase (3'- phosphoadenylylsulfate:galactosylceramide 3')/CST	602300	NM_004861	*****
			Heparan sulfate (glucosamine) 3-O-sulfotransferase 1/HS3ST1	603244	NM_005114	*****

Table 1

Class	Pathway	Function	Name	OMIM	GiD	Locus
Phase II Drug Metabolism (conjugation and catabolism	Conjugation	Sulfation	Heparan sulfate (glucosamine) 3-O-sulfotransferase 2/HS3ST2	604056	NM_006043	16p12
			Heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1/HS3ST3A1	604057	NM_006042	17p12- p11.2
			Heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1/HS3ST3B1	604058	NM_006041	17p12- p11.2
			Heparan sulfate (glucosamine) 3-O-sulfotransferase 4/HS3ST4	604059	AF105378	16p11.2
		Sulphydrylation	Methylguanine methyltransferase (O6-alkylguanine detoxification)	156569	M29971	10q26
			thiosulfate thiotransferase/rhodanese/TST (cyanide detoxification)	180370	D87292	22q11.2- qter
		UDP- Glycosyltransfer ases	UDP glycosyltransferase 1/UGT1	191740	NM_001072	Chr. 12
			UDP glycosyltransferase family 2, member B4/UGT2B4	600067	NM_001073	4q13
			UDP glycosyltransferase family 2, member B7/UGT2B7	600068	NM_001074	1q14
			UDP glycosyltransferase family 2, member B10/UGT2B10	600070	NM_001075	*****
			UDP glycosyltransferase family 2, member B15/UGT2B15	600069	U06641	4q13
			UDP glycosyltransferase family 2, member B17/UGT2B17	601903	NM_001077	1q14
			UDP glycosyltransferase 8/UGT8	601291	U30930	4q26
			UDP-glucuronosyltransferase	218800	AJ005162	Chr.2
		Carbon Unit Activation for SAM	methionine adenosyltransferase I, alpha/MAT1A	250850	NM_000429	10q22

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Phase II Drug Metabolism (conjugation and catabolism)	Conjugation	Carbon Unit Activation for SAM	methionine adenosyltransferase II, alpha/MAT2A	601468	NM_005911	2p11.2
			Folate Receptor Alpha/FOLR1	136430	M28099	11q13.3-q13.5
			Folate Receptor Beta/FOLR2	136425	AF000380	11q13.3-q13.5
		Carbon Unit Activation for Folate	Folate Receptor Gamma/FOLR3	602469	Z32564	*****
			Folate Transporter (SLC19A1)	600424	U19720	21q22.3
			Vitamin B12 binding protein	275350	NM_000355	22q11.2-qter
			folylpolyglutamate synthetase/FPGS	136510	M98045	9cen-q34
			gamma-glutamyl hydrolase/GGH	601509	U55206	*****
			Methylenetetrahydrofolate reductase/MTHFR	236250	U09806	1p36.3
			Dihydrofolate reductase/DHFR	126060	J00140	5q11.2-q13.2
			5,10-methylenetetrahydrofolate dehydrogenase, 5,10-methylenetetrahydrofolate cyclohydrolase, 10-formyltetrahydrofolate synthetase/MTHFD1	172460	NM_005956	14q24
			5,10-methenyltetrahydrofolate synthetase (5-formyltetrahydrofolate cyclo-ligase)/MTHFS	604197	NM_006441	Chr. 15
			phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase/GART	138440	NM_000819	21q22.1
			folate hydrolase 1/FOH1	600934	NP_004467	11q14
			6-pyruvoyl tetrahydrobiopterin synthase/PTPS	261640	Q03393	11q22.3-q23.3
			serine hydroxymethyltransferase 1 (soluble)/SHMT1	182144	NM_004169	17p11.2

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Phase II Drug Metabolism (conjugation and catabolism)	Conjugation	Carbon Unit Activation for Folate	serine hydroxymethyltransferase 2 (mitochondrial)/SHMT2	138450	NM_005412	12q13
			Glycine aminotransferase/glycine cleavage T protein/GAT	238310	NM_000481	3p21.2-p21.1
			5-methyltetrahydrofolate-homocysteine methyltransferase/methionine synthase/MTR	156570	NM_000254	1q43
			glutamate formiminotransferase/dihydrofolate synthetase	229100	*****	*****
	Conjugation	Methylation	catechol-O-methyltransferase/COMT	116790	NM_000754	22q11.2
			phenylethanolamine N-methyltransferase/PNMT	171190	NM_002686	17q21-q22
			nicotinamide N-methyltransferase/NNMT	600008	NM_006169	11q23.1
			Thiopurine methyltransferase (6-mercaptopurine detoxification)	187680	U12387	6p22.3
	Conjugation	Carbon Unit Activation for Acetyl-CoA	pyruvate dehydrogenase E1-alpha subunit/PDHA1	312170	L48690	Xp22.2-p22.1
			pyruvate dehydrogenase (lipoamide) beta/PDHB	179060	NM_000925	3p13-q23
			pyruvate dehydrogenase complex, lipoyl-containing component X/E3-binding protein/PDX1	245349	NM_003477	11p13
			pyruvate dehydrogenase complex E3 subunit/DLD	246900	NM_000108	7q31-q32
	Conjugation	Acylation	sterol-O-acyl transferase 1/SOAT1	102642	L21934	1q25
			sterol-O-acyl transferase 2/SOAT2	601311	*****	chr. 12
			N-acetyltransferase 1/arylamine acetylase 1/NAT1	108345	NM_000662	8p23.1-p21.3
			N-acetyltransferase 2/arylamine acetylase 2/NAT2	243400	NM_000015	8p23.1-p21.3
	Conjugation	Glutathione S-Transferase	Glutathione-S-transferase 6	138391	*****	*****

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Phase II Drug Metabolism (conjugation and catabolism)	Conjugation	Glutathione Transferase	Glutathione-S-transferase, alpha 1/GSTA1	138359	L13269	6p12.2
			Glutathione-S-transferase, alpha 2/GSTA2	138360	M15872	6p12.2
			Glutathione-S-transferase, kappa 1/GSTK1	602321	*****	*****
			Glutathione-S-transferase 1/MGST1 (microsomal)	138330	AH003674	Chr.12
			Glutathione-S-transferase 2/MGST2 (microsomal)	601733	NM_002413	4q28-q31
			Glutathione-S-transferase, mu 1-like/GSTM1L	138270	*****	Chr. 3
			Glutathione-S-transferase, mu 1/GSTM1	138350	J03817	1p13.3
			Glutathione-S-transferase, mu 2/GSTM2 (muscle)	138380	NM_000848	1p13.3
			Glutathione-S-transferase, mu 3/GSTM3 (brain)	138390	NM_000849	1p13.3
			Glutathione-S-transferase, mu 4/GSTM4	138333	NM_000850	1p13.3
			Glutathione-S-transferase, mu 5/GSTM5 (brain/lung)	138385	NM_000851	1p13.3
			Glutathione-S-transferase, pi/GSTP1	134660	NM_000852	11q13
			Glutathione-S-transferase, theta 1/GSTT1	600436	NM_000853	22q11.2
			Glutathione-S-transferase, theta 2/GSTT2	600437	NM_000854	22q11.3
			Glutathione-S-transferase, zeta 1/maleylacetoacetate isomerase/MAAI/GSTZ1	603758	NM_001513	14q24.3
	Catabolism	γ -Glutamyl- transpeptidase	Gamma-glutamyltranspeptidase 1/GGT1	231950	J04131	22q11.1- q11.2
			Gamma-glutamyltranspeptidase 2/GGT2	137181	AH002728	22q11.1
			Gamma-glutamyltransferase-like activity 1/GGTLA1	137168	NM_004121	*****
	Catabolism	Esterases	paraoxonase 1/PON1 (arylesterase)	168820	AH004193	7q21.3
			paraoxonase 2/PON2	602447	L48513	7q21.3
			paraoxonase 3/PON3	602720	*****	7q21.4
			esterase C/ESC (acetyl esterase)	133270		
			esterase A4/ESA4	133220	*****	11q13- q22
			esterase B/buteryl esterase/ESB (erythrocyte)	133260	*****	*****
			esterase B3/ESB3	133290	*****	Chr.16

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Phase II Drug Metabolism (conjugation and catabolism)	Catabolism	Esterases	esterase A5/A7/acytylesterase/ESA5/ESA7 (brain)	13230	*****	*****
			acetylcholinesterase/ACHE	100740	M55040	7q22
			butyrylcholinesterase 1/serum cholinesterase 1/BCHE1	177400	NM_000055	3q26.1-q26.2
			butyrylcholinesterase 2/serum cholinesterase 2/BCHE2	177500	*****	2q33-q35
			carboxylesterase 1/serine esterase/CES1 (hepatic)	114835	SEG_HUM CESTG	16q13-q22.1
		Thioesterase	arylacetamide deacetylase/AADAC	600338	NM_001086	3q21.3-q25.2
			acyl-CoA thioester hydrolase 1, long chain/acyl-CoA thioesterase 1/ACT1	602586	*****	*****
			acyl-CoA thioester hydrolase 2, long chain/acyl-CoA thioesterase 2/ACT2	602587	*****	*****
			esterase D/S-formylglutathion hydrolase/ESC (thioesterase)	133280	M13450	13q14.11
			aminoacylase 1/ACY1	104620	NM_000666	3p21.1
		Amidase	aminoacylase 2/ACY2/aspartoacylase (Canavan disease)/ASPA	271900	NM_000049	17pter-p13
			fatty acid amide hydrolase/FAAH	602935	NM_001441	1p34-p35
		Epoxide Hydratases	epoxide hydrolase 1/EPHX1 (microsomal)	132810	NM_000120	1p11-qter
			epoxide hydrolase 2/EPHX2 (cytosolic)	132811	*****	8p21-p12
		Proteases	bleomycin hydrolase/BLMH	602403	NM_000386	17q11.2
Excretion	Canalicular Uptake and Concentration	Transporters	Multidrug resistance protein MDR3/P-glycoprotein 3/PGY3	602347	X06181	7q21.1
			Familial intrahepatic cholestasis 1, (progressive, Byler disease and benign recurrent) /FIC1	602397	NM_005603	18q21
			Bile salt export pump/BSEP	603201	NM_003742	2q24

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Excretion	Canalicular Uptake and Concentration	Transporters	Microsomal triglyceride transfer protein large subunit/MTP	157147	NM_000253	4q22-q24
			Solute carrier family 6, member 6/SLC6A6 (taurine)	186854	U16120	3p25-q24
			Solute carrier family 10, member 1/SLC10A1 (taurocholate)	182396	NM_003049	chr. 14
			Solute carrier family 10, member 2/SLC10A2 (taurocholate)	601295	NM_000452	13q33
			Solute carrier family 13, member 2/SLC13A2 (dicarboxylic acids)	604148	NM_003984	17p11.1-q11.1
			Solute carrier family 19, member 1/SLC19A1 (reduced folate)	600424	U19720	21q22.3
			Solute carrier family 21, member 3/SLC21A3 (organic anion)	602883	NM_005075	12p12
			Solute carrier family 22, member 1/SLC22A2 (organic cation)	602607	NM_003058	6q26
			multidrug resistance protein MDR1	171050	X96395	7q21.1
			multidrug resistance associated protein	601107	NM_000392	10q24
			MRP2/CMOAT			
			multidrug resistance protein MDR3/P-glycoprotein 3/PGY3	602347	X06181	7q21.1
		Bile Salt Synthesis	Bile acid Coenzyme A: amino acid N-acyltransferase (glycine N-choloyltransferase)/BAAT	602938	NM_001701	9q22.3
			cytochrome P450, subfamily XLVI (cholesterol 24-hydroxylase)/CYP46	604087	NM_006668	14q32.1
			cytochrome P450, subfamily VIIA (cholesterol 7- α -hydroxylase), polypeptide 1/CYP7A1	118455	M89803	8q11-q12
			cytochrome P450, subfamily VIIB (oxysterol 7- α -hydroxylase), polypeptide 1/CYP7B1	603711	AF029403	8q21.3

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Excretion	Canalicular Uptake and Concentration	Bile Concentration	ATPase, Na ⁺ /K ⁺ transporting, alpha 1 polypeptide/ATP1A1	182310	NM_000701	1p13-p11
			ATPase, Na ⁺ /K ⁺ transporting, alpha 1 polypeptide-like/ATP1A1L	182360	NM_001676	13q12.1-q12.3
			ATPase, Na ⁺ /K ⁺ transporting, alpha 2 polypeptide/ATP1A2	182340	NM_000702	1q21-q23
			ATPase, Na ⁺ /K ⁺ transporting, beta 1 polypeptide/ATP1B1	182330	NM_001677	1q22-q25
			ATPase, Na ⁺ /K ⁺ transporting, beta 2 polypeptide/ATP1B2	182331	X16645	17p
			ATPase, Na ⁺ /K ⁺ transporting, beta 3 polypeptide/ATP1B3	601867	NM_001679	3q22-q23
			solute carrier family 4, bicarbonate/chloride anion exchanger, member 1/SLC4A1	109270	NM_000342	17q21-q22
			solute carrier family 4, sodium bicarbonate cotransporter, member 4/SLC4A4	603345	NM_003759	4q21
			solute carrier family 4, sodium bicarbonate cotransporter, member 5/SLC4A5	603318	NM_003788	4q21
			Solute carrier family 9, member A2/SLC9A2 (sodium/hydrogen ion)	600530	NM_003048	2q11.2
			Solute carrier family 9, member A3/SLC9A3 (sodium/hydrogen ion)	182307	*****	5p15.3
			chloride channel 5/CLCN5	300008	NM_000084	Xp11.22
			chloride channel, calcium activated, family member 1/CLCA1	603906	NM_001285	1p31-p22
			chloride channel, calcium activated, family member 2/CLCA2	604003	NM_006536	*****
			cystic fibrosis transmembrane conductance regulator/CFTR	602421	NM_000492	7q31.2

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Excretion	Canalicular Uptake and Concentration	Bile Concentration	aquaporin 1/AQP1	107776	NM_000385	7p14
			aquaporin 3/AQP3	600170	NM_004925	9p13
		Bile Secretion	Cholecystokinin/CKK	118440	L00354	3pter-p21
			Cholecystokinin A receptor/CKKAR	118444	L13605	4p15.2-p15.1
			Cholecystokinin B receptor/CCKBR	118445	L08112	11p15.5-p15.4
	Renal Tubular Uptake and Concentration	Deconjugating Enzymes	Cytoplasmic cysteine conjugate-beta lyase/glutamine transaminase K/CCBL1	600547	NM_004059	Chr.9
			Galactosamine (N-acetyl)-6-sulfate sulfatase (Morquio syndrome)/GALNS	253000	NM_000512	16q24.3
			Iduronate-2-sulfatase (Hunter syndrome)/IDS	309900	NM_000202	Xq28
			Arylsulfatase A/steroid sulfatase/ARSA	250100	NM_000487	22q13.31-qter
			Arylsulfatase B/steroid sulfatase/ARSB	253200	NM_000046	5q11-q13
		Uptake and Reuptake Transporters	Arylsulfatase C, isozyme s/steroid sulfatase/ARCS1	308100	NM_000351	Xp22.32
			Arylsulfatase D/steroid sulfatase/ARSD	300002	*****	Xp22.3
			Arylsulfatase E/steroid sulfatase/ARSE	300180	NM_000047	Xp22.3
			Arylsulfatase F/steroid sulfatase/ARSF	300003	NM_004042	Xp22.3
			renal transport of beta-amino acids/AABT	109660	*****	Chr.21
			Solute carrier family 3 member 1/SLC3A1 (aa transporter)	104614	*****	2p16.3
			Solute carrier family 5 member 2/SLC5A5 (Na/glucose transporter)	182381	A56765	16p11.2
			Solute carrier family 6, member 6/SLC6A6 (taurine)	186854	U16120	3p25-q24
			Solute carrier family 7, member 9/SLC7A9 (neutral AA)	604144	*****	19q13.1

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Excretion	Renal Tubular Uptake and Concentration	Uptake and Reuptake Transporters	Solute carrier family 13, member 2/SLC13A2 (dicarboxylic acids)	604148	NM_003984	17p11.1-q11.1
			solute carrier family 17 (sodium phosphate), member 1/SLC17A1	182308	NM_005074	6p23-p21.3
			Solute carrier family 22, member 1/SLC22A2 (organic cation)	602607	NM_003058	6q26
			Solute carrier family 22, member 1-like/SLC22A1L (organic cation)	602631	AF037064	11p15.5
			Solute carrier family 22, member 4/SLC22A4 (organic cation)	604190	NM_003059	Chr. 5
			Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377	NM_003060	5q33.1
			Solute carrier family 34, member 1/SLC34A1 (sodium phosphate)	182309	NM_003052	5q35
		Acidosis	H ⁺ -ATPase beta 1 subunit /ATP6B1	267300	AH007312	2cen-q13
			solute carrier family 4, sodium bicarbonate cotransporter, member 4/SLC4A4	603345	NM_003759	4q21
			solute carrier family 4, sodium bicarbonate cotransporter, member 5/SLC4A5	603318	NM_003788	4q21
			carbonic anhydrase II/CA2	259730	NM_000067	8q22
			carbonic anhydrase IV/CA4	114760	NM_000717	17q23
			carbonic anhydrase XII/CA12	603263	AF051882	15q22
			solute carrier family 4, bicarbonate/chloride anion exchanger, member 1/SLC4A1	109270	NM_000342	17q21-q22
			Solute carrier family 9, member A1/SLC9A1 (sodium/hydrogen ion)	107310	M81768	1p36.1-p35
			Solute carrier family 9, member A2/SLC9A2 (sodium/hydrogen ion)	600530	NM_003048	2q11.2

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Excretion	Renal Tubular Uptake and Concentration	Acidosis	Solute carrier family 9, member A3/SLC9A3 (sodium/hydrogen ion)	182307	*****	5p15.3
		Lithosis	Solute carrier family 13, member 2/SLC13A2 (dicarboxylic acids)	604148	NM_003984	17p11.1-q11.1
		Sodium Tolerance	3'(2'), 5'-bisphosphate nucleotidase 1/BPNT	604053	NM_006085	*****
		Urine Concentration	chloride channel 5/CLCN5	300008	NM_000084	Xp11.22
			chloride channel Ka, kidney/CLCNKA	602024	NM_004070	1p36
			chloride channel Kb, kidney/CLCNKB	602023	NM_000085	1p36
			solute carrier family 12 (sodium/potassium/chloride transporters), member 1/SLC12A1	600839	NM_000338	15q15-q21.1
			solute carrier family 12 (sodium/potassium/chloride transporters), member 2/SLC12A2	600840	NM_001046	5q23.3
			solute carrier family 12 (sodium/chloride transporters), member 3/SLC12A3	600968	NM_000339	16q13
			ATPase, Na ⁺ /K ⁺ transporting, alpha 1 polypeptide/ATP1A1	182310	NM_000701	1p13-p11
			ATPase, Na ⁺ /K ⁺ transporting, alpha 1 polypeptide-like/ATP1A1L	182360	NM_001676	13q12.1-q12.3
			ATPase, Na ⁺ /K ⁺ transporting, alpha 2 polypeptide/ATP1A2	182340	NM_000702	1q21-q23
			ATPase, Na ⁺ /K ⁺ transporting, beta 1 polypeptide/ATP1B1	182330	NM_001677	1q22-q25
			ATPase, Na ⁺ /K ⁺ transporting, beta 2 polypeptide/ATP1B2	182331	X16645	17p
			ATPase, Na ⁺ /K ⁺ transporting, beta 3 polypeptide/ATP1B3	601867	NM_001679	3q22-q23

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Excretion	Renal Tubular Uptake and Concentration	Urine Concentration	arginine vasopressin receptor 2 (nephrogenic diabetes insipidus)/AVPR2	304800	NM_000054	Xq28
			aquaporin 1/AQP1	107776	NM_000385	7p14
			aquaporin 2/AQP2	107777	NM_000486	12q13
			aquaporin 3/AQP3	600170	NM_004925	9p13
			aquaporin 6/AQP6	601383	NM_001652	12q13
			Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_000454	21q22.1
Organ and Tissue Damage	Protection from Radical Damage	Superoxide Dismutase	Superoxide Dismutase 2/SOD2 (mitochondrial)	147460	X65965	6q25.3
			Superoxide Dismutase 3/SOD3 (extracellular)	185490	NM_003102	4pter-q21
			aldehyde dehydrogenase 1/ALDH1 (liver cytosol)	100640	AH002598	9q21
		Aldehyde Dehydrogenase	aldehyde dehydrogenase 2/ALDH2 (liver mitochondria)	100650	K03001	12q24.2
			aldehyde dehydrogenase 3/acetaldehyde dehydrogenase/ALDH3 (stomach)	100660	M74542	17p11.2
			aldehyde dehydrogenase 5/acetaldehyde dehydrogenase/ALDH5	100670	NM_000692	9p13
			aldehyde dehydrogenase 5, member A1/succinic semialdehyde dehydrogenase/ALDH5A1	271980	NM_001080	6p22
			aldehyde dehydrogenase 6/acetaldehyde dehydrogenase/ALDH6	600463	NM_000693	15q26
			aldehyde dehydrogenase 7/acetaldehyde dehydrogenase/ALDH7	600466	NM_000694	11q13
			aldehyde dehydrogenase 8/ALDH8	601917	NM_000695	chr. 11
			aldehyde dehydrogenase 9/g-aminobutyraldehyde dehydrogenase/ALDH9	602733	NM_000696	1q22-q23
			aldehyde dehydrogenase 10/ALDH10	270200	NM_000382	17p11.2
		Glutathione	glutathione synthetase/GSS	601002	NM_000178	20q11.2
			glutathione peroxidase/GPX1	138320	M21304	3p21.3

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Organ and Tissue Damage	Protection from Radical Damage	Glutathione	glutathione peroxidase GPX2	138319	X68314	14q24.1:
			glutathione peroxidase GPX3	138321	X58295	5q32-q33.1
			glutathione peroxidase GPX4	138322	X71973	19p13.3
		Metallothionein	glutathione peroxidase GPX5	603435	AJ005277	*****
			glutathione reductase	138300	X15722	8p21.1
			metallothionein 1A/MT1A	156350	NM_005953	16q13
		Miscellaneous	metallothionein 1B	56349	AH001510	16q13
			metallothionein 1E	156351	M10942	16q13
			metallothionein 1F	156352	M10943	16q13
			metallothionein 1G	156353	J03910	16q13
			metallothionein 2A/MT2A	156360	NM_005953	16q13
			metallothionein 3	139255	NM_005954	16q13
Immune Response	Mast Cell and T-Cell Response	IgE Production	glucose-6-phosphate dehydrogenase/G6PD (mitochondrial)	305900	NM_000402	Xq28
			8-oxoguanine DNA glycosylase/OGG1	601982	NM_002542	3p26.2
			Peptide methionine sulfoxide reductase/MSRA	601250	*****	*****
			succinate dehydrogenase complex, subunit C, integral membrane protein/SDHC	602413	NM_003001	1q21
			phospholipase A2 group IB/PLA2G1B	172410	NM_000928	12q23-q24.1
			lipoprotein, Lp(a)/LPA	152200	NM_005577	6q27
			Catalase/CAT	115500	NM_001752	11p13
			thioredoxin-dependent peroxide reductase/TDPX1	600538	NM_005809	13q12
			interleukin 4 receptor/IL4R	147781	X52425	16p12.1-p11.2
			interferon gamma/IFNG	147570	L07633	12q14
			mast cell growth factor/MGF	184745	NM_003994	12q22

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Immune Response (additional genes in Inflammation)	Mast Cell and T-Cell Response	Mast Cell Proliferation	interleukin 9 receptor/IL9R	300007	M84747	Xq28
			interleukin 3 receptor/IL3R)	308385	M74782	Xp22.3
		Degranulation of Mast Cells	mast cell IgE receptor alpha polypeptide/FCER1A	147140	*****	1q23
			mast cell IgE receptor beta polypeptide/FCER1B	147138	NM 000139	11q13
			mast cell IgE receptor beta polypeptide/FCER1G	147139	NM 004106	1q23
			SH2-containing inositol 5-phosphatase/SHIP	601582	U57650	2q36-q37
			secretory granule proteoglycan peptide core/PRG1	177040	J03223	10q22.1
		Histamine	Histidine Decarboxylase	142704	M60445	15q21-q22
			Histamine receptor H1	600167	AF026261	3p21-p14
			Histamine receptor H2	142703	M64799	*****
			Histamine N-methyltransferase	*****	D16224	chr. 2
			Amine oxidase (copper-containing) 2/AOC2	602268	D88213	17q21
			Amine oxidase (copper-containing) 3/AOC3	603735	AF054985	17q21
		Serotonin	aromatic L-Amino Acid Decarboxylase/AADC	107930	M76180	7p11
			tryptophan hydroxylase/TPH	191060	X52836	11p15.3-p14
			14-3-3 protein ETA	113508	X78138	22q12
			14-3-3 protein ZETA	601288	M86400	2p25.2-p25.1
			14-3-3 protein BETA	601289	X57346	20q13.1
			14-3-3 protein SIGMA	601290	X57348	*****
			serotonin 5-HT receptors 5-HT1A, G protein-coupled	109760	X57829	5q11.2-q13
			serotonin 5-HT receptors 5-HT1B, G protein-coupled	182131	M81590	6q13
			serotonin 5-HT receptors 5-HT1C, G protein-coupled	312861	U49516	Xq24
			serotonin 5-HT receptors 5-HT1D, G protein-coupled	182133	M81590	1p36.3-p34.3

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Immune Response (additional genes in Inflammation)	Mast Cell and T-Cell Response	Serotonin	serotonin 5-HT receptors 5-HT1E, G protein-coupled	182132	M91467	6q14-q15
			serotonin 5-HT receptors 5-HT1F, G protein-coupled	182134	L05597	3p12
			serotonin 5-HT receptors 5-HT2A, G protein-coupled	182135	D87030	13q14-q21
			serotonin 5-HT receptors 5-HT2B, G protein-coupled	601122	X77307	2q36.3-q37.1
			serotonin 5-HT receptors 5-HT2C, G protein-coupled	312861	U49516	Xq24
			serotonin transporter	182138	X70697	17q11.1-q12
			monoamine oxidase A/ MAOA	309850	M69226	Xp11.23
			monoamine oxidase B MAOB	309860	M69177	Xp11.23
			serotonin N-Acetyltransferase/SNAT	600950	U40347	17q25
			tryptophan 2,3-dioxygenase/TDO2	191070	NM_005651	4q31-q32
		Neutrophil and Eosinophil Chemotaxis	eotaxin precursor/small inducible cytokine, family A, member 11/SCYA11	601156	U46572	17q21.1-q21.2
			monocyte-derived-neutrophil chemotactic factor/interleukin 8/IL8	146930	M26383	4q12-q13
		Proteases	tryptase alpha/TPS1	191080	NM_003293	Chr.16
			tryptase beta/TPS2	191081	NM_003294	Chr.16
			chymase 1, mast cell/CMA1	118938	NM_001836	14q11.2
		Release of Membrane Lipids (common to PAF, leukotriene, and prostaglandin pathways)	phospholipase A2 group IIA/PLA2G2A	172411	NM_000300	1p35
			phospholipase A2 group IB/PLA2G1B	172410	NM_000928	12q23-q24.1
			phospholipase A2 group X/PLA2G10	603603	*****	16p13.1-p12
			phospholipase A2 group IVA/PLA2G4A	600522	U08374	1q25
			phospholipase A2 group VI/PLA2G6	603604	AF064594	22q13.1
			phospholipase A2 group IVC/PLA2G4C	603602	*****	chr. 19

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Immune Response (additional genes in Inflammation)		Release of Membrane Lipids	phospholipase A2 group IVC/PLA2G4C	603602	*****	chr. 19
			phospholipase A2 group V/PLA2G5	601192	NM_000929	1p36-p34
			phospholipase C beta 3	600230	U26425	11q13
			lysosomal acid lipase	278000	NM_000235	10q24-q25
	Mast Cell and T-Cell Response	Platelet Activating Factor (PAF)	CDP-choline:alkylacetyl glycerol cholinephosphotransferase	*****	*****	*****
			platelet activating factor receptor/PTAFR	173393	M88177	1p35-p34.3
			platelet activating factor acetylhydrolase 1/PAFAH1	601690	NM_005084	6p21.2-p12
			platelet activating factor acetylhydrolase, isoform 1B, alpha subunit/PAFAH1B1	601545	NM_000430	17p13.3
			platelet activating factor acetylhydrolase, isoform 1B, beta subunit/PAFAH1B2	602508	NM_002572	11q23
			platelet activating factor acetylhydrolase, isoform 1B, gamma subunit/PAFAH1B3	603074	NM_002573	19q13.1
			platelet activating factor acetylhydrolase 2/PAFAH2	602344	NM_000437	*****
			arachidonate 5-lipoxygenase/ALOX5	152390	NM_000698	Chr.10
			arachidonate 5-lipoxygenase-activating protein/FLAP/ALOX5AP	603700	NM_001629	13q12
			leukotriene A4 hydrolase/LTA4H	151570	NM_000895	12q22
			leukotriene C4 synthase/LTC4S	246530	NM_000897	5q35
			Gamma-glutamyltranspeptidase 1/GGT1	231950	J04131	22q11.1-q11.2
			Gamma-glutamyltranspeptidase 2/GGT2	137181	AH002728	22q11.1
			Gamma-glutamyltransferase-like activity 1/GGTLA1	137168	NM_004121	*****
			renal microsomal dipeptidase/DPEP1	179780	NM_004413	16q24.3
		Leukotriene				

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Immune Response (additional genes in Inflammation)	Mast Cell and T-Cell Response	Leukotriene	cysteinyl leukotriene receptor 1/CYSLT1	300201	NM_006639	Xq13-q21
			leukotriene b4 receptor (chemokine receptor-like 1)/LTB4R	601531	NM_000752	14q11.2-q12
		Prostaglandins	prostaglandin endoperoxide synthetase 1/COX1/PTGS1	176805	AH001520	9q32-q33.3
			prostaglandin endoperoxide synthetase 2/COX2/PTGS2	600262	NM_000963	1q25.2-q25.3
			thromboxane A synthase 1/TBXAS1	274180	SEG_D34613S	7q34
			prostaglandin D2 synthase	602598	M61900	*****
			prostaglandin I2 synthase/prostacyclin synthase/PTGIS	601699	SEG_D83393S	20q13
			prostaglandin E receptor 1, EP1 subtype/PTGER1	176802	NM_000955	19p13.1
			prostaglandin E receptor 2, EP2 subtype/PTGER2	176804	*****	5p13.1
			prostaglandin E receptor 3, EP3 subtype/PTGER3	176806	NM_000957	1p31.2
			prostaglandin E receptor 4, EP4 subtype/PTGER4	601586	NM_000958	5p13.1
			prostaglandin F receptor/PTGFR	600563	L24470	1p31.1
			prostaglandin F2 receptor negative regulator/PTGFRN	601204	U26664	1p13.1-q21.3
			prostaglandin I2 receptor/PTGIR/prostacyclin receptor	600022	SEG_HUMIP	19q13.3
			15-hydroxyprostaglandin dehydrogenase/HPGD	601688	NM_000860	4q34-q35
			aldo-keto reductase family 1, member C2/AKR1C2	600450	NM_001353	10p15-p14
		Formation of Reactive Drug Metabolites	myeloperoxidase/MPO	254600	J02694	17q23.1
			eosinophil peroxidase/EPX	131399	NM_000502	*****
			calreticulin/CALR	109091	CALR	19p13.2
			calnexin/CANX	114217	L18887	5q35

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Immune Response (additional genes in Inflammation)	Mast Cell and T-Cell Response	Formation of Reactive Drug Metabolites	ceruloplasmin (ferroxidase)/CP	117700	NM_000096	3q21-q24
			MHC class II transactivator/MHC2TA	600005	NM_000246	16p13
		Antigen Presentation	MHC class II HLA DR-alpha chain/HLA-DRA	142860	X83114	6p21.3
			MHC class II HLA DR-beta chain/HLA-DRB	142857	M11161	6p21.3
			MHC class II HLA DP-alpha chain/HLA-DPA	142880	M23905	6p21.3
			MHC class II HLA DP-beta chain/HLA-DPB	142858	AH002893	6p21.3
			MHC class II HLA DM-alpha chain/HLA-DMA	142855	NM_006120	6p21.3
			MHC class II HLA DM-beta chain/HLA-DMB	142856	NM_002118	6p21.3
			MHC class II HLA DQ-alpha chain/HLA-DQA	146880	M11124	6p21.3
			MHC class II HLA DQ-beta chain/HLA-DQB	*****	M24364	6p21.3
			MHC class II HLA DN-alpha chain/HLA-DNA	142930	X02882	6p21.3
			MHC class II HLA DO-beta chain/HLA-DOB	600629	NM_002120	6p21.3
	T-Cell Receptor		MHC class II antigen gamma chain/CD74	142790	K01144	5q32
			antigen peptide transporter 1/MHC 1/TAP1	170260	NM_000593	6p21.3
			antigen peptide transporter 2/MHC 2/TAP2	170261	NM_000544	6p21.3
			T-cell antigen receptor, alpha subunit/TCRA	186880	Z24457	14q11.2
			T-cell antigen receptor, beta subunit/TCRB	186930	AF011643	7q35
			T-cell antigen receptor, gamma subunit/TCRG	186970	M17325	7p15-p14
			T-cell antigen receptor, delta subunit/TCRD	186810	L36384	14q11.2
			thymocyte antigen receptor complex CD3G, gamma polypeptide (TiT3 complex)/CD3G	186740	NM_000073	11q23
			thymocyte antigen receptor complex CD3D, delta polypeptide (TiT3 complex)/CD3D	186790	NM_000732	11q23
			thymocyte antigen receptor complex CD3E, epsilon polypeptide (TiT3 complex)/CD3E	186830	NM_000733	11q23

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Immune Response (additional genes in Inflammation)	Mast Cell and T-Cell Response	T-Cell Receptor Rearrangement	thymocyte antigen receptor complex CD3Z, zeta polypeptide (TiT3 complex)/CD3Z	186780	NM_000734	1q22-q23
			ataxia telangiectasia mutated (includes complementation groups A, C and D)/ATM	208900	NM_000051	11q22.3
			recombination activating gene 1/RAG1	179615	NM_000448	11p13
			recombination activating gene 2/RAG2	179616	M94633	11p13
			interleukin 7 receptor/IL7R	146661	NM_002185	5p13
			v-myb avian myeloblastosis viral oncogene homolog/MYB	189990	NM_005375	6q22
			core binding factor, alpha 1 subunit/CBFA1	600211	AH005498	6p21
			core-binding factor, beta subunit/PEBP2B/CBFB	121360	L20298	16q22
			ligase I, DNA, ATP-dependent/LIG1	126391	NM_000234	19q13.2-q13.3
			ligase IV, DNA, ATP-dependent/LIG4	601837	NM_002312	13q22-q34
			X-ray repair, complementing defect in Chinese hamster/Ku antigen, 80 kD/KU80/XRCC5	194364	*****	2q35
			thyroid autoantigen, 70 kD/KU70/G22P1	152690	NM_001469	22q11-q13
		T-Cell Expansion	T-cell antigen T4/CD4	186940	X87579	12pter-p12
			T-cell antigen CD8, alpha polypeptide (p32)/CD8A	186910	NM_001768	2p12
			T-cell antigen CD8, beta polypeptide/CD8B	186730	AH003859	2p12
			T-cell antigen CD28 (Tp44)/CD28	186760	NM_006139	2q33-q34
			cytotoxic T-lymphocyte-associated 4/CTLA4	123890	L15006	2q33
			CD80 antigen (CD28 antigen ligand 1, B7-1 antigen)/CD80	112203	NM_005191	3q21

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Immune Response <i>(additional genes in Inflammation)</i>	Mast Cell and T-Cell Response	T-Cell Expansion	CD86 antigen (CD28 antigen ligand 2, B7-2 antigen)/CD86	601020	NM_006889	3q21
			T cell receptor-associated protein tyrosine kinase ZAP-70/ZAP70	176947	S69911	2q12
			leukocyte common antigen T200/CD45	151460	M23492	1q31-q32
			nuclear factor of activated T-cells, cytoplasmic 1/NFATC1	600489	NM_006162	18q23
			nuclear factor of activated T-cells, cytoplasmic 2/NFATC2	600490	*****	20q13.2-q13.3
			nuclear factor of activated T-cells, cytoplasmic 3/NFATC3	602698	L41066	16q13-q24
			nuclear factor of activated T-cells, cytoplasmic 4/NFATC4	602699	L41067	*****
			interleukin 2 receptor alpha/IL2RA	147730	X01057	10p15-p14
			interleukin 2 receptor beta/IL2RB	146710	M26062	22q11.2-q13
			interleukin 2 receptor gamma/IL2RG	308380	D11086	Xq13
			interleukin 6 receptor/IL6R	147880	X12830	1q21
			interleukin 9 receptor/IL9R	300007	M84747	Xq28
			interleukin receptor 13 alpha/IL13RA1	300119	S80963	Chr.X
			interleukin receptor 13 alpha2/IL13RA2	300130	X95302	Xq24
			interleukin 15 receptor alpha/IL15RA	601070	U31628	10p15-p14
			transforming growth factor/TGFB1	190180	M60315	19q13.1-q13.3
			transforming growth factor/TGFB2	190220	M19154	1q41
			transforming growth factor/TGFB3	190230	X14149	14q24

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Immune Response (additional genes in Inflammation)	Mast Cell and T-Cell Response	T-Cell Expansion	tumor necrosis factor beta/TNFB/lymphotoxin alpha/LTA	153440	NM_000595	6p21.3
			tumor necrosis factor ligand superfamily, member 6/TNFSF6	134638	NM_000639	1q23
			tumor necrosis factor receptor superfamily, member 6/TNFRSF6	134637	NM_000043	10q24.1
	B-Cell Response	Receptors	caspase 10, apoptosis-related cysteine protease/CASP10	601762	NM_001230	2q33-q34
			B-cell antigen CD20/B-lymphocyte differentiation antigen B1/CD20	112210	AH003353	11q13
			B-cell antigen CD72/CD72	107272	NM_001782	9p
			natural resistance-associated macrophage protein 1/NRAMP1/solute carrier family 11, member 1/SLC11A1	600266	AH002806	2q35
			natural resistance-associated macrophage protein 2/NRAMP2/solute carrier family 11, member 1/SLC11A2	600523	AB015355	12q13
			T-lymphocyte antigen CDW52 (CAMPATH-1 antigen)/CDW52	114280	NM_001803	*****
			B-cell antigen CD22/CD22	107266	NM_001771	19q13.1
			B-cell antigen CD24/CD62 ligand/CD24	600074	X69397	6q21
			leukocyte antigen CD156/disintegrin and metalloprotease domain 8/ADAM8/CD156	602267	NM_001109	10q26.3
			platelet antigen CD151/platelet-endothelial cell tetraspan antigen 3/PETA3/CD151	602243	NM_004357	11p15.5
			antigen CD32/low-affinity receptor IIA for Fc fragment of IgG/FCGR2A/CD32	146790	NM_004001	1q21-q23

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Immune Response (additional genes in Inflammation)	B-Cell Response	Immunoglobulin Heavy Chains	immunoglobulin G heavy chain constant region locus 1/IGHG1	147100	*****	14q32.33
			immunoglobulin G heavy chain constant region locus 2/IGHG2	147110	*****	14q32.33
			immunoglobulin G heavy chain constant region locus 3/IGHG3	147120	*****	14q32.33
			immunoglobulin G heavy chain constant region locus 4/IGHG4	147130	*****	14q32.33
			immunoglobulin M heavy chain constant region locus/IGHM	147020	*****	14q32.33
			immunoglobulin heavy chain variable region locus 1/IGHV1	147070	X92279	14q32.33
			immunoglobulin heavy chain variable region locus 2/IGHV2	600949	*****	16p11
			immunoglobulin heavy chain diversity region locus 1/IGHDY1	146910	X97051	14q32.33
			immunoglobulin heavy chain diversity region locus 2/IGHDY2	146990	L25544	15q11-q12
			immunoglobulin heavy chain joining region locus/IGHJ	147010	*****	14q32.33
		Immunoglobulin Gene Rearrangement	recombination activating gene 1/RAG1	179615	NM_000448	11p13
			recombination activating gene 2/RAG2	179616	M94633	11p13
			immunoglobulin kappa J region recombination signal binding protein/RBPJK/IGKJRB1	147183	L07872	9p13-p12
			Bruton agammaglobulinemia tyrosine kinase/BTK	300300	NM_000061	Xq21.3-q22
			interleukin 7 receptor/IL7R	146661	NM_002185	5p13
			interferon-gamma receptor 1/IFNGR1	107470	NM_000416	6q23-q24

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Immune Response (additional genes in Inflammation)	B-Cell Response	Immunoglobulin Gene Rearrangement	interferon-gamma receptor 2/IFNGR2	147569	NM_005534	21q22.1-q22.2
			interleukin 4 receptor precursor/IL4R	147781	NM_000418	16p12.1-p11.2
			interleukin 4 receptor precursor/IL4R	147781	NM_000418	16p12.1-p11.2
			ligase I, DNA, ATP-dependent/LIG1	126391	NM_000234	19q13.2-q13.3
			ligase IV, DNA, ATP-dependent/LIG4	601837	NM_002312	13q22-q34
			X-ray repair, complementing defect in Chinese hamster/Ku antigen, 80 kD/KU80/XRCC5	194364	*****	2q35
		Immunoglobulin Gene Transcription	thyroid autoantigen, 70 kD/KU70/G22P1	152690	NM_001469	22q11-q13
			nuclear factor kappa-B DNA binding subunit 1/NFKB1	164011	M58603	4q23-q24
			nuclear factor kappa-B DNA binding subunit 2/NFKB2	164012	NM_002502	10q24
			nuclear factor kappa-B subunit 3/NFKB3	164014	Z22949	11q12-q13
			nuclear factor of kappa light chain gene enhancer in B cells, inhibitor alpha/NFKBIA	164008	*****	14q13
			nuclear factor of kappa light chain gene enhancer in B cells, inhibitor beta/NFKBIB	603258	NM_002503	8p11.2
			YY1 transcription factor/YY1	600013	NM_003403	14q
			immunoglobulin transcription factor 1/ITF1/transcription factor 3/TCF3	147141	*****	19p13.3
			immunoglobulin transcription factor 2/ITF2/transcription factor 4/TCF4	602272	NM_003199	18q21.1

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Immune Response (additional genes in Inflammation)	B-Cell Response	Immunoglobulin Gene Transcription	immunoglobulin mu binding protein 2/IGHMBP2	600502	NM_002180	11q13.2-q13.4
			transcription factor binding to IGHM enhancer 3/TFE3	314310	NM_006521	Xp11.22
			homeobox protein OCT1/POU domain transcription factor 2, class 1/POU2F1	164175	NM_002697	1q22-q23
			homeobox protein OCT2/POU domain transcription factor 2, class 2/POU2F2	164176	M22596	Chr.19
			POU domain, class 2, associating factor 1/POU2AF1	601206	NM_006235	11q23.1
			inhibitor of DNA binding 1, dominant negative helix-loop-helix protein/ID1	600349	NM_002165	20q11
			inhibitor of DNA binding 2, dominant negative helix-loop-helix protein/ID2	600386	NM_002166	2p25
			B-cell antigen CD40/tumor necrosis factor receptor superfamily, member 5/CD40/TNFRSF5	109535	NM_001250	20q12-q13.2
			paired box gene 5/B-cell lineage-specific activator protein/BSAP/PAX5	167414	*****	9p13
			lymphocyte function-associated antigen, type 3/LFA3/LEU7/CD58	153420	NM_001779	1p13
		Immunoglobulin Isotype Switching	interleukin 10 receptor, alpha/IL10RA	146933	NM_001558	11q23.3
			lymphocyte antigen CD45/protein tyrosine phosphatase, receptor type, c polypeptide/PTPRC/CD45	151460	NM_002838	1q31-q32
			prostaglandin E receptor 1, EP1 subtype/PTGER1	176802	NM_000955	19p13.1
			prostaglandin E receptor 2, EP2 subtype/PTGER2	176804	*****	5p13.1
			prostaglandin E receptor 3, EP3 subtype/PTGER3	176806	NM_000957	1p31.2
			prostaglandin E receptor 4, EP4 subtype/PTGER4	601586	NM_000958	5p13.1
			interleukin 13 receptor, alpha 1/IL13RA1	300119	NM_001560	Chr.X

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Immune Response (additional genes in Inflammation)	B-Cell Response	Immunoglobulin Isotype Switching	interleukin receptor 13 alpha2/IL13A2	300130	X95302	Xq24
			interferon-gamma receptor 1/IFNGR1	107470	NM_000416	6q23-q24
			interferon-gamma receptor 2/IFNGR2	147569	NM_005534	21q22.1-q22.2
			interleukin 5 receptor alpha/IL5RA	147851	M96652	3p26-p24
			transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53kD)/TGFBRI	190181	NM_004612	9q33-q34
			transforming growth factor, beta receptor II (70-80kD)/TGFBRII	190182	NM_003242	3p22
			transforming growth factor, beta receptor III (betaglycan, 300kD)/TGFBRII	600742	NM_003243	1p33-p32
			X-ray repair, complementing defect in Chinese hamster/Ku antigen, 80 kD/KU80/XRCCC5	194364	*****	2q35
			thyroid autoantigen, 70 kD/KU70/G22P1	152690	NM_001469	22q11-q13
			granulocyte-macrophage colony stimulating factor 2/CSF2	138960	NM_000758	5q31.1
	Myeloid Differentiation	Granulocyte, Macrophage, Erythrocyte and Platelet Differentiation	macrophage-specific colony-stimulating factor/CSF1	120420	AH005300	1p21-p13
			granulocyte colony stimulating factor 3/CSF3	138970	NM_000759	17q11.2-q12
			colony stimulating factor 1 receptor/CSFR1	164770	U63963	5q33.2-q33.3
			granulocyte-macrophage colony stimulating factor 2 receptor, alpha, low-affinity/CSF2RA	306250	NM_006140	Xp22.32
			granulocyte-macrophage colony stimulating factor 2 receptor, beta/CSF2RB	138981	U18373	22q12.2-q13.1
			granulocyte-macrophage colony stimulating factor 2 receptor, alpha, Y chromosomal/CSF2RY	425000	*****	Yp11

Table 1

Class	Pathway	Function	Name	OMIM	GID	Locus
Immune Response (additional genes in Inflammation)	Myeloid Differentiation	Granulocyte, Macrophage, Erythrocyte, and Platelet Differentiation	flt3 ligand/FMS-related tyrosine kinase 3 ligand/FLT3LG	600007	U03858	19q13.3
			STAT induced STAT inhibitor 3/SSI-3	604176	NM_003955	*****
			erythropoietin/EPO	133170	NM_000799	7q21
			erythropoietin receptor/EPOR	133171	NM_000121	19p13.3-p13.2
			Janus kinase 2 (a protein tyrosine kinase)/JAK2	147796	NM_004972	9p24
			STAM-like protein containing SH3 and ITAM domains 2/STAM2	*****	NM_005843	*****
			ribosomal protein S7/RPS7	603474	NM_001011	19q13.2
			signal transducer and activator of transcription 5A/STAT5A	601511	NM_003152	17q11.2
			BCL-X/BCLX	600039	Z23115	*****
			thrombopoietin (MLV oncogene ligand, megakaryocyte growth and development factor)/THPO	600044	NM_000460	3q26.3-q27
			myeloproliferative leukemia virus oncogene/MPL/thrombopoietin receptor/TPOR	159530	NM_005373	1p34
			FMS-related tyrosine kinase 3/FLT3	136351	NM_004119	13q12

Table 2

	Pathway	Efficacy	Safety			
			Blood Dyscrasias	Cutaneous Toxicity	Systemic Toxicity	CNS Toxicity
Absorption and Distribution	Gastrointestinal Drug Metabolism					
	Drug Binding					
	Drug Transport					
Phase I Drug Metabolism (<i>oxidation and reduction</i>)	Cytochrome P450s					
	NAD(P)-Linked Oxidoreductases					
	Flavin-Dependent Oxidoreductases					
	Fatty Acid β -Oxidation					
	Conjugation					
Phase II Drug Metabolism (<i>conjugation and catabolism</i>)	Hydratases and Lyases					
	Canalicular Uptake and Concentration					
	Renal Tubular Uptake and Concentration					
	Protection from Reactive N and O Species					
Excretion	Mast Cell and T-Cell Response					
	B-Cell Response					
	Myeloid Differentiation					
Oxidative Stress						
Immune Response						

Table 2

	Pathway	Safety			
		Hepatic Toxicity	Cardiovascular Toxicity	Pulmonary Toxicity	Renal Toxicity
Absorption and Distribution	Gastrointestinal Drug Metabolism				
	Drug Binding				
	Drug Transport				
Phase I Drug Metabolism (oxidation and reduction)	Cytochrome P450s				
	NAD(P)-Linked Oxidoreductases				
	Flavin-Dependent Oxidoreductases				
	Fatty Acid β -Oxidation				
	Conjugation				
Phase II Drug Metabolism (conjugation and catabolism)	Hydratases and Lyases				
	Canalicular Uptake and Concentration				
	Renal Tubular Uptake and Concentration				
Excretion	Protection from Reactive N and O Species				
Oxidative Stress	Mast Cell and T-Cell Response				
	B-Cell Response				
	Myeloid Differentiation				

Hugo	GID	OMIM ID	VGX	Symbol	Description
	Variance	Start		Variance	
	X07674	X07674	138130	GEN-1EC	Human mRNA for
					glutamate dehydrogenase (EC 1.4.1.3., GDH)
5		646		633A>G	Silent
		668		655A>G	I219V
		721		708C>T	Silent
		859		846T>C	Silent
		911		898G>A	G300R
10		955		942A>G	Silent
		1483		1470G>A	Silent
	X12387	X12387	124010	GEN-1LZ	Cytochrome P-450,
					CYP3A4
		1751		1682T>A	3'
15		1847		1778C>A	3'
	AF185589	AF185589	124010	GEN-MVA	Homo sapiens
					cytochrome P450 3A4 (CYP3A4) gene, promoter region
		8653		8653C>T	Intron
	AF209389	AF209389	124010	GEN-MVI	Homo sapiens
20					cytochrome P450 IIIA4 (CYP3A4) gene, exons 1 through 13 and complete
					cds
		732		732T>C	Intron
		755		755C>T	Intron
		1870		1870A>G	Intron
25		1925		1925A>G	Intron
		2253		2253G>C	Intron
		2444		2444A>G	Intron
		2523		2523A>G	Intron
		3136		3136C>T	Intron
30		3352		3352G>A	Intron
		4768		4768A>T	Intron
		4808		4808G>T	Intron
		7208		7208T>A	Intron
		7445		7445A>G	Intron
35		13115		13115T>G	Intron
		17890		17890C>T	Intron
		17997		17997C>G	Intron
		18651		18651T>G	Intron
		19100		19100A>T	Intron
40		23187		23187C>T	Intron
		23489		23489G>C	Intron
	SOAT	L21934	102642	GEN-25C	Human acyl coenzyme
					A:cholesterol acyltransferase mRNA, complete cds
		490		(-907)C>G	5'
45		676		(-721)T>G	5'
		814		(-583)C>T	5'
		1993		597C>T	Silent
		2170		774C>T	Silent
		2365		969C>T	Silent
50		2821		1425G>C	Silent
		2973		1577G>A	R526Q
		3083		1687G>T	3'
	AF038007	AF038007	602397	GEN-2QG	Homo sapiens P-type
					ATPase F1C1 mRNA, partial cds
55		152		152A>C	N51T
		829		829C>A	Silent
		2873		2873G>A	R958Q
		3495		3495C>T	Silent
	U53347	U53347	109190	GEN-34A	Human neutral amino
60					acid transporter B mRNA, complete cds

	272	(-348)C>T	5'	
	281	(-339)T>C	5'	
	337	(-283)T>C	5'	
5	1447	828C>T	Silent	
	1777	1158C>T	Silent	
	1789	1170C>T	Silent	
	1976	1357A>C	I453L	
	2074	1455T>C	Silent	
	2153	1534G>C	V512L	
10	2527	1908G>A	3'	
	M80244	M80244	600182	GEN-3UJ
	complete cds			Human E16 mRNA,
	1111	801C>T	3'	
	1119	809C>T	3'	
15	1324	1014T>A	3'	
	1473	1163C>G	3'	
	1493	1183A>G	3'	
	1614	1304G>A	3'	
	1862	1552G>T	3'	
20	1918	1608C>A	3'	
	2102	1792T>A	3'	
	2591	2281A>G	3'	
	2728	2418G>T	3'	
	2811	2501C>T	3'	
25	2917	2607G>A	3'	
	2933	2623C>A	3'	
	2992	2682A>G	3'	
	X96395	X96395	601107	GEN-4AM
	canalicular	multidrug resistance protein		H.sapiens mRNA for
30	1286	1249G>A	V417I	
	2971	2934G>A	Silent	
	3144	3107T>C	I1036T	
	4525	4488C>T	Silent	
	4564	4527C>T	Silent	
35	4581	4544G>A	C1515Y	
	AJ005200	AJ005200	None	GEN-MT6
	gene, promoter region			Homo sapiens MRP2
	211	211A>G	Intron	
	1206	1206C>T	5'	
40	U21943	U21943	602883	GEN-L97
	transporting polypeptide (OATP) mRNA, complete cds			Human organic anion
	1964	1911A>T	Silent	
	2183	2130C>A	3'	
	2229	2176G>A	3'	
45	2295	2242A>C	3'	
	Y08062	Y08062	None	GEN-MT8
	transporter, promoter			Organic anion
	310	310C>T	Intron	
	689	689G>A	Intron	
50	726	726G>A	Intron	
	799	799G>A	Intron	
	908	908T>A	Intron	
	X96751	X96751	114835	GEN-LUL
	promoter			Carboxylesterase I,
55	235	235T>C	Intron	
	258	258^insC	Intron	
	328	328T>C	Intron	
	939	939G>T	Intron	
	975	975A>G	Intron	
60	984	984G>C	Intron	

	X57303	X57303	104615	GEN-MEB	H.sapiens REC1L mRNA
		573	423C>G	Silent	
		582	432C>T	Silent	
		630	480G>A	Silent	
5		1026	876G>A	Silent	
		1059	909G>A	Silent	
		1185	1035T>C	Silent	
		1332	1182C>T	Silent	
		1401	1251C>G	Silent	
10		1551	1401G>C	Silent	
		1656	1506T>C	Silent	
		1672	1522A>G	I508V	
		1747	1597G>A	A533T	

005230" EET 24960

Claims

What is claimed is:

- 5 1. A nucleic acid probe comprising a nucleic acid sequence 7 to 500 nucleotide bases in length that specifically binds under selective binding conditions to a nucleic acid sequence comprising at least one variance in a gene selected from the group consisting of Human glutamate dehydrogenase (EC 1.4.1.3., GDH), Cytochrome P-450 (CYP3A4), Human acyl coenzyme A:cholesterol acyltransferase, Homo sapiens
10 P-type ATPase FIC1, Human neutral amino acid transporter B, Human E16, H.sapiens canalicular multidrug resistance protein, Human organic anion transporting polypeptide (OATP), Carboxylesterase I, H.sapiens REC1L or a sequence complementary thereto or an RNA equivalent.
- 15 2. The probe of claim 1, wherein said probe comprises a nucleic acid sequence 200 nucleotide bases or fewer in length.
3. The probe of claim 1, wherein said nucleic acid sequence is 100 or fewer nucleotide bases in length.
- 20 4. The probe of claim 1, wherein said nucleic acid sequence is 25 or fewer nucleotide bases in length.
5. The probe of claim 1, wherein said probe comprises DNA.
- 25 6. The probe of claim 1, wherein said probe comprises DNA and at least one nucleic acid analog.
7. The probe of claim 1, wherein said probe comprises peptide nucleic acid (PNA).
- 30 8. The probe of claim 1, further comprising a detectable label.
9. The probe of claim 8, wherein said detectable label is a fluorescent label.
- 35 10. The probe of claim 1, wherein said at least one variance is listed in Table 3.
11. An isolated, purified or enriched nucleic acid sequence of 15 to 500 nucleotides in length, comprising at least one variance, wherein said sequence has the base sequence of a portion of an allele of a gene selected from the group
40 consisting of Human glutamate dehydrogenase (EC 1.4.1.3., GDH), Cytochrome P-

450 (CYP3A4), Human acyl coenzyme A:cholesterol acyltransferase, Homo sapiens P-type ATPase FIC1, Human neutral amino acid transporter B, Human E16, H.sapiens canalicular multidrug resistance protein, Human organic anion transporting polypeptide (OATP), Carboxylesterase I, H.sapiens REC1L or a sequence complementary thereto or an RNA equivalent.

12. The nucleic acid sequence of claim 11, wherein said nucleic acid sequence is 15 to 100 nucleotide bases in length.

13. The nucleic acid sequence of claim 11, wherein said nucleic acid sequence is 15 to 25 nucleotide bases in length.

14. The nucleic acid sequence of claim 11, wherein said at least one variance comprises a variance listed in Table 3.

15. A method for determining the presence or absence of a variance in a gene selected from the group consisting of Human glutamate dehydrogenase (EC 1.4.1.3., GDH), Cytochrome P-450 (CYP3A4), Human acyl coenzyme A:cholesterol acyltransferase, Homo sapiens P-type ATPase FIC1, Human neutral amino acid transporter B, Human E16, H.sapiens canalicular multidrug resistance protein, Human organic anion transporting polypeptide (OATP), Carboxylesterase I, H.sapiens REC1L or a sequence complementary thereto or an RNA equivalent comprising contacting at least a portion of said gene or a sequence complementary thereto with a probe as described in claim 1 under selective binding conditions.

16. The method of claim 15, wherein said at least one variance comprises a variance listed in Table 3.

005230 "E" 244960

Methods for identifying and utilizing variances in genes relating to efficacy and safety of medical therapy and other aspects of medical therapy are described,

5 including methods for selecting an effective treatment.

Variable	Mean	SD	Min	Max
Age	34.5	10.5	20	55
Gender	Male	Female	Male	Female
Marital status	Married	Single	Married	Single
Education	High school	College	High school	College
Occupation	Manager	Worker	Manager	Worker
Income	\$10,000	\$20,000	\$10,000	\$20,000
Health status	Good	Poor	Good	Poor
Smoking status	Smoker	Non-smoker	Smoker	Non-smoker
Alcohol consumption	Regular	Occasional	Regular	Occasional
Exercise frequency	Regular	Occasional	Regular	Occasional
Stress level	High	Low	High	Low
Life satisfaction	High	Low	High	Low
Depression score	10	20	10	20
Loneliness score	10	20	10	20
Self-esteem score	10	20	10	20
Resilience score	10	20	10	20
Optimism score	10	20	10	20
Gratitude score	10	20	10	20
Forgiveness score	10	20	10	20
Empathy score	10	20	10	20
Compassion score	10	20	10	20
Kindness score	10	20	10	20
Generosity score	10	20	10	20
Patience score	10	20	10	20
Self-control score	10	20	10	20
Emotional stability score	10	20	10	20
Psychological well-being score	10	20	10	20
Life satisfaction score	10	20	10	20
Overall health score	10	20	10	20

**DECLARATION
Utility Application**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention **GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE, IN GENES RELATING TO DRUG PROCESSING** the specification of which

(Check One) ☒ is attached hereto OR
☐ was filed on _____ as United States Application Serial No. _____; PCT
International Application No.
and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Date of Filing	Priority Claimed	
			Yes	No


I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date
60/139,440	June 15, 1999
60/131,334	April 26, 1999

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date	Status-Patented, Pending or Abandoned
09/590,783		June 8, 2000	Pending
09/501,955		February 10, 2000	Pending
	PCT/US00/01392	January 20, 2000	Pending
09/427,835		October 26, 1999	Pending
09/300,747		April 26, 1999	Pending

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

201	FULL NAME OF INVENTOR	FIRST Name Vincent	MIDDLE Initial P.	LAST Name Stanton, Jr.	
	RESIDENCE & CITIZENSHIP	City Belmont	State or Foreign Country Massachusetts	Country of Citizenship U.S.A.	
	POST OFFICE ADDRESS	32 Royal Road	City Belmont	State or Country Massachusetts	Zip Code 02178
INVENTOR'S SIGNATURE				DATE <u>August 15, 2000</u>	